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ABSTRACT 
For many cancers research led to controversial results regarding frequency and identity 
of cancer stem cells, cells that self-renew and are able to reconstitute the full phenotype 
of the original malignancy. In some malignancies such as acute myeloid leukaemia the 
hierarchical stem cell model that suggests that only rare and immunophenotypically 
immature blasts exhibit stem cell characteristics, resembling the normal physiological 
haematopoietic hierarchy, has been well established. In contrast to that, the stochastic 
model states that all or at least a substantial proportion of malignant cells has stem cell 
potential whereby this is supported by extrinsic stimuli. Initially, several studies 
suggested that acute lymphoblastic leukaemia (ALL) also is organised in a hierarchy. 
However, using more immunocompromised mouse strains and refined transplantation 
techniques for in vivo xenotransplantation models, previous findings regarding 
frequency and restriction of stem cells to very early B-precursor cell stages have been 
challenged in more recent studies. 
In order to address the questions of identity and frequency of stem cells in ALL, a robust 
orthotopic mouse model with the most immunocompromised mouse strain currently 
available (NOD/scid IL2Rγnull; NSG) was established. Primary diagnostic patient ALLs 
or blasts harvested from engrafted mouse bone marrow were sorted for B-cell lineage 
differentiation markers CD10, CD19, CD20 or CD34 to purify candidate stem cell 
populations of different maturity. All transplanted cell populations, from the most 
immature CD34+CD19low stage to the already more differentiated stage of 
CD19+CD20high cells were able to reconstitute the original ALL in mouse bone marrow 
and followed a typical dissemination pattern with infiltration of the spleen. Furthermore, 
this more mature CD19+CD20high subpopulation proved self-renewal ability in serial 
transplantation experiments. To investigate, whether stem cells in ALL are a rare entity 
or more abundant, unsorted bulk leukaemia blasts were transplanted in limiting dilutions 
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from 1 x 104 to 10 cells per mouse. Cell numbers required for engraftment varied 
between leukaemias but the leukaemia engrafted in mice when only 10 to 1,000 cells 
were transplanted. The limiting dilution experiments were repeated with sorted blast 
populations according to the surface antigens CD10, CD20 and CD34. Stem cell 
frequencies in all sorted populations were comparable and as few as 10 to 100 cells were 
sufficient to reconstitute the leukaemia in mice. 
Stem cells do not seem to be restricted to immature blast populations as in the 
hierarchical model but a broad spectrum of different blast immunophenotypes display 
stem cell capabilities. Furthermore, the frequency of stemness among unsorted bulk 
ALL cells as well as subpopulations of different maturity according to the blast 
immunophenotype is high and similar. The results from this thesis provide strong 
evidence for the stochastic cancer stem cell model in B precursor ALL. 
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Chapter 1: Introduction 
1.1 General Introduction 
Every year, one in 500 children under the age of 15 years faces the diagnosis of one 
form of cancer in the United Kingdom, which adds up to around 1,500 new cases per 
year. This accounts for only 0.5% of all cases of cancer in the whole population and 
therefore childhood cancer is a very rare disease compared to adulthood. Despite this 
low incidence it is the second most common cause of death after non-disease related 
death in the age group from 1 – 14 years, with nearly 300 children dying from cancer in 
the UK every year. The incidence (ratio of around 1.2:1) as well as the mortality (ratio 
of around 1.4:1) of malignancies is slightly higher in boys than in girls 
(CancerResearchUK, 2010).  
The most common types of cancer in children are leukaemias, accounting for 
approximately one third of childhood cancers. In contrast to adults the acute forms of 
leukaemias are far more common than the chronic forms. Acute forms are further 
classified according to their cell lineage into lymphoid and myeloid leukaemias. In 
children around 80% of the leukaemias are acute lymphoblastic leukaemias (ALL). 
Acute myeloid leukaemias (AML) account for approximately 15% and chronic myeloid 
leukaemias (CML) make less than 4% of all forms of leukaemia (Cancer Research UK 
2010). Today, with current multiagent chemotherapy regimens, overall long-term 
relapse-free survival of children affected by ALL is around 80% but within this group of 
leukaemias several cytogenetic subgroups have been described that correlate well with 
different prognostic outcomes (Möricke et al., 2008; Pui et al., 2004). In developed 
countries survival rates of affected children are still variable due to the distinct biologies 
rather than access to and use of modern treatment (Pui et al., 2002). ALL is the subject 
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of considerable research with more than 1,000 relevant papers released in 2010 (PubMed 
search: Acute lymphoblastic leukemia). However, continued research is necessary both 
to increase survival rates and reduce short and long-term toxic side effects. 
 
1.2 Acute Lymphoblastic Leukaemia 
1.2.1 Historical Background 
The first descriptions of alterations in the blood that retrospectively can be interpreted as 
leukaemias date back to the early nineteenth century. However, these observations 
published by Cullen in 1811, Alfred Velpeau in 1827, Alfred Donné in 1844 and David 
Craigie in 1845 were interpreted as inflammation with purulent cells in the blood by the 
authors. When David Craigie admitted another patient to the Royal Infirmary Edinburgh 
with similar symptoms as the patient he had described in 1845, a post mortem was 
carried out by the Scottish pathologist John Hughes Bennett and he was the first who 
concluded that the alterations in the blood and the spleen were independent of 
inflammation and were entities of their own. Only six weeks after Bennet´s publication 
in the Edinburgh Medical and Surgical Journal the German physician and pathologist 
Rudolf Virchow at the Charité in Berlin reported a similar patient in “Weisses Blut” 
with a history of weakness and bleeding and autopsy findings of an enlarged spleen and 
white blood corpuscles. In 1847 he eventually gave this disease the name Leukhemia, 
from the Greek words for white (leukos) and hemia (blood) (Piller, 2001). 
 
1.2.2 Classification of Leukaemias 
Leukaemias are characterised by the replacement of normal bone marrow by malignant 
blasts. The term blast refers to primitive precursor cells that show no or minimal signs of 
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differentiation. Leukaemias are principally categorised according to the lineage and 
stage of differentiation of the leukaemic cells that form the malignancy. Leukaemias can 
either arise from the lymphatic or the myeloid lineage of haematopoiesis and both can 
present as an acute form when immature haematopoietic or lymphoid precursors are 
involved or a chronic form when the clone consists of more mature cells. Today, 
morphology and cytochemistry have lost importance and immunophenotypic 
classification is leading the way to diagnosis of subtypes (Silverman, 2009). The World 
Health Organisation (WHO) regularly updates and publishes a comprehensive 
classification of tumours of haematopoietic and lymphoid origin according to their 
morphology, cytogenetics, immunology, cytochemistry and cytogenetics (Swerdlow et 
al., 2008). 
The following subchapters focus mainly on childhood B cell precursor (BCP) ALL that 
arise within the B lineage of lymphatic development. 
 
1.2.3 Epidemiology 
Leukaemias are the most common of all cancers among children under the age of 15, 
accounting for around one third (31%) of the approximately 1,500 yearly cases. Between 
1991 and 2000 on average 470 children per year were given the diagnosis Leukaemia in 
the UK of which 372 (79%) were of the acute lymphoblastic form. This results in an 
annual age-specific incidence of 36 childhood ALL cases in 1,000,000 in the UK. The 
peak incidence of the disease occurs in children aged 2 and 3 years and decreases after 
that. Comparable with childhood cancer in general, ALL more often affects boys than 
girls with a ratio of 1.3:1. Each year approximately 300 children under the age of 15 die 
from cancer in the UK. The 5 year event free survival (EFS) rate for children is now 
80% and the 5 year overall survival rate is close to 90%. However, because of the 
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relatively high incidence, leukaemia still is responsible for 30% of all deaths from 
cancer in children, being second only to deaths from tumours of the central nervous 
system (CNS, brain and spinal cord) (32%) (CancerResearchUK, 2010; Pui et al., 2010).  
In developed countries there are racial and ethnic differences in EFS of children with 
ALL. Treated using the same Children´s Cancer Group (CCG) therapeutic protocols in 
the USA, children of Asian origin had a significant better outcome compared to white 
children, while children from a black family background and of Hispanic origin did 
worse. So far the reasons for this remain unclear (Bhatia et al., 2002), even allowing for 
differences in socioeconomic status. It has been established that in developing countries 
there is a lower peak incidence of ALL in early childhood and this was thought to be due 
to lower socioeconomic status, although under-diagnosis cannot be excluded (Greaves et 
al., 1993; Stiller and Parkin, 1996). An interesting retrospective analysis from the Czech 
Republic was able to add more evidence to support the hypothesis that poor 
socioeconomic status is related to a reduced incidence of ALL. Hrusák and colleagues 
found a marked increase in the incidence of ALL among children 1 to 4 years old in the 
last two decades of the last century. This increase paralleled the improved 
socioeconomic status of the post communist countries in these years and was especially 
marked in girls (Hrusák et al., 2002). 
 
1.2.4 Clinical Presentation 
In general the presenting symptoms of patients with ALL are rather non-specific and are 
mainly caused by the rapid proliferation of the leukaemic blasts and the resulting effect 
on the different organs of the body. The clonal expansion of blasts in the bone marrow 
eventually leads to the suppression of normal physiologic haematopoiesis. As a result 
progressive anaemia causes fatigue and lethargy and patients may appear pale. 
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Neutropenia makes patients more susceptible to infections with concomitant fever, one 
of the most common presenting features. Children may show signs of bleeding and 
bruising as a consequence of thrombocytopenia. Other features are caused by 
dissemination of leukaemic blasts. Infiltration of the spleen and liver cause 
splenomegaly and hepatomegaly respectively and accumulation of blasts in lymph nodes 
leads to enlargement of mainly cervical and nuchal glands. Pain in the legs and a 
resulting refusal to walk or limping, mainly in younger children, is presumably caused 
by infiltration of bones and the periostium although this is not entirely proven. 
Involvement of the thymus and mediastinal lymph nodes is more common in T-cell ALL 
and can result in narrowing of the trachea or bronchi with dyspnoea whereas infiltration 
of mesenteric lymph nodes can potentially lead to obstruction of the bowels due to 
invagination and present with abdominal pain. Involvement of the CNS can be found in 
up to 20% of patients but only rarely causes clinical symptoms. If present, they include 
signs of raised intracranial pressure or cranial nerve palsies. Occasionally indolent 
swelling of the testes can be observed (Schrappe, 2005; Silverman, 2009).  
 
1.2.5 Prognosis 
1.2.5.1 Significance of prognostic factors 
Without therapy the outcome of all leukaemias in children is dire but treatment 
according to the current intensive multidrug chemotherapy regimens has led to an 
overall cure rate of ALL in children of over 80%. This stands in contrast to adult patients 
where only 40% to 50% of patients can be cured (Onciu, 2009; Pui et al., 2004). 
However, treatment outcome in ALL patients varies extensively and a number of 
significant clinical and biological prognostic factors have been established to separate 
leukaemias that fare better from those with a less favourable outcome. It is important to 
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note that any prognostic factor is established in the context of the specific treatment 
modalities applied at the time of observation and its significance regarding 5 year EFS 
may not be relevant in all regimes. An increasing number of prognostic factors are taken 
into account by current treatment protocols and are used to allocate patients to different 
treatment arms in clinical trials. With the intensified treatment regimens now in use the 
actual chance of survival for patients carrying adverse prognostic factors can be 
improved and be comparable to that of patients without these prognostic features in 
some cases (Möricke et al., 2008). 
 
1.2.5.2 Clinical prognostic factors 
Of clinical factors, the age at diagnosis and the presenting peripheral blast count are the 
strongest prognostic indicators. Children between 1 and 9 years of age have a better 
outcome than infants and children aged 10 years and above. Regarding the peripheral 
blast count it has been established that patients with counts of less than 50,000/µl have a 
more favourable outcome than patients with higher counts at presentation due to a 
smaller risk of relapse. Additionally, the detection of lymphoblasts in the cerebrospinal 
fluid at diagnosis is an adverse prognostic factor (Smith et al., 1996). The current 
UKALL 2003 trial and others use these National Cancer Institute (NCI) criteria for risk 
stratification. 
 
1.2.5.3 Immunophenotype as a prognostic factor 
Determining the immunophenotype still is very important in the process of establishing 
the diagnosis and classifies ALL into pro-B ALL, common ALL, pre-B ALL and T-cell 
ALL with significant differences in treatment outcome (Schrappe et al., 2000b). 
However, with advances made in cytogenetics immunophenotyping has lost some of its 
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independent prognostic value. Differences in outcome that were previously attributed to 
specific immunophenotypes now can more precisely be assigned to specific cytogenetic 
changes within the subgroups. In pre-B ALL the generally poorer outcome observed in 
earlier treatment studies was found to be caused by the cytogenetic subgroup of patients 
that carry the t(1;19) translocation (Crist et al., 1990). However, treatment intensification 
now results in an overall outcome for this subgroup comparable to that of the standard 
risk group (Kager et al., 2007; Schrappe et al., 2000a; Uckun et al., 1998). Conflicting 
reports were published regarding the prognosis of ALL with coexpression of myeloid 
cell surface antigens on the lymphoblasts. However, myeloid coexpression has been 
found more often in association with chromosomal translocations like the Philadelphia 
chromosome, MLL rearrangements and the ETV6/RUNX1 (TEL/AML1) fusion gene and 
is not considered to be of independent prognostic value outside the context of these 
cytgogenetic features anymore (Carbonell et al., 1996; Pui et al., 1998; Putti et al., 
1998). Cure rates in childhood T-cell acute lymphoblastic leukaemia historically were 
inferior to average rates but with intensified treatment EFS now is similar to patients 
with B-precursor ALL (Goldberg et al., 2003). 
 
1.2.5.4 Cytogenetic prognostic factors 
Chromosomal abnormalities have an important impact on the prognosis of ALL and are 
considered in risk stratification. They include gains or losses of parts or whole 
chromosomes or reciprocal translocations between two chromosomes and can be 
associated with either a good or a poor prognosis. 
ALL with high hyperdiploidy (blasts carrying 51 to 65 chromosomes) usually have a 
lower risk of relapse due to the high sensitivity of leukaemic blasts to chemotherapy, 
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especially Methotrexate, and a high tendency to undergo apoptosis. They comprise 
approximately 25% of childhood cases (Ito et al., 1999; Pui et al., 2004).  
The ETV6/RUNX1 (formerly known as TEL/AML1) fusion results from a balanced 
reciprocal translocation of the chromosomes 12 and 21 (t(12;21)) and is associated with 
an excellent treatment outcome of the affected 22% of paediatric ALL patients. ETV6 as 
well as RUNX1 code for genes of transcription factors which are involved in 
haematopoiesis and the fusion protein affects the self-renewal and differentiation ability 
of haematopoietic stem cells (HSC) (Loh et al., 2006; Pui et al., 2004). Interestingly, this 
translocation was found to arise prenatally as it could be detected in DNA isolated from 
blood spots of Guthrie cards but is not sufficient to cause malignant transformation on 
its own (Wiemels et al., 1999b). 
The Philadelphia chromosome (Ph) was the first specific genetic lesion identified in 
human cancers by Nowell and Hungerford and the first report of it being involved in 
ALL was published by Propp and Lizzi in 1970 (Nowell, 2007; Propp and Lizzi, 1970). 
This translocation between the chromosomes 9 and 22 (t(9;22)) consists of a fusion of 
the human homologue of the Abelson Murine leukaemia virus ABL1 (a tyrosine kinase) 
on 9q34 with the breakpoint cluster region BCR (a signalling protein) on 22q11 and an 
in-frame BCR/ABL1 fusion transcript leads to an upregulation of ABL activity. Three 
different breakpoints in the BCR gene result in three main BCR/ABL1 chimeric 
transcripts and the molecular masses of the protein products are 190, 210 and 230 kDa 
respectively. Three to 5% of children with ALL carry the Philadelphia chromosome with 
the majority expressing the p190 BCR/ABL1 protein, the constitutively activated 
tyrosine kinase (Jones and Saha, 2005). For leukaemic transformation, secondary 
oncogenic events in addition to the expression of the BCR/ABL1 fusion protein are 
necessary. The deletion of the IKZF1 gene with consecutive loss of function of the 
encoded Ikaros transcription factor, required in lymphoid development, has been found 
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in most B-precursor ALL as well as in CML during the phase of transition to lymphoid 
blast crisis and is assumed to be a cooperating oncogenic lesion. Less frequent deletions 
have been found of CDKN2A and PAX5 (Mullighan et al., 2008). On the basis of 
genome wide gene expression arrays, more recently, one subgroup of patients has been 
identified that clusters with BCR/ABL1 positive patients and also has an unfavourable 
prognosis. This subtype was called BCR/ABL-like ALL (Den Boer et al., 2009). 
Patients with Ph+ ALL are always generally allocated to the high risk treatment group 
but still have a poor survival of less than 50% (Pui et al., 2002; Schrappe et al., 1998a). 
A subgroup of ALL patients (2%) carrying an intrachromosomal amplification of 
chromosome 21 (iAMP21) resulting in additional copies of the RUNX1 gene has been 
recently identified and found to have a significantly higher risk of relapse. These 
patients are now stratified to the high risk treatment arm in the current UKALL 2003 
study and monitored if improved survival can be achieved with treatment intensification 
(Moorman et al., 2007). 
Another chromosomal abnormality associated with an unfavourable outcome in ALL 
consists of rearrangements of the MLL gene on chromosome 11, the most commonly 
found being t(4;11), t(11;19) and t(9;11) (Pui et al., 2004; Szczepański et al., 2010). 
MLL rearrangements occur in around 80% of infant leukaemias and only 30% to 40% of 
cases with this abnormality can be cured. Physiologically, MLL acts as a transcriptional 
repressor but in MLL rearranged cells, overexpression of HOXA5, HOXA9 and MEIS1 
can be detected by gene expression profiling and this is believed to play an important 
role in leukaemogenesis (Harper and Aplan, 2008). In contrast to the BCR/ABL1 
(t(9;22)) and the ETV6/RUNX1 (t(12;21)) fusions, rearrangements of the MLL gene 
seem to be sufficient for leukaemic transformation of haematopoietic cells without a 
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second leukaemogenic event (Clarkson et al., 2003; Krivtsov et al., 2006; Mori et al., 
2002; Szczepański et al., 2010; Wiemels et al., 1999a). 
 
1.2.5.5 Response to treatment 
The prognosis of a patient under current treatment protocols is highly dependent on the 
initial response to induction chemotherapy treatment. The morphologically identifiable 
persistence of blasts in peripheral blood one week into treatment has been shown to be 
an independent poor prognostic factor after administration of prednisone (and one dose 
of intrathecal Methotrexate) alone, as well as after one week of multidrug chemotherapy 
(Gajjar et al., 1995; Möricke et al., 2010). 
A more recently established highly predictive and independent prognostic marker for the 
risk of ALL relapse is the detection of sub-microscopic minimal residual disease (MRD) 
early in the course of treatment, at the end of induction treatment. Patients with a high 
MRD load have an unfavourable prognosis independent of other risk factors classically 
used for risk stratification. Several methods to detect very low numbers of residual blasts 
in the bone marrow have been developed. Multicolour flow cytometry detects blasts 
utilising the leukaemia specific immunophenotype while real-time quantitative 
polymerase chain reaction (RQ-PCR) detects leukaemia associated fusion gene 
transcripts or leukaemia specific immunoglobulin gene or T-cell receptor gene 
rearrangements. With these methods a sensitivity of up to one cell in 10-4 (3 to 4 colour 
flow cytometry) or 10-6 (RQ-PCR based methods) can be achieved. The ALL-BFM 2000 
protocol measured MRD levels at 33 and 78 days after start of treatment and used them 
for risk stratification for the first time. MRD of 10-3 or more at the later time point was 
classified as MRD high risk, negative MRD levels (10-4 or less) at both time points as 
MRD standard risk and levels in between as MRD intermediate risk. Applying this post-
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induction risk stratification had an excellent correlation with treatment outcome in the 
ALL BFM 2000 study and interestingly, MRD was able to discriminate the risk of 
relapse in subgroups defined by conventional stratification criteria and could 
additionally identify patients with favourable outcomes in patients with BCR/ABL1 
positive ALL, traditionally regarded as being at high risk for relapse (Conter et al., 2010; 
Szczepański, 2007). 
 
1.2.5.6 Clinical and treatment-induced complications and their impact on prognosis 
There are factors other than relapse or resistance to therapy that have an influence on 
survival. Massive accumulation of blasts in the vascular system and the effects of 
induction therapy are mainly responsible for deaths occurring early after diagnosis of 
ALL. Hyperleukocytosis with only poorly deformable blasts and counts higher than 100 
x 109 per litre can lead to increased viscosity of the blood and intravascular clumping. 
Resulting local hypoxaemia may lead to endothelial damage with the consequence of 
haemorrhage and infarction particularly involving the lungs and central nervous system 
(Nicolin, 2002). The tumour lysis syndrome is mainly treatment related but can occur 
spontaneously and is caused by the release of metabolites and electrolytes from dead 
blasts. Renal failure can result from crystallisation of uric acid and precipitation of 
calcium phosphate in renal tubules and life threatening arrhythmias can follow high 
serum potassium concentrations (Halfdanarson et al., 2006). During intensive 
chemotherapy treatment bacterial infections during phases of neutropenia pose the major 
threat of therapy related death. 
 
Chapter 1  1.2 Acute Lymphoblastic Leukaemia 
13 
 
1.2.5.7 Secondary malignancies 
Survivors of cancer face a higher risk of developing an unrelated form of malignancy 
than would be expected by chance alone. Chemotherapy, radiotherapy and genetic 
predisposition are thought to be the most important factors contributing to the increased 
risk. In children treated for ALL a significantly higher risk of developing a secondary 
AML has been recognised for over 20 years and is linked to the administration of the 
epipodophyllotoxins; Etoposide and Teniposide (Pui et al., 1991). Therapy related AML 
was also the most common type of secondary malignancies after treatment according to 
the ALL-BFM protocols, followed in frequency by neoplasms of the CNS, lymphomas 
and thyroid cancer. Overall, 15 years after initial therapy, children treated for ALL had a 
14-fold increased risk of developing cancer as compared to children not being treated for 
cancer before. Among those, patients treated with cranial radiotherapy had a higher risk 
for secondary cancers than non-irradiated patients (Löning et al., 2000). 
 
1.2.6 Therapy of acute lymphoblastic leukaemia 
Until the middle of the last century ALL was an inevitably lethal disease. The first 
complete, albeit only temporary, remission in a child with ALL was achieved by Farber 
and colleagues in 1947 by intramuscular administration of the folic acid antagonist 
aminopterin (Farber and Diamond, 1948). Following this several single agent therapies 
in the 1950s and early combination chemotherapies in the 1960s led to complete 
remissions but all failed to cure the disease and resulted in fatal relapse. With 
recognition of the CNS as a blast sanctuary site and the introduction of specific CNS-
directed treatment first cure rates of around 50% were eventually achieved in the 1970s 
(Silverman, 2009). Studies on cycling times of leukaemic cells in relation to normal 
haematopoietic cells and the finding that non-cycling blasts go into cycle as a response 
to chemotherapy led to elaborated time courses of combined antiproliferative 
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chemotherapy to increase the chance to hit all blasts in the vulnerable phase of cell 
division (Cheung et al., 1972; Lampkin et al., 1971; Rubinow and Lebowitz, 1976). All 
the main drugs that are still used in the treatment of ALL were already known to be 
effective in the 1950s (corticosteroids, 6-Mercaptopurine and Methotrexate) and 1960s 
(anthracyclines, Asparaginase and epipodophyllotoxins) but it was the introduction of 
consecutive large-scale multi-centre clinical trials that led to the great improvements in 
patient outcome. The main contributing factors to the increasing success rate of several 
treatment protocols in the next decades were the sophisticated design of complex 
multidrug chemotherapy regimens, the introduction and adaption of risk-stratified 
treatment arms, development of specifically CNS-directed compartment treatment and 
major improvements in supportive care. Risk-adapted regimens were continuously 
developed further, when new prognostic factors could be established that separated 
patients with successful treatment from those that relapsed. The ultimate goal of risk-
adapted regimens is to give patients with a low risk of relapse as little toxic 
chemotherapy as possible and high risk patients as intensive therapy as necessary to 
achieve the best possible 5 year EFS for all (Möricke et al., 2008; Silverman, 2009).  
Most contemporary paediatric protocols use the prognostic characteristics mentioned 
above for risk stratification. Once allocated to the different risk groups, treatment is 
usually given in four phases of remission induction, CNS-directed therapy and 
intensification or consolidation followed by less intensive and toxic, but longer, 
continuation or maintenance therapy.  
Remission induction therapy is designed to diminish the presenting tumour burden 
ideally to a morphologically and MRD undetectable level. Complete remission is 
achieved if the bone marrow consists of less than 5% blasts, no blasts can be detected in 
peripheral blood and CNS and if no localised disease can be detected. Drugs usually 
given in induction include a corticosteroid (prednisone or dexamethasone), Vincristine, 
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L-Asparaginase and an anthracycline (Möricke et al., 2008). Most children (>95%) 
achieve complete remission after induction therapy and induction failure mainly occurs 
in the high risk treatment groups (Oudot et al., 2008). CNS treatment is also started early 
in induction with intrathecal application of chemotherapy given at the first diagnostic 
lumbar puncture in order to prevent seeding of lymphoblasts from peripheral blood to 
the CNS (Gajjar et al., 2000). It was soon discovered that after successful remission 
relapse was often initiated from residual blasts in the CNS occupying a “pharmacologic 
sanctuary” where the blood-brain barrier prevents penetration of systemically 
administered chemotherapeutic drugs (Evans et al., 1970). The consecutive introduction 
of cranial radiation therapy and later combinational intrathecal compartment and high 
dose systemic chemotherapy greatly reduced treatment failure due to CNS relapse 
(Rivera et al., 1993; Schrappe et al., 2000b). Because of the serious side effects on IQ, 
growth, neuroendocrinology and the higher risk of radiation induced secondary 
malignancies, modern treatment regimens for B precursor ALL mainly use intensified 
systemic treatment including Methotrexate and Dexamethasone (with a better CNS 
penetration than Prednisone) in combination with frequent intrathecal therapy as an 
effective substitute for radiotherapy (Hill et al., 2004; Pui et al., 2003; Pui et al., 2010; 
Schrappe et al., 1998b). This CNS compartment treatment is mainly contained in 
intensification or consolidation phases of ALL treatment protocols. They are risk 
adapted and also aim to reduce the remaining leukaemic burden and to reach other 
sanctuary places like the testes and use drugs mainly identical to those used in the phase 
of remission induction. The intensive phases of treatment are followed by two to three 
years of lower dose continuation or maintenance therapy to further reduce the risk of 
relapse initiated by remaining blasts that possibly evaded the previous phases of 
chemotherapy (Eden et al., 1991; Möricke et al., 2010; Pui et al., 2010; Silverman et al., 
2010). 
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1.3 Haematopoiesis 
Leukaemias are non-epithelial cancers that arise from the haematopoietic system and 
cancer research has made huge progress by applying and investigating the concepts 
of physiological haematopoiesis to the malignant disease. Haematopoiesis describes 
the process by which all mature cell components (red cells, granulocytes, monocytes 
and lymphocytes) as well as platelets are generated. For learning more about the 
biology of any type of leukaemia it is essential to understand the process of 
physiological haematopoiesis first. It harbours a great potential to improve our 
knowledge about disease initiation and progression, cellular interactions, but also 
about possible relapse. Finally and most importantly the gained insights can 
potentially be exploited to develop better therapies in the future. Much about 
haematopoiesis has been learned from animal models as this process is highly 
conserved in vertebrate evolution (Orkin and Zon, 2008). 
 
1.3.1 Introduction to the haematopoietic system 
The corpuscular part of the blood system consists of three main components, red cells 
(erythrocytes), white cells (leukocytes) and platelets (thrombocytes). While the main 
function of red cells is the transport of oxygen to the different organs, the white cells are 
mainly involved in protecting the body from infections and the platelets have an 
invaluable impact in maintaining the integrity of the vascular system. Throughout life 
the homeostasis of blood formation needs to be maintained and every day an adult 
person approximately produces about 1012 blood cells of the different lineages (Dick, 
2003; Ogawa, 1993). As the terminally differentiated blood cells are relatively short 
lived, they constantly need to be replenished by stem cells. Therefore haematopoiesis is 
organised in a hierarchy. Rare haematopoietic stem cells (HSC) with long term blood 
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reconstituting capability (LT-HSC) reside at the top of this hierarchy and give rise to all 
blood cell lineages (Osawa et al., 1996). They produce haematopoietic stem cells with 
short term blood reconstituting capability (ST-HSC), also called multipotent progenitors 
(MPPs), which can still produce all lineages but already have limited self-renewal 
potential. They consecutively give rise to the lineage committed common lymphoid 
progenitor (CLP) cells and common myeloid progenitor (CMP) cells. At this point, 
myeloid and lymphoid development is thought to become separated and mutually 
exclusive (Akashi et al., 2000; Bryder et al., 2006; Kondo et al., 1997). However, one 
group has suggested the existence of an intermediate progenitor unable to undergo 
erythroid and megakaryocyte lineage differentiation, but still harbouring a combined 
lympho-myeloid differentiation potential and have named it the lymphoid-primed 
multipotent progenitor (LMPP) (Adolfsson et al., 2005). Extensive proliferation takes 
place during the progression of the progenitor cells through the hierarchy and while 
increasingly losing self-replicative capacity, they continue to differentiate to finally 
become effector cells. Terminally differentiated functional cells arising from the 
myeloid lineage comprise erythrocytes, neutrophilic, eosinophilic and basophilic 
granulocytes, monocytes and macrophages, mast cells and thrombocytes (cell fragments 
of perisinusoidally located megakaryocytes that are sequestered into the vasculature). 
The lymphoid lineage results in B- and T-lymphocytes and natural killer (NK) cells 
(Schrappe, 2005). 
Figure 1 depicts a schematic model of the process of sequential differentiation and 
increasing commitment of the progenitor cells starting with the HSC and eventually 
leading to terminally differentiated mature blood effector cells. 
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Figure 1: Simplified model of haematopoietic development. Long-term HSCs stand at the apex of 
the haematopoietic hierarchy. In a stepwise differentiation process, developing cells become more 
lineage committed and progressively lose the ability to self-renew to finally become postmitotic 
effector cells. Only lymphocyte lineages retain the ability for clonal expansion. 
HSC, haematopoietic stem cells; MHP, multipotent haematopoietic progenitor; LMPP, lymphoid-
primed multipotent progenitor; CMP, common myeloid progenitor; CLP, common lymphoid 
progenitor; MkEP, megakaryocyte-erythroid progenitor; GMP, granulocyte-macrophage progenitor. 
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1.3.2 Haematopoietic stem and progenitor cells 
1.3.2.1 Origin of haematopoietic stem cells 
Haematopoietic stem cells belong to the group of pluripotent adult stem cells and are, 
due to relatively easy accessibility, probably the best characterized in the field of stem 
cell biology. Much of the origin of haematopoietic stem cells has been learned from 
animal models. The first haematopoietic stem cells are descendents of the 
haemangioblast which itself originates from mesodermal precursor cells and migrate to 
the yolk sac where they initially form “blood islands” of primitive erythroid cells 
followed by precursors of the other blood cell lineages. Whether the progenitor cells of 
the extraembryonic yolk sac contribute to definitive adult haematopoiesis via seeding 
into the embryo is yet unclear. Early intraembryonic haematopoiesis occurs in the aorta-
gonad-mesonephros (AGM) and progenitor cells from this region migrate to the fetal 
liver where they expand and from there finally to the fetal bone marrow, the 
physiological site of the adult HSC pool and definitive haematopoiesis (Huang et al., 
2007; Orkin and Zon, 2008).  
 
1.3.2.2 Defining properties of haematopoietic stem cells 
In a recent study, the frequency of haematopoietic stem cells, defined as 
CD34+CD90+CD38-CD45RA-CD10- was determined as lying between 0.001 and 0.01% 
(Kuranda et al., 2011), which actually is very similar to findings of the first attempts to 
quantify HSC more than 50 years ago (Till and McCulloch, 1961). This very small 
number of multipotent HSC needs to replace all terminally differentiated and postmitotic 
cells of the blood system during the entire life without being depleted themselves (Dick, 
2003). Therefore these stem cells must combine two apparently conflicting properties 
which had already been recognised by Till et al. in the early 1960s. They must be able to 
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give rise to all lineages of the committed progenitors and finally mature effector cells 
and at the same time they must be able to maintain or even expand their own pool of 
multipotent and undifferentiated adult stem cells (Till and McCulloch, 1961; Till et al., 
1964). To meet both criteria of differentiation and self-maintenance, stem cells have one 
outstanding characteristic; they are able to undergo asymmetric as well as symmetric 
cell division. In a steady state haematopoietic situation with constant replenishment of 
terminally differentiated blood cells, HSC usually perform asymmetric cell divisions 
with one daughter cell adequately replacing the stem cell that underwent division and the 
other daughter cell pursuing the path of exponential proliferation and differentiation. A 
symmetric division on the other hand can drive in two directions. It can either result in 
two daughter cells identical to their ancestor which leads to expansion of the stem cell 
pool or the generation of two multipotent progenitor cells (MPP) which inevitably will 
lose stem cell characteristics and become committed to differentiation (Ho, 2005; 
Warren and Rossi, 2008). The latter decision of a stem cell will lead to a diminished 
total number of stem cells but growth in early life, haematologic stress and regeneration 
make it necessary to shift the balance towards symmetric cell division. The process of 
asymmetric cell division was elegantly demonstrated in human haematopoietic 
progenitor cells by Leary et al. (Leary et al., 1984; Leary et al., 1985). The different 
options of cell divisions in stem cells are illustrated in Figure 2. 
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Figure 2: Haematopoietic stem cell division options. a) Symmetric stem cell division with both 
daughter cells retaining stem cell properties resulting in expansion of the stem cell pool. b) 
Asymmetric stem cell division with one daughter cell remaining a stem cell and the other becoming a 
committed progenitor cell resulting in tissue homeostasis. c) Symmetric stem cell division into two 
committed progenitor cells resulting in stem cell depletion and extinction of the clone. 
 
Although the ability of HSC to self-renew is often described as unlimited, this may not 
be true. As differentiated mature blood cells still need to be replenished throughout life, 
stem cells must be available at all times to give rise to these progeny effector cells 
(Warren and Rossi, 2008). Therefore it was proposed by Kay that most HSC within the 
bone marrow lie dormant in a non-cycling state and only enter the cell cycle in the 
manner of a clonal succession, once previously cycling stem cells were depleted (Kay, 
1965). However, a recent study using clonal tracking of presumed HSC in a murine 
a)
b)
c)
Stem cell Progenitor cell Self-renewal ability
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model could not support this hypothesis but suggested that individual HSC may 
contribute to haematopoiesis throughout life (McKenzie et al., 2006). 
In summary, the two main properties of HSC, self-renewal and differentiation, enables 
them to maintain the entire haematopoietic system throughout life. 
 
1.3.2.3 Characteristics of haematopoietic stem and progenitor cells 
The low cycling frequency allows the stem cell to maintain its genomic integrity to a 
great extent as replication of DNA during the process of cell division and therefore the 
risk of mitosis associated mutation, are reduced. The G0 phase of the cell cycle is also 
associated with a low rate of metabolism and therefore a reduction of exposure to 
metabolic products or reactive oxygen species. Lineage committed precursor cells have 
a great proliferation potential but progressively lose the ability to self-renew and the 
main expansion of blood cells takes place in this compartment (Bryder et al., 2006). 
Committed precursor cells, however, eventually result in non-proliferating and 
differentiated cells and for this reason are thought to have a lower chance of 
accumulating cancer initiating mutations (Dick, 2003). In contrast, despite the low 
proliferative pressure with infrequent cell divisions, the longevity of stem cells and their 
capability to self-renew makes them an ideal collector of the multiple genetic hits that 
usually are involved in the process of oncogenesis. The rising incidence of 
haematological cancers with age supports this assumption (Warren and Rossi, 2008). 
 
1.3.2.4 The haematopoietic stem cell niche 
Definitive adult haematopoiesis is a dynamic process and mainly takes place in the bone 
marrow. Only at times of haematopoietic stress, the liver and the spleen can serve as 
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alternative sites of blood production (Kiel and Morrison, 2008). The homeostasis of the 
defining properties of self-renewal and differentiation needs to be tightly regulated and 
this is the function of the stem cell niche (Orkin and Zon, 2008). The niche is a 
specialised supportive and regulatory microenvironment, which, through cell to cell 
interaction regulates the balance of self-renewal, differentiation and quiescence. The 
concept of a niche composed of differentiated somatic cells, extracellular matrix and the 
stem cells themselves as well as part of their progeny was first proposed by Schofield in 
1978 (Eckfeldt et al., 2005; Schofield, 1978). Under normal physiological conditions the 
niche provides an environment that predominantly inhibits both proliferation and 
differentiation although it provides proliferating signals intermittently to support tissue 
regeneration (Li and Neaves, 2006). The inner surface of the bones, the bone marrow 
endosteum, with its osteoblasts, osteoclasts and dense vascularisation has long been 
thought to play a major part in providing the HSC niche (Gong, 1978). Osteoblasts 
secrete the soluble and diffusible factors angiopoietin and thromopoietin that trigger 
quiescence of the stem cells and also the stromal-cell derived factor (SDF)-1 (often 
referred to as chemokine ligand CXCL12) which is involved in migration and homing of 
stem cells to the bone marrow (Kiel and Morrison, 2008; Kollet et al., 2002). However, 
osteoblasts are not the only source of these factors and they could as well diffuse from 
other sites of production to the bone marrow (Kiel and Morrison, 2008). Furthermore, 
whether or not N-cadherin is necessary for anchoring stem cells to the osteoblasts 
remains unclear. Even specific signalling pathways in HSC like the notch pathway that 
is activated by Jagged1 produced by osteoblasts and together with WNT-signalling 
supports self-renewal and inhibits differentiation, do not seem to be crucial for stem cell 
maintenance. Osteoclasts seem to play a role as well. Their proteases can release growth 
factors like stem cell factor (SCF) from membranes and extracellular matrix and also 
remodel bone to provide space for the niche (Duncan et al., 2005; Kiel and Morrison, 
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2008). The observation that extramedullary tissues like the liver and the spleen can take 
over or contribute to haematopoiesis, suggests that osteoblasts and osteoclasts are not the 
only cell types that can provide a suitable niche. SDF-1/CXCL12-secreting perivascular 
reticular cells and mesenchymal progenitors that additionally produce angiopoietin, 
together with endothelial cells of sinusoids and megakaryocytes are believed to provide 
such an environment outside the bone marrow. However, they also can be found within 
it and adult HSC have been localised in their immediate vicinity. As the endosteum is 
very well vascularised, the endosteal and the vascular niche may well not be 
independent or clearly separated entities and it is entirely possible that they indeed form 
a common niche with a contribution of all cells to stem cell maintenance, differentiation 
and localisation (Kiel and Morrison, 2008; Lo Celso et al., 2009). 
 
1.3.3 CD surface antigens and haematopoietic hierarchy 
During the development from the haematopoietic stem cell to the various effector cells, 
the progenitor and precursor cells pass through several maturation stages in a multistep 
differentiation process. It was only possible to unravel this differentiation pathway by 
finding ways to precisely separate cells of one defined developmental step from the ones 
further upstream and downstream. Furthermore, if biological or pathobiological 
properties and functional behaviour is to be addressed within distinct cells of this 
hierarchical haematopoietic system or within blasts of the supposedly related 
leukaemias, means to differentiate and physically separate discrete populations from the 
whole is indispensable. Morphology only very roughly allows categorisation into earlier 
and more mature cells but every cell displays an abundance of cell surface antigens, 
which now can be exploited for deeper characterisation. The cluster of differentiation 
(CD) antigens are a heterogeneous group of molecules (proteins, glycoproteins and 
glycolipids) first described on leukocytes and often involved as receptors or ligands in 
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cell signalling or in cell adhesion. Each subset of leukocytes exhibits a unique 
combination of these epitopes. Specific monoclonal antibodies (mAb) have been 
developed to bind these antigens. Binding of these antibodies can be used to estimate the 
number of cells in a mixed population bearing a specific CD antigen and also to measure 
the amount of it on individual cells (Mason et al., 2002; Zola, 2006). 
Methods also have been developed to separate cell populations according to their CD 
surface antigen pattern and fluorescence activated cell sorting (FACS) uses specific 
antibodies conjugated with a fluorescent dye to purify cells with the same expression 
level of these markers. Usually combinations of several markers are necessary to 
identify distinct cell populations and this is possible by using different fluorescent dyes 
bound to different mAbs. 
Within the haematopoietic hierarchy, expression profiles for CD antigens are well 
defined for different subpopulations and progressively change during maturation. By 
analogy, the same marker combinations are used in malignancies of haematopoietic 
origin to identify subpopulations and to position them in a hypothetical corresponding 
malignant hierarchy. 
 
1.3.3.1 B-cell differentiation 
Like all other cells of the haematopoietic system, B lymphocytes are developed from the 
haematopoietic stem cell through multiple steps of differentiation. Mature B cells have 
to recognise an enormous number of antigens not innate of its own organism to 
ultimately protect the body from infective agents. For this purpose a broad repertoire of 
immunoglobulin antigen receptors is created by gene rearrangements in the 
immunoglobulin (Ig) heavy (H)- and light (L)-chain during the process of B cell 
differentiation. Every step of this complex process can be separated in a time response or 
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developmental manner and the distinct subpopulation of B lineage committed cells 
identified by the state of IgH and IgL rearrangements can then be correlated with the 
expression profile of CD surface antigens (Ghia et al., 1998; Noordzij et al., 2002b).  
B cell development is initiated when multipotent CD34+/lin- (CD3/13/19/33/56-) cells 
commit themselves to become pro-B cells. Only at that stage in the hierarchical 
development of B cells the immunoglobulin recombination machinery is first activated 
and creates double strand (ds) DNA breaks between segments of the IGH loci, which it 
then re-ligates in the following steps of nonhomologous end joining (NHEJ). Pro-B cells 
are the earliest cells in the B cell lineage and can be characterised by the surface 
expression of CD34 and CD22 but not yet CD19. These pro-B cells initiate gene 
rearrangements between the genes for the diversity (D) and joining (J) segments of the 
immunoglobulin heavy chain but they do not start rearranging the variable (V) segment 
to the DJ rearranged segment. In the next step of differentiation pro-B cells progress to 
pre-B-I cells with expression of the specific marker profile CD34+CD19+CD10+CD20-. 
At this level of maturation rearrangements, still only within the IGH locus, between the 
already existent DJH segment and the VH segment are first observed and the DH to JH 
rearrangements decline in percentage. When pre-B-I cells move forward in the B-cell 
hierarchy they emerge as pre-B-II large cells which undergo some cycles of proliferation 
mediated by a pre-B-cell receptor (BCR) formed by the already completed heavy chain 
together with a surrogate light chain. These large cycling pre-B-II cells are now devoid 
of CD34 and are characterised by the distinct immunophenotype CD34-
CD19+CD10+CD20dim. When the pre-B-II large cells give rise to the pre-B-II small cells, 
they lose the only low expression of CD20 and become CD34-CD19+CD10+CD20-. At 
this phase of B-cell development, pre-B-II small cells begin with IgL gene 
rearrangements between the V and J segments of the IGK and the IGL loci respectively. 
In the case of successful expression of a functional Ig light chain a surface membrane 
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immunoglobulin, the complete B cell receptor, is formed together with the IgH chain 
and displayed on immature B cells. The CD20 antigen is now highly up-regulated and 
the immature B cell defining surface marker pattern is CD34-CD19+CD10+CD20+. Only 
non-autoreactive immature B cells finally leave the bone marrow and home to peripheral 
lymphatic organs as naive mature B cells that lose CD10 expression (Galy et al., 1995; 
Hystad et al., 2007; LeBien, 2000; Loken et al., 1987; van Zelm et al., 2005).  
This B cell development is described as being linear in the cited publications. However, 
recent work by Sanz and colleagues suggests parallel but distinct developmental 
pathways of first pre/pro CD34+CD10-CD19+ and then CLP/early-B CD34+CD10+CD19- 
cells from CD34+CD10-CD19- stem cells, at least in cord blood (Sanz et al., 2010). 
 
 
Figure 3: CD surface antigen expression during B cell development. The stem cell marker CD34 
is expressed on HSC´s but also retained in B lineage committed cells up to the pre-B-I developmental 
stadium. Of surface markers restricted to B cell development in the haematopoietic hierarchy, CD10 
expression only slightly precedes first expression of CD19 but disappears on mature B cells while 
CD19 remains positive. CD20 shows the latest appearance of these markers with expression initiated 
only at the level of pre-B-II large cells. CD20 as well is found on mature B cells. 
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1.3.3.2 CD10 
The CD10 surface antigen was first described by Greaves and co-workers in 1975 in an 
attempt to produce antisera in rabbits that would be able to reliably differentiate between 
ALL and other types of leukaemia or normal cells respectively. Their efforts resulted in 
antisera that were reactive to a large subgroup of ALL but only very few other types of 
leukaemia and it was assumed that it probably could define an antigen relatively specific 
to ALL. However, binding to a small number of cells in adult bone marrow and spleen 
as well as in fetal liver was observed as well (Greaves et al., 1975). Later, when 
monoclonal antibodies against CD10 could be produced, the expression of CD10 on B-
lineage ALL was confirmed and evidence was provided that the original rabbit 
antiserum, despite being polyclonal and containing antibodies to other cell surface 
antigens, indeed recognized the CD10 molecule (Greaves et al., 1983; LeBien and 
McCormack, 1989).  
Because of the widespread reactivity with ALL, this antigen was first named common 
ALL antigen (CALLA) It was subsequently given the cluster of differentiation number 
10 during the first international workshop on human leukocyte differentiation antigens in 
Paris 1982 (Bernard and Boumsell, 1984). Clinically, the subgroup of ALL expressing 
CALLA and therefore termed common ALL (cALL), soon was associated with a better 
prognosis in comparison to other types of ALL (Greaves, 1981). 
The initial observation that the anti-CD10 rabbit antiserum reacted to very few normal 
lymphoid bone marrow cells strongly suggested the origin of ALL in normal lymphoid 
progenitor cells (Hokland et al., 1983; Janossy et al., 1979). As a consequence, using 
this new marker, CD10 expressing lymphoid cells could be further analysed. It was 
found that CD10+ lymphoid cells represent early stages of B cell development and they 
only represented a very small part of the B lineage population (<1% of bone marrow 
cells). Under further scrutiny they always co-expressed CD19 and subpopulations also 
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CD34, but mostly not CD20, which could be detected on more mature cells that already 
presented IgM on the cell surface (Loken et al., 1987; Ryan et al., 1986). Mature 
peripheral blood B cells were found to be devoid of CD10 surface antigen (Stashenko et 
al., 1981). Today, CD10 is a well established marker in lymphoid development used in 
many studies. Recently it was established by Ichii and co-workers that differentiation 
potential is increasingly lost with up-regulation of CD10 expression in B lymphoid 
development but that strict B lineage commitment occurs only in CD34+CD10high cells, 
whereas CD34+CD10low cells still harbour some myeloid differentiation potential (Ichii 
et al., 2010). 
Expression of CD10 is not restricted to the haematopoietic system and the related 
leukaemias and lymphomas but has also been detected in several other tissues and 
cancers (LeBien and McCormack, 1989). Regarding its function, CD10 was found to be 
identical to neprilysin, a zinc metalloendopeptidase on the cell surface. It hydrolyses 
regulatory oligopeptides and thereby terminates their function of initiating intracellular 
signalling (Turner et al., 2001). 
 
1.3.3.3 CD19 
Early in the 1980s CD19, then known as B4 or Leu-12, was characterised as a 
glycoprotein being expressed uniformly and specifically throughout B-cell development 
from the earliest stages to mature B cells. Resting as well as activated B lymphocytes are 
CD19+ and the expression is not lost when B cells terminally differentiate and become 
plasma cells. It was also found on B lymphoid derived malignancies but neither on 
normal and activated T lymphoid cells and their malignant counterparts nor on other 
haematopoietic cells (Harada et al., 1993; Hokland et al., 1983; Meeker et al., 1984; 
Stamenkovic and Seed, 1988). Indeed, lymphoid progenitor cells with the 
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immunophenotype CD34+CD10+CD19- are still not completely B lineage restricted and 
are able to additionally generate T cell progeny, dendritic cells and natural killer cells 
(Galy et al., 1995; Hystad et al., 2007; LeBien, 2000). 
CD19 plays an important role in the generation of germinal centres and in antibody 
production after contact to antigens as demonstrated in CD19 deficient mice that failed 
to do so (Carter and Myers, 2008). Hypogammaglobulinaemia was also found in patients 
carrying homozygous mutations in the CD19 gene that resulted in lack of CD19 antigen 
display on the cell surface (van Zelm et al., 2006). On mature B lymphocytes CD19 
usually is present in a complex with CD21, CD81 and CD225 which is involved in the 
activation of B cells. When it co-ligates with the B cell receptor it significantly decreases 
the threshold for B cell activation upon antigen contact. This enables B lymphocytes to 
respond to very low concentrations of antigens and through that the highly specific BCR 
gains a high sensitivity (Carter and Fearon, 1992; van Zelm et al., 2010). 
 
1.3.3.4 CD20 
CD20 or formerly named B1 and Leu-16, is a marker recognised to be expressed only on 
later stages in B-cell development and is retained on mature peripheral blood B 
lymphocytes. Pre B II cells are the first that initiate display of CD20 on their cell 
membrane and expression reaches the highest levels on immature B cells. However, 
when peripheral B lymphocytes are activated and develop into terminally differentiated 
and Ig-secreting plasma cells, CD20 expression usually disappears (Harada et al., 1993; 
Noordzij et al., 2002a; Stashenko et al., 1981). CD20 is a phosphoprotein and like 
CD19, it is exclusively found on members of the B cell lineage. Studies with blocking 
antibodies to CD20 provided some evidence that it is involved in B cell activation and 
differentiation (Tedder et al., 1985). The natural ligand of CD20 is not known but 
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employing monoclonal antibodies it was suggested that it can serve as a calcium channel 
and probably is involved in intracellular signalling and also has effects on the cell cycle 
(Bubien et al., 1993; Kanzaki et al., 1995; Perosa et al., 2010). However, in a murine 
model, lack of CD20 surface expression in CD20-/- mice did not have a major effect on 
B cell function (Uchida et al., 2004). 
With its specificity to the B lineage and expression on mature B lymphocytes, the CD20 
surface antigen constitutes an effective target for mAbs and these are now widely 
applied in immunotherapy of autoimmune diseases as well as in oncology (Oflazoglu 
and Audoly, 2010; Perosa et al., 2010). 
 
1.3.3.5 CD34 
The surface glycophosphoprotein CD34 (in earlier publications termed My10) is one of 
the most important marker proteins in haematopoietic stem cell research. CD34+ 
populations clearly contain rare haematopoietic stem and progenitor cells with long-term 
repopulating ability but lineage committed progenitors progressed further down in the 
haematopoietic hierarchy and mature blood cells are CD34 negative. In normal bone 
marrow, only 1.5% of all low density mononuclear cells (MNCs) are CD34 positive 
(Krause et al., 1996). However, expression is not restricted to early haematopoietic cells. 
CD34 is also expressed in the vascular endothelium, not only in adults, but already in 
endothelial cells of the yolk sac and the aorta-gonad-mesonephros region of the 
developing embryo. Furthermore, the presence of CD34 antigen on some subsets of 
stromal progenitor cells of the bone marrow, the muscle and the placenta suggests that at 
least some mesenchymal stem cells are part of the CD34+ population (Furness and 
McNagny, 2006). 
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The function of CD34 still remains largely unknown or controversial. Its expression in 
non-quiescent activated haematopoietic precursor cells may suggest that it plays a role in 
supporting proliferation and impeding differentiation. It also has been implicated in 
leukocyte migration and homing of progenitors to the niche and this characteristic was 
connected to the pro-adhesive properties of the molecule (Furness and McNagny, 2006; 
Krause et al., 1996). 
As the CD34 antigen is expressed on early haematopoietic stem and progenitor cells, it 
was not too surprising to discover that the CD34+ cell fraction was capable of 
reconstituting and maintaining the haematopoietic system, first in animal models and 
then in humans. This knowledge led to important and now routinely used clinical 
applications. CD34 usually is not expressed in solid tumours and sorted CD34+ 
haematopoietic cells that are purged of tumour cells can be used for autologous bone 
marrow transplantation in patients that have undergone myeloablative high dose 
chemotherapy (Berenson et al., 1991). In diseases of the haematopoietic system itself, 
haematopoietic cells enriched in CD34+ progenitors are used for allogeneic 
transplantation (Krause et al., 1996). 
However, haematopoietic stem cell characteristics do not seem to be exclusively 
confined to CD34+ cell populations, although this was first thought to be the case. 
Initiation of long-term lympho-myeloid reconstitution has also been demonstrated in 
very rare CD34-c-kit-Sca-1-Lin- cells in mouse to mouse transplantation experiments 
(Osawa et al., 1996) and following this also in xenotransplant mouse models for human 
cells with the immunophenotype Lin-CD34-CD38- (Bhatia et al., 1998; Wang et al., 
2003). Interestingly, the surface expression of CD34 on reconstituting human HSC 
seems to be reversible to some extent. This has been demonstrated by Dao et al by 
showing that in a first round of xenotransplantation primary human bone marrow CD34+ 
cells can convert to CD34- cells that do have long-term repopulating capability and 
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themselves give rise to CD34+ progeny in a secondary round of transplantation (Dao et 
al., 2003). However, as proved by years of successful clinical SCT with longterm 
haematopoietic reconstitution from purified CD34+ cells, HSCs certainly are enriched in 
the CD34+ subfraction and CD34- stem cells are only detected in Lin- and CD38- CD34- 
cells but not in CD34- cells that are further down of CD34+ cells in the haematopoietic 
hierarchy which make up for the vast majority of CD34- cells. Furthermore, as 
determined by limiting dilution experiments, SCs seem to be a very rare entity (one in 
125,000) within the Lin-CD34-CD38- fraction (Bhatia et al., 1998). 
 
1.3.3.6 CD38 
CD38 is a surface glycoprotein that, unlike CD19 and CD20, is not restricted to the B 
lineage and can also be found on other blood cells including T lymphocytes, NK cells, 
monocytes, myelocytes, red cells and platelets as well as on cells of various solid tissues. 
CD38 is multifunctional; it can function as an ectoenzyme and is involved in the 
degradation of NAD+ by hydrolysis and can act as a receptor and in cell-to-cell 
adhesion. Because of the two latter properties and the finding that its ligand, CD31, is 
mainly expressed on vascular endothelial cells, it has been connected with lymphocyte 
transendothelial trafficking and migration. CD38 seems to have contrasting impacts on 
cells of the B lineage. While ligand activation of the receptor initiates proliferation in 
mature splenic B lymphocytes, it signals towards apoptosis in immature bone marrow B 
cells (Deaglio et al., 2001). 
As CD38 is displayed on cells of the blood system, the differential degree of its 
expression has also contributed to elucidation of the haematopoietic hierarchy. However, 
the expression pattern in physiological haematopoiesis is somewhat different to other 
markers; CD38 is not displayed over a continuous time span of development but has its 
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first appearance at the level of normal multipotent progenitors before it disappears until 
the level of mature lymphocytes, where it is expressed again. The highest surface density 
in the B cell lineage is found after differentiation to plasma cells (Malavasi et al., 2008; 
Ramos et al., 2010). 
It was first shown by Dick´s group in Toronto that the CD34+CD38- bm cell fraction is 
able to reconstitute the haematopoietic system (Bhatia et al., 1997; Larochelle et al., 
1996) and later, using CD38 as a marker for sub classification of human CD34+ 
haematopoietic cells it was possible to functionally separate different stages of 
maturation. Hogan and colleagues demonstrated that CD34+CD38- cells were able to 
repopulate NOD/SCID mice and maintain haematopoiesis of human origin for more than 
20 weeks, while haematopoietic reconstitution from CD34+CD38+ cells was short lived 
(Hogan et al., 2002). 
 
1.4 Cancer stem cells 
1.4.1 Definition 
With a growing body of evidence emerging that, at least in some forms of cancer, only a 
small number of cells within the tumour harbour the ability to sustain the cancer, this 
subset of cells has gained a lot of attention. It was self-evident that these cells needed to 
be the target of any efficient cancer therapy that aimed at eliminating the possibility of 
relapse. These cancer stem cells would be functionally analogous to physiological stem 
cells. To compare the work published on cancer stem cells made it necessary to find a 
consensus definition regarding the exact properties of this subset of cells. For this 
purpose a group of specialists in the field formed a workshop on cancer stem cells at the 
meeting of the American Association for Cancer Research in Lansdowne, Virginia, USA 
in 2006. Cancer stem cells were defined as the cells within a tumour that have a) self-
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renewal capacity and b) were able to generate the heterogeneous lineages of cancer cells 
present in tumours Although it was noticed that normal stem cells with their inherent 
capacity to self-renew were the ideal object of malignant transformation, it was stated 
that cancer stem cells could also evolve from progenitor cells that re-acquired self-
renewal properties. It was also clarified that cancer stem cells must contain not only the 
ability to proliferate but in fact have the capacity of symmetrical or asymmetrical self-
renewing cell divisions like their normal counterparts in non-cancerous tissues (see 
Figure 2) (Clarke et al., 2006). 
 
1.4.2 The history of cancer stem cell research 
Already with the relatively rough means of staining techniques and light microscopy 
alone it has been noticed, that most malignancies, haematological and solid tumours 
alike, are not a homogenous assembly of completely identical cells but rather consist of 
cell types with significantly differing morphology. In epithelial cancers, blasts even 
seemed to resemble various differentiation stages of the normal corresponding tissue. 
This was thought to be caused by the influence of the microenvironment and the cancer 
inherent genomic instability on the actual phenotype of different cells within the tumour 
(Clarke et al., 2006).  
Malignancies were for a long time thought to be caused by transmissible agents, namely 
viruses and therefore any cell transduced by such a vector would be expected to be 
imbued with the same ability regarding initiation and maintenance of abnormal and 
uncontrolled proliferative growth, the main characteristic of cancer. With the 
development of the first murine in vivo assays, huge and rapid progress regarding 
research into the functional biology behind the morphologic heterogeneity of normal and 
malignant tissues was initiated. Remarkable work in this field was conducted by Furth 
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and Kahn and published in 1937. They used inbred and therefore largely syngenic mice 
for their experiments, thereby elegantly overcoming immunologic barriers that 
inevitably negatively effect any functional in vivo assay. From murine leukaemic 
tumours that were initiated by subcutaneous inoculation of leukaemic blasts they 
produced single cell suspensions and transplanted those subcutaneously, 
intraperitoneally or intravenously into inbred sister mice. Using two different mouse 
leukaemias they were able to successfully initiate the original disease in 5 out of 97 mice 
transplanted intravenously with a single cell only. Aliquots with crushed cells from their 
cell suspensions, in contrary, were not able to reconstitute the leukaemia in mice and 
they concluded that live cells rather than cell free agents were essential to transmit the 
leukaemia (Furth and Kahn, 1937). 
With their experiments they not only showed that it is blasts from which the leukaemia 
is recapitulated in the host but they made another important observation; not every cell 
seemed to be capable of transferring the disease but only a low percentage has this 
ability, an important contribution towards the hypothesis of functional heterogeneity 
within malignancies. Following this seminal publication, further evidence of functional 
heterogeneity accompanying the morphologic heterogeneity arose from several 
publications. Hewitt et al performed experiments with a mouse lymphocytic leukaemia 
that they transplanted intraperitoneally on inbred mice and confirmed that acellular 
suspensions could not re-establish a leukaemia and that leukaemia growth could not be 
initiated by every cell (Hewitt, 1958).  
Similar experiments were also performed using isolated rat sarcoma cells. Single cells 
from these solid cancers could grow tumours following intraperitoneal inoculation but 
the success rate varied considerably. Furthermore, serial transplantations were conducted 
and chromosomal characteristics of the tumours were compared between the different 
generations and the original tumour. While the initial tumour contained cells with 
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various chromosome constitutions, the tumours grown from single cells exclusively 
showed one distinct set of chromosomes that was maintained over several transplant 
generations (Makino, 1956; Makino and Kano, 1955). These experiments proved self-
renewal abilities of the transplanted cells and also suggested that different subsets of 
tumour cells were able to reconstitute the sarcoma. 
Other groups followed another in vivo approach to assess the biology of normal and 
tumour growth. After Till and McCulloch developed their quantitative spleen colony 
forming assay in sub-lethally irradiated mice and first determined the frequency of HSC, 
this assay was soon adapted and applied to malignancies as well (Till and McCulloch, 
1961). Bruce and van der Gaag transplanted lymphoma cells from several mice with 
spontaneous lymphomas into irradiated and non-irradiated host mice and found a range 
of 100 to 100,000 cells being necessary to result in one colony per spleen (Bruce and 
Van Der Gaag, 1963).  
The single cell transplantation assays and the spleen colony forming assays, both of 
normal and malignant cells, provided strong evidence that only a small minority of cells 
had the capability to transfer tumour growth on host animals. The serial transplantations 
additionally demonstrated the self-renewal capacity of the transplanted cells. It was the 
work of these groups that founded the first body of evidence for the concept of cancer 
stem cells. 
In addition, in the 1960´s Pierce and colleagues observed that in teratocarcinomas, 
embryonal carcinoma cells were able to differentiate into mature postmitotic and 
therefore benign tissues. They understood that this type of carcinoma was organised in a 
hierarchy with the embryonal cancer cells at the apex and proposed the concept that 
cancers mimic physiological tissue proliferation and differentiation, in which regulation 
is deregulated (Pierce and Speers, 1988; Pierce and Verney, 1960). 
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Further progress in CSC research was made with another approach. In 1946 Belanger 
and Leblond developed a method for the direct experimental visualization of a 
hierarchical organization of normal and malignant tissues. They exposed a photographic 
gelatine emulsion to histological sections of radiolabelled (P32 or I131) tissues and 
developed it. Additionally they stained the slide with Methylene blue or Haematoxylin 
and were then able to locate the cells within the tissue that had incorporated the 
radioactive molecules (Belanger and Leblond, 1946). Applying this autoradiographic 
method on blood smears, several studies were performed to investigate the cellular 
proliferation kinetics of normal haematopoietic and acute myeloid and lymphoblastic 
leukaemic cells using H3-Thymidine (Cheung et al., 1972; Clarkson et al., 1967; 
Clarkson et al., 1975; Todo et al., 1971). Interestingly it was observed that during 
continuous infusions of H3-Thymidine the kinetics of uptake was different according to 
the blast size. Large leukaemic cells were radiolabelled much faster than small cells and 
it was concluded that these small cells lay dormant for most of the time, have self-
renewal capacity and replenish the large blasts (Clarkson et al., 1970). 
However, while these studies were able to show the heterogeneity in blast populations of 
leukaemias and led to the suggestion of a minor, slow-cycling stem cell fraction within 
the leukaemia that replenishes rapidly proliferating cells, prospective isolation of these 
cells could not be performed with the methods available, making functional enquiries 
impossible. 
 
1.4.3 Models of tumour heterogeneity 
As described above, cancer cells, in addition to their morphologic heterogeneity, do 
apparently exhibit pronounced functional heterogeneity regarding their proliferative and 
cancer initiating potential. Two mutually exclusive models in terms of the nature of 
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cancer stem cells giving rise to the heterogeneous cancer populations exist (see Figure 
4).  
In the stochastic model, CSC are not biologically distinct but form the bulk tumour 
population. In this model any random cell within the tumour has the rare capability to 
acquire CSC properties in response to endogenous and/or exogenous factors. 
Endogenous factors could, for example, comprise variable expression of transcription 
factors, differential induction of signalling pathways and several cell cycle control 
mechanisms while extrinsic factors include the combination of cytokines a particular 
cancer cell is exposed to, cell to cell communication and especially the location in 
respect to the microenvironment of the stem cell niche (Dick, 2008b). Given the 
appropriate stimuli, any cell within a tumour can act as a CSC and initiate and maintain 
the complete tumour phenotype but any cell can as well revert to a tumour cell lacking 
CSC characteristics as the stimuli do not confer stable changes onto exposed cells. It is 
therefore the ability of any cell within a tumour to acquire CSC status that makes it a 
potential CSC but not any cell necessarily needs to actually be in that functional state at 
any given time point. In fact, there may even be an equilibrium between the CSC and 
non-CSC state within a tumour that can shift according to differing signals from the 
microenvironment and this plasticity of cells has been called bidirectional 
interconvertibility (Gupta et al., 2009). 
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Figure 4: The hierarchical and stochastic cancer stem cell model. a) Only rare cancer stem cells 
(depicted in green) within the malignancy are able to self-renew and reconstitute the tumour 
heterogeneity. The bulk population of tumour cells is progressed in a developmental hierarchy 
(represented by cells of different colours) and lost CSC properties. b) Cancer cells of different 
phenotypes have the same CSC capabilities given the appropriate stimulus. A hierarchical order of 
cell development as existent in the physiological tissue counterparts, in which the malignancies 
originated can not be established. 
 
Opposed to the stochastic model stands the hierarchy model. In this model the 
organisation of a cancer mimics the tightly regulated normal tissue development. 
Biologically distinct stem cells stand at the apex of a hierarchy in which the ability to 
self-renew is increasingly lost with differentiation. These cells maintain themselves via 
symmetric or asymmetric cell divisions to produce identical daughter cells and therefore 
maintain the malignant clone. Their progeny differentiates into the heterogeneous cells 
comprising the tumour but despite potentially still having pronounced proliferative 
capacities lack self-renewal characteristics. It needs to be borne in mind that, although it 
provides a likely target, the cell of origin of a cancer is not necessarily a normal stem 
cell. 
a) Hierarchical model b) Stochastic model
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The concept of a hierarchy of cells existing in tumours led to research to identify the 
cells that stand at the apex. To prove the hierarchy model, it must be possible to 
prospectively isolate distinct cell fractions that exclusively have the ability to 
reconstitute a certain tumour. On the other hand, if the stochastic model is correct, cell 
populations sorted in regards to any chosen characteristic should have the same potential 
to initiate tumour formation (Dick, 2008b). While the stochastic model describes the 
older view of cancer, the hierarchy model is the one that was more recently developed 
and favoured. However, there is emerging evidence coming from research on different 
cancer entities, that while the hierarchy model might be applicable to some tumour 
entities, other tumours may support the stochastic model. 
In addition to the two described models of tumour heterogeneity, more lately the concept 
of clonal evolution of tumour cell populations has begun to influence CSC research and 
adds considerable complexity to it. In a review of the then available literature, Nowell in 
1976 proposed the concept of clonal evolution for cancers. Mirroring Darwin´s natural 
selection theory, malignant cells are exposed to external pressures on survival and have 
to pass evolutionary bottlenecks that modulate or dictate their fates. An initial event in a 
single cell imposes a growth advantage on it that leads to clonal expansion. The 
unlimited proliferation potential of that clone, combined with increased genetic 
instability of transformed cells eventually leads to genetic alterations in some progeny 
resulting in subclonal genetic diversity. Most genetic changes in the cells will lead to 
cell death but by chance one mutation will confer the cell with additional selective 
advantage and a new dominant clone emerges. This stepwise process goes along with 
the biological features of tumour progression (Nowell, 1976). Although it was 
acknowledged that this may confer chemoresistance, clonal evolution was regarded as a 
process of sequential selection leading to increasingly more malignant characteristics of 
a tumour.  
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Malignant clonal evolution was recently demonstrated by the group led by Greaves in 
ETV6-RUNX1 positive ALL. They found up to eight genetic abnormalities in single 
leukaemic cells using multiplexing FISH probes and were able to infer the existence of 
up to ten subclones with different genetic profiles. Of note, these subclones showed 
sequential as well as concurrent, branching occurrence. From these data they gained 
insight into the subclonal architecture and deduced the likely ancestral relationships of 
the clonal evolution. Most interestingly, and deviating from sequential clonal evolution, 
they demonstrated the leukaemia propagating potential of cells from different subclones 
and therefore the existence of CSC within these subclones (Anderson et al., 2011). John 
Dick and his group in Toronto also contributed to this evolving field of subclonal 
diversity in CSC in Philadelphia chromosome positive ALL. In diagnostic patient 
samples they detected several genetically distinct subclones with leukaemia propagating 
capability by using DNA copy number alteration (CNA) assessment and the NSG 
xenotransplant model. In agreement with the Mel Greaves group they reconstituted a 
branching rather than a sequential ancestral tree of clonal evolution by CNA profiling 
(Notta et al., 2011). 
However, the branching clonal evolution theory can be integrated into both the 
stochastic and the hierarchical model of cancer heterogeneity. It seems obvious that it 
will have an impact on the kinetics of disease progression, invasion and metastasis, 
potential relapse after treatment and inevitably successful treatment strategies as 
different genetic subclones might well have to be targeted in a different way. 
 
1.4.4 Identification of cancer stem cells in leukaemias 
Technical improvements paved the way for identifying the first stem cells in human 
cancers. Two major problems had to be overcome in order to do so. First, if candidate 
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stem cells are to be investigated, it is essential to discriminate them reliably from the rest 
of the malignant population and also to separate them so that they can be further used in 
functional assays.  
The ability to sort bulk populations of cells into distinct fractions according to their 
expression of surface antigens by the development of monoclonal antibodies and 
fluorescence activated cell sorting (FACS) opened the field for functional analysis. With 
the identification of distinguishable patterns of surface antigen expression in different 
fractions of the bulk cancer population these immunophenotypically defined fractions 
could be purified and following this their properties could be investigated in functional 
assays. 
The second problem lies in the functional assay itself. The appropriate assay would need 
to prove the essential characteristics of stem cells: long term self-renewal, high 
proliferation potential and differentiation into different daughter cells. Human cells are 
generally not able to survive for a long time in vitro and cell lines derived from 
physiologic or malignant tissues are not suitable for identifying a possible hierarchy as 
they consist of rather homogenous populations of cells that have been immortalised. An 
important achievement to circumvent this problem was the development of suitable 
xenotransplant animal models that can host human cells. In a healthy condition the 
mammalian body mainly defends its integrity against foreign organisms or agents with 
the help of the innate and acquired immune system and the highly complex and 
coordinated interplay between them. Transplanting foreign cells into immunocompetent 
animals would soon activate the hosts’ immune system and lead to the rejection of the 
foreign material. To create a hospitable xenoenvironment, increasingly 
immunocompromised mice were bred taking advantage of naturally occurring accidental 
immune defects and by actively manipulating genes involved in immune defence. For 
studies on lymphoid cells an additional advantage is that animals that lack lymphoid 
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tissues readily provide empty niches to accommodate transplanted lymphocytes (Dick, 
2008a). 
 
1.4.4.1 AML stem cells 
Seminal work in the process of identifying haematopoietic and consecutively cancer 
stem cells was carried out by researchers in the laboratory led by Dick in Toronto, 
Canada. He developed powerful assays and his work inspired the search for cancer stem 
cells in many other malignancies. 
Already in in vitro experiments rather short term reconstituting AML-colony forming 
units (CFU) with variable replating abilities could be established suggesting a 
hierarchical order of AML blasts (McCulloch, 1983). Building on their insights in HSC 
John Dick and colleagues then tried to characterise long term repopulating AML stem 
cells by transplanting flow sorted candidate stem cells into their murine xenotransplant 
model. As distinguishing markers they used the surface antigens CD34 and CD38. For 
normal haematopoiesis it was already known that early CD34 positive cells increasingly 
express CD38 during maturation. Flow cytometric studies on AML discovered 
differential expression of these developmental markers in fractions of the tumour 
population as well. Correlating the patterns of CD34 and CD38 expression with risk of 
relapse, an event initiated by LSC surviving chemotherapy, again the existence of a 
hierarchical organization comparable to that in normal haematopoiesis was suggested 
but LSC were not formally proved to be present (Terstappen et al., 1992).  
Using severe combined immune-deficient (SCID) mice in their assay, the search for 
AML LSC was finally successful. First, they transplanted unsorted patient AML samples 
of the FAB subtypes M1, M2 and M4 into the tail veins of sublethally irradiated mice 
and samples of all subtypes led to disease in the mice with a morphology and 
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dissemination patterns similar to the patients from which the cells were taken. 
Furthermore, not only the number of human cells but also the number of AML-CFU 
initiating cells increased over time in the bone marrow of mice, indicating that these 
arose from more immature AML stem cells in the process of proliferation and 
differentiation. Then they went on and transplanted cell fractions of one M1 AML 
purified according to CD34 and CD38 surface marker expression. Engraftment of the 
leukaemia could only be observed in mice transplanted with the CD34+CD38- blast 
population but not with CD34+CD38+ cells. As both fractions contained AML-CFU 
initiating cells it was concluded, that more mature CD34+CD38+ cells developed from 
CD34+CD38- cells that constitute AML stem cells. These cells were then termed SCID 
leukaemia-initiating cells (SL-IC) (Lapidot et al., 1994). However, the SCID 
transplantation assay only allowed the group to successfully show a hierarchy for a 
primitive AML M1 sample and other types of AML could potentially not follow this 
model.  
With the development of the more immunocompromised nonobese diabetic SCID 
(NOD/SCID) mice the hypothesis eventually could be extended to other types of AML. 
This more robust murine model was already successfully used to characterise normal 
haematopoietic stem cells to be of the CD34+CD38- immunophenotype (Bhatia et al., 
1997; Larochelle et al., 1996). In limiting dilution xenotransplantation experiments also 
the frequency of LSC in unsorted populations of different types of AML (M1, M4 and 
M5) was examined. The frequency was found to be between 0.2 and 200 SL-IC in one 
million unseparated AML mononuclear cells in this quantitative assay and was found to 
have no correlation with factors such as FAB subtype, patient age and sex or CD34+ cell 
proportion in the sample.  
To identify the immunophenotype of the SL-IC the surface markers CD34 and CD38 
were used for purification, as in the preceding experiments on the AML M1 and studies 
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of the normal haematopoietic stem cells. In all transplanted AML samples, the 
undifferentiated M1 phenotype as well as the myelomonocytic lineage designated M4 
and M5 AML, the CD34+CD38- cell subfraction exclusively harboured the SL-IC. 
Furthermore, the leukaemias initiated by these cells clinically resembled the original 
AML subtypes, were able to give rise to more differentiated blasts that acquired lineage 
markers and the cells displaying the immunophenotype CD34+CD38- were maintained in 
serial transplantations into secondary recipients, indicating self-renewal potential. Taken 
together, these studies strongly suggested a hierarchical organisation for human AML 
clones similar to that in the physiological developmental pathway. As SL-IC for the 
different AML subtypes were all found in the cells with the CD34+CD38- 
immunophenotype, it was concluded that leukaemic transformation took place in early 
haematopoietic stem cells and not in committed progenitor cells regardless of the AML 
subtype (Bonnet and Dick, 1997).  
Further studies elucidated an even more complex hierarchical composition in AML. In 
normal HSC individual cells with short-term and long-term repopulating abilities could 
be detected where increased differentiation goes along with reduced self-renewal 
capacity and a transition from long-term to short term repopulating capacity (Guenechea 
et al., 2001). Similar experiments were then performed on AML by lentiviral clonal 
tracking of individual clones in the xenotransplant model. In serial transplantations 
clones were identified that largely contributed to the bulk leukaemia in several rounds of 
transplantation indicating extensive self-renewal potential. Other clones only 
reconstituted the AML in the primary recipient mice but disappeared in secondary 
transplantations therefore representing short-term SL-IC. A third type of clone emerged 
in secondary mice after apparently having remained dormant in the primary transplant. 
These cells were called quiescent long-term SL-IC. Furthermore, it was possible to 
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demonstrate that short-term SL-IC were generated by long-term SL-IC and that 
quiescent long-term SL-IC gave rise to both of these cell types (Hope et al., 2004).  
Support that haematopoietic stem cells are the target for malignant transformation came 
from a study of Kroon and colleagues. They showed that a combined over expression of 
Hoxa9 and Meis1a in primary bone marrow cells resulted in the development of a 
hierarchically organised AML and that malignant transformation took part in primitive 
haematopoietic cells (Kroon et al., 1998). These striking similarities in the organisation 
between haematopoiesis and AML in the succession of clones highly suggest that the 
cell of origin for AML is a HSC. 
The hypothesis that AML stem cells are a rare entity did not remain unchallenged. 
Syngenic mouse models that are devoid of the caveats of xenotransplantation models 
provided opposing results. When single blasts from a mouse AML, caused by PU.1 
deficiency, were transplanted into syngenic recipients, positive engraftment could be 
detected, at least in some mice. Certainly, human and murine leukaemias do not match 
each other in many respects, but the much higher proportion of AML initiating cells in 
the syngenic model may well point out, that a xenotransplant model underestimates the 
real frequency of stem cells (Kelly et al., 2007). However, to argue against a hierarchical 
model in human AML, the existence of LSC would need to be proved in cells of other 
immunophenotypes than the rare CD34+CD38- cells but mostly, even in more recent 
studies using the most immunocompromised NSG mice available, the earlier findings 
that SL-IC in human AML are exclusive to the CD34+CD38- compartment were 
confirmed (Ishikawa et al., 2007). However, there are first studies now, which identified 
LICs in immunophenotypically more mature CD34+CD38+ or CD34- blast subfractions 
in cases of AML carrying a nucleophosmin mutation (Taussig et al., 2008; Taussig et al., 
2010). Furthermore, another study provided convincing evidence that LICs are present 
in AML blast populations resembling normal granulocyte-macrophage progenitors 
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(GMP) and lymphoid-primed multipotential progenitors (LMPPs) (Goardon et al., 
2011). 
 
1.4.4.2 ALL stem cells 
Unlike in AML where the model of hierarchical organisation of the tumour population is 
widely accepted, the situation for ALL is quite different. Investigations focussing on 
LSC in lymphoid malignancies were long held back as in contrast to AML suitable 
clonogenic in vitro assays were limited. However, the extensive body of work done on 
AML paved the way for the search of CSC in other malignancies. In particular, in the 
case of ALL, the SCID mouse model was shown to successfully engraft primary patient 
samples, providing a powerful tool to investigate candidate stem cell populations 
(Kamel-Reid et al., 1989). Applying this method, investigations could be performed to 
establish whether ALL follows the hierarchical model or whether many cell types, 
resembling the stem cell as well as the progenitor compartment of normal 
haematopoiesis could sustain the disease, thereby supporting the stochastic model of 
CSC. 
The discovery that in AML, regardless of the actual immunophenotype of the bulk blast 
population, LSC only can be detected in the multipotent CD34+CD38- compartment that 
had not undergone maturation towards lineage commitment led to the assumption that 
this could also be the case for ALL. Undeniably, earlier studies on ALL pointed in this 
direction. In a murine xenotransplant model Cobaleda et al indeed determined only a 
very low frequency of SL-IC between 0.2 and 41 in one million cells of Ph+ ALL 
samples and transplantation of CD34+CD38- and CD34+CD38+ subfractions only 
resulted in mouse engraftment from the less mature CD34+CD38- cells. Furthermore, 
engrafted blasts partly expressed CD19, a clear sign of differentiation along the B 
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lineage and CD34+CD38- cells were able to serially repopulate mice proving self-
renewal capacity of these immature cells (Cobaleda et al., 2000). These results strongly 
argued in favour of a hierarchical organisation of ALL.  
Following this, Cox and colleagues investigated 16 mainly standard risk pre-B ALL and 
c-ALL samples. To achieve engraftment between 5.0 x 105 and 1.0 x 106 blasts had to be 
transplanted. In further experiments with blast populations sorted according to CD34, 
CD10 and CD19 expression they found that only CD34+CD10- and CD34+CD19- 
subfractions but not cells of the CD34-, CD34+CD10+ or CD34+CD19+ 
immunophenotype could reconstitute the ALL in mice. Again self-renewal capability of 
engrafting populations was proved in serial transplantations (Cox et al., 2004). These 
results of a second study confirmed the findings of Cobaleda et al and supported the 
assumption that stem cells in ALL were only present in the pluripotent immature cell 
fraction which gives rise to more differentiated blasts without stem cell characteristics. 
Cox et al subsequently confirmed their hypothesis of a hierarchical order in ALL with 
other surface markers 5 years later. CD133 was earlier found to characterise very early 
multipotent HSC (Gallacher et al., 2000; Kuçi et al., 2003) and was chosen as it was 
shown to be a useful marker in identifying CSC of a variety of solid cancers, including 
those of the colon and the CNS but also to be differentially expressed on leukaemic cells 
(Bühring et al., 1999; O'Brien et al., 2007; Singh et al., 2004). Blasts with co-expression 
of CD133 and CD19 or CD38 were sorted as candidate stem cell populations and 
transplanted onto mice. Again, only immature immunophenotypes with CD133+CD19- 
or CD133+CD38- expression were able to transfer the original ALL onto mice. 
Additionally they demonstrated a relative high resistance of these subgroups towards 
Dexamethasone and Vincristine. Drug resistance is thought to be especially pronounced 
in stem cells (Cox et al., 2009). 
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Other groups did not confirm these results and a dispute was ignited whether or not only 
rather immature and not lineage restricted blasts harboured SL-IC in ALL. In 2005 
Castor et al published their findings in ETV6/RUNX1 and BCR/ABL1 positive ALL. 
Firstly they confirmed earlier findings that the ETV6/RUNX1 fusion gene can be 
detected in the CD34+CD38- subfraction of leukaemic cells but when they subjected 
these cells to further scrutiny they found that the translocation was only found in an 
aberrant, but largely predominant, population with the immunophenotype CD34+CD38-
CD19+ and not in the very small CD34+CD38-CD19- population which constitutes an 
immature developmental stage of the normal haematopoietic hierarchy. CD19 
expression only occurs in already B-lineage committed lymphoid precursor cells and, in 
combination with the finding that none of additionally isolated CD34+CD33+CD19- 
myeloid cells carried the ETV6/RUNX1 fusion gene, they concluded that leukaemic 
transformation takes place after definite separation of myeloid and lymphoid 
development with the multipotential immature CD34+CD38-CD19- compartment being 
unaffected. In Ph+ ALL they had different findings. While in ALL with the p210 
BCR/ABL1 fusion the CD34+CD38-CD19- compartment was involved and lymphoid as 
well as myeloid cell lineages continued to express the fusion gene, in ALL harbouring 
p190 BCR/ABL1 the fusion gene could only be detected in the lymphoid restricted 
lineage. Leukaemia reconstitution ability was then assayed in irradiated NOD/SCID 
mice by intravenous cell transplantation. As expected for ETV6/RUNX1 and p190 
BCR/ABL1 positive ALL, the original leukaemia only was reconstituted and serially 
transplantable from CD19+ and not CD19- blasts but surprisingly this was also the case 
for p210 BCR/ABL1 positive ALL. In conclusion, LSC in all investigated types of ALL 
were only part of the lymphoid committed precursor cell compartment (Castor et al., 
2005).  
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These data contradicted the studies of Cobaleda et al and Cox et al and reopened the 
debate regarding the nature of LSC in ALL. In support of the findings of Castor et al, 
Hong et al demonstrated tumour propagating abilities in B-lineage restricted 
lymphocytic blasts. They purified the same abnormal CD34+CD38low/-CD19+ cells from 
an ETV6/RUNX1 positive c-ALL, an immunophenotype that is not part of normal 
haematopoiesis. This population, containing the t(12;21) translocation, from four patient 
samples engrafted and reproduced itself in primary and secondary generations of 
NOD/SCID mice, providing evidence for self-renewal. The group interestingly also 
showed that this specific subpopulation must form part of an ancestral pre-leukaemic 
clone as they detected it, including the t(12;21) translocation, in the blood of the still 
healthy identical twin sister of one patient, whereas her other progenitor B cells or non 
lineage committed HSC did not express the fusion transcript. The leukaemic blasts of 
the patient had an additional loss of the not translocated ETV6 allele (Hong et al., 2008). 
This is a known “second hit” in this subtype of ALL (Zuna et al., 2004). 
More studies continued to provide support for the hypothesis that ALL blast populations 
with an already committed B-precursor immunophenotype have leukaemia propagating 
abilities. Kong et al intravenously injected purified populations, not only of the aberrant 
CD34+CD38-CD19+ but also of the CD34+CD38+CD19+ immunophenotype which 
resembles a physiological B-cell precursor, into the more recently developed and even 
more immunocompromised NOD/SCID/IL2rγnull (NSG) mice. Remarkably, both 
subfractions were able to transfer the patient ALL onto the mice with a typical ALL 
dissemination pattern and to show self-renewal by serial transplantation. The samples 
used were from higher risk paediatric patients, one defined by a high presenting blast 
count and two by the presence of the MLL-rearrangement. However, again opposing to 
the studies performed earlier, no leukaemic but only normal haematopoietic engraftment 
was achieved from the immature CD34+CD38+CD19+CD10- compartment (Kong et al., 
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2008). The decisive contribution of this work regarding the dispute over the 
differentiation level of LIC in ALL is that it not only determined LIC in the abnormal 
CD34+CD38-CD19+ population but also in the CD34+CD38+CD19+ fraction, that truly 
resembles a committed stage in the physiological lymphoid hierarchy. Additionally 
supporting the hypothesis that immunophenotypically B-lineage committed blasts 
harbour LIC le Viseur et al published the observation that not only CD34+CD19- and 
CD34+CD19+ but interestingly as well developmentally further progressed CD34-CD19+ 
and CD19+CD20low/- or CD19+CD20+ blasts serially reconstituted the patient leukaemia. 
This study used mice and transplantation techniques most favourable of 
xenoengraftment known to date. In contrast to earlier studies, additionally candidate 
LSC populations were orthotopically injected into the bone marrow of the mice femora. 
The hosts consisted of either NOD/SCID mice in which residual natural killer cells (NK-
cells) were depleted by anti-CD122 treatment or NSG mice that naturally lack any NK-
cells (le Viseur et al., 2008). 
Another recent study did not address the question of the immunophenotypic identity of a 
potential ALL stem cell but aimed to establish the frequency of LIC within the unsorted 
bulk ALL population. The high frequency that was found in their NSG mouse model, 
with 1 to 100 blasts being sufficient to transfer the leukaemia, provided additional 
support that LIC could not be restricted to the very small compartment of immature blast 
immunophenotypes (Morisot et al., 2010).  
To compare these in vivo studies can be challenging as they all were carried out using 
xenotransplant models with marked experimental differences. These lie in the use of 
markers and antibodies but more importantly are affected by the development of 
increasingly immunocompromised mouse strains that were available in the time course 
of the studies. Refined transplantation techniques (orthotopic transplantations) are as 
well likely to have contributed to the conflicting findings. 
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In summary, these studies leave the identity or the distribution of LSC in subpopulations 
of ALL open to question. However, the aim to develop specifically designed and 
targeted therapies that are able to improve clinical patient outcome can only be 
addressed and potentially realised once the identity of the target LSC is convincingly 
established. 
 
1.4.4.3 Cancer stem cells in solid tumours 
The attractive prospect of developing targeted therapies for leukaemias has initiated a 
huge interest in identifying CSC for solid cancers as well as they comprise the majority 
of malignancies in adulthood with frequently very low success rates using current 
treatment strategies. Despite significantly more difficulties in investigating stem cells in 
solid tumours, an increasing number of publications now address a variety of tumour 
entities. Besides problems with accessibility, one major obstacle lies in the lack of 
clearly established and tissue specific developmental hierarchies defined by differential 
surface marker expressions that can be used for the discrimination of cell subsets within 
cancers (Clevers, 2011). Studies on solid cancers performed so far therefore often used 
markers that are known to be differentially expressed in certain cancers rather than being 
known as specific stem cell markers in the referring normal tissue.  
One of the first studies successful in identifying a definable subset of cells with CSC 
characteristics was performed on breast cancer using the surface markers CD24 and 
CD44 in combination. CD24 and CD44 both belong to the group of adhesion molecules. 
Al-Hajj and colleagues transplanted sorted cell subsets of human primary breast cancers 
or metastasic pleural effusions orthotopically into the mammary fat pads of NOD/SCID 
mice and evaluated serial transplantation potential. They found that, of the tumour cells, 
those with the CD44+CD24-/low immunophenotype were highly enriched in tumourigenic 
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cells with self-renewal and differentiation capabilities (Al-Hajj et al., 2003). However, 
malignant cells of the CD44+CD24-/low immunophenotype can only be detected in about 
one third of breast carcinomas, particularly on the BRCA1 hereditary basal-like 
subgroup (Honeth et al., 2008). Pancreatic cancer stem cells, in contrast, have been 
suggested in populations being positive for surface marker expression of CD44 and 
CD24 (Li et al., 2007). CD44+ subfractions of cells have also been associated with stem 
cells of gastric cancer and ovarian cancer (Alvero et al., 2009; Bapat et al., 2005; 
Takaishi et al., 2009). Another surface marker widely used to identify CSC of solid 
tumours in xenotransplant mouse models is CD133. In brain tumours (medulloblastomas 
and glioblastomas), Singh et al could demonstrate that while as few as 100 cells of the 
purified minor CD133+ subfraction were able to give rise to a brain tumour in mice that 
could be recapitulated over several generations, none developed after intracranial 
injection of 105 cells of the larger supplementary CD133- subpopulation, thereby 
suggesting a functional hierarchy (Singh et al., 2004). Advanced aggressive stages of 
gliomas were also found to have a higher proportion of CD133+ cells and these are also 
more radioresistant than the bulk tumour mass (Bao et al., 2006; Thon et al., 2010). 
Similar results were obtained from transplant experiments on colon cancer. Despite 
CD133 not being expressed on the majority of tumour cells, colon cancer initiating cells 
were highly enriched in the minor CD133+ cell fraction compared to the unfractionated 
cell population in the studies of O´Brien et al and Ricci-Vitiani et al (O'Brien et al., 
2007; Ricci-Vitiani et al., 2007). However, as in ALL, the existence of a functional 
hierarchy for colon cancer has recently been challenged by another group, which showed 
tumour engraftment from CD133+ as well as CD133- subpopulations. Additionally they 
showed that CD133 is universally expressed in the differentiated normal colon 
epithelium and linked CD133 expression to the expression of CD24 and CD44. 
Interestingly, CD133+ cells were CD44lowCD24+ but CD44+CD24- cells, previously 
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described to identify CSC of other tumour entities, could be found among the CD133- 
population (Shmelkov et al., 2008). CD44 in combination with CD133 expression has 
also been found in a small fraction of prostate cancer cells that exhibit stem cell 
characteristics in vitro (Collins et al., 2005). CD133 additionally has been linked to 
hepatic, pancreatic and lung cancer propagating cells (Eramo et al., 2008; Hermann et 
al., 2007; Ma et al., 2007). 
Other groups used the so-called side population in the search for CSC, cells identified by 
flow cytometry with the ability to exclude Hoechst dye due to ATP-binding cassette 
transporter family expression and therefore regarded to be enriched for normal and 
malignant stem cells. Side population cells with enriched tumour initiating capability 
and other stem cell characteristics like self-renewal, differentiation ability and cell cycle 
quiescence were found in lung cancer, gliomas and gastric cancers (Fukuda et al., 2009; 
Harris et al., 2008; Ho et al., 2007). For oral squamous cell cancer, CSC within this side 
population were additionally found to be associated with CD133 surface marker 
expression (Chiou et al., 2008). 
Interesting conflicting findings have been reported from the field of melanoma stem cell 
research. Melanoma has been suggested to be organised in a hierarchical order following 
the cancer stem cell model by in vitro and in vivo experiments (Fang et al., 2005). 
Schatton et al found malignant melanoma initiating cells with self-renewal and 
differentiation capacity enriched in a subpopulation of cells expressing the 
chemoresistance mediator ABCB5 in a non-irradiated NOD/SCID xenotransplantation 
assay after subcutaneous tumour cell injection. In unsorted cell populations 
approximately 1 in 106 cells had stem cell activity and that rose to 1 in around 1.5 x 105 
cells in the ABCB5+ subfraction (Schatton et al., 2008). Notably, the percentage of 
tumour initiating cells in unfractionated melanoma cells shortly after was heavily 
adjusted upwards to approximately 25% by the group of Morrison. Interestingly, that 
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was achieved by using the more immunodeficient NSG mouse model and by improving 
the tumour cell environment by coinjection of Matrigel, an extracellular protein mixture. 
Furthermore, they tested melanomas for heterogeneous expression of a variety of surface 
markers, among them CD133 and CD166 which correlate with the expression of 
ABCB5 and CD44. When purified according to these surface markers, none of the 
subgroups was found to be enriched in CSC´s. Additionally, CD133+ as well as CD133- 
subfractions both reconstituted the opposing immunophenotype in NSG host mice. In 
conclusion, this study puts the hypothesis of a hierarchical organisation in malignant 
melanomas into question and also challenged studies on other tumour entities that used 
less immunocompromised NOD/SCID mice (Quintana et al., 2008). In contrast, the 
Weissman group at Stanford, California, suggested in a recent very sophisticated study, 
that a hierarchy in melanoma does exist and can be found in early stages but that a self-
renewing CSC population outgrows in later stages, being the only population detectable. 
The CSC subfraction in early stages of malignant melanoma was characterised by the 
expression of the neural crest stem cell marker CD271 (Boiko et al., 2010). However, 
this study was challenged by the Morrison group, who reported that in a comparable 
patient group CD271+ as well as CD271- single primary malignant melanoma cells had 
CSC frequencies of around 25% (Quintana et al., 2010). 
These examples of solid cancers illustrate how complex and controversial the field of 
CSC research is and that many, if not all, questions regarding the definite identity and 
proportion of CSC within various cancers still remain unanswered.  
 
1.4.5 The cell of origin in cancers 
As a clonal disease, cancer is initiated in a single cell of origin in the process of 
malignant transformation and the whole tumour mass subsequently arises from it. The 
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observation that the hierarchical organisation of AML stem cells closely mimics the 
normal HSC compartment with reduced self-renewal capacity in cells which are further 
progressed in the differentiation pathway strongly suggests that the cell that undergoes 
malignant transformation is part of the HSC compartment. This is also supported by the 
fact that, despite different maturation stages of blasts in different AML samples, their 
LSC all had an undifferentiated immunophenotype resembling that of a normal HSC 
(Bonnet and Dick, 1997; Hope et al., 2004). However, an alternative model could also 
be true. The initiating step in cancer development could also take place in an already 
committed progenitor cell that had already lost self-renewal capacity but retains 
proliferation potential. It would then be essential that this cell reacquires the ability to 
self-renew in order to establish a hierarchy (Passegué et al., 2003). The first scenario 
appears to be more attractive for a cancer organised in a hierarchy. If the normal stem 
cell inherent hallmark of self-renewal is simply taken over and maintained by CSC, 
fewer mutagenic events need to accumulate in the process of malignant transformation 
than if a progenitor cell would need to gain this property to drive tumour progression 
and survival. The fact that stem cells persist over a very long time in the organism, gives 
them a much higher chance to collect transforming mutations in comparison to rather 
short lived, more differentiated, cells of a tissue hierarchy (Reya et al., 2001). On the 
other hand, the leukaemic transformation of committed progenitor cells was successfully 
demonstrated in a murine model and it could be shown that this involved reactivation of 
some genes normally highly expressed in haematopoietic stem cells and associated with 
self-renewal. Krivtsov and colleagues expressed the MLL/AF9 fusion protein in mouse 
granulocyte macrophage progenitors and these led to the development of an AML in 
their syngenic siblings (Krivtsov et al., 2006). However, MLL-rearrangements are 
thought to have leukaemogenic transformation potential as a single hit and extended 
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survival of progenitor cells therefore does not seem to be necessary to acquire the 
otherwise required second hit (Szczepański et al., 2010). 
For chronic myeloid leukaemia (CML) it was shown more that 30 years ago that the cell 
of origin lies within the HSC compartment. The finding that non-leukaemic lymphocytes 
arose from the same precursor as the malignant clone indicated that a multipotential 
HSC must have been the cell of origin of the CML (Fialkow et al., 1978).  
The situation in ALL could be different as lymphocytes maintain self-renewal capacity 
even in advanced stages of differentiation and only loose it when they progress to 
become immunoglobulin secreting plasma cells. 
 
1.4.7 Implication of cancer stem cells on therapeutic strategies 
Current therapeutic strategies for curing cancer generally consist of chemotherapy, 
radiotherapy, surgery or different combinations of these. All these strategies have one 
aim in common; they are designed to eliminate all cells comprising the malignancy. In 
other terms, they are highly unspecific. This approach pays tribute to the classical 
stochastic theory that all or at least the majority of malignant cells within a tumour 
contribute to its growth by having the equal and unlimited ability to proliferate. As 
chemotherapy and radiotherapy both mainly target rapidly dividing cells, they not only 
kill cancer cells but also have cytotoxic effects on normal cells, especially of highly 
regenerative tissues like the gastrointestinal mucosa or the bone marrow. As a simple 
general rule, successful treatment of cancers will need to effectively eradicate those cells 
which sustain the disease and lead to its progression. With emerging evidence for the 
more recent cancer stem cell model for at least some cancer entities new challenges but 
also new therapeutic chances arise. If cancers are organised in a similar way to 
physiologic non-malignant tissues with a stem cell at the apex of a cell hierarchy, then 
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only these cancer stem cells are responsible for maintaining the tumour and give rise to 
progenitor or transit amplifying cells with no, or limited, self-renewal potential. From a 
therapeutic aspect that would mean that the cells that form the bulk cancer mass do not 
need to be eliminated but that the CSC are the prime target of any therapy as they would 
initiate possible relapse. Learning more about the biology of these CSC offers a great 
opportunity to develop specific therapies with higher effectiveness and potentially fewer 
side effects. The challenges, however, are partly imposed by the biological features of 
stem cells themselves. Stem cells usually lie dormant in their niches and only very 
occasionally enter a cycling status in response to physiological demand. This imposes a 
natural resistance to current therapies that target cycling cells (Clarke et al., 2006).  
Like their normal counterparts, LSC are also believed to lie quiescent for most of the 
time and therefore are difficult to eradicate with treatment modalities that are cell-cycle 
dependent (Holyoake et al., 1999; Ravandi and Estrov, 2006). Even if malignant cells 
with stem cell properties could be targeted selectively it still might be necessary to 
eradicate non-CSC as well. The stem cell phenotype may not be a stable trait but subject 
to bidirectional interconvertibility between the CSC and the non-CSC compartment as 
proposed by Gupta et al. In this case non-CSC could replenish CSC after those have 
been eliminated successfully with targeted therapy (Gupta et al., 2009). Similarly, the 
more recent findings of subclonal diversity of leukaemic blasts with tumour propagating 
potential impose another level of complexity to cancer therapy. If mutant molecules are 
specifically targeted, they may only be present in one distinct subclone of tumour 
propagating cells that was dominant at presentation. However, relapse could then derive 
from other subclones that lack this mutant molecule and become dominant because of 
the selective evolutional pressure as a consequence of the targeted therapy (Anderson et 
al., 2011; Notta et al., 2011; Nowell, 1976). Difficulties of a similar type can arise in 
CML. It is established that the disease is initiated in HSC that naturally are endowed 
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with self-renewal capacity and would need to be eradicated if therapy is to be successful. 
However, in the case of CML progression to blast crisis malignant cells of the 
downstream progenitor population have been shown to reacquire self-renewal capability 
resulting in LSC status of these cells (Jamieson, 2008).  
Selectively targeting CSC with all its therapeutic advantages is a very attractive prospect 
but will be very difficult to achieve considering how challenging it is to identify them. 
An alternative approach is to force stem cells out of their quiescent stage and to make 
them vulnerable to classic antiproliferative cancer therapy. First evidence for the success 
of this strategy was provided in an AML mouse model. Entry into the cell cycle could be 
induced in quiescent AML CD34+CD38- LIC by administration of granulocyte colony-
stimulating factor (G-CSF) and they then became susceptible to conventional 
chemotherapy (Saito et al., 2010). 
Relapse can emerge not only from residual LSC of the dominant or minor malignant 
subclones but also from a persistent preleukaemic clone that, as a result of an 
independent second hit, initiates overt leukaemia. This possibility has been demonstrated 
for ETV6/RUNX1 positive ALL (Zuna et al., 2004). To include a preleukaemic clone 
with self-renewal capacity in treatment strategies would add another level of complexity. 
Additionally, the inherently cytoprotective abilities of stem cells such as enhanced drug 
exclusion due to up-regulation of ABC/MDR transporter genes may partially explain 
why cancers initially often respond well to chemotherapy but that treatment fails to 
completely eradicate the disease, finally resulting in relapse (Rossi et al., 2005; Zhou et 
al., 2001). Furthermore, upregulation of anti-apoptotic genes like Bcl-X(L) and Bcl-2 in 
leukaemic CD34+ cells impose a resistance to apoptotic stimuli in the blasts and increase 
chance of survival of LSC. In AML blasts, expression of BCL-2 has also been found to 
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be inversely correlated with the ability to enter the cell cycle, thereby additionally 
protecting blasts from chemotherapy (Konopleva et al., 2002; Tacke et al., 2004).  
The aim of CSC directed treatment is not only to specifically target them but also to 
preserve their normal equivalents within the non-malignant tissue. As malignant stem 
cells supposedly only accumulated the smallest number of mutagenic events within the 
bulk tumour and are still most similar to normal stem cells, this aim remains a big 
challenge in cancer research (Ravandi and Estrov, 2006).  
However, it has been shown, that at least cells of some cancers are still able to 
differentiate to acquire a postmitotic cell status. In in vitro and in vivo studies on 
teratocarcinomas, Pierce et al convincingly demonstrated differentiation abilities of 
malignant cells (Pierce and Verney, 1960) and suggested that this could potentially be 
exploited for cancer therapy. A differentiation therapy would force malignant cells to 
terminally differentiate to benign progeny in response to administered chemicals or 
naturally occurring factors (Pierce and Speers, 1988). Induction of differentiation by 
using all-trans-retinoic acid (ATRA) is successfully applied in one form of leukaemia, 
the acute promyelocytic leukaemia (Sanz and Lo-Coco, 2011).  
The described potential consequences of CSC characteristics for cancer treatment 
strategies have already been investigated in some exemplary cancers and were found to 
be a hindrance for conventional antiproliferative chemotherapy. In glioblastomas, for 
instance, it has been shown that CD133+ cells represent CSC that are able to initiate and 
maintain the disease in a xenotransplant assay and that these cells are especially resistant 
to chemotherapy as well as to radiation therapy (Bao et al., 2006; Liu et al., 2006; Singh 
et al., 2004). Similarly, in breast cancers, the subset of CD44+CD24-/low cells was found 
to be more chemotherapy resistant than the bulk tumour population (Li et al., 2008). 
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1.5 Significance and summary 
Improvement in treatment outcomes of childhood ALL from the first achieved 
remissions over 60 years ago to a cure rate of now over 80% is an outstanding story of 
success. Additionally, allocation of patients to treatment arms of different intensity by 
applying increasingly refined prognostic markers at diagnosis and during chemotherapy 
has led to a significant reduction of adverse events and long-term sequelae resulting in a 
higher quality of life of former ALL patients, almost comparable to the general 
population. Despite this, due to the relative high incidence, ALL still remains one of the 
major threats for the life of children and adolescents and new therapeutic strategies to 
successfully treat those who fail to be cured by current chemotherapy approaches are yet 
to be developed. Much hope is invested in the field of cancer stem cell research, with the 
ultimate prospect of specifically targeting the cells that are responsible for tumour 
maintenance and growth. However, drug development essentially relies on the definitive 
identification and characterisation of these stem cells but cancer researchers, especially 
those interested in ALL, have obtained inconsistent and partly contradictory insights 
regarding the frequency and identity of these candidate target cells. Several recent 
studies provide possible explanations for these differences by demonstrating the critical 
impact of the experiment set up, especially in the in vivo murine model but also of the 
preparative steps and transplantation techniques. Using the most sensitive assays 
available to date and taking experimental pitfalls into account as well as standardising 
experiments between research groups holds the biggest promise in finally succeeding to 
decisively settle the dispute over the nature of the leukaemic stem cell in ALL. 
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1.6 Hypothesis and aims of study 
On the basis of findings for AML, in which LSC represent a rare immature entity at the 
apex of a developmental hierarchy, closely related to normal physiological 
haematopoiesis, it traditionally is assumed that ALL follows an analogous pattern. More 
recent findings, however, suggest the possibility that opposed to AML and several solid 
cancers, ALL may not follow the classical hierarchical model of stem cells. 
This study addresses the question whether the immunophenotypic heterogeneity of ALL 
reflects a functional heterogeneity of blasts regarding stem cell characteristics and 
whether or not LIC are a rare occurrence within ALL. 
 
Conflicting results in the field of ALL stem cell research produced by experimental 
models that altered significantly in the last two decades highlight the need for an assay 
that reliably and consistently generates reproducible results. Considering this, the 
purpose of this research is to: 
 Establish a robust in vivo murine transplant model for ALL, using the most 
appropriate mouse strain available and applying the most promising 
transplantation techniques to address the defining leukaemic stem cell properties 
of self-renewal and leukaemia reconstitution. 
 Develop a flow cytometry based method of reliably and quantitatively detecting 
leukaemic blasts of human origin in a murine xenoenvironment. 
 
Studies published prior to the start and during the time course of this project (Castor et 
al., 2005; Hong et al., 2008; Kong et al., 2008; le Viseur et al., 2008; Morisot et al., 
2010) suggest that not only blasts with an immature immunophenotype similar to HSC´s 
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are capable to transfer ALL onto severely immunocompromised mice but also leukaemic 
cells of the CD19+ population and that LIC may have a higher frequency than 
demonstrated by earlier studies. Therefore, this study addresses following questions: 
 Do blast populations of various maturity, defined by the differentially expressed 
surface marker antigens CD10, CD19, CD20 and CD34, have the capability to 
initiate ALL in an orthotopic severely immunodeficient murine xenotransplant 
model? 
 Are blast populations of different maturity able to serially engraft several 
generations of mice, providing evidence of self-renewal? 
 Do identified LSC immunophenotypes reconstitute the original and complete 
patient immunophenotype? 
 What is the frequency of LIC in unsorted blast populations of different ALLs? 
 If leukaemic subfractions of different maturity are able to transfer the leukaemia, 
is there a difference in LSC frequency between these subfractions? 
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Chapter 2: Materials and Methods 
2.1 General equipment and reagents 
2.1.1 General equipment 
IKA MS3 basic vortex mixer (Fisher Scientific, Leicestershire, UK) 
Allegra X-12R centrifuge (Beckman Coulter, Buckinghamshire, UK) 
Allegra X-22R centrifuge (Beckman Coulter) 
5415 R microfuge (Eppendorf, Cambridgeshire, UK) 
Olympus CK30 transmitted light microscope (Olympus, Japan) 
 
2.1.2 General reagents 
Phosphate buffered saline (PBS) was prepared by dissolving PBS tablets (Invitrogen, 
Life Technologies, Paisley, UK) in deionised water. For sterilisation, the solution was 
autoclaved at >120°C.  
Phosphate buffered saline 0.2% w/v bovine serum albumin (0.2% w/v PBSA) solution 
was prepared by adding 1 g bovine serum albumin (Sigma-Aldrich, Gillingham, Dorset, 
UK) to 500 ml sterile PBS followed by sterile filtration. 
Ammonium chloride red cell lysis buffer was prepared by dissolving 8.3 g NH4Cl, 1 g 
KHCO3 and 0.036 g EDTA (all Sigma-Aldrich) in 800 ml ddH2O, adjusting the pH to 
7.35 with 0.1 M NaOH and then adding ddH2O to the total volume of 1000 ml. 
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2.2 Flow cytometry 
2.2.1 General equipment, materials and solutions 
BD FACSCanto II flow cytometer equipped with 488 nm and 633 nm wavelength lasers, 
fitted with photomultiplier tube (PMT) detectors to allow up to 6 colour multiparameter 
flow cytometry (including FITC, PE, PerCP-Cy5.5, PE-Cy7 and APC) (Becton 
Dickinson Biosciences, Franklin Lakes, NJ, USA). 
FACSDiva analysis software, v6.1.2 (BD Biosciences). 
FACS tubes (BD Biosciences). 
0.2% w/v PBSA 
 
2.2.2 Directly fluorochrome labelled surface antigen antibodies for flow cytometry 
Commercially available monoclonal antibodies to specific human and mouse surface 
antigen markers of interest directly labelled to fluorescent dyes were used for 
multicolour flow cytometry and fluorescence activated cell sorting (FACS). All 
antibodies were obtained from BD Biosciences. Details of the antibodies used in this 
project are listed in Table 1. Differences between flow cytometry and FACS existed 
only in the choice of the conjugated fluorochrome. 
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Target surface 
antigen 
Target 
species 
Clone Fluorochrome 
Volume per 
10
6
 cells [µl] 
Application 
CD10 Human HI10a FITC 20 Flow cytometry / FACS 
CD19 Human SJ25C1 PE 20 Flow cytometry / FACS 
CD20 Human L27 
PerCP-Cy5.5 20 Flow cytometry 
FITC 20 FACS 
CD34 Human 8G12 
APC 5 Flow cytometry 
FITC 20 FACS 
CD38 Human HB-7 PE-Cy7 5 Flow cytometry 
CD45 Mouse 30-F11 
PE-Cy7 5 Flow cytometry 
APC 5 FACS 
TER-119 Mouse TER119 
PE-Cy7 5 Flow cytometry 
APC 5 FACS 
Table 1: Monoclonal antibodies directly conjugated to fluorochromes used for flow cytometry 
and FACS. 
 
2.2.3 Reference normal human peripheral blood mononuclear cells (PBMC) 
Human PBMCs were used for compensation experiments and as reference cells in the 
setup of multicolour flow cytometry. Healthy volunteers donated approximately 10 ml 
of peripheral venous blood after informed consent. An aliquot of the samples was 
diluted with 10 volumes of 1x ammonium chloride red cell lysis buffer and incubated for 
10 minutes at room temperature. The red cell lysed cell suspension was centrifuged at 
650 g for 5 minutes at room temperature and after decanting the supernatant, the 
resulting cell pellet was resuspended in 10 ml PBS and centrifuged with the same 
centrifuge settings for a first washing step. A second washing step was carried out 
identically and the cells finally resuspended in 0.2% w/v PBSA for counting and further 
use in flow cytometry. 
 
2.2.4 Principles of flow cytometry 
Flow cytometry is a method that became very popular in both biomedical research and 
clinical medicine over the last 30 to 40 years. The basic principle of flow cytometry is 
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that it can rapidly identify a variety of surface or intracellular markers of an individual 
cell or particle by measuring emitted optical signals, mostly fluorescence. The optical 
signals from several variables then can be analysed electronically in detail to identify 
and characterise different populations within a single cell suspension (Robinson, 2004). 
In haematology and oncology flow cytometry now is an invaluable tool of modern 
diagnostics (Brown and Wittwer, 2000; Kroft, 2004).  
In order to analyse single cells, it is necessary to generate a stream of individual cells 
separated by fluid. This physical cell separation is carried out in the flow cell of the 
fluidic system of the flow cytometer. Through an injection tube, cells from a single cell 
suspension are delivered into the centre of a stream of sheath fluid, resulting in a coaxial 
flow. A laminar flow of this coaxial fluid stream is then generated when the fluid is 
forced under pressure from a larger diameter through a smaller orifice. This creates a 
parabolic velocity profile with the highest velocity at the centre of the fluid stream. The 
acceleration of fluid speed in the centre spreads the cells out, resulting in a 
hydrodynamically focused stream of single, spatially separated cells in a file. The 
individual cells now can be analysed according to their light emission profile if specific 
antibodies conjugated with fluorescent molecules (fluorochromes) are bound to the cell. 
When they pass through the interrogation point the various fluorochromes are usually 
excited by gas-ion or solid state lasers with distinct specific excitation wavelengths 
matching the absorption spectra of the fluorochromes. On excitation, electrons of atoms 
of the fluorescent conjugate to the antibody are elevated to an orbital of higher energy 
and when they leave the laser beam, the electrons return to their initial state, emitting a 
specific wavelength of less energy (longer wavelength). The more antibodies with a 
specific fluorochrome bind to a single cell, the more intense the emission signal 
becomes, allowing a quantitative in addition to a qualitative analysis. Each emission 
spectrum is then registered and amplified by a spectral wavelength specific detector, the 
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photo multiplier tube (PMT). A complex optical system with dichroic mirrors directing 
the different emission spectra and narrow bandpass filters in front of the PMTs allows 
recording various wavelengths simultaneously. Figure 5 illustrates these principles of 
flow cytometry. 
 
 
Figure 5: The principles of flow cytometry.The flow cell of the fluidic system generates a stream of 
spatially separated single cells. The various fluorochromes of the directly labelled surface antigen 
antibodies bound to the cells are excited by laser beams at the interrogation point and consecutively 
emit light of a specific longer wave length. The emitted light is diverted by various dichroic mirrors 
before it passes narrow bandpass filters and finally is detected and amplified by photo multiplier 
tubes. The analogue signals are converted to a digital output and analysed with specialised software at 
the work station.  
PMT, photo multiplier tube; nm, nanometers 
 
Laser light is also scattered by the cells that pass the laser beam. Unlike photons emitted 
by the fluorochromes that have a longer wavelength (lower energy) than the laser used 
for excitation, the scattered light of the laser is not altered in wavelength. Laser light is 
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scattered in a small angle to the direction of the laser beam (forward scatter) in 
proportion to the size or volume of the cell. It is also scattered orthogonal to the laser 
beam (side scatter) and this is proportional to the complexity of the cell content 
(granularity). Measuring the forward and side scatter profile of cells can provide 
important information about cell morphology.  
The analogue signals generated by the photons in the PMT are converted to a digital 
output which is then fed into a computer and analysed with specialised flow cytometry 
software.  
Contemporary research often requires the analysis of several surface markers on a single 
cell and this can be achieved by labelling the cells with distinct mAbs conjugated with 
fluorochromes of different emission spectra. However, for example both a PMT with a 
band pass filter for FITC (525 nm fluorescent emission wavelength) and a PMT with a 
band pass filter for PE (550 nm fluorescent emission wavelength) will register photons 
emitted by FITC and PE as the emission bands are very close to each other and partly 
overlap (fluorescence spillover). To determine which of the two fluorochromes actually 
generated the photons, spectral compensation is necessary. In this process, a signal 
detected in one PMT must be subtracted from the signal in the other PMT as a 
percentage. The more fluorochromes with different overlapping spectral bands are used, 
the more complex this system gets as a percentage of each signal must be subtracted 
from all other PMTs (Kumar et al., 2007; Robinson, 2004). 
 
2.2.5 Multicolour staining for flow cytometry 
PBMCs of healthy donors, cells of primary patient samples or cells retrieved from 
transplanted mice upon bone marrow punctures (bmp), bm harvests or single cell 
suspensions of spleens, livers or kidneys were resuspended in 200 µl of 0.2% w/v PBSA 
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in a FACS tube. The bovine serum albumin reduces unspecific antibody binding during 
incubation with the antibody panel. Saturating amounts of antibodies according to Table 
1 (section 2.2.2) were added to each FACS tube. The content of the FACS tubes was 
briefly spun down and tubes then vortexed to assure that cells were evenly mixed with 
all antibodies. Thereafter, the samples were incubated for 20 minutes, protected from 
light to avoid fluorochrome bleaching. Occasionally the samples were flick-mixed to 
prevent irregular staining of cells due to sedimentation. Subsequently, the samples were 
washed twice to remove unbound excess antibodies. For both washing steps 2.5 ml of 
0.2% w/v PBSA were added to each sample, the FACS tubes were centrifuged at 650 g 
for 5 minutes at ambient temperature and the supernatant was then carefully discarded. 
After the second wash, stained cells were resuspended in 500 µl 0.2% w/v PBSA and the 
samples were kept in the dark until the flow cytometer was ready for use. 
Before the first xenotransplantation experiment, surface antigen expression of CD10, 
CD19, CD20, CD34 and occasionally CD38 was determined on a small cell aliquot of 
each diagnostic patient ALL sample in order to characterise the original ALL 
immunophenotype. Cells from mouse bmps, bm harvests and single cell suspensions of 
mouse spleens, livers or kidneys were routinely stained with anti-human CD10, CD19, 
CD20 and CD34 and anti-mouse CD45 and TER119 to identify human cells in a 
xenotransplant background and to characterise their CD surface antigen expression 
pattern. 
 
2.2.6 FACS analysis of cell samples  
FACS analysis was performed on a FACSCanto II flow cytometer. A maximum flow 
rate of 10,000 events/second was set in order to avoid cell blockage of the flow 
cytometer nozzle and also to prevent automatic interruption of data acquisition due to 
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limitations of the computing system. Routinely, 100,000 events were recorded and then 
analysed using FACSDiva analysis software, v6.1.2. Details of data analysis are 
described and discussed in chapter 3. 
 
2.3 Fluorescence activated cell sorting (FACS) 
2.3.1 General equipment, materials and solutions 
BD FACS Vantage SE cell sorter (BD Biosciences) 
0.2 µm Minisart syringe filter (Sartorius Stedim Biotech, Germany) 
50 µm Cup Filcons syringe to tube filters (BD Biosciences) 
0.2% w/v PBSA, sterilised by filtration with 0.2 µm syringe filters 
 
2.3.2 Directly fluorochrome labelled surface antigen antibodies for FACS 
All directly fluorochrome labelled monoclonal antibodies used for FACS were of the 
same clones as those used for flow cytometry and purchased from the same 
manufacturer (BD Biosciences). In some cases the mAbs were conjugated to different 
fluorochromes (see Table 1, section 2.2.2).  
Where primary diagnostic patient ALL samples were sorted, cells were only labelled 
with antibodies to human surface antigens of interest. In case of sorting material from 
bm harvests of engrafted mice for serial transplantation experiments, anti-mouse CD45 
and anti-mouse TER-119 mAbs conjugated to APC were added in the staining process. 
This helped to clearly discriminate between cells of human and mouse origin and to set 
appropriate sorting gates. 
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2.3.3 Principles of fluorescence activated cell sorting 
Flow cytometry was a major advance in cell characterisation and could be performed on 
living cells. There soon was the desire not only to identify apparently distinct 
populations within a heterogeneous cell suspension but also to separate them physically 
to a high purity and at high speed to address further biomedical questions by assaying 
these subpopulations. Several developments in the 1960s and 1970s eventually led to the 
principal components of FACS as they are still used today. The initial process of 
identification of the cells of interest is identical to flow cytometry but after that, distinct 
cells have to be first detached from the fluid stream and in a second step collected in 
separate locations (for example FACS tubes or microscopic slides). To achieve this, the 
flow cell nozzle and thereby the coaxial fluid stream emerging from it is vibrated at high 
frequencies (10,000 to 300,000 Hz) by a piezoelectric crystal oscillator, thereby 
breaking it apart into small droplets, each containing one single and already identified 
cell only. If the droplet breaking off the stream contains a cell of interest, it is charged 
either positive or negative by charging electrodes before it passes electrostatically 
charged deflection plates. Opposite charged plates will attract the droplets and divert 
them into the direction of a collection system such as FACS tubes, pre-filled with 
collecting medium to maintain cell viability. The cell is not harmed by imposing a 
charge onto the droplet as the sheath fluid acts like a Faraday´s cage, protecting the cell. 
It is also possible to perform cell sorting under sterile conditions- if that is desirable for 
further biological assays. High speed cell sorting is a very complex process in which 
variables of nozzle diameter, generation of a stable laminar flow, sheath pressure, 
droplet generation frequency and analysis computing time play an important role. 
Higher droplet frequencies can only be achieved by decreasing the size of the nozzle and 
increasing the stream pressure. This increasing pressure and the smaller volume of the 
droplet, which eventually is limited by the size of the cells to be sorted, pose threats to 
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cell viability and therefore limit the speed of cell sorting. However, taking pressure 
limitations to cell viability into account, droplet and sorting frequencies currently can be 
increased to around 100,000/s with the latest generations of sorters and high speed 
computing technologies (Kumar et al., 2007; Robinson, 2004). 
 
2.3.4 Multicolour staining for FACS 
Usually 5 x 106 to 1 x 107 cells of primary patient samples or bm recovered from mice 
engrafted with human ALL in previous experiments were resuspended in 200 µl of 
sterilised 0.2% w/v PBSA in a FACS tube. Appropriate amounts of antibodies according 
to manufacturer’s instructions were added, the FACS tube content spun down and 
briefly vortexed to mix cells and antibodies sufficiently. The samples were incubated 
and washed in the same way as described in the staining process for flow cytometry (see 
section 2.2.5). Following the second wash and centrifugation step, the cell pellet was 
resuspended in 3 ml 0.2% w/v PBSA and the samples were kept in the dark until the BD 
FACS Vantage SE cell sorter was ready for cell sorting. 
2.3.5 Cell sorting 
In preparation for fluorescence activated cell sorting, the fluid channels of the BD FACS 
Vantage SE cell sorter were thoroughly sterilised by running 70% v/v ethanol through 
the system. After rinsing the system with ddH2O and cell medium for approximately one 
minute each, around 1,000 cells from the stained sample were acquired and visualised in 
dot plots in a first step. Sorting gates were set around target populations with a low and 
high expression of the CD surface marker of interest (CD10, CD19, CD20 or CD34). 
The cell sorting rate was set to 1 to 1.5 x 103 cells/second and the sorted cells were 
collected in fresh sterile cell medium. 
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2.3.6 Purity analysis of sorted cell populations 
After desired numbers of cells with low and high expression of a specific surface marker 
were sorted and collected, purity analysis was performed. For this purpose, 500 to 1,000 
cells of each population were acquired on the FACS Vantage SE cell sorter. Ideally, 
cells sorted according to a high or low expression level of a specific surface marker 
would form tight clusters with the desired level of antigen expression. However, 
contamination of sorted populations with cells of the opposing antigen expression profile 
is difficult to avoid. To determine the percentage of this contamination, one gate was 
drawn around the desired cluster and one around all cells with a lower expression of the 
antigen in case of a population sorted for high levels of surface markers or around all 
cells with a higher expression of the antigen in case of a population sorted for low levels 
of the specific surface marker. The number of cells in the gate with the contaminating 
cells was then divided by the combined cell numbers of both gates and the calculated 
percentage deducted from 100%. The percentage gained from this calculation 
represented the sorting purity.  
2.3.7 Preparation of sorted cell samples for xenotransplantation 
Preparation of sorted cell samples for xenotransplantation followed the same protocol as 
described for samples with unsorted cells (see section 2.6.6). Briefly, the content of 
viable sorted cells in FACS tubes was counted (see section 2.6.5) and after a 
centrifugation step (1,750 rmp (713 g), 5 minutes, room temperature) and removal of 
supernatant, the cell pellet was resuspended in an appropriate volume of cell medium to 
gain the desired cell concentration. Cell numbers were again counted to confirm 
accuracy of the cell concentration or to adjust the cell concentration if necessary. 
Transplantations were then carried out with as little delay as possible. 
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2.4 Fluorescence in situ hybridization (FISH) 
2.4.1 General equipment and materials  
Hybrite, thermocontrolled programmable hotplate (Abbott diagnostics, Illinois, USA) 
Menzel-Gläser superfrost microscope slides, 10 mm circular and 22x50 mm 
coverglasses (Fisher scientific) 
Diamond pen (Fisher scientific) 
Olympus BX61 fluorescent microscope fitted with a 100x/1.30 oil objective and CCD 
camera (Olympus) fitted with digital imaging software by Metasystems (v5.1.9 
Metasystems) and Applied Imaging (cytovision v4.5) 
 
2.4.2 General reagents 
0.75 M potassium chloride solution, prepared from potassium chloride salt (Sigma-
Aldrich) dissolved in distilled deionised water. 
Carnoy’s fixative solution, comprising of 3 parts methanol and 1 part glacial acetic acid 
(both chemicals purchased from Fisher Scientific). 
Hybridisation buffer (Abbott Diagnostics), containing formamide, dextran sulphate, 
blocking DNA, salt solution (SSC) and detergent. 
2x SSC solution, prepared from 20x SSC solution (Fisher Scientific) and distilled 
deionised water. 
Wash buffer 1, prepared from 20x SSC (17.5% w/v NaCl, 8.8% w/v Sodium Citrate 
Dihydrate) solution diluted 1 to 50 with distilled deionised water and addition of 3 ml of 
the detergent NP40 (Sigma-Aldrich) (0.4x SSC/0.3% w/v NP40). 
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Wash buffer 2, prepared from 2x SSC working solution with addition of 1 ml Igepal-
CA-630 detergent (Sigma-Aldrich) per litre (2x SSC/0,1% w/v Igepal-CA-630). 
4',6-diamidino-2-phenylindole (DAPI) cell nucleus counterstaining solution (1.5 µg/ml) 
(Sigma-Aldrich). 
BCR/ABL1 fusion fluorescent FISH probe (Spectrum Green/Spectrum Orange) (Abbott 
Molecular Diagnostics, formerly Vysis). 
 
2.4.3 Principles of FISH 
Fluorescence in situ hybridisation (FISH) is an invaluable method in molecular biology 
to determine the cytogenetics of an individual cell nucleus. Chromosome numbers 
(ploidy) as well as structural chromosome abnormalities can be detected with this 
technique. FISH is widely used in the clinical diagnostic setting, including ALL initial 
diagnostics and cytogenetic findings contribute to risk stratification when established as 
a prognostic factor (Szczepański et al., 2010). Fluorescently labelled probes 
complementary to specific genomic DNA regions are hybridised to the chromosomes of 
immobilised cells and chromosome copy numbers and chromosomal alterations can then 
be determined with fluorescence microscopy. First, the FISH probes are added to cells 
on a glass slide and the directly labelled probe and the target DNA are both denaturated 
at 72°C. In the following hybridisation step at 37°C, the probe anneals to the specific 
target DNA sequence on the chromosome over several hours. After hybridisation, 
washing steps with solutions of low salt concentrations ensure that only probes that bind 
precisely to the complementary DNA sequence without mismatches remain on the 
chromosomes. Following that, DAPI counter stain is added which colours nuclei blue. 
The fluorescent signals from the FISH probes can now be allocated to one individual 
cell nucleus (O´Connor, 2008). The principles of FISH are illustrated in Figure 6. 
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Figure 6: Principles of fluorescence in situ hybridisation (FISH). The DNA of the chromosomes 
of cells fixed to a microscopic glass slide is denaturated over 2 minutes at 72°C in order to generate 
single DNA strands. Fluorescently labelled FISH-probes (spectrum orange and spectrum green) 
complementary to specific genomic DNA regions are hybridised to single DNA strands at 37°C over 
night. A fluorescence microscope is used to visualise the fluorescent signals. Intact DNA regions are 
either labelled with an orange (chromosome a)) or a green (chromosome b)) signal, while a 
translocation between chromosome a) and chromosome b) (t(a;b)) results in a yellow fusion signal. 
 
2.4.4 Cell fixation and slide preparation 
1-5 x 106 fresh or thawed cells were pelleted by centrifugation at 2,000 rpm (932 g) for 5 
minutes at ambient temperature and resuspended in 5 ml 0.75 M potassium chloride 
solution prewarmed to 37°C in a waterbath. During incubation in hypotonic potassium 
chloride solution over 10 minutes the cells swell due to osmotic water influx. The cell 
suspension was again pelleted under the same conditions, the supernatant was carefully 
cell
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and completely discarded and 5 ml of Carnoy’s fixative solution was added drop by drop 
during vortexing. After another centrifugation step, fresh Carnoy´s solution was added 
until the cell suspension appeared clear and the cell suspension was stored at -20°C if the 
FISH procedure was not carried out immediately afterwards. 
3-5 µl of the fixed cell suspension were dropped onto a pre-labelled microscope glass 
slide from approximately 5 cm height, allowed to air dry and then aged at 60°C for 15 
minutes on a hotplate. Dropping the suspension with the swollen cells causes the cell 
membrane to burst and allows the nucleus to spread out on the slide as the Carnoy’s 
fixative evaporates. This procedure improves access of the FISH probe to the target 
DNA and brings the chromosomes closer to one focal layer. 
 
2.4.5 Hybridisation 
In the hybridisation step, the FISH probe is annealed to the chromosome DNA. The 
commercially available BCR/ABL1 fusion fluorescent FISH probe (Spectrum 
Green/Spectrum Orange) from Abbott Molecular Diagnostics was chosen as it is well 
established in research and clinical diagnostics. For each slide 0.2 µl of BCR/ABL1 
FISH probe were combined with 1.8 µl of the provided hybridisation buffer to prepare a 
probe mixture of which 2 µl were applied to a round coverslip. The area with the fixed 
cells was marked with a diamond pen on the back of the slide and the slide was inverted 
over the coverslip to which it adhered due to surface tension. The edges of the coverslip 
were sealed with rubber cement to prevent drying of the probe during denaturation and 
hybridisation. The slides were transferred to a Hybrite chamber, incubated at 72°C for 2 
minutes to denature probe and chromosome DNA and then incubated at 37°C overnight 
for hybridisation. 
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2.4.6 Post hybridisation washes 
Washing steps after hybridisation are performed to remove unbound or only loosely 
bound FISH probes. The rubber cement was carefully removed from the coverslips with 
the help of tweezers and the slides were placed in ambient temperature 2x SSC solution 
to allow the coverslip to soak off without washing off the cells. The slide were then 
placed in preheated wash buffer 1 and incubated for 2 minutes at 72°C. This step 
removes background fluorescence from non-specific binding of the probe. The slides 
thereafter underwent a second wash at room temperature for 2 minutes in wash buffer 2 
to remove any remaining unbound probe. 
2.4.7 Nuclear counterstaining 
The counterstaining of the nucleus allows mapping of the FISH probes to one single cell 
nucleus. The slides were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) 
directly after the hybridisation washes. 5 µl of DAPI were added to a coverslip and the 
slides inverted onto the coverslip leading to adhesion. The slides were then stored in the 
dark at 4°C to prevent bleaching of the fluorochromes. 
 
2.4.8 Fluorescence microscopy 
The Olympus BX61 fluorescence microscope was used to visualise the fluorescent FISH 
probes and the slides were assessed for cytogenetic abnormalities. The x10 objective 
with a filter for DAPI was initially used to focus on cells. Following this the x100 
objective oil immersion lens were used in combination with a red, a green or a combined 
filter to visualise fluorescent signals of the FISH probe within the blue DAPI stained 
nuclei. Example images of representative cells were captured using the triple filter that 
allowed the red, green and DAPI signals to be imaged simultaneously. 
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2.5 May-Grünwald-Giemsa (MGG) staining 
2.5.1 General materials  
Menzel-Gläser superfrost microscope slides (Fisher scientific) 
Menzel-Gläser 22x50mm coverglasses (Fisher Scientific) 
2.5.2 General reagents 
May-Grünwald stain (contains eosin, methylene blue, methanol, water) (Sigma-Aldrich) 
Giemsa Stain (contains azure B, methylene blue, methanol, glycerine) (Sigma-Aldrich) 
DPX Mountant (contains xylenes, polystyrene, dibutyl phthalate) (Sigma-Aldrich) 
 
2.5.3 Principles of MGG staining 
The MGG staining procedure is commonly applied in a clinical diagnostic as well as 
research setting for morphological examination of blood and bone marrow smears. May-
Grünwald stain mainly is applied to stain granulas. While eosin has a high affinity to 
acidic granulas, methylene blue enriches in basophilic granulas. The Giemsa solution 
stains the DNA of the nucleus purple and the cytoplasm blueish. The staining process is 
largely dependent on the pH of the solutions. ALL blasts have immature cell 
morphology as a differentiation arrest occurs at B-cell precursor developmental stages. 
Applying MGG-staining, lymphoblasts typically appear relatively small and show a high 
nuclear-to-cytoplasmic ratio. The cytoplasm is usually pale blue without granules and 
constitutes only a small rim around the relatively round nucleus which is characterised 
by homogeneous material and indistinct nucleoli. Blast forms are a normal part of 
haematopoiesis but should only represent up to 5% of bone marrow cells. More than 5% 
blast forms in the bone marrow or any blasts detected in peripheral blood are highly 
suspicious of leukaemia. After staining with May-Grünwald and Giemsa solutions, 
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microscopic glass slides are visualised in normal brightfield microscopy (Schrappe, 
2005; Silverman, 2009). 
 
2.5.4 Microscopic slide preparation and staining 
Fresh or thawed lymphoblastic cell suspensions with 1-5 x 106 cells were centrifuged at 
2,000 rpm (932 g) for 5 minutes at ambient temperature, the supernatant was discarded 
and the cell pellet was resuspended in a small volume of PBS (usually 100 µl) to yield a 
cloudy suspension. 5-10 µl of cell suspension were added on a labelled microscope slide 
and left to air dry. In a first step, 1.5 ml of May-Grünwald solution was added onto the 
slide for an incubation time of 3 minutes. Following that, 1.5 ml of deionised water were 
pipetted onto the slide and mixed with the May-Grünwald solution. After incubation of 5 
minutes, the mixture was removed from the slides by inversion and in the next step 
1.5 ml Giemsa solution, 1 to 10 diluted with deionised water were pipetted onto each 
slide for another 15 minutes of staining. The slides were again drained by inversion, 
rinsed with deionised water to remove remaining staining solutions and then air dried 
before finally mounting in DPX mountant. 
 
2.5.5 Brightfield microscopy 
MGG stained slides were visualised under the x10 and the x40 objective lens of 
conventional brightfield microscopy. Samples were analysed regarding content of cells 
with the typical immature lymphoblast morphology of ALL. 
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2.6 Transplant ALL Samples 
2.6.1 General equipment and materials 
BIOMAT2 Class II microbiological safety cabinet (Medical Air Technology Ltd, 
Lancashire, UK) 
Improved Neubauer Counting Chamber (Hawksley, Sussex, UK) 
All plasticware including sterilin universal (20 ml) and bijou tubes (5 ml), Greiner bio-
one falcon tubes (50 ml) and pipettes (2 ml, 5 ml, 10 ml and 25 ml) were purchased from 
Fisher Scientific. As the only exception, cryovials (1.5 ml) were purchased from 
Invitrogen Life Technologies. 
2.6.2 General reagents 
RPMI 1640 medium, foetal calf serum (FCS) and trypan blue 0.4% w/v solution were 
purchased from Sigma-Aldrich. 
Unless otherwise stated, RPMI 1640 medium supplemented with 10% v/v foetal calf 
serum was used as a cell suspension medium for all sample processing steps with 
primary human ALL samples or engrafted and non-engrafted bone marrow harvested 
from mice including thawing, sorting, transplanting and for bone marrow punctures. 
Hereafter this medium is simply referred to as ‘cell medium’. 
 
2.6.3 Patient ALL samples 
Unsorted or sorted original patient diagnostic bone marrow or peripheral blood ALL 
samples were used for primary xenotransplantation experiments. Excess bone marrow 
from initial diagnostic bone marrow punctures or peripheral blood samples from 
venopunctures was processed to remove erythrocytes applying density gradient 
centrifugation or red cell lysis and cryopreserved in the Newcastle Biobank after written 
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informed consent was obtained from patients or their legal guardians (Ethical approval 
was obtained, reference numbers – 2002/111 and 07 H0906). ALL samples from the 
Netherlands and Germany were kindly provided by the Dutch Childhood Oncology 
Group (DCOG)-ALL8/9 and the ALL-Berlin-Frankfurt-Münster (BFM) 2000 studies, 
both approved by institutional review boards and written informed consent was obtained 
from parents or legal guardians. Suitable ALL patient samples for intrafemoral 
transplantation were chosen by availability of viable material, cytogenetics, expression 
array profiling and immunophenotype. Cell viability was determined by counting cell 
suspensions in a haemocytometer after mixing 1:1 with 0.4% w/v trypan blue. Living 
cells are able to exclude the dye and can be distinguished from dead cells which appear 
dark blue in normal light microscopy (see section 2.6.5). 
 
2.6.4 Cell thawing 
Cryopreserved human primary patient samples were removed from the -80°C freezer or 
liquid nitrogen storage tank and thawed rapidly in a waterbath at 37°C. The thawed cell 
suspension (usually 1-2 ml) was slowly diluted up to a volume of 10 ml by drop by drop 
addition of cell medium, a small aliquot from the diluted cell suspensions (usually 5 µl) 
was taken for immediate cell counting (see section 2.6.5) and the cell suspension was 
then centrifuged at 1,750 rpm (713 g) for 5 minutes at room temperature. The 
supernatant was discarded and the cell pellet was resuspended in a small volume of fresh 
cell medium (usually 200 µl to 2 ml) to achieve a high cell concentration for further 
procedures. 
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2.6.5 Cell counting and determination of cell viability 
In order to determine total cell numbers and cell viability, small aliquots from the 
thawed and diluted cell suspensions (usually 5 µl) were mixed with 0.4% w/v trypan 
blue solution (ratio 1:1). This mixture was placed in an improved Neubauer 
haemocytometer and cells were counted under the light microscope using the x20 
objective lens. Living cells exclude the trypan blue solution and appear bright while 
dead cells lose the efflux ability, retain the dye and therefore look blue. Numbers of dead 
and alive cells were counted and the percentage of viable cells was calculated. Cell 
viability of both primary human ALL samples and harvested bone marrow from mice 
was usually high, typically in the range of 80-95%. 
 
2.6.6 Sample preparation for xenotransplantation 
After cell counting, centrifugation and resuspension of cells in fresh cell medium to a 
high cell concentration, cell suspensions were directly used for transplantation if 
relatively high but non-defined cell numbers were to be transplanted. In the case that 
exact numbers of cells were to be injected into mice, the cell concentrations were 
adapted by addition of fresh cell medium in order to yield the desired number of cells 
per mouse in an aliquot volume of 30 µl. The total cell suspension volume prepared for 
each transplantation group was in excess of number of mice transplanted times 30 µl, to 
have some spare transplant cell suspension. Intrafemoral (if) bone marrow 
transplantations were subsequently carried out with as little delay as possible to avoid 
sample degradation and cell death. The cell suspensions were kept in FACS tubes and 
only just before injection drawn into an insulin syringe after careful flip-mixing the tube 
to resuspend the cells homogenously. 
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2.7 In vivo xenotransplantation experiments 
2.7.1 General equipment and materials 
Faster Ultrasafe Class II Microbiological safety cabinet (Wolf laboratories Ltd, 
Yorkshire, UK) 
MIE Cavendish 500 anaesthesia machine, fitted with an Ohmeda Isotec 400 volatile 
anaesthetic vaporiser and Fluovac scavenge system (Key Health Solutions Ltd, 
Wiltshire, UK) 
Curved blade dissection scissors (Fisher Scientific) 
Curved pointed dissection forceps (Fisher Scientific) 
BD Biosciences 40 µm cell strainers (VWR, Leicestershire, UK) 
2.7.2 General reagents 
Isoflurane (IsoFlo, Abbott laboratories, Maidenhead, UK) 
Carprofen (Rimadyl, Pfizer, Kent, UK) 
Chlorohexidine disinfectant spray (Hydrex Pink, Ecolab, Yorkshire, UK) 
 
2.7.3 Mice for xenotransplantation 
The immunocompromised mouse strain used for this project was the NOD/LtSz-Scid IL-
2Rγ -/- (NSG) hybrid strain. This strain is currently the most immunocompromised 
mouse strain available, with no functional B, T or NK cells. NSG mice in addition have 
functionally impaired macrophages and a compromised complement system. The highly 
suppressed immune system profoundly prevents rejection of transplanted non-syngenic 
material by the host. The lack of host lymphocytes potentially also facilitates human 
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lymphocyte or lymphoblast engraftment as transplanted cells do not have to compete for 
the niche microenvironment with cells of murine origin. Additionally, NSG mice have a 
comparably long life span of around 16 months and a low tendency to become “leaky” 
(regaining some degree of immune function), attributes that make them especially 
suitable for xenotransplant experiments that potentially require an extended period of 
time. NSG mice have recently been shown to be probably the most ideal hosts for 
human haematopoietic engraftment (Agliano et al., 2008; Ishikawa et al., 2005; 
McDermott et al., 2010; Shultz et al., 2007; Shultz et al., 2005). 
Due to the severe immunosuppression, great care was taken to prevent any contact with 
potential pathogens. All procedures involving mice were carried out carefully under 
maximally aseptic conditions. The breeding colony was maintained in the animal facility 
of the Newcastle University. Usually 3 to 6 mice of the same sex were held in 
individually ventilated cages (IVCs) and provided with irradiation sterilised food and 
sterile water from individual 500 ml water bags fitted with an autoclaved steel nozzle. 
Mice were only taken out of the IVCs in the protected environment of a Class 2 safety 
cabinet or changing station with laminar air flow. All staff involved in mouse care or 
research had to wear disposable, individually packed lab coats or clean surgical gowns 
as well as disposable nitrile gloves. Glove covered hands were disinfected regularly 
between handling of different IVCs. Animal care, xenotransplantation and bone marrow 
punctures were performed in conformance to personal or group project license 
regulations. In the case of suspected infection or other problems with the mice, advice 
was sought and potential treatment was discussed with the on-site veterinary staff. 
Whenever mice seemed to become ill from overt leukaemia or appeared to suffer for 
other reasons, experiments were terminated and mice were killed by high cervical 
dislocation. 
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2.7.4 General anaesthesia of NSG mice 
General anaesthesia of mice was induced in an anaesthesia chamber connected to an 
Isoflurane vaporiser and oxygen. For safety reasons, excess anaesthetic was scavenged. 
For induction of anaesthesia, 5% v/v Isoflurane in a constant flow of 1,500-
2,000 ml/min oxygen was lead into the anaesthesia chamber until animals became 
unconscious. Mice were then transferred to a mouse face mask that as well supplied 
Isoflurane in oxygen (usually 3-5% v/v Isoflurane) to maintain a deep anaesthesia. To 
determine if an appropriate depth of general anaesthesia was achieved, a pain stimulus 
was applied to one foot of a mouse and in case of foot withdrawal, the level of 
anaesthesia was adjusted prior to carrying out any procedure. The non-steroidal anti-
inflammatory drug Carprofen was given to mice following intrafemoral bone marrow 
transplantation or bone marrow punctures to provide post-interventional analgesia and to 
prevent inflammatory reactions at the site of the invasive procedure. Carprofen solution 
was diluted to 5 µg/µl with sterile water and 10 µl of the solution per 10 g mouse body 
weight was usually injected subcutaneously in the abdominal area. After procedures, 
mice were transferred back to their IVC and observed for full recovery. Femoral 
puncture sites were carefully inspected for signs of prolonged bleeding. All steps 
involved in anaesthetising mice were carried out under maximally aseptic conditions. 
 
2.7.5 Intrafemoral (if) transplantation procedure 
ALL originates from haematopoietic cells in the bone marrow and blasts home to their 
appropriate niche within it. Transplanting human lymphoblasts directly into the bm in an 
orthotopic mouse model carries several advantages. The necessity of homing of 
intravenously injected blasts to the bm is made redundant and clearance of blasts due to 
a residual host immune system can possibly be avoided and superior results of 
orthotopic transplant models compared to conventional intravenous transplantation 
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techniques have been published (Kushida et al., 2001; Taussig et al., 2008; van Hennik 
et al., 1999). The rationale for orthotopic xenotransplantation will be discussed in more 
detail in 3.1.2. In order to endow ALL blasts with the highest chance of engraftment, the 
orthotopic intrafemoral xenotransplantation technique was the method of choice in this 
study.  
As soon as mice were adequately anaesthetised, they were set in supine position and the 
right knee was soaked thoroughly with Chlorohexidine, a disinfectant solution 
commonly used for surgical procedures. In addition to providing an aseptic skin area, 
wetting the fur made it stick to the skin, making it easier to locate the correct site for the 
transplantation procedure. The knee joint was bent to around 90 degree and fixed 
between the index finger, the middle finger and the thumb of the left hand. First a hole 
was drilled through the intercondylar fossa of the distal femur into the cavity of the 
femur diaphysis using an insulin syringe (30 g). The correct position of the needle was 
checked by bending and straightening the leg and palpating for an incorrectly located 
needle. The leg then was firmly retained in the bent position and the drilling needle 
carefully withdrawn. The insulin syringe pre-filled with the cells for transplantation was 
inserted through the same hole and the position of the needle carefully checked again by 
moving it up and down slightly with minor changes of direction. The needle was 
correctly positioned in the bone cavity if the rough inner surface of the bone corticalis 
could be felt. Following this, a 30 µl aliquot was slowly injected into the bone marrow 
cavity. The injection needle was withdrawn and the leg immediately straightened in the 
knee joint in order to close the site of the injection hole, preventing outflow of the 
transplant suspension as much as possible. Transplanted mice were then referred back to 
the IVC for recovery from anaesthesia. 
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2.7.6 Mouse bone marrow punctures 
Bone marrow punctures of NSG mice were always performed under general anaesthesia 
(see 2.7.4). Mice were positioned and the right leg manually fixed as described for if 
transplantation (2.7.5). After disinfection, a hole for access was drilled through the 
intercondylar fossa of the femur using a 25 g ½” needle, attached to a 2.5 ml syringe. 
After ensuring the correct position of the needle in the femur cavity it was withdrawn 
and a new 25 g ½” needle attached to a 2.5 ml syringe containing 200 µl of 0.2% w/v 
PBSA was inserted. Negative pressure was applied by pulling back the plunger of the 
syringe and slowly released as soon as a little amount of bm flowing into the syringe 
could be detected. The aspiration needle was pulled out and the leg straightened in the 
knee joint to maximally prevent bleeding from the puncture site. Punctured mice were 
referred back to the IVC for recovery from anaesthesia. The bm collected in the volume 
of 200 µl 0.2% w/v PBSA was transferred into a labelled FACS tube for direct staining 
with a desired combination of antibodies for flow cytometry.  
 
2.7.7 Harvest of mouse bone marrow and tissue samples 
Generally individual mouse experiments were terminated when a mouse appeared to 
become ill either from developing overt ALL or for any other non transplant related 
reason. Occasionally, a previous bmp showing a very high percentage of human 
engraftment indicated that deterioration of the mouse condition was imminent. 
Additionally, paleness or a progressively distended abdomen due to spleen enlargement 
were reliable signs that a mouse had to be killed soon even if it still was active and not 
obviously affected by disease. Mice were also killed when they approached their natural 
life expectancy.  
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The final bm harvest from mice served two main purposes. One was to determine a 
terminal engraftment level and the other was to collect and preserve bone marrow for 
following serial xenotransplantation experiments or other analyses. Routinely, bm was 
collected from both femora and tibiae. Both legs were disarticulated in the hip joints and 
the skin and muscles stripped of the bones. Femur and tibia were separated by 
overextending the knee joint and cutting the ligaments and remaining connective tissue 
with a pair of scissors. The epiphysis of both bone ends was snipped off with the help of 
tweezers to reveal the bone cavity and bm was flushed out from both ends with cell 
medium. A 25 g ½” needle attached to a 2.5 ml syringe containing the cell medium was 
used for this purpose and the bm was usually collected in a total volume of 
approximately 5 ml. 
On the majority of mice that had bm engraftment in a previous bmp a post mortem 
splenectomy was performed to analyse blast infiltration into the organ. A single cell 
suspension of cells contained in the spleen was prepared by grinding the spleen through 
a 40 µm BD cell strainer with the help of a syringe plunger and collecting the 
disaggregated cells in cell medium for further procedures. Spleen single cell suspensions 
were routinely cryopreserved and stored in liquid nitrogen in addition to bm samples. 
From selected mice with obvious hepatomegaly or infiltrated kidneys (indicated by 
enlargement and subcapsular petechiae) these organs were taken out as well and single 
cell suspension prepared as described for spleen. Liver and kidney samples were only 
analysed by flow cytometry and not cryopreserved. 
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2.7.8 Cryopreservation, long time storage and thawing of mouse bone marrow and 
spleen single cell suspensions 
In order to use mouse bone marrow or spleen single cell suspensions from engrafted 
mice for further analysis or future xenotransplantation experiments, both cell materials 
were frozen down and stored in a liquid nitrogen tank. Viable cell numbers for bm but 
not for spleen samples were counted in an improved Neubauer chamber using trypan 
blue exclusion as described in 2.6.5 and cells pelleted by centrifugation at 1,750 rpm 
(713 g) for 5 minutes at room temperature. After decanting the supernatant, the cell 
pellet was resuspended in 1 ml of foetal calf serum containing 10% v/v DMSO (freeze 
mixture) per aliquot of approximately 5 x 106 viable bm cells. 1 ml each of the freeze 
mixture cell suspension was then transferred into a pre-labelled polypropylene cryovial 
tube. The tubes were then wrapped into paper tissue to enable slow freezing in a -80°C 
freezer. The cryovials were kept for a minimum of 12 hours at -80°C and then 
transferred to the liquid nitrogen tank for long term storage. 
 
When cryopreserved cell samples stored in liquid nitrogen were needed for further 
analysis or serial xenotransplantation experiments, individual cryovials were removed 
from the liquid nitrogen tank and quickly thawed at 37°C in a waterbath. Immediately 
after thawing the cell suspension was pipetted into a 20 ml universal tube and cell 
medium, prewarmed to 37°C was added drop by drop to a total volume of 10 ml to 
enable slow diffusion of DMSO out of the cells. A small cell suspension aliquot (usually 
5 µl) was taken and the viable cell content of the sample was determined as described 
above. The cells were centrifuged at 1,750 rpm (713 g) for 5 minutes at ambient 
temperature and after removing the fluid supernatant, the resulting cell pellet was 
resuspended in a volume of cell medium adequate for the planned further procedures. 
  
 
CHAPTER 3: DELIVERY, ENGRAFTMENT 
AND DETECTION OF HUMAN ALL IN NSG 
MICE 
 
 
Chapter 3  3.1 Introduction 
95 
 
Chapter 3: Delivery, engraftment and detection of 
human ALL in NSG mice 
 
3.1 Introduction 
Research on cancer stem cells has yielded contradictory results regarding their identity 
and frequency within the malignant population for many cancers and in particular for 
ALL. Cancer stem cells are the cells within a cancer that maintain the disease and 
therefore must combine two defining characteristics. Being capable of self-renewal 
ensures that the malignant clone does not die out and the ability to differentiate into 
diverse subpopulations generates and maintains the heterogeneity of blast populations 
within a tumour. These two properties must be proved for distinct cell populations 
within a specific cancer, if they are to be identified as cancer stem cells (Clarke et al., 
2006). Consequently, to address cancer stem cells an experimental model has to be able 
to: 
 
 identify distinct cell populations within a tumour and to purify these in order to 
assay their stem cell properties 
 demonstrate self-renewal and the ability to reconstitute tumour heterogeneity of 
candidate stem cell populations 
 
Leukaemic cells generally express a panel of surface markers that constitute their 
immunophenotype and within a heterogeneous tumour population these blast surface 
markers are differentially expressed regarding their type and number to characterise 
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distinct tumour subpopulations. Leukaemias are believed to originate in the normal 
hierarchically organised haematopoietic system, where different developmental stages 
are well characterised and can be determined by a specific surface antigen expression 
profile. Assessment of the cell specific surface antigen expression pattern on individual 
cells can be achieved by flow cytometry. Modern multicolour flow cytometry allows to 
simultaneously interrogate the expression of several different surface markers on a 
single cell with a high sensitivity, making this method suitable to identify 
subpopulations within a tumour and to determine their contribution to the bulk tumour 
mass. Through establishing the cell specific surface marker expression, the 
immunophenotypes of leukaemic cells can be compared to those of normal 
haematopoietic maturational stages. The development of FACS made it possible to 
accurately purify viable cells of a heterogeneous population into distinct subpopulations. 
These subpopulations subsequently can be further scrutinised in clonogenic assays 
regarding their potential stem cell characteristics. 
Currently, the defining stem cell characteristics of self-renewal and the capability to 
reconstitute the heterogeneous lineages of a certain tumour can only be evaluated in in 
vivo animal xenotransplantation assays (Clevers, 2011). Methylcellulose or semisolid 
agar based clonogenic in vitro experiments played an invaluable role in identifying 
several progenitor cells of normal haematopoiesis, especially myeloid development. 
Colony-forming cell assays usually only detect already lineage restricted progenitor cells 
and the most immature developmental stage that can be identified is the multipotent 
myeloid progenitor colony forming unit granulocyte, erythrocyte, macrophage and 
megakaryocyte (CFU-GEMM). The lymphoid lineage is far more difficult to assess and 
even progenitor cells require complex co-culture methods. However, self-renewal of 
stem cells can not be addressed with these short-term assays and the gold standard to 
measure stem cells in normal and malignant haematopoietic cells are long-term 
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repopulating assays (Purton and Scadden, 2007; Spangrude, 2002). These in vivo 
xenotransplant models usually involve highly immunocompromised mice. The trait of 
self-renewal can be addressed by determining the ability of candidate stem cell 
populations to serially repopulate several generations of host mice without dying out. 
The ability to reconstitute the full tumour or normal haematopoietic cell heterogeneity 
can be determined by comparing the immunophenotypes of the engrafted populations 
with the original sample by the means of flow cytometry. 
Murine xenograft assays were essential in elucidating the normal haematopoietic 
hierarchy and now are commonly used in the field of cancer stem cell research. 
 
3.1.1 Selecting a murine xenotransplant model 
Despite FACS and flow cytometry being essential in purifying candidate stem cells for 
further investigations and in studying engrafted cell populations in mouse bone marrow 
and other tissues, the crucial part of the experiments, assaying CSC properties of 
leukaemic cell subpopulations, relies on the xenotransplant model. It is essential that the 
assayed cells meet the best possible conditions for engraftment. The means of delivery 
of cells into the mouse xenoenvironment (transplantation technique) and the ability of 
the host mice to provide a maximally supporting microenvironment for the transplanted 
material are critical for success. 
The crucial determinant of mice for successfully hosting human xenotransplant material 
is the immune system. The immune system is designed to recognise and eliminate 
xenogenic material in order to protect the integrity of a body system. As a consequence 
and under normal circumstances, foreign material only has a reasonable chance to 
survive and thrive in a host environment if the immune defence of the recipient is 
compromised. Obviously, the more pronounced this immunosuppression is, the higher is 
Chapter 3  3.1 Introduction 
98 
 
the sensitivity of the assay in detecting xenogenic cell populations with stem cell 
characteristics.  
Combining the most promising way of delivery of ALL cells into the appropriate niche 
and the use of the most suitable host for accommodating the ALL graft holds the 
prospect of the highest sensitivity for demonstrating stem cell properties of various blast 
subpopulations. Several immunocompromised mouse strains have been used in stem cell 
research over the last decades and their efficacy to engraft human cells proved to be 
substantially variable and closely linked to the immune status of the mice. 
 
3.1.1.1 Nude mouse strains 
Nude mice developed following a spontaneous single gene mutation in BALB/c mice. 
Flanagan published the first detailed description of these mice in 1966 but it was 
Pantelouris two year later who described the lack of a functional thymus in homozygote 
mice (Pantelouris, 1968). The underlying defect in nude mice is a mutation in the Foxn1 
gene (a transcription factor) which results in a failure of T-cell development. Nude mice 
were the first described to have a certain degree of immunosuppression and are still used 
in pharmacological and imaging studies on human tumour xenografts. However, these 
animals still have a partly intact humoral immunity with an ability to produce IgM but 
not IgG, an increased NK-cell activity and in mice of advanced age, some cells with a T-
cell immunophenotype develop. Haematopoietic cells of human origin fail to engraft this 
mouse strain and therefore they cannot be used in haematopoietic or leukaemic stem cell 
research (Belizário, 2009; Shultz et al., 2007). 
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3.1.1.2 Scid mouse strains 
Severe combined immunodeficiency (Scid) in CB17 mice also developed after a 
spontaneous mutation and these mice were discovered and described by Bosma et al 
(Bosma et al., 1983). The autosomal recessive mutation in the PrkdcScid gene that codes 
for a DNA-dependent protein kinase, results in a defect of non-homologous end joining 
of double-stranded DNA, a crucial process in the development of functional B- and T-
cells, ultimately leading to agammaglobulinaemia. (Shultz et al., 2007). These mice lack 
mature B- and T-lymphocytes and due to the defect in non-homologous end joining of 
double-stranded DNA they are very sensitive to radiation (Fulop and Phillips, 1990). 
The mice have pronounced innate immunity and NK-cell activity and are prone to 
develop “leakiness” with the generation of B- and T-cells when they get older (Bosma et 
al., 1988; Greiner et al., 1998). However, besides their initial main use in human 
immunodeficiency virus research, these mice were the first described to successfully 
engraft human haematopoietic cells, at least to a low level. Intrestingly, transplanting 
CD34+ human cord blood cells, it could be elegantly demonstrated that Scid mice 
reconstitute the whole physiologic hierarchy of normal human haematopoietic cells from 
Scid repopulating cells over long term culture initiating cells to colony forming units and 
mature effector cells (Pflumio et al., 1996). This haematopoietic engraftment ability led 
to the employment of these mice in many haematological studies providing important 
insights into normal and malignant haematopoiesis but due to the development of mouse 
strains with better acceptance of human haematopoietic cells this mouse strain is now 
mainly of use for tissues and cancers of non-haematologic origin (Lapidot et al., 1992; 
Mosier et al., 1988; Vormoor et al., 1994). 
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3.1.1.3 bg/nu/xid (BNX) mouse strains 
The innate immunity, enhanced NK-cell and lymphokine-activated killer cell (LAK) 
activity of the nude and Scid mouse strains still has a pronounced negative impact on 
human cell growth in mice receiving xenotransplants, especially cells of the myeloid 
lineage. In order to overcome these problems of graft rejection, a more 
immunocompromised mouse strain was needed. In the bg/nu/xid (BNX) mouse strain 
the advantages of reduced NK cell numbers of mice with the beige (bg) mutation and 
reduced number of LAKs from mice with the xid mutation, which both have an 
important role in the reaction of the host against the xenograft were transferred on 
athymic mice with the nude (nu) mutation by cross-breeding (Andriole et al., 1985; 
Fodstad et al., 1984). Dick and colleagues used this more immunocompromised mouse 
strain that finally made it possible to not only engraft normal lymphoid but also normal 
myeloid cells from human bone marrow. However, high numbers of cells need to be 
transplanted and the additional substituion of human growth factors and irradiation of 
the mice is necessary for successful engraftment of human cells (Kamel-Reid and Dick, 
1988). Little later, an ALL cell line (A-1) was as well successfully transplanted into this 
mouse strain by the same group (Kamel-Reid et al., 1989). 
 
3.1.1.4 NOD/Scid hybrid mouse strains 
Backcrossing the scid mutation onto the non-obese diabetic (NOD/Lt) mouse strain 
resulted in the NOD/Scid hybrid strain. NOD mice were originally used to model 
autoimmune type 1 diabetes mellitus but were also found to harbour a profound 
functional deficit in NK-cells and antigen presenting cells and to lack serum 
complement factors, all important contributors to the innate immune system (Shultz et 
al., 1995). The combination of the multiple functional deficiencies in the innate 
immunity of the NOD strain with the impact of the scid mutation on B- and T-lymphatic 
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development highly improved the long term engraftment of human haematopoietic cells 
in the NOD/Scid hybrid strain (Cashman et al., 1997; Lowry et al., 1996; Shultz et al., 
2007). Like in Scid mice the whole physiologic hierarchy of haematopoietic cells is 
similarly reconstituted in the NOD/Scid mouse strain (Pflumio et al., 1996). 
Furthermore, with the use of NOD/Scid mice it was possible for the first time to prove 
that human cord blood contains transplantable totipotent progenitor cells with the ability 
to differentiate into B and T lymphocytes, natural killer cells and granulocytes (Robin et 
al., 1999). As a consequence, NOD/Scid mice have also been used in leukaemia stem 
cell research and were shown to have superior engraftment abilities. To gain the same 
levels of engraftment of AML blasts, 10 to 20 times fewer leukaemic cells were required 
for transplantation in NOD/Scid hybrid mice than in mice with the scid mutation alone 
(Bonnet and Dick, 1997). Of note, NOD/Scid hybrid mice do not develop diabetes but 
there are limitations in their sensitivity as they retain low levels of innate immunity and 
at least some NK-cell activity. In order to overcome the engraftment barriers related to 
residual NK-cell activity, an antibody directed against the IL-2Rβ chain (anti-CD122) 
can be administered to NOD/Scid mice to deplete remaining NK-cells and further 
members of the innate immune system like macrophages and other myeloid cells (Kerre 
et al., 2002). This treatment helped to identify members of the haematopoietic hierarchy 
with short-term repopulating activity (McKenzie et al., 2005; Shultz et al., 2003). A 
major disadvantage is the relatively short life span of NOD/Scid hybrid mice, limited to 
around 8 to 9 months at which age they commonly develop thymic lymphomas. This 
impedes their employment in long-term engraftment studies or limiting dilution 
experiments with very low numbers of cells transplanted which usually need an 
extended time of observation (Shultz et al., 1995). 
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3.1.1.5 β2 microglobulin-deficient (B2m-/-) NOD/Scid mouse strains 
A mouse strain that lacks NK-cell activity was developed by crossing NOD/Scid mice 
with mice deficient of β2 microglobulin expression. This additional defect leads to the 
absence of major histocompatibility complex (MHC) class 1 molecules essential for NK-
cell development (Christianson et al., 1997). Using these mice in human Scid 
repopulating cell assays showed a superior engraftment ability of this strain. The SRC 
frequency of normal haematopoiesis read out more than 11-fold higher than in 
conventional NOD/Scid mice and previously unknown members of the haematopoietic 
hierarchy, one with short-term myeloid and one with short-term myeloid and lymphoid 
repopulating ability could be identified that completely failed to be detected in 
NOD/Scid mice (Glimm et al., 2001; Kollet et al., 2000). However, this mouse strain 
also has a relatively short life expectancy of around 6 months due to the development of 
thymic lymphomas and the mice were also found to accumulate iron in the liver leading 
to the development of haemochromatosis (Christianson et al., 1997; Shultz et al., 2007). 
As in NOD/Scid mice this short lifespan imposes a disadvantage on these mice when the 
experiments require a long observation period. Furthermore, NOD/Scid mice 
additionally treated with anti CD122 and transplanted intrafemorally proved to be better 
hosts for human haematopoietic cell engraftment than NOD/Scid B2m-/- mice in one 
study of John Dick´s group (McKenzie et al., 2005). 
 
3.1.1.6 NOD/Scid IL-2Rγ -/- (NSG) mouse strains 
The finding that even a very low NK-cell activity in NOD/Scid or NOD/Scid B2m-/- 
mice has a significant impact on human haematopoietic engraftment and lymphomyeloid 
differentiation prompted efforts to develop immunodeficient mice that lack NK-cell 
function completely. From X-chromosome linked Scid in humans it is known that the 
IL-2 common γ-chain, a signalling component of the IL-2, IL-4, IL-7, IL-9, IL-15 and 
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IL-21, is essential for lymphoid development and mice created with a homozygous 
disruption in the gene for the IL-2 common γ-chain completely lack NK cells and have 
severely reduced B- and T-lymphocytes (Asao et al., 2001; Cao et al., 1995). Crossing 
IL-2Rγ-/- mice with mice of the NOD/LtSz-Scid hybrid strain resulted in the new, highly 
immunocompromised NOD/LtSz-Scid IL-2Rγ -/- hybrid strain NSG that combined the 
immunodeficiency characteristics of both maternal strains. These mice readily engrafted 
human HSCs to high levels and supported multilineage differentiation (Shultz et al., 
2005). When compared to conventional NOD/Scid and NOD/Scid B2m-/- mice, NSG 
mice as well were found to engraft patient samples that failed to reconstitute the 
leukaemia in both other strains as well as to engraft AML and ALL cell lines or other 
primary patient samples faster and to a higher level (Agliano et al., 2008). Another big 
advantage that makes NSG mice highly suitable for long-term engraftment studies and 
for limiting dilution experiments which potentially need extended time for follow up 
when small cell doses are transplanted, is the comparably old age of more than 16 
months that these animals can achieve. This is partly owed to the fact that NSG mice are 
highly unlikely to get lymphomas at advanced age or even when sublethal irradiation is 
applied. Furthermore, NSG mice additionally only have a small tendency to become 
“leaky” (Ishikawa et al., 2005; Shultz et al., 2005).  
Another group used mice with a truncated IL-2 chain for backcrossing on NOD/Scid 
mice and generated the NOD/Shi-Scid IL-2Rγ-/- strain (NOG). They also demonstrated 
superior engraftment and multilineage differentiation abilities of these mice compared to 
anti-asialo GM1 antibody (to deplete residual NK-cells) treated NOD/Scid and 
NOD/Scid B2m-/- mice (Hiramatsu et al., 2003; Ito et al., 2002). 
A potential disadvantage of the NOG to the NSG strain is that in the first the IL-2Rγ-
chain is not completely absent but only truncated and still can bind cytokines (Shultz et 
al., 2007). Indeed, in a recent HSC engraftment study, conducted by McDermott et al, 
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both the NOG and the NSG strain showed much higher engraftment sensitivity and 
multilineage engraftment than NOD/Scid mice treated with anti CD122 antibody but 
NSG mice were found to have slightly higher bone marrow engraftment of human 
haematopoietic cells than all other transplanted mouse strains (McDermott et al., 2010). 
The superior ability of NSG mice to engraft human haematopoietic cells compared to 
other mouse strains with higher residual levels of innate and adaptive immunity proved 
in several studies, combined with the longevity of these mice made the NSG strain a 
robust mouse model of choice for this project. 
 
3.1.2 Intrafemoral transplantation technique 
In addition to the applied mouse model, the transplantation technique is another critical 
step in an in vivo xenotransplantation setup. Ideally, every human cell delivered into the 
mouse should meet the same and most supportive conditions to allow it to prove, if 
existent, its self-renewal and differentiation capability. Insights regarding the identity 
and frequency of stem cells closest resembling those in their natural habitat can only be 
gained if artificial impediments imposed by the experimental setup are alleviated to the 
smallest possible degree. Stem cells are dependent on the microenvironment of their 
niche and in a first step after transplantation any stem cell has to find its way into this 
niche in order to have the chance to engraft. For the conventional approach of 
intravenous injection of candidate stem cells this means that transplanted cells first 
circulate through the blood system and have to adhere to and migrate through the 
endothelial wall of blood capillaries to home in the appropriate bone marrow stroma. 
The seeding efficiency of normal HSCs (the percentage of HSCs that reaches the murine 
bone marrow after intravenous injection) has been investigated in irradiated NOD/Scid 
mice by van Hennik et al and found to be only around 5% (van Hennik et al., 1999). 
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As homing ability is not a defining characteristic of stem cells it and therefore should be, 
if possible, excluded from the assay. In order to circumvent this step, several groups 
have tried to establish an orthotopic transplantation approach in which assayed cells are 
directly delivered into the most accessible bone marrow in the mouse femur or tibia. 
Although the orthotopic transplantation technique is more elaborate and time consuming 
than intravenous injection, as mice have to be anaesthetised in order to inject the cells 
through a pre-drilled hole into the mouse femur or tibia, the increase of sensitivity in 
revealing stem cell activity is convincing. The method was developed by Kushida et al 
in a syngenic mouse model in 2001 and Yahata et al were the first to apply this approach 
in the human to mouse xenotransplant setting and to prove its superiority to the 
conventional intravenous transplantation technique (Kushida et al., 2001; Yahata et al., 
2003). The frequency of HSCs in CD34+CD38- umbilical cord blood cells, as 
determined by intratibial injection into NOD/Scid mice, was found to be 15-fold higher 
than after intravenous injection (Yahata et al., 2003). By transplanting subfractions of 
human umbilical cord blood cells intrafemorally into NOD/Scid mice, John Dick´s 
group even managed to identify a new class of rapid myeloerythroid repopulating stem 
cells that evaded detection by the conventional intravenous transplantation procedure 
(Mazurier et al., 2003). The advantage of orthotopic transplantation was subsequently 
demonstrated for several mouse models (NOD/Scid mice, NOD/Scid mice treated with 
anti CD122 antibody and NOD/Scid B2m-/- mice) by the same group (McKenzie et al., 
2005). 
In addition to the advantage of delivering the transplanted cells as close as possible to 
their ideal microenvironment, the intrafemoral transplantation approach potentially also 
diminishes the problem of antibody mediated clearance of intravenously injected cells 
by residual peripheral immune cells as suggested by Taussig et al (Taussig et al., 2008). 
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3.2 Aims 
 
The primary aims of the initial phase of the study were: 
 
 To establish multicolour flow cytometry to detect, characterise and quantify 
human ALL cells in the NSG murine background with a high sensitivity and 
specificity. 
 
 To establish the intrafemoral orthotopic transplantation technique for ALL in 
NSG mice in order to assess the existence and frequency of blasts with LSC 
characteristics in purified subfractions defined by the immunophenotype. 
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3.3 Materials and methods 
Flow cytometry has played an invaluable role in elucidating B-cell development and the 
haematopoietic hierarchy in general through the identification of distinct patterns of 
surface antigens in a time dependant manner (Loken et al., 1987). For 
xenotransplantation experiments it is also essential to clearly separate cells of mouse 
origin from human cells. This can also be achieved by taking differential surface antigen 
expression into account. 
The interrogation of a single cell to assess its expression of several surface antigens can 
be realized by multiparameter flow cytometry that in addition to forward and side light 
scatter profiles uses multi-colour staining and detection (multi-colour flow cytometry). 
With a higher number of defining antibodies and therefore colours used in one single 
assay, the resolving power of flow cytometry increases. Several single fluorochromes 
(also named fluorophores) or tandem dyes with distinct fluorescence emission spectra 
are available which can be conjugated to specific mAbs. The detection and intensity of 
fluorescent signals from individual cells then proportionally indicates the expression 
profile of certain marker antigens on the cell of interest. 
The more fluorescent colours are used in one experiment, the more spectral overlap 
occurs between different emission spectra of fluorochromes and this creates a problem 
in unambiguously allocating signals received by a PMT to a specific fluorochrome. 
Spectral overlap between two fluorochromes is schematically depicted in Figure 7. To 
prevent false results due to spillover of fluorescent signals into PMTs assigned to other 
colours the process of compensation is mandatory as bandpass filters are not able to 
completely filter out light from other fluorochromes. Compensation is designed to 
mathematically subtract signals generated by several fluorochromes not assigned to a 
specific PMT detector from the total signal received by it (Roederer, 2001). 
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Figure 7: Spectral overlap between two fluorochromes. Emitted light from fluorochromes covers a 
broad spectrum of wavelengths, although of variable intensity. The emission spectra and overlap 
between two fluorochromes is shown in this schematic figure. Bandpass filters (a and b, indicated by 
vertical lines) are designed to allow only light within a narrow bandwidth around the emission 
maximum of a specific fluorochrome to pass to the PMT. In case of spectral overlap falling into the 
bandwidth of a bandpass filter, light of a fluorochrome not assigned to the PMT is recorded and has to 
be compensated for in order to prevent false positive signalling. 
 
3.3.1 Preparation of human and NSG mouse cells for flow cytometry 
Human peripheral blood lymphocytes were regarded as being appropriate for the setup 
of flow cytometry as normal human bone marrow was not available for this procedure. 
After informed consent, approximately 10 ml of peripheral blood was taken from 
healthy volunteers via venesection. Red cell lysis was carried out with 1x ammonium 
chloride buffer and the remaining mononuclear cells were washed twice with PBS (see 
section 2.2.3). Compensation experiments were carried out with fluorochromes 
conjugated to the anti-CD3 surface marker antibody (see section 2.2.2). CD3 is 
commonly expressed on T-lymphocytes as part of the T-cell receptor complex (Clevers 
et al., 1988). Lymphocytes usually represent 20 to 45% of all peripheral white blood 
cells and T-lymphocytes make up for 40 to 75% of total lymphocytes in a differential 
full blood count (Blumenreich, 1990). PBMCs were counted in an improved Neubauer 
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counting chamber (see section 2.6.5), cell aliquots distributed in FACS tubes and cells 
were labelled with saturating amounts of one or several monoclonal antibodies to CD3 
directly conjugated to FITC, PE, PerCP-Cy5.5, PE-Cy7 or APC. PBMCs were also 
labelled with anti-CD10 FITC, anti-CD19 PE, anti-CD20 PerCP-Cy5.5, anti-CD38 PE-
Cy7 and anti-CD34 APC (see section 2.2.5). All stained and unstained samples were 
acquired on the BD FACSCanto II flow cytometer equipped with FACSDiva analysis 
software, v6.1.2 (see section 2.2.6). 
In order to detect engraftment of human cells in peripheral blood of transplanted mice, a 
different method of lysis for mouse red cell was performed. After incubating peripheral 
blood from mice (usually 30 – 50 µl diluted to 200 µl with 0.2% w/v PBSA) for 20 
minutes with antibodies of interest, the samples were incubated for an additional 7 
minutes with fixative and lysis buffer, commercially available from BD Biosciences (1x 
BD FACS Lysis buffer) at room temperature in the dark. Samples were centrifuged at 
1,750 rpm (713 g) for 5 minutes at room temperature, the supernatant discarded and then 
washed twice with 3 ml PBS using the same parameters for centrifugation. Cells were 
then resuspended in 500 µl of 0.2% w/v PBSA solution for flow cytometry. 
 
3.3.2 Setup of multi-colour flow cytometry 
To set up for calculation of a compensation matrix, an unstained cell sample as well as 
one sample for each individual fluorochrome that is due to be part of multi-colour 
staining in later experiments, is needed. Data from all samples are acquired into the 
compensation mask, provided by the FACSDiva analysis software, v6.1.2. Acquisition 
of the unstained cell sample is needed first in order to set the PMT voltages. Unstained 
cells have some degree of autofluorescence overlapping the fluorescence spectra of 
individual fluorochromes. This autofluorescence has to be excluded from being regarded 
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as a true signal in the PMT. Therefore the autofluorescent signal from unstained cells 
has to be set into the first quadrant of a signal intensity histogram for each colour 
recorded by a PMT by adjusting the signal amplifying voltage across the PMT. Signals 
in the first quadrant are counted as being negative. After adjusting PMT voltages for 
autofluorescence, the individually stained samples are acquired to record a positive 
signal for each fluorochrome and to check if clearly defined and separable positive and 
negative signals are present from populations of cells that did, or did not, bind the 
fluorochrome conjugated antibody. In the case of acquisition of well defined negative 
and positive signals for each fluorochrome, the FACSDiva software is able to calculate a 
compensation matrix. This compensation matrix then adjusts for spectral overlap 
between the individual fluorochromes, enabling to record fluorescent signals only from 
cells that actually did bind the specific antibody-fluorochrome conjugate. 
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3.4 Results 
3.4.1 Compensation matrix for 5-colour flow cytometry 
Compensation experiments were performed on the BD FACSCanto II to set up a 
compensation matrix for multi-colour flow cytometry by using the FACSDiva analysis 
software, v6.1.2. It was possible to compensate for a combination of 5 different 
fluorochromes. The different steps involved in the process of generating the 
compensation matrix are shown in Figure 8. This allows the discrimination of expression 
of 5 different human surface antigens in the case of labelling primary patient samples 
that are not contaminated with mouse cells with antibodies directed at human surface 
markers only. The combination of anti-CD10 FITC, anti-CD19 PE, anti-CD20 PerCP-
Cy5.5, anti-CD38 PE-Cy7 and anti-CD34 APC, comprising stem cell markers and 
surface antigens expressed in B-cell development was generally used for this purpose. 
To analyse cells from transplanted mice, one colour was dedicated to antibodies against 
mouse cells, anti-mouse CD45 and anti-mouse TER-119. Both antibodies were 
conjugated to the same fluorochrome (PE-Cy7) as the purpose of identifying mouse cells 
within mouse human chimerae only was to exclude the cells of mouse origin from 
analysis and not to measure individual expression levels of these mouse antigens. 
Determining the expression of 4 human antigens (CD10, CD19, CD20 and CD34) on 
cells of human origin in the mouse background was considered as being sufficient to 
characterise the immunophenotype of engrafted blasts. 
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Figure 8: The process of creating a compensation matrix with FACSDiva analysis software, 
v6.1.2. a) The normal light scatter profile of human PBMCs is depicted after light scatter voltages 
have been adjusted to clearly separate the three distinct PBMC populations of lymphocytes (gated in 
P1), monocytes (P2) and granulocytes (P3). The relatively small lymphocytes with cytoplasm of low 
complexity show a typical low SSC and FSC profile. b) The voltages across PMTs for different 
fluorochromes were adjusted to place autofluorescence signals of lymphocytes (P1) in the first 
quadrant of the histograms, defined as being negative. c) Each of 5 lymphocyte samples was labelled 
with one individual fluorochrome directly conjugated to an anti-CD3 antibody and the positive signals 
were recorded and gated. Spectral overlap between the fluorochromes was identified and 
automatically compensated for. d) To test the result, lymphocyte samples individually stained with 
anti-CD3 PE and anti-CD3 APC were mixed, recorded on the FACSCanto II and depicted as a dot 
plot. Cell populations with no bound antibody or labelled with one of the two fluorochromes are 
distinct and clearly separable. 
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3.4.2 Excluding murine cells from analysis of human blast engraftment by using 
antibodies to murine CD45 and TER-119 
Flow cytometry analysis of all transplantation experiments had to meet two essential 
criteria for this project, high specificity and high sensitivity of detecting blasts of human 
origin in the xenoenvironment of the NSG host mice. The purpose of that was to find out 
whether or not the leukaemia was in general able to engraft into the NSG mice and in the 
case of successful engraftment to determine the percentage of chimerism between cells 
of human and mouse origin as reliably and exactly as possible. At later stages of the 
project it was also necessary to dependably detect very low engraftment levels of human 
blasts within the mouse bone marrow compartment, comparable to MRD levels in 
human leukaemia follow up diagnostics, as it could be expected that mice transplanted 
with only 10 cells in the limiting dilution experiments would need a rather long time to 
engraft the NSG mice and that the life span of around 16 months of these mice would 
probably still not be long enough to engraft the blasts to a higher percentage. Detecting 
first minimal signs of bone marrow engraftment was as well necessary to address the 
question of differences in engraftment kinetics between sorted blast populations and also 
in limiting dilution experiments of unsorted and sorted blasts. The rational for this was 
that in ALL usually an exponential growth pattern is expected and that, with the limited 
allowed number of bmps and minimum intervals of two weeks between consecutive 
bmps it would have been difficult to see differences in time to engraftment once the log 
phase of leukaemic growth with higher engraftment levels was reached. A third reason 
for the need to undoubtedly document a very low chimerism of human cells was 
inherent of the animal model. Working with highly immune compromised mice, it was 
unavoidable that some animals would die during the course of the experiments for other 
reasons than developing the full clinical picture of an ALL or approaching their expected 
life expectancy. As this could happen at any time point during the course of 
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experiments, it was possible that engraftment was only marginal at the last bone marrow 
puncture before the loss of the individual mouse. 
To match these criteria, first of all it was crucial to reliably differentiate between human 
and mouse cells in the flow cytometry analysis of murine chimeric bone marrow. The 
light scatter profiles of mouse cells and human lymphocytes were not suitable for 
discriminating these cells as there is significant overlay between cells of mouse origin 
and human lymphocytes. Additionally, staining native mouse bone marrow with a panel 
of human surface antigen antibodies that would be used for characterisation of engrafted 
leukaemic blasts (antibodies to human CD10, CD19, CD20 and CD34) according to the 
staining protocol described in section 2.2.5 showed a substantial degree of non specific 
binding to mouse bone marrow cells (see Figure 9). This unspecific binding would make 
it difficult to detect and exclusively depict human leukaemic blasts in the murine bone 
marrow background, especially if only a low number of blasts were engrafted.  
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Figure 9: Similar light scatter profiles of human lymphocytes and murine cells and unspecific 
binding of anti-human surface marker antibodies to murine cells hamper detection of human 
cells in a murine bm background. a) Human lymphocytes depicted in a light scatter dot plot are 
overlaid by murine cells with a similar light scatter profile. b) Bone marrow, spleen cells and 
peripheral blood from native, not transplanted NSG mice were stained with anti-human CD10 FITC, 
CD19 PE, CD20 PerCP-Cy5.5 and CD34 APC according to standard protocol and dot plots compared 
to unstained samples (only shown for bm). Mouse cells of all three sources show significant 
unspecific binding of antibodies to human surface antigens. 
 
To circumvent the problem of nonspecific binding antibodies against mouse white and 
red cell lineages were used to gate out the majority of cells of mouse origin in the flow 
cytometry and exclusively leave engrafted cells of human origin for analysis using the 
antibody panel directed against human surface antigens (CD10, CD19, CD20 and 
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CD34). Anti mouse CD45 (alternate names Leukocyte Common Antigen (LCA), Ly-5, 
T200) which binds to all cells of haematopoietic origin except erythroid cells and anti 
mouse TER-119 (alternate name Ly-76) which binds to erythroid cells from pro-
erythroblasts through to mature erythrocyte stages were chosen for this purpose and 
evaluated regarding their ability to gate out murine bone marrow cells from engraftment 
analysis. Initially it was planned to serially analyse bone marrow samples only but from 
post mortem examinations of mice it soon became obvious after the first sets of 
successful transplantations that these leukaemias were spreading in the NSG mice and 
apparently were infiltrating and thereby enlarging the spleens of the animals. This 
observation suggested analysing harvested mouse spleens regarding their content of 
human leukaemic blasts as well.  
To validate whether a gating strategy to exclude mouse cells from analysis would be 
feasible, human peripheral blood mononuclear cells, mouse bone marrow, mouse 
peripheral blood and later a single cell suspension of mouse spleen cells were stained 
with anti-mouse CD45 (mCD45) or anti-mouse TER-119 (mTER-119) individually and 
also in combination and analysed by flow cytometry. First the extent of unspecific 
binding of mouse antibodies to cells of human origin was assessed. As the best substitute 
for normal human bone marrow, a sample of human leukocytes isolated from peripheral 
blood of healthy volunteers after red cell lysis first was incubated only with anti mouse 
CD45 and the fluorescence profile was depicted in a flow histogram. Over 98% of 
human lymphocytes in a normal distribution could be included into a gate P1 that 
reached from zero to 103 of mCD45 mean fluorescence intensity (MFI). Applying the 
same strategy, mTER-119 was evaluated. By placing the same gate P1 from zero to 103 
of mTER-119 MFI, nearly 95% of the human cells were captured within P1. Staining 
human lymphocytes with both murine antibodies simultaneously placed over 95% of the 
analysed cells into the same gate P1 in an additional experiment. These data are shown 
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in Figure 10 and proved that the mouse antibodies CD45 and TER-119 exhibit only low 
levels of nonspecific binding to blood lymphocytes of human origin and that therefore 
only a low number of human blood cells would be lost for analysis, if cells with an MFI 
of higher than 103 of mCD45 and mTER-119 in combination were excluded.  
 
 
 
 
 
 
 
 
 
 
 
Figure 10 (page 118): Separating cells of human and mouse origin with anti-mouse CD45 and 
TER-119. The histogram gates P1 and P2 separate cells of MFIs lower and higher than 10
3
 
respectively.
 
a) Human lymphocytes show only little binding of anti-mouse CD45 and TER-119 
mAbs. b) More than 97% of NSG mouse bm cells stained with mCD45 and mTER-119 in 
combination lie in P2. c) More than 83% of mouse spleen cells are included in P2 with the 
mCD45/mTER-119 combination and mouse blood cells almost completely fall in P2 when labelled 
with both mouse mAbs (d)). Analysing only events in P1 for human CD marker expression excludes 
the vast majority of mouse cells and diminishes the possibility of false positive results from unspecific 
human mAb binding to murine cells. 
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In a second step it was assessed if cells of mouse origin could be readily excluded from 
analysis with this staining and gating strategy, thereby preventing possible false positive 
results for human engraftment as much as possible. For this purpose full bone marrow, a 
single cell suspension generated from a spleen and peripheral blood from a healthy NSG 
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mouse were stained with the same antibodies individually and in combination. Using 
mCD45 on murine bone marrow cells alone left less than 30% of the analysed cells in 
the established gate P1 from zero to 103 of mCD45 MFI. Staining another sample of the 
bone marrow cells with mTER-119 showed acquisition of only less than 35% of murine 
cells within P1. When both antibodies were used in combination on a third bone marrow 
sample the exclusion of mouse cells from the gate P1 increased to 97.4% and only less 
than 3% of mouse cells remained in the gate P1 in which cells were supposed to be 
analysed for human surface marker expression in the xenotransplant experiments. 
Accordingly, exclusion experiments were conducted on the mouse spleen cells. Staining 
the single cell suspension with mCD45 led to less than 40% remaining in the gate P1 
and staining the spleen cells with mTER-119 showed that only less than 37% of the 
mouse cells were included into gate P1. Again, the combination of both anti-mouse 
antibodies, mCD45 and mTER-119, was able to greatly increase the percentage of 
mouse cells that successfully could be excluded from being analysed regarding the 
expression of human surface antigens. The same antibody labelling and histogram gating 
strategy was applied on peripheral blood from mice. The mCD45 antibody only labelled 
a very small amount of mouse cells, most likely due to a very low peripheral white cell 
count, whereas mTER-119 binding approached 100%. The combination of both 
antibodies therefore could not increase the fraction of mouse cells excluded from P1. 
Figure 10 illustrates and summarizes the experiments that lead to the labelling and 
gating strategy applied to mouse bone marrow, spleen and peripheral blood samples in 
initial xenotransplantation experiments.  
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3.4.3 A histogram based gating algorithm for flow cytometry analysis on human 
mouse chimeric cell samples 
The experiments with the anti-mouse antibodies directed at mouse white lineage and red 
lineage cells, CD45 and TER-119 respectively, showed that the majority of cells from 
mouse bone marrow and peripheral blood could be labelled with a combination of these 
two antibodies. On the other hand, it could be established that human peripheral 
lymphocytes were only stained with the two anti-mouse antibodies to a very little extent. 
The gate placed in the histograms from zero to 103 MFI promised to readily isolate cells 
of human origin out of a chimeric mouse bone marrow and peripheral blood. These 
binding characteristics and the gate placement founded the basis for a gating algorithm 
(mainly suggested by PhD fellow student Kerrie Wilson).  
Whenever possible, 100,000 events were recorded from a bmp or peripheral blood. A 
histogram was drawn and a gate P1 set to cover the MFI of PE-Cy7 (the fluorochrome 
conjugated to both mCD45 and mTER-119) from zero to 103. A second gate was set to 
cover the MFI of PE-Cy7 from 103 to maximum. Events restricted to P1 were then 
depicted in a light scatter dot plot in a second step. Cells that showed a scatter profile 
typical of lymphocytes or blasts of lymphocyte origin were again gated (P3) to exclude 
cell debris from analysis and the number of cells within this gate could be used to 
calculate the percentage of engraftment. In a third step the P3 gated cells from the 
previous dot plot were consecutively portrayed in several dot plots of the various 
combinations of fluorochromes on the x- and y-axis representing the human surface 
antigens CD10, CD19, CD20 and CD34, as well as the mouse surface antigen CD45 in 
combination with TER-119. These dot plots could then be used for assessment of the 
immunophenotype of engrafted human cells. This gating strategy is illustrated in Figure 
11. 
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Figure 11: Gating algorithm based on flow histogram (example on bmp1, mouse M19, patient 
sample A67). a) The majority of NSG mouse cells are excluded from further analysis by gating them 
out with P2 set between 10
3
 and maximum MFI for mCD45 and mTER-119. b) Only cells falling into 
P1 are then visualised in a light scatter dot plot and another gate P3 set to enclose cells with a light 
scatter profile resembling lymphoblasts. c) Cells from P3 are then depicted in dot plots for surface CD 
antigen expression. 
 
3.4.4 First bone marrow xenotransplantations and engraftment analysis 
After developing a method to detect and characterize potential engraftment of human 
leukaemic blasts in a NSG mouse xenograft background by applying the established 
gating strategy on a 5 colour flow cytometry, the next crucial step was to carry out first 
bone marrow transplantations onto NSG mice. These transplantations were performed to 
assess the technical success of the procedure and to gain a first insight into the behaviour 
of a human ALL in the xenoenvironment. On the technical side it was essential to see 
whether all the procedures involved in the xenotransplantation assay would lead to 
successful engraftment of human ALL blasts into NSG mice and whether engrafted cells 
could indeed be reliably detected in the mouse background. This involved the steps of 
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thawing the primary patient material, transplanting it intrafemorally into several NSG 
mice and following this, performing a series of bone marrow punctures and finally a full 
bone marrow harvest with application of the flow cytometry analysis on the acquired 
cells. In the case of positive results for engraftment, the second issue was to determine 
whether it was possible to amplify blast cell numbers in the mouse for further sorting 
experiments. An important pathophysiological question was to compare the original 
diagnostic ALL immunophenotype with the immunophenotype of human blasts grown 
in the xenotransplant assay and to determine whether or not the xenoenvironment would 
change the immunophenotypic character of the ALL.  
For these reasons, and to achieve the highest possible chance of positive results, the first 
experiments were kept as simple as possible with relative high cell numbers of freshly 
thawed and unmanipulated, unsorted diagnostic material used for transplantation. 
Initially the investigations additionally concentrated on the high risk treatment group of 
BCR/ABL1 positive ALL patients as high risk leukaemias have been considered to have 
increased engraftment capabilities compared to ALL samples from lower risk groups. 
Two diagnostic ALL patient bone marrow samples with different characteristic were 
chosen. Sample 8849 (BCR/ABL1 positive, adult patient, sample frozen for 11 years) 
was transplanted intrafemorally with 1 x 106 cells for each of four mice. Sample A67 
(BCR/ABL1 positive, paediatric patient, sample frozen for just over one year) was 
transplanted into four mice but with a lower cell number of 3 x 105 each. 
 
3.4.4.1 Engraftment analysis from mouse bone marrow punctures and bone 
marrow harvests 
Bone marrow punctures form an essential part of patient initial and follow up 
diagnostics as ALL cells can be present in bm while peripheral blood appears to be 
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normal. Analysis of cells from bmps was therefore used to detect human engraftment in 
NSG mice. The first bone marrow punctures of the mice transplanted with the two 
different patient samples were carried out after 56 days (8 weeks) for sample 8849 and 
after 65 days (approximately 9 weeks) for sample A67 respectively. The individual 
samples were stained with the established antibody panel of anti-human CD10 FITC, 
CD19 PE, CD20 PerCP-Cy5.5 and CD34 APC according to the staining protocol 
described in 2.2.5 to characterize the potentially engrafted human blast population and 
with anti-mouse CD45 PE-Cy7 and TER-119 PE-Cy7 in order to exclude cells of mouse 
origin from flow analysis as described in section 3.4.2. One mouse transplanted with 
sample 8849 died before the first bmp was carried out. Of the remaining 3 mice the first 
bmp was performed on day 56 post intrafemoral transplantation and after staining the 
samples with the established antibody panel, 100,000 events from each sample were 
acquired on the BD FACSCanto II. Only one mouse (M1) showed engraftment, albeit to 
a low level of only 0.02%, as determined using the gating strategy described in 3.4.3. 
This is illustrated in Figure 12 a). The distribution of CD10 and CD19 expression among 
the engrafted lymphoblasts of mouse M1, despite the low cell number detected, shows 
close similarities to the original patient blast immunophenotype. All 4 mice transplanted 
with patient sample A67 were available for the first bmp on day 65 post if transplant. 
The bmp aspirates were stained with the same anti-human and anti-mouse antibodies 
and 100,000 events were recorded for mice M5 and M8, while only 10,000 events could 
be acquired for mice M6 and M7. Flow cytometry data of mice M7 and M8 show human 
chimerism of 1.1% and 0.1% respectively. As already seen for patient 8849 (Figure 12 
a)), levels of expression for CD10 and CD19 in the bmp samples mimic the expression 
observed in the original patient sample. In the dot plot of CD19 against CD10 expression 
of mouse M5, only 7 events were detectable with the applied gating strategy. In addition 
to the very low number, the events do not form a coherent cluster but rather form two 
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groups and as a consequence they can not confidently be regarded as positive evidence 
of human lymphoblast engraftment. Dot plots of the original patient sample (A67) and 
of the bmps from transplanted mice (M5, M6, M7 and M8) with CD19 expression on the 
y-axis and CD10 expression on the x-axis are shown in Figure 12 b). 
 
 
 
 
 
 
 
 
 
 
Figure 12 (page 125): Analysis of first bone marrow punctures on 8849 and A67. a) Dot plots 
with analysis of human CD10 and CD19 expression on the original patient sample 8849 and below on 
cells from the bmp 56 days post if transplant are shown of the 3 mice (M1, M2 and M3) transplanted 
each with 1 x 10
6
 cells. 100,000 events were recorded from each bmp sample. While mouse M1 
shows very little engraftment of 0.02%, no cells expressing human CD10 or CD19 were detected in 
mice M2 and M3. b) Dot plots analysis of human CD10 and CD19 expression on the original patient 
sample A67 and below on cells from the bmp 65 days post if transplant are shown of the 4 mice (M5, 
M6, M7 and M8) transplanted each with 3 x 10
5
 cells. 100,000 events were acquired from mice M5 
and M8 and 10,000 events from mice M6 and M7. Mice M7 and M8 exhibit clear clusters of cells 
representing 1.1% and 0.1% of the total number of events acquired respectively. The only 7 events 
recorded from mouse M5 do not appear as a clear cluster and were therefore not counted as 
engraftment. 
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In order to follow up engraftment levels of human cells, up to 5 consecutive bmps could 
be performed on mice with a minimum interval of 14 days between two punctures. 
However, if a mouse appeared to be ill from leukaemia or due to other reasons before 
completion of 5 bmps, the mouse was killed and a bone marrow harvest from the two 
femora and tibiae was carried out at that time point. All mice from the first two 
xenotransplantation experiments with patient samples 8849 and A67 underwent further 
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bmps for engraftment monitoring. Mouse M1 (patient 8849) showed generally 
increasing levels of human chimerism over the observed time course. At the time of 
bone marrow harvest, the overall engraftment level was determined to be 19.3%. The 
immunophenotype of the harvested bone marrow cells has a generally high expression 
of CD19 and a spread from low to high CD10 expression, comparable to the expression 
profile of the original patient blasts. While only two mice (M7 and M8) transplanted 
with A67 patient material showed engraftment at the time of the first bmp, all 4 mice 
were positive for cells of human origin, when the samples of the second bmp were 
analysed. The levels of human chimerism generally increased over the next bmps. This 
is illustrated in Table 2 (additionally engraftment analyses from bmps of all mice are 
listed in the table with raw date of Appendix 1). 
 
 
Table 2: Human chimerism of all bone marrow punctures from the first two xenotransplantation 
experiments on patient samples 8849 and A67. 
Wk, week; *, positive outside limits 
 
Analysis of the consecutive bmps usually also showed high consistency in the 
expression levels of human surface CD antigens. The majority of human lymphoblasts 
aspirated from mouse M5 at the fourth bmp, however, showed only low expression of 
CD10. Nevertheless, this expression profile was inconsistent to the one determined at 
Mouse 
ID
Patient / 
Leukemia
BMP1 Result 
Wk 8
BMP2 Result 
Wk 10
BMP3 Result 
Wk 13
BMP4 Result 
Wk 16
BMP5 Result 
Wk 21
Wk
Final 
Engraftment
M1 0.039% 0.134% 0.09% 4.0% 7.8% 25 75.7%
M2 0 0 0 0 0 49 0
M3 0 0 0 0 >16
M4 <8
Mouse 
ID
Patient / 
Leukemia
BMP1 Result 
(Wk 9)
BMP2 Result 
(Wk 12)
BMP3 Result 
(Wk 15)
BMP4 Result 
(Wk 16)
BMP5 Result 
(Wk 19)
Wk
Final 
Engraftment
M5 0.008*% 1.40% 5.2% 4.2% 16 40.6%
M6 0 0.057% 0.041% 0.32% 18 14.8%
M7 2.1% 3.7% 14 74.8%
M8 0.51% 0.064% 8.6% 3.2% 22.5% 19 75.8%
8849 prim
A67 prim
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bmp3 and also for the final bone marrow harvest. A major downregulation of CD10 on 
most cells therefore seemed to be unlikely and was probably caused by a problem during 
the process of antibody labelling leading to a false negative result. All 4 mice 
transplanted with patient material A67 were killed and bone marrow was harvested 
when the ALL became clinically overt. Final bone marrow engraftment levels were 
determined and the immunophenotype of the harvested cells compared to the original 
diagnostic patient blasts. CD19 expression was uniformly high at presentation as well as 
on cells grown in mice. CD10 expression also was generally high in both original patient 
blasts and bone marrow obtained from engrafted mice. Only a minor proportion of 
engrafted human cells showed downregulation of CD10 to some degree in the bm 
harvests. Figure 13 shows dot plots of the original material from patient A67, 4 
consecutive bmps and the final bm harvest.  
The first bmp on mouse M5 resulted in only very few cells exhibiting a CD surface 
marker profile comparable to that of the A67 patient sample and they were not regarded 
as engraftment due to low number and widespread distribution of events in the dot plot. 
Considering that this mouse proved to be successfully engrafted with the ALL in the 
second and following bmps, retrospectively the recorded events in bmp1 were indeed 
likely to be caused by cells of human origin as the mouse must have had already some 
albeit very low human chimerism at this stage of the experiment. 
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Figure 13: Serial bone marrow punctures and final bone marrow harvest of mouse M5 (Patient 
A67). Dot plots with analysis of human CD10 and CD19 expression on the original patient sample 
A67 as well as 4 consecutive bmps and the final bone marrow harvest (both femora and tibiae) of 
mouse M5 transplanted with 3 x 10
5
 cells are shown. 100,000 events from each bmp and 150,000 
events from the final bm harvest were acquired and analysed. The serial bmps show an increase in 
human chimerism over the time course observed. Final engraftment in harvested bm was determined 
to be 32.1%. Bmps 2 and 3 as well as the final harvest show an immunophenotype closely resembling 
that of the original patient sample. Cells from bmp 4 appear to express less CD10, most likely due to 
technical staining issues. Retrospectively, the events recorded from bmp1 probably can be considered 
as first but very low human engraftment. 
 
Harvested bm of all engrafted mice transplanted with diagnostic material from patients 
8849 and A67 was frozen down and stored in liquid nitrogen. A total of 8 x 107 cells was 
retrieved from the only mouse (M1) engrafted from sample 8849. Bone marrow harvests 
from mice M5-M8, transplanted with patient sample A67, yielded between 2.7 and 3.3 x 
107 cells. These high numbers of recovered cells were then available for use in further 
xenotransplantation experiments. 
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3.4.4.2 Engraftment analysis on mouse peripheral blood samples 
Although analysis of bm is the best way of detecting engraftment only 5 bmps could be 
performed because of considerations of animal welfare. Analysis was therefore also 
performed using peripheral blood. The time point of first signs of engraftment and 
engraftment kinetics towards a fully developed picture of leukaemia could be variable 
between mice even among groups transplanted with the same cell number from the same 
sample, making it necessary to monitor individual mice for presenting with ALL even 
when all 5 bmps had already been performed. Additionally, information would be 
gained whether the xenotransplant experiment would also lead to elevated blast numbers 
in peripheral blood of the mice, resembling the clinical picture of ALL in humans.  
Blood samples of around 50 µl were taken from the tail vein of mice, diluted to a 
volume of 200 µl with 0.2% PBSA, then incubated with the usual antibody panel and 
finally the red cell content of the sample was lysed with BD FACS Lysis buffer as 
described in 3.1.1. Mice transplanted with patient sample 8849 were the first analysed 
for the presence of peripheral human blood lymphoblasts around week 20 after the start 
of the experiment. At this time human engraftment of mouse M1 was already well 
established whereas in the bone marrow of mice M2 and M3 no human cells could be 
detected via flow cytometry. In conformance to these findings, mouse peripheral blood 
as well only exhibited human chimerism in mouse M1 and not in mice M2 and M3 
(Figure 14).  
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Figure 14: Presence of human lymphoblasts in mouse peripheral blood. Solid human ALL 
engraftment of 5.4% is detected in the bm of mouse M1 at week 21 post xenotransplantation. 
Peripheral blood taken from the same mouse 6 days earlier also contains cells of human origin as 
depicted in the second dot plot from the left. Mice M2 and M3 were not bm engrafted at week 21 and 
also do not show peripheral human blasts.  
 
Peripheral blood analysis for human engraftment was performed on 22 additional mice 
from early xenotransplantation experiments performed on cells harvested from mice M5, 
M6 and M7 (patient A67, secondary material). In 18 of these mice, the leukaemia could 
be detected in the mouse blood samples with flow cytometry and in all cases it closely 
resembled the original patient immunophenotype. However, of the remaining 4 mice 
with no apparent peripheral human lymphoblasts, 3 already showed bm engraftment of 
1.7%, 6.2% and 15.7% prior to analysis of the corresponding blood samples. These 
findings indicated that reconstitution of human cells in the mouse would not be detected 
in at least some mice if only peripheral blood is analysed. 
 
3.4.4.3 Engraftment analysis from mouse spleen single cell suspension 
Enlargement of the spleen due to blast infiltration is a commonly found at clinical 
presentation of ALL in humans. The spleens of mice transplanted with human ALL cells 
were also found to be increasingly enlarged concordant with higher human chimerism in 
mouse bm. Following this observation from the first xenotransplantation experiments 
and the desire to yield as many as possible human ALL blasts from every individual 
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mouse, the mouse spleens also were regarded as a possible source for a high number of 
human cells that could be used in following experiments. Confirmation of blast 
infiltration into the spleens of transplanted mice additionally would show even closer 
resemblance of the original clinical disease pattern in the experiment animals. 
In order to analyse the spleen for human cell content with flow cytometry, a single cell 
suspension had to be prepared first. Spleens were passed through a 40 µm cell strainer to 
disaggregate the tissue and part of the cells were resuspended in 0.2% PBSA for surface 
marker labelling with the antibody panel already used for mouse bmps, bm harvests and 
peripheral blood samples. Routinely, 100,000 events were recorded and analysed for 
expression of human surface antigens. The first mice that were assessed post mortem for 
infiltration of the spleens were mice transplanted with secondary material from patient 
A67. Spleens of 3 mice (M13, M14 and M17) from that experiment were available for 
analysis. All 3 mice showed positive human engraftment (M13: 4.0%, M14: 21.5% and 
M17: 37.7%) in cells from the bm harvest and consecutively were as well found to have 
lymphoblast infiltrated spleens. Figure 15 shows dot plots of CD19 versus CD10 
expression of the bone marrow and spleen from mouse M13 as well as from the spleens 
of mice M14 and M17. In comparison, the immunophenotypes of human blasts from bm 
or spleen do not differ to a great extent in the expression profiles of surface antigens. 
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Figure 15: Infiltration of host mice spleens with human lymphoblasts. Enlarged spleens of 
euthanized mice were assessed for infiltration with cells of the transplanted ALL (secondary material 
of patient A67) in addition to analysis of harvested bm. Flow cytometry analysis data are shown as 
dot plots for bm and a single cell suspension of the spleen of mouse M13 and additionally of two 
further spleen single cell suspensions from mice M14 and M17. Cells of human origin can be 
identified in all 3 spleens depicted. Comparison of cells from spleens and bm from the 3 mice reveals 
similarities of immunophenotypes. This is depicted for mouse M13. 
 
After these first analyses of spleens detected substantial fractions of human 
lymphoblasts within the spleen tissue, every individual mouse with positive bm 
engraftment at the time of bm harvest from all further experiments was assessed for 
splenic involvement. Single cell suspensions of all harvested spleens containing human 
ALL blasts were routinely frozen down and stored in liquid nitrogen for further use. 
With the large numbers of cells retrieved from a single spleen in addition to bm, a large 
supply of material could be made available for future experiments. 
Furthermore, with bm and spleen chimerism determined by flow cytometry, the level of 
bm engraftment associated with infiltration of the spleen with lymphoblasts could also 
be assessed. In mice that had a human chimerism of higher than 10% in bm at the time 
of harvest, cells of human origin with an immunophenotype resembling that of the bm 
ALL cells could be detected in the spleen. Therefore, only mice with an engraftment 
level of less than 10% at the time of experiment termination were assessed for splenic 
involvement. Mice without overt leukaemia (less than 25% blasts in bm) usually are not 
clinically unwell and therefore the number of mice that were killed when they still had 
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relatively low levels of human engraftment was limited. However, of altogether 14 mice, 
transplanted with cells of 11 different ALLs, bm showed an engraftment of less than 
10% at the time of experiment termination. Spleens taken at that time were investigated 
for the content of leukaemic cells. 
 
Exp. 
No 
Mouse 
ID 
Patient 
Cells 
transplanted 
Cell No 
Weeks 
to 
harvest 
Engraftment [%] 
bm spleen 
KR4 M13 A67 CD34
+
Cd19
low 
2 x 10
3 
20 7.0  61.7 
KR24 M126 2510 CD19
+
CD10
low 
6.9 x 10
3 
30 1.2 0 
KR35 M228 L858 Unsorted 1 x 10
3 
36 1.9 0 
KR39 M276 WB51 Unsorted 1 x 10
2 
20 0.25 0 
KR44 M334 737c Unsorted 1 x 10
2
 19 4.7 25.5 
KR47 M377 M120 CD19
+
CD10
high 
2 x 10
3 
58 9.1 8.6 
KR49 M394 758b Unsorted 1 x 10
4 
48 0.4 0 
KR52 M427 A67 Unsorted 1 x 10
4 
15 1.8 3.2 
KR53 M448 L876 unsorted 1 x 10
2
 31 3.1 0.03 
KR56 M512 737c CD19
+
CD10
low
 1 x 10
2
 46 7.7 43.4 
KR59 
M568 
WB51 CD19
+
CD34
high
 1 x 10
1 
19 0.47 0 
M572 22 1.5 1.3 
KR61 M616 4540a CD19
+
CD34
high
 1 x 10
2
 29 8.9 15.7 
KR62 M645 L784 CD19
+
CD34
high
 1 x 10
3
 36 2.7 20.3 
Table 3: Infiltration of the spleen with lymphoblasts takes part early in the xenotransplantation 
experiment. 14 mice transplanted from 11 different patients had bm engraftment of less than 10% at 
the time of experiment termination. 5 of these mice, all with bm engraftment of less than 2%, had no 
signs of ALL within the spleens. In contrast, another 2 mice (transplanted from A67 and WB51), with 
engraftment of less than 2% in bm, had 1.3% and 3.2% spleen involvement respectively. Migration 
and settling of lymphoblasts to the spleen seems to take place at around 1% to 2% bm engraftment. 
 
The data shown in Table 3, together with the finding that all mice with a bm engraftment 
of higher than 10% already had spread of cells to the spleen without exception (see table 
with raw data of all experiments in the Appendix) show that dissemination of ALL takes 
place at a relatively early stage of the disease. Negative spleen involvement was seen in 
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only 5 mice and they all had bm engraftment of less than 2%. However, in 2 cases of 
only 1.5% and 1.8% human chimerism in bm respectively, the spleen already harboured 
human lymphoblasts. The threshold for human lymphoblasts to migrate to the spleen and 
colonize it appears to have reached when bm engraftment exceeds 1% to 2%.  
 
3.4.5 Development of a dot plot based gating algorithm for more accurate 
quantification of human engraftment 
The gating algorithm applied to bone marrow cells from punctures and harvests as 
described in section 3.4.3 was highly specific in detecting human engraftment but it soon 
became obvious from the initial xenotransplantation experiments of different patient 
samples, that blasts of human origin did bind mouse specific antibodies (mCD45 and 
mTER-119) to a greater extent than normal PBMCs from healthy volunteers. This 
possibility was not considered when the initial gating algorithm was developed. When 
the gating strategy was performed on xenotransplantation experiments with the ALL 
samples, however, the method led to the exclusion of a significant proportion of human 
lymphoblasts contributing to the engraftment level, finally resulting in an 
underestimation of the real human chimerism. Furthermore, the cells excluded by the 
initial gate P1 were lost for immunophenotype analysis in the subsequent steps. Figure 
16 illustrates how cells of apparent human origin are excluded from further analysis by 
the boundaries of P1 and P2 respectively.  
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Figure 16: The histogram based gating algorithm excludes a significant proportion of human 
lymphoblasts from analysis (example on bm harvest, mouse M1, patient sample 8849). a) Gating 
is based on the algorithm described in subchapter 3.4.3. Gate P3, surrounding cells with a light scatter 
profile of human lymphoblasts on the dot plot in the middle image is a subgate of gate P1 (histogram 
on the left). Human ALL engraftment calculated with the cell number enclosed in P3 is 58.1%. The 
engrafted human cells are characterised by a high expression of CD19 and low to high expression of 
CD10 (dot plot on the right). b) A gate P3 is set in the histogram adjacent to the original gate P1, 
enclosing cells of assumed human origin. The lower boundary of original gate P2 is moved to a 
higher MFI for mCD45/mTER-119 in continuation of P3. 14.2% of the total acquired cell number fall 
into P4, a subgate dependent on P3 only and exhibit an immunophenotype pattern highly resembling 
the one of human cells analysed in a). Adding this percentage of 14.2% to the 58.1% gained in a) 
results in a significantly higher total human chimerism of 72.3%.  
 
Eliminating significant numbers of human cells from analysis by the fixed position of 
gate P1 in a first gating step could also have the consequence that low numbers of 
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human cells in the mouse bm background would be missed completely and a mouse 
would be considered as not being engrafted. Especially later in the project, when 
limiting dilution experiments were introduced and proved to be very important for the 
conclusions of this work, a higher sensitivity in detecting human cells in the murine cell 
background became necessary.  
In order to more accurately quantify human chimerism in the xenotransplantation assay, 
a possible gating strategy needed to fulfil two essential criteria. Most importantly it was 
necessary to unambiguously separate cells of mouse origin visually from human cells. 
The initial histogram based gating strategy was not designed to differentiate between 
mouse and human cells but rather to reliably exclude the vast majority of mouse cells. 
This was done by negative selection. Only cells that had no affinity to mouse directed 
antibodies (mCD45 and mTER-119) were included in further analysis. The method did 
not allow for unspecific binding of mouse antibodies to human cells as seen in human 
lymphoblasts but not normal human lymphocytes. The second essential criterion of 
including human cells as completely as possible in the following analysis steps of 
establishing a realistic engraftment level could therefore not be met. The problem was 
resolved by including a positive selection parameter for human cells in addition to the 
negative mouse specific selection markers into the process of differentiating between 
cells of human or mouse origin. The obvious choice from the panel of routinely labelled 
human surface antigens CD10, CD19, CD20 and CD34 was the human marker CD19. 
This surface marker is most consistently expressed to a high level on human 
lymphoblasts of B cell precursor ALL unlike the other markers CD10, CD20 and CD34 
which can either be completely negative on some forms of ALL (CD10 on infant ALL) 
or more frequently present with a biphenotypic expression profile. On a dot plot with 
CD19 expression on the y-axis versus expression of the mCD45/mTER-119 
combination on the x-axis populations of human and mouse origin were separated into 
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distinct cell clusters. The population of high CD19 expression was surrounded by a gate 
and visualised in a gate dependent light scatter dot plot. In the next step cells with a 
characteristic appearance of lymphoblast according to the light scatter profile were again 
gated and the cells enclosed in this gate were scrutinised for their expression pattern of 
human surface antigens. This gating hierarchy is shown in Figure 17 using the example 
of flow cytometry data for the bm harvest of mouse M1, patient sample 8849. For 
comparison, the same data were used as for the illustration how cells of human origin 
are lost for analysis using the strict histogram based gating algorithm (see Figure 16 and 
text above). Engraftment levels determined by the histogram method and the improved 
dot plot method are 58.1% and 73.6% respectively. This accounts for a considerable 
difference of 15.5% and demonstrates the superiority of the dot plot based gating 
algorithm.  
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Figure 17: A dot plot based gating algorithm more accurately measures human cells in the NSG 
bm background (example on bm harvest, mouse M1, patient sample 8849). a) A gate P1 is drawn 
around the definable cell cluster of presumably human origin with relatively high expression of 
CD19. The enclosed population includes cells with increasing levels of bound mouse specific 
antibodies (mCD45/mTER-119). A second distinct population, representing mouse bm cells, is 
characterised by high expression of mCD45/mTER-119 and is encircled by gate P2 (this gate is drawn 
for illustration only and does not form a part of the gating hierarchy). b) Events contained in gate P1 
are depicted as a light scatter dot plot and a gate P3 is set to surround cells with a typical light scatter 
profile of human lymphoblasts. Human ALL engraftment calculated with the cell number enclosed in 
P3 is 73.6%. This engraftment level is even higher than the one determined with the already extended 
gates of the histogram gating algorithm of the same flow cytometry analysis (see Figure 16 and text). 
c) The engrafted human cells are characterised by a high expression of CD19 and a low to high 
expression of CD10 (upper dot plot) as well as a generally high expression of CD34 and a low to high 
expression of CD20 (lower dot plot).  
 
3.4.6 Definition of thresholds for minimal positive engraftment 
The gating method proved to be able to filter out very low percentages of human 
engraftment in a NSG mouse bm background. Very low numbers of cells were found to 
form clusters of a specific human leukaemic immunophenotype in flow cytometry 
analysis and therefore were indeed assumed to be of human origin. This created the 
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requirement to set levels for the minimal number of clustered events from which a 
minimal percentage of human chimerism could be calculated that was counted as a 
reliable positive human engraftment of a mouse in this project.  
The high sensitivity of flow cytometric analysis is well established and multi-colour 
flow cytometry has already been tested by several studies for use in monitoring MRD in 
ALL to complement or even substitute PCR based methods. These analyses need to 
reliably detect a minimal number of positive events. Additionally, these measurements 
cannot use antibodies to gate out most cells of host origin in a xenotransplant setting, but 
rather have to identify lymphoblasts with a specific leukaemia-associated 
immunophenotype (LAIP) in a syngenic human bm background. Nevertheless, very low 
levels of leukaemic cells were shown to be measurable in syngenic human bm by 
identifying blasts with a LAIP. The UK flow MRD group established a highly sensitive 
4 colour flow MRD method that reliably detected malignant cells in a healthy bm 
background down to a level of 0.01% and lower when a minimum of 50 events forming 
a cell cluster for one specific LAIP were recorded. Furthermore, the data closely 
correlated to the gold standard of molecular MRD measurement (Irving et al., 2009). A 
Swedish multi-centre study also comparing PCR and flow cytometry based MRD 
measurement even considered a sample MRD positive when a minimum of only 10 or 
more LAIP clustered cells could be detected by multicolour flow cytometry. They also 
found a high concordance with the PCR based method (Thörn et al., 2011). The same 
threshold number of 10 clustered events, associated with a light scatter profile typical of 
lymphoid cells, was applied by another multi-centre study, in context of the AIOP-BFM-
ALL 2000 trial (Dworzak et al., 2008; Ratei et al., 2009). Taking the criteria from these 
studies as guidance, thresholds were set to consider a mouse as being positively 
engrafted with human cells in this project. In order to be counted as engraftment, at least 
20 clustered events that showed a lymphoid light scatter profile had to be identified and 
Chapter 3  3.4 Results 
140 
 
represent 0.01% or more of all recorded events including those from obvious cell debris. 
However, in most cases, cell material of consecutive bmps or bm harvests was available 
and all of those showed eventually increasing human chimerism, indicating that, 
applying the defined criteria, the risk of getting false positive results was very low. If 
one of the two criteria was not met, the mouse was regarded as not being engrafted with 
human cells. In some cases a theoretical engraftment level of less than 0.01% was 
determined or only less than 20 clustered events of a leukaemic immunophenotype could 
be recorded. Results of these bmps were counted as negative but labelled as positive 
outside limits (pol). 
 
3.4.7 Comparison of engraftment levels between the two gating algorithms 
The levels of unspecific binding of the anti mouse specific antibodies mCD45 and 
mTER-119 to engrafted human lymphoblasts were found to be different between 
transplanted patient samples and also between mice transplanted with the same material. 
This would not result in a systematic error with equal underestimation of bm 
engraftment among different mice but rather to different percentages of human cells 
included for further analyses between individual mice. For example, mouse M1 
transplanted with patient sample 8894, used to demonstrate the difference of human 
engraftment levels determined with the two gating methods in section 3.4.5, did not bind 
the mCD45/TER-119 antibody combination to a particularly high extent. Other samples 
were found to exhibit much higher mean levels of unspecific mouse antibody binding 
according to mCD45/mTER-119 expression histograms. This would result in a much 
more pronounced underestimation of engraftment. In order to evaluate the range of this 
underestimation, the two gating algorithms were compared on bmps and bm harvests for 
an extended set of samples from different experiments. Human engraftment percentages 
were measured on 29 individual mice transplanted with 7 different ALL samples. 
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Altogether 101 bmps and 27 final bm harvests were analysed according to both methods 
and difference in the determined engraftment level was calculated. In general, the dot 
plot based method resulted in higher human chimerism than the histogram based method 
in both bmps and final bm harvests. At the time of bmp1, 14 out of 29 mice showed the 
beginning of bm engraftment. The mean engraftment was 3.45% higher when 
determined with the dot plot based method than with the histogram based method. 
Differences for individual samples ranged from 0.02% to 13%. At bmp2, 23 engrafted 
out of 28 alive and punctured mice had a mean difference of engraftment of 3.58% 
(range 0.01% - 26%), at bmp3 17 engrafted out of 21 alive and punctured mice had a 
mean difference of engraftment of 5.1% (range 0.01% - 26.1%), at bmp4 11 engrafted 
out of 14 alive and punctured mice had a mean difference of engraftment of 2.94% 
(range 0.03% - 12.2%) and at the last bmp5, 7 engrafted out of 9 alive and punctured 
mice had a mean difference of engraftment of 2.76% (range 0.04% - 8.4%). Bm of 27 
mice was harvested and of those, 25 had engrafted the ALL. The mean increase of 
engraftment levels determined with the dot plot gating algorithm as compared to the 
histogram gating algorithm was 16.26% and differences ranged from 0.02% to a 
maximum of 66.7%. Furthermore, low levels of engraftment were found in 8 bmps with 
the dot plot method but could not be identified with the histogram method highlighting 
the higher sensitivity of the dot plot method. The results of the comparison between the 
two gating strategies are summarised in Table 4. 
 
Table 4 (pages 142 and 143): Comparison of human engraftment levels in NSG mice determined 
by the histogram or dot plot gating method. The table contains the bm engraftment levels of all 
bmps and the final bm harvest from 7 different xenotransplantation experiments. Engraftmen levels 
are given for the histogram gating method and the dot plot gating method and the difference of 
measured human engraftment between the two methods is calculated. 
*
 indicates results that are 
positive outside limits (pol).  
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Histogram Dot plot Difference Histogram Dot plot Difference Histogram Dot plot Difference
M5 0.00% 0.008%* 0.008%* 0.97% 1.40% 0.43% 4.20% 5.20% 1.00%
M6 0.00% 0.00% 0.00% 0.02% 0.06% 0.04% 0.02% 0.04% 0.02%
M7 1.50% 2.10% 0.60% 2.90% 3.70% 0.80%
M8 0.30% 0.51% 0.21% 0.05% 0.06% 0.02% 4.60% 8.60% 4.00%
M29 10.80% 14.00% 3.20% 14.70% 16.80% 2.10% 20.50% 25.30% 4.80%
M30 1.60% 3.40% 1.80% 9.20% 15.30% 6.10% 47.70% 55.80% 8.10%
M31 1.10% 1.30% 0.20% 11.50% 12.40% 0.90% 20.40% 24.10% 3.70%
M64 7.80% 11.40% 3.60%
M65 8.30% 19.40% 11.10% 1.90% 8.40% 6.50%
M66 32.60% 43.30% 10.70% 5.10% 12.80% 7.70%
M67 14.80% 27.80% 13.00% 3.80% 7.70% 3.90%
M333 0.07% 0.18% 0.11% 1.00% 3.90% 2.90%
M334 0.70% 3.30% 2.60% 29.40% 55.40% 26.00%
M335 0.00% 0.016%* 0.016%* 0.03% 0.21% 0.18% 5.70% 11.90% 6.20%
M336 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
M337 0.20% 1.30% 1.10% 15.40% 33.40% 18.00%
M357 0.00% 0.00% 0.00% 0.00% 0.004%* 0.004%* 0.07% 0.15% 0.08%
M358 0.00% 0.00% 0.00% 0.00% 0.03% 0.03% 0.09% 0.60% 0.51%
M359 0.00% 0.00% 0.00% 0.05% 0.10% 0.05% 0.00% 0% d 0.00%
M360 0.00% 0.00% 0.00% 0.00% 0.07% 0.07% 0.00% 0.24% 0.24%
M443 0.00% 0.02% 0.02% 0.00% 0.03% 0.03% 0.02% 0.09% 0.07%
M444 0.00% 0.00% 0.00% 0.02% 0.13% 0.11% 54.90% 74.40% 19.50%
M445 0.00% 0.00% 0.00% 0.00% 0.03% 0.03% 0.00% 0.63% 0.63%
M446 0.00% 0.00% 0.00% 0.17% 0.35% 0.18% 29.80% 36.30% 6.50%
M466 0.00% 0.003%* 0.003%* 0.00% 0.00% 0.00% 0.17% 0.32% 0.15%
M467 0.00% 0.03% 0.03% 2.40% 8.60% 6.20% 18.40% 23.50% 5.10%
M468 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
M469 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
M470 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 21.00% 47.10% 26.10%
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Histogram Dot plot Difference Histogram Dot plot Difference Histogram Dot plot Difference
M5 3.50% 4.20% 0.70% 16 30.50% 40.60% 10.10%
M6 0.21% 0.32% 0.11% 18 6.60% 14.80% 8.20%
M7 14 39.00% 74.80% 35.80%
M8 2.30% 3.20% 0.90% 13.50% 22.50% 9.00% 19 75.30% 75.80% 0.50%
M29 25 29.60% 30.90% 1.30%
M30 25 48.30% 56.50% 8.20%
M31 25 28.40% 30.60% 2.20%
M64 11 29.00% 58.60% 29.60%
M65 16 14.20% 80.90% 66.70%
M66 14 7.80% 51.70% 43.90%
M67 14 26.40% 55.50% 29.10%
M333 0
M334 19 3.10% 4.70% 1.60%
M335 1.10% 1.70% 0.60% 0.31% 0.32% 0.01% 33 55.30% 65.10% 9.80%
M336 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 47 0.03% 0.10% 0.07%
M337 19 37.70% 69.50% 31.80%
M357 0.90% 4.90% 4.00% 32.10% 43.10% 11.00% 43 24.20% 43.60% 19.40%
M358 1.40% 2.00% 0.60% 7.20% 8.50% 1.30% 43 18.00% 32.50% 14.50%
M359 4.10% 8.90% 4.80% 17.10% 18.60% 1.50% 40 17.40% 33.10% 15.70%
M360 0.27% 0.30% 0.03% 27
M443 25 0.04% 0.06% 0.02%
M444 22 1.80% 3.40% 1.60%
M445 0.00% 0.00% 0.00% 35 0.00% 0.00% 0.00%
M446 25 20.10% 26.40% 6.30%
M466 19.60% 28.00% 8.40% 28.70% 29.70% 1.00% 40 17.40% 25.40% 8.00%
M467 25 26.60% 51.20% 24.60%
M468 0.00% 0.00% 0.00% 0.01% 0.01% 0.00% 40 0.00% 0.002%* 0.002%*
M469 0.16% 0.20% 0.04% 3.60% 8.00% 4.40% 40 22.90% 51.50% 28.60%
M470 60.00% 72.20% 12.20% 28 23.70% 32.50% 8.80%
1916
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737c prim 24 31
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3.4.8 FISH analysis and morphology of engrafted ALL samples 
3.4.8.1 Fluorescence in situ hybridization (FISH) 
The first transplanted patient samples successfully engrafted mice and human cells 
recovered from NSG mice proved to have an immunophenotype closely resembling that 
of the original ALL sample. In order to provide additional validation of the concordance 
of diagnostic ALL lymphoblasts and human cells engrafted in the murine xenotransplant 
setting, cytogenetic characteristics were analysed on a selection of mouse bm samples. 
FISH analysis for the presence of the BCR/ABL1 fusion gene (t(9;22)) was an obvious 
choice as transplantation experiments with Philadelphia chromosome positive ALL 
formed a substantial part of this project. Altogether 22 diagnostic and engrafted bm 
samples from 9 different Philadelphia chromosome positive patients were analysed. 
Additionally, single cell suspensions of the spleen and kidney were analysed in one case 
(patient sample M120, mouse M376). Hybridisation with the BCR/ABL1 fusion 
fluorescent FISH probe (Spectrum Green/Spectrum Orange) was performed as described 
in section 2.4 of the materials and methods chapter.  
Mouse M1 was the first mouse engrafted with a Philadelphia chromosome positive ALL 
from patient 8849. Mice were transplanted with relatively high numbers (1 x 106 
cells/mouse) of unsorted patient material. Cells from the final bm harvest were found to 
be positive for the t(9;22) reciprocal translocation (see Figure 18 a). 
High cell numbers (3 x 105 cells/mouse) of blasts from patient A67 were also 
transplanted without prior cell sorting. Harvested bm of mouse M6 contained human 
lymphoblasts that presented with 3 Philadelphia chromosomes (Figure 18 b). Engrafted 
bm from the first transplant experiments were consecutively used for secondary 
transplants. Harvested bm of mouse M6 was sorted according to expression of surface 
antigen CD20 and M43, injected with 2 x 104 CD19+CD20high cells, as well as M45, 
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injected with 2 x 104 CD19+CD20low cells, showed 3 Philadelphia chromosomes in 
human cells of the bm from the final bm harvest. Mice M14 and M17 were transplanted 
with 2 x 103 bm cells from mouse M7 (primary unsorted transplant experiment) sorted 
into CD34+CD19low and CD34+CD19high fractions respectively. Bm blasts from both 
mice also proved to have 3 Philadelphia chromosomes (Figure 18 b).  
Diagnostic patient sample WB51 was transplanted unsorted into M64 (9.8 x 104 cells) 
and after two passages through mice, again after sorting into CD19+CD34high (M551, 
injected with 1 x 103 cells) and CD19+CD34low (M553, injected with 1 x 103 cells). As 
already seen in transplanted mice from ALL A67, all engrafted material that underwent 
FISH analysis presented blasts with 3 BCR/ABL1 fusions.  
A primary sort of patient sample HV101 into a CD34+CD20high population (transplanted 
with 3 x 103 cells into M183) and a CD34+CD20low population (transplanted with 3 x 103 
cells into M187) resulted in engraftment of both fractions. FISH analysis of cells from 
the bm harvests of both engrafted mice showed two Philadelphia chromosomes, as did 
blasts from the primary patient sample. 
Patient 2003 primary material and cells from the bm harvest of M525, transplanted with 
1 x 103 unsorted primary ALL cells, were both found to have two Philadelphia 
chromosomes. ALL sample 4917 was also transplanted without sorting onto mice with a 
cell dose of 1 x 103/mouse and analysis of cells from M539 confirmed the presence of 
two BCR/ABL1 translocated chromosomes as found in the transplanted original sample. 
ALL patient sample 4540a was directly sorted into fractions of CD19+CD34high and 
CD19+CD34low expressing cells. M609 and M611 represent one mouse each of two 
groups of 5, which were transplanted with 1 x 103 cells per mouse of the opposing cell 
populations. In engrafted bm cells of both mice ALL blasts with two copies of the 
Philadelphia chromosome were identified.  
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M122 (patient 2510) was transplanted with 4.5 x 103 CD19+CD10high sorted cells of 
secondary material from M31, which engrafted the unsorted original patient ALL. This 
bm was repopulated with lymphoblasts that carried 3 Philadelphia chromosomes. 
 
 
Figure 18: Presence of Philadelphia chromosomes in engrafted mouse bm cells. a) Mouse M1 
was transplanted with 1 x 10
6
 unsorted cells of patient sample 8849. Cells from the bm harvest were 
analysed regarding the presence of the t(9;22) reciprocal translocation. The BCR gene at chromosome 
22q11.2 is visualised with a green fluorophore labelled DNA probe and the ABL1 gene on 
chromosome 9q34 with a red fluorophore labelled DNA probe. The one green and one red signal 
represent the intact chromosomes 9 and 22 respectively while the yellow fusion signal becomes 
visible upon t(9;22) translocation which co-locates the green and red signal. b) Cells from M6, 
transplanted with unsorted cells of patient A67 show two non translocated chromosomes 9 (green) 
and 22 (red) and 3 Philadelphia chromosomes (yellow fusion signal). A secondary transplantation was 
carried out with CD34
+
CD19
low
 and CD34
+
CD19
high
 fractions on representative mice M14 and M17 
respectively. As cells in the primary transplantation (M6), both cell fractions reconstitute ALL cells 
harbouring one normal chromosome 9, one normal chromosome 22 and 3 Philadelphia chromosomes 
(green, red and 3 yellow fusion signals). 
 
An unsorted limiting dilution experiment was done with diagnostic material from patient 
M120. M357 was transplanted with the highest cell concentration of 1 x 104 cells and 
engrafted with human cells in which two Philadelphia chromosomes were detected by 
FISH analysis. The primary sample of this patient was also used for a primary sort 
regarding CD10 expression levels. M376 was transplanted with 2 x 103 CD19+CD10high 
cells and in addition to the expectedly enlarged spleen at the time of harvest, it also 
b) A67a) 8849
M1 M6 M14 M17
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presented with obviously ALL infiltrated enlarged kidneys. FISH analysis of single cell 
suspensions of the spleen and kidney showed two Philadelphia chromosomes as well. 
 
3.4.8.2 Lymphoblast morphology 
Additional slides of the same diagnostic patient samples and cells recovered from bm 
harvests of engrafted mice that were used for FISH analysis (section 3.4.8.1 above) were 
stained according to the May-Grünwald-Giemsa (MGG) protocol to analyse lymphoblast 
morphology. The French-American-British (FAB) Cooperative Working group 
classified ALL morphology in 3 groups L1-L3. L1 morphology is characterised by 
rather small and monomorphic cells with a high nuclear to cytoplasmic ratio. The thin 
rim of cytoplasm around a dominant round or clefted dark blue nucleus stains pale blue. 
Around 90% of childhood ALL present with L1 morphology. Cells of a L2 type 
represent 5 to 15% of ALL cases and have a more variable size with more cytoplasm 
and prominent nucleoli. L3 morphology is exclusively found in mature B ALL (around 
1% to 2% of cases) and exhibits large cytoplasmic vacuoles in a dark cytoplasm 
(Silverman, 2009). Lymphoblasts of primary diagnostic patient material (patients WB51, 
HV101, 2003 and 4917) as well as human cells of the bm harvests of engrafted primary, 
secondary and tertiary transplantation experiments (mice M1, M6, M14, M17, M43, 
M45, M64, M122, M183, M187, M357, M437, M525, M539, M551, M553, M609 and 
M611) all showed typical undifferentiated FAB L1 morphology. 
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3.5 Discussion 
Work described in this chapter was mainly intended to establish a robust murine 
xenotransplantation assay that would be able to address the stem cell properties of self-
renewal and capability to generate the heterogeneous lineages of cancer cells in ALL. 
The transplantation technique needed to be learned and carried out on a small initial 
number of mice and a flow cytometry based method had to be developed to reliably 
detect human chimerism in bm from mouse bmps or bm harvests.  
In order to set up flow cytometry, bm cells of mouse origin were available, but original 
ALL patient samples could not be used for that as they were reserved for the actual 
xenotransplantation experiments. Human lymphoblasts, that had been passaged through 
mice and harvested in abundance, for example from mouse spleens, understandably were 
also not present at the initial stages of the project. The presumably best substitute for 
ALL blasts, normal human bm cells, were also not accessible due to ethical constraints. 
PBMCs were therefore utilized as an alternative. In contrast to mouse bm cells that 
showed considerable unspecific binding of anti-human mAbs, PBMCs did not seem to 
take up anti-mouse mAbs to a great extent. The problem with unspecific binding of anti-
human mAbs to mouse bm cells could be solved by staining the mouse cells with two 
antibodies that labelled the vast majority of mouse leucocytes (mCD45) and cells of the 
mouse erythroid lineage (mTER-119). Cells of mouse origin then could simply be gated 
out, eliminating those that were bound by antibodies against human surface antigens 
from further analysis. This first gating algorithm (see section 3.4.3) was based on a 
histogram that showed MFI of PE-Cy7, the fluorochrome that was conjugated to both 
mCD45 and mTER-119 and all events with an MFI of 103 or higher were excluded from 
further analysis. This greatly simplified the dependent dot plots and meant that human 
lymphoblasts could subsequently be identified much more easily. This method proved to 
be very specific for visualising human cells and also already very sensitive as 
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engraftment below 1% could clearly be identified. However, it became obvious from 
bmps and bm harvest of the first xenotransplantation experiments that human ALL 
blasts apparently exhibited a much higher and more variable degree of unspecific 
binding of anti-mouse mAbs than did normal PBMCs. Consequently, more cells of 
human origin were gated out by applying the histogram gating method resulting in either 
not detecting human engraftment of a very low level at all or in determining erroneous 
and generally too low percentages of human chimerism. Additionally, the variable 
degree of unspecific mouse mAb binding led to the exclusion of very changeable 
proportions of human cells for further analyses when the rather inflexible histogram 
gating algorithm was applied. This analysis bias, inherent in the histogram based 
method, urged the need to develop a new gating strategy that would include cells of 
human origin as completely as possible in further analysis steps. The resultant 
standardised dot plot based gating algorithm described in section 3.4.5, was able to 
include human cells to a much higher extent for determining engraftment levels. A 
retrospective comparison between the histogram and the dot plot based gating strategies 
on a test panel of various xenotransplantation experiments showed a considerably higher 
human chimerism with differences ranging from 0.02% to 66.7% with a mean increase 
of 16.26%. Capturing more cells of human origin also resulted in a higher sensitivity of 
the dot plot gating algorithm making it the method of choice for this project. 
The first two xenotransplantation experiments were kept as simple as possible with high 
numbers of unsorted human ALL cells injected intrafemorally. This resulted in 
successful engraftment of both leukaemias but of the first transplanted sample (8849), 
only one out of 3 mice that could be analysed reconstituted the leukaemia despite 1 x 106 
cells used for transplantation. Of the second transplanted sample (A67, 3 x 
105cells/mouse) all mice did engraft but engraftment kinetics were inconsistent. With 
high cell numbers transplanted, it could be expected that engraftment kinetics would be 
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similar but at least, that if engraftment occurs it would do in all mice. However, as these 
experiments were the first that were performed, preparation of the samples and the mice 
as well as the actual transplantation process took considerably longer than later, when it 
became a routine procedure. It is also possible that some of the if injections partly or 
completely failed at a time when the procedure still had to be established. On the other 
hand, stem cell frequency could indeed have been very low in general but higher in the 
second sample (A67) with the consequence that individual mice received a different and 
very small number of leukaemic stem cells or none at all leading to failure to engraft. 
Bone marrow punctures of mice were effective in monitoring human engraftment in 
mice without having to kill them. Analysing cells obtained from bmps could be assessed 
for engraftment and mice subsequently could be left alive in order to develop an overt 
ALL with high levels of engraftment and a final bm harvest of a high number of human 
cells for further experiments. However, successive bmps sometimes resulted in lower 
percentages of human blasts at a later time point as compared to the previous bone 
marrow sample. Reference to clinical literature provides a possible explanation for these 
decreased blast counts. It is known from consecutive human sternal bone marrow 
punctures that due to compartmentalization of the sternum, haemorrhage resulting from 
a previous puncture can occupy the relatively small marrow space and affect the results 
of subsequent aspirates from the same site (Bierman and Kelly, 1956). The mouse femur 
contains a very small volume from which the bone marrow samples are taken. Even with 
the most cautious puncture, a relatively high negative pressure has to be applied to 
release cells from this compartment. This inevitably leads to variable volumes of the 
aspirates and the resulting cavity will consecutively be filled with blood. As a 
consequence following samples may well contain less human blasts. It is not possible to 
circumvent this problem as in mice the femur is already the bone with the highest 
volume that is easily accessible. Additionally, blasts are vulnerable cells and the force 
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which has to be applied to aspirate them potentially leads to damage of a variable 
amount of cells, especially as they are drawn through a needle with a small diameter. 
Variable amounts of cell debris in the analysis additionally lead to a bias in 
determination of engraftment levels.  
The problems for analysis inherent in bmps would probably be less pronounced in 
analysis of peripheral blood lymphoblasts and also the number of venesections is not 
restricted unlike bmps, which can only be performed up to 5 times on one mouse. 
However, although lymphoblasts could be detected in peripheral blood of most mice that 
were already bone marrow engrafted, this was not the case for all mice and positive 
engraftment could potentially been missed if only peripheral blood was analysed. Serial 
analysis of the bm therefore was the preferred mode to assess human engraftment levels. 
Additionally, ALL primarily is a malignant disease of bm origin and orthotopic 
xenotransplantation as well would lead to initial proliferation of blasts in the initially 
injected femur making it the most likely site to detect early and low chimerism. Data 
obtained from mice transplanted with different ALLs by Kerrie Wilson, a fellow PhD 
student, additionally demonstrated a much higher frequency of mice in which bone 
marrow engraftment not necessarily went along with detection of human chimerism in 
peripheral blood samples taken from the animals. These findings confirmed that flow 
cytometry performed on bm aspirates would be more sensitive in identifying human 
ALL engraftment. 
 
From early post mortem examinations, enlargement of the spleen and sometimes the 
liver and kidneys was observed. In order to assess whether this enlargement was caused 
by infiltration of human lymphoblasts, single cell suspensions of these organs were 
analysed by flow cytometry. All organs proved to be colonised with human cells. 
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Spleens of bm engrafted mice were subsequently analysed regularly and served as a rich 
source of cells for further experiments. Furthermore, these infiltration patterns 
demonstrated that the transplanted ALL samples repopulated mice with a leukaemia that 
highly reproduced the clinical pattern typically found in humans. 
All engrafted human material harvested from mice was analysed regarding the 
expression of the human surface antigens CD10, CD19, CD20 and CD34. The early 
transplantation experiments showed that the leukaemia reconstituted in the mouse 
xenoenvironment closely resembled the immunophenotypic pattern determined for the 
original patient sample. However, only unsorted samples were transplanted with high 
cell numbers and it could have been possible that cells with a different 
immunophenotype were reconstituted by different cells within the transplanted sample 
only.  
Additional evidence that human cells engrafted in mice were definitely malignant 
lymphoblasts and not of normal human haematopoietic origin was provided by 
morphological and FISH analyses of examples of bm samples taken from mice 
transplanted with BCR/ABL1 positive patient samples. Morphologic examination 
showed an abundance of typical leukaemic blasts in the bm and FISH analysis visualised 
the Philadelphia chromosome in all examined samples. Human cells with two non-
translocated chromosomes 9 and 22 each could not be identified, clearly demonstrating 
that engrafted human cells were exclusively lymphoblasts.  
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3.6 Conclusion 
Initial ALL xenotransplant experiments on NSG mice were performed successfully with 
reconstitution of the full leukaemia in bm and a infiltration of blasts into spleens and 
other organs of the recipients and flow cytometry analysis proved to be a robust method 
to answer the questions of engraftment and pattern of surface antigen expression.  
With a robust murine xenotransplantation assay and a method that reliably identified 
cells of human origin in a mouse background with a high sensitivity and specificity 
powerful tools were established to address questions surrounding the frequency and 
identity of leukaemic stem cells in ALL.  
  
  
 
CHAPTER 4: DIVERSITY OF CANCER STEM 
CELLS IN ACUTE LYMPHOBLASTIC 
LEUKAEMIA 
 
 
Chapter 4  4.1 Introduction 
155 
 
Chapter 4: Diversity of cancer stem cells in acute 
lymphoblastic leukaemia 
 
4.1 Introduction 
Leukaemias account for the most common form of cancer in children and approximately 
one third are of the acute lymphoblastic form. With multiagent chemotherapy given 
according to sophisticated treatment protocol schedules cure rates of now 80% 5 year 
EFS are achieved (Möricke et al., 2008; Pui et al., 2004). However, due to the high 
incidence, ALL still causes 30% of all deaths from cancer (CancerResearchUK, 2010). 
The most common reason for treatment failure is relapse of the disease originating from 
malignant blasts that evade chemotherapy. In order to reconstitute the full ALL, a 
remaining blast cell must combine the two defining characteristics of cancer stem cells; 
the ability to self-renew and to give rise to all different cells comprising the tumour. 
Current treatment strategies are generally more effective at killing proliferating cells. 
Stem cells, however, only infrequently undergo cell division making them a poor target 
for cell cycle dependent cytotoxic agents. Improvements in ALL survival have been 
achieved by risk group stratification with adaption of chemotherapy and better 
supportive care than by finding ways to specifically eradicate the cells that essentially 
are responsible for reviving the ALL. In order to develop a targeted treatment option 
against cancer stem cells, they first have to be identified and their underlying biology 
elucidated.  
In AML, rare leukaemic cells with stem cell abilities and their descendants, forming the 
major part of the malignant clone but not being able to reconstitute the leukaemia, could 
be identified in immunodeficient mouse xenotransplantation models. The leukaemic 
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stem cells were characterised by an immature immunophenotype (CD34+CD38-), 
resembling that of normal early haematopoietic cells and were found to be a very rare 
entity at the apex of a hierarchically organised tumour (Bonnet and Dick, 1997; Lapidot 
et al., 1994).  
The hierarchical model for AML is widely accepted and unchallenged, however, for 
ALL, conflicting results regarding frequency and identity of LSCs have been published 
in the past and the debate whether the hierarchical or the stochastic model applies to 
ALL is still ongoing. In an experiment setup, nearly identical to that used by John Dick´s 
group for work done on AML, an early study on high risk Philadelphia chromosome 
positive ALL suggested that the hierarchical model would hold true for ALL as well, 
with stem cell properties found only in 0.2 to 41 in one million leukaemic cells. In an 
attempt to characterise these stem cells, the authors reported that only cells of a 
CD34++CD38- but not of the CD34+CD38+ immunophenotype were able to transfer the 
leukaemia to intravenously transplanted irradiated NOD/SCID mice, as already 
established for AML. These LICs therefore resembled early, not yet lineage committed 
normal haematopoietic cells and the hierarchical model was considered to be applicable 
on ALL as well (Cobaleda et al., 2000).  
Philadelphia chromosome positive ALL belongs to the high risk group of ALLs and 
hence it was necessary to investigate whether or not other types of ALL would lead to 
similar conclusions. In a study reported by Cox et al which included standard risk ALLs 
with the ETV6/RUNX1 translocation, hyperdiploidy or no abnormal cytogenetics, 
primary limiting dilution experiments on unsorted cells confirmed a low frequency of 
stem cells within the bulk leukaemic population with 5 x 105 to 1 x 107 cells being 
necessary to transfer the disease onto irradiated NOD/SCID mice after intravenous 
injection. In order to differentiate between immature and more mature blast fractions 
they sorted according to the expression of the surface markers CD10 and CD19 which 
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are upregulated earliest in the pre-B-I cell stage of normal haematopoietic development. 
Upon transplantation, they found that only the immature subfractions (CD34+CD10- and 
CD34+CD19-) were able to initiate ALL in the murine xenotransplant setting and that 
with down to 7 x 104 cells per mouse far fewer cells were necessary to achieve this 
compared to unsorted lymphoblasts of the same samples (Cox et al., 2004). The 
hierarchical model was confirmed for standard risk ALL with this study and ALL was 
seen as a disease which is initiated by transformation of early, not lineage restricted 
HSCs that retain their stem cell properties to establish and maintain the leukaemia. 
The data presented by Cobaleda and Cox were in agreement but soon after their 
publication, work by Castor and colleagues was published which could not confirm that 
LSCs in human ALL were confined to immature populations. Initially they found that 
blasts of 6 ETV6/RUNX1 positive standard risk ALL were indeed detectable in the 
immunophenotypically immature subfraction of CD34+CD38- cells but they went on and 
additionally characterised this subfraction towards its expression of the lineage 
restricting surface marker CD19. What they found was an aberrant but due to expression 
of CD19 apparently more mature population of CD34+CD38-CD19+ lymphoblasts that 
does not have an immunophenotypic correlate in normal haematopoiesis but as well 
contained the ETV6/RUNX1 fusion. Furthermore, the CD34+CD38-CD19- immature cell 
populations of the patients did not harbour the t(12;21) translocation. Albeit on grounds 
of an aberrant immunophenotype, this finding suggested, that the leukaemia originated 
in an already committed B-cell developmental stage. Further substantiation for this came 
from the fact, that in addition to the CD34+CD38-CD19- compartment, myeloid 
restricted CD34+CD33+CD19- progenitor cells as well were devoid of the 
ETV6/RUNX1 fusion. In xenotransplantation experiments with tail vein injection into 
irradiated NOD/SCID and NOD/Scid B2m-/- recipients the aberrant population then 
proofed its capability to reconstitute the leukaemia. In additional experiments, the 
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aberrant CD34+CD38-CD19+ compartment could also be detected in p190 and p210 
BCR/ABL1 positive ALLs, but while the immature CD34+CD38-CD19- compartment 
was not included in the malignant clone for minor breakpoint Ph+ cases, identical to the 
situation in ETV6/RUNX1 positive ALL, in major breakpoint Ph+ ALL the t(9;22) 
translocation could also be detected in CD34+CD38-CD19- as well as myeloid 
committed CD34+CD33+CD19- cells. Most interestingly, for both subtypes of Ph+ ALL 
it was the more mature CD34+CD38-CD19+ fraction only, that could transfer the 
leukaemia in vivo (Castor et al., 2005). Despite not addressing the question of stem cell 
frequency, these findings could not be brought into accordance with the proposition that 
LICs in ALL are restricted to an immature and not lineage restricted stage in a 
developmental hierarchy.  
In another study it was demonstrated that transduction of ETV6/RUNX1 into human 
cord blood cells resulted in the development of the aberrant CD34+CD38-CD19+ clone, 
but it was also shown, that while this population did cause leukaemia in intratibially 
transplanted NOD/SCID mice, cells of the presumably little more mature 
CD34+CD38+CD19+ fraction did not and this pointed out that in ALL a hierarchy still 
might exist albeit with LICs not being restricted to very immature and not lineage 
restricted cell subfractions (Hong et al., 2008).  
However, in contrast to findings of Hong et al, evidence that CD34+CD38+CD19+ as 
well as CD34+CD38-CD19+ lymphoblasts and also early multipotent CD34+CD38-CD19- 
cells have stem cell properties was provided by Kong and colleagues. The group 
demonstrated successful serial engraftment for two high risk MLL positive and one high 
presenting blast count B-cell precursor ALL by iv injection of candidate cells into 
irradiated newborn NSG mice through the facial vein (Kong et al., 2008). Other 
developmental stages of the B-cell hierarchy or stem cell frequency were not addressed, 
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but the study again shifted the threshold of LIC containing fractions further towards 
progressed developmental stages.  
Immunophenotypically B-lineage restricted lymphoblasts with stem cell properties were 
also found by le Viseur et al. In addition to CD34+CD19- and CD34+CD19+ cells, also 
already CD34-CD19+ and even CD19+CD20low/- or CD19+CD20+ blasts engrafted in 
NOD/SCID mice treated with anti-CD122 antibodies or NSG mice after intrafemoral 
transplantation, suggesting that a hierarchical model based on immunophenotypes could 
not be sustained (le Viseur et al., 2008).  
The low frequency of LIC established by earlier studies was also put in question little 
later, when a limiting dilution study by Morisot and colleagues demonstrated that at least 
1 of 1000 but often as few as 1 in 100 or even 1 in10 unsorted leukaemic cells had the 
ability to reconstitute the leukaemia in iv transplanted irradiated NSG mouse recipients 
(Morisot et al., 2010).  
Studies addressing the questions of how far lymphoblasts progressed through 
immunophenotypically defined maturation stages until they lose their stem cell 
characteristics or how frequent LICs are with different findings are difficult to compare. 
Outcomes of experiments performed in these studies highly depend on the experimental 
setup itself. The recipient mouse strains in particular, with pronounced disparities in the 
level of immunosuppression, have a great impact on the chance of any cell population to 
engraft. Furthermore, the transplantation technique applied influences the number of 
cells that has to be injected to achieve repopulation. During the time in which these 
studies were carried out and published, mouse strains with increasing 
immunosuppression were developed and new transplantation techniques established. As 
a consequence, NOD/SCID mice, with or without anti-CD122 treatment to deplete 
residual immunity from NK-cells, NOD/Scid B2m-/- mice or the NSG strain were used. 
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Mice were transplanted at different ages and intravenously either into tail veins or facial 
veins but also orthotopically into femora or tibiae. Finally, the different studies could not 
access identical patient ALL samples. This created a high number of parameters 
potentially being responsible for different findings. 
One factor that was not taken into account previously but could have influenced 
experiments profoundly was exhibited recently. Usually antibodies for purification by 
FACS were considered to have no effect on engraftment ability of transplanted cells. 
However, when this general assumption was tested by Taussig et al, they found that in 
particular antibodies directed against CD38 could label cells in a way that they would be 
cleared via an mAb Fc receptor mediated process by the residual immune function of the 
host. This effect was demonstrated to be more pronounced in less immunocompromised 
mice like those of the NOD/SCID strain than in the more recently developed NSG mice. 
Additionally, NK-cell depletion or orthotopic transplantation methods were attenuating 
this effect (Taussig et al., 2008). CD38 played an essential role for sorting of candidate 
stem cell populations in the above mentioned studies published by Cobaleda, Cox and 
Hong. All three used NOD/SCID mice and an iv transplantation technique and in the 
light of the findings from Taussig et al, not surprisingly, populations with surface 
expression of CD38 were not able to engraft suggesting that they lacked stem cell 
properties. Thus the difference in findings, at least for identifying LICs in different 
immunophenotypic subpopulations could probably be explained. However, clearance of 
CD38 labelled cells could not be responsible for the differences in stem cell frequencies 
determined for unsorted leukaemic cells. These probably have to be assigned to the 
mouse strains and transplantation techniques applied or to the individual biological 
characteristics of the transplanted leukaemias. 
In 2009, Cox et al again addressed the question whether or not stem cell characteristics 
were restricted to immunophenotypically immature blast populations. For purification of 
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putative ALL stem cells this time they used the differentiation marker CD133 present on 
early normal HSCs, in addition to CD38 and CD19 and found that only CD133+CD19- 
and the CD133+CD38- blast populations engrafted intravenously injected irradiated 
NOD/SCID (Cox et al., 2009). These findings were in line with their previous study but 
again could have been biased by the use of CD38 for sorting and the NOD/SCID mouse 
model with a more residual immunity than more recently introduced mice, like those of 
the NSG strain. 
Nevertheless, despite the indications that the earlier findings could have been biased by 
the experiment model and the identification of cells with LIC character in already B-cell 
lineage restricted progenitor cells, there still is no agreement in the research community 
regarding which stem cell model, the hierarchical or the stochastic, holds true for ALL. 
 
The experiments presented in this chapter will address the questions of blast 
immunophenotypes connected with stem cell capabilities and their frequencies within 
the bulk leukaemic population using the most suitable mouse strain available for 
orthotopic xenotransplantation and by avoiding the use of CD38 antibodies for cell 
purification. 
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4.2 Aims 
In order to conclusively elucidate the distribution of stem cells in ALL the aims of this 
study were: 
 
 To address the question if leukaemia repopulating ability is restricted to 
relatively immature ALL cell populations or can be found on cells already 
progressed to more mature stages of B-cell development indicated by expression 
of CD10, CD19, CD20 and loss of CD34. 
 To determine if the most mature cell populations that engraft mice are able to 
self-renew and repopulate several generations of mice in serial transplantation 
assays. 
 To determine the frequency of cells with leukaemia repopulating ability within 
unsorted and sorted fractions of the ALL. 
 To investigate whether or not ALL blast populations from different maturation 
stages reconstitute the immunophenotypic pattern of the original patient ALL  
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4.3 Materials and methods 
4.3.1 Patient samples 
Patient 
ID 
Sex Material Cytogenetics 
Age at 
presentation 
WCC (x10
9
/l) 
at diagnosis 
L784 M BM Dicentric 9;20 18 52.2 
L858 F BM No abnormalities 14 27.0 
4917 M BM - 9 13.4 
L876 F PB t(4;11) <1 258 
WB51 M BM t(9;22) 15 184 
A67 M BM t(9;22) 13 230 
HV101 F BM t(9;22) 3 55.9 
M120 M BM t(9;22) 16 66.2 
2003 M PB t(9;22) 15 179 
2510 M BM t(9;22) 16 44.2 
4540a M BM t(9;22) 2 71.0 
8849 M BM t(9;22) 20 360 
9406 M BM 
cryptic BCR/ABL 
rearrangement 
39 - 
737c M PB BCR/ABL like* 4 264 
758b M PB BCR/ABL like* 5 97.5 
Table 5: Clinical features and cytogenetics of patient samples. When available, the sex, the source 
of material, cytogenetics, age at presentation and initial peripheral white cell count is given. 
M male, F female, BM bone marrow, PB peripheral blood, WCC white cell count. 
 
4.3.2 Statistical analysis of limiting dilution experiments 
Analysis of limiting dilution experiments was performed using the open access software 
ELDA (extreme limiting dilution analysis, http://bioinf.wehi.edu.au/software/elda/). In 
stem cell research limiting dilution experiments aim to quantify the proportion of cells 
with stem cell activity within a larger cell population and therefore the active stem cell 
frequency. Generally, a single hit model is assumed in stem cell research. This means, 
that a single active stem cell is capable of resulting in a positive response. In the 
experiments, the cell dose usually is diluted down to numbers that fail to result in or lead 
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to a very low response only, however, sometimes none or all individual experiments 
result in a positive response. Furthermore, due to the nature of models applied in stem 
cell research, the number of replicates of experiments is usually low. ELDA accounts for 
these constraints by combining appropriate statistical techniques. Ninety-five percent 
confidence intervals are given for the stem cell frequency in each population group and 
upper or lower bounds are calculated with an exact one-sided 95% confidence interval in 
case no response is achieved or all individual experiments resulted in a response.  
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4.4 Results 
4.4.1 Blast populations of different maturation stages are endowed with ALL 
repopulating capability 
One important question was to determine if leukaemia propagating abilities are restricted 
to immature blast populations characterised by the absence of CD10, CD19 and CD20 
B-lineage differentiation marker expression or if blasts of progressive 
immunophenotypic maturity could as well re-establish the leukaemia in mice. 
Furthermore, it was investigated whether leukaemic cells would lose engraftment 
abilities upon downregulation of the stem cell marker CD34. NSG mice were 
transplanted intrafemorally with highly FACS purified blast populations of differing 
immunophenotypes and monitored for engraftment by flow cytometry of cells from bone 
marrow aspirates. Successfully engrafted human ALL was analysed regarding the 
reconstituted surface marker expression pattern.  
 
4.4.1.1 CD34+CD19low and CD34+CD19high ALL cells reconstitute the ALL 
Expression of CD19 is initialised relatively early in normal B-cell development at the 
stage of pre-B-I cells (see section 1.3.3.1 and Figure 3) and maintained throughout 
maturation up to the stage of mature B-lymphocytes. Hence, cell sorting according to 
expression of CD19 separates distinct populations at a very early B-cell differentiation 
phase. The CD34+CD19low subfraction resembles cells in normal haematopoiesis that are 
not yet lineage committed or represent the very early stage of pro-B cells only while the 
CD34+CD19high subfraction resembles pre-B-I cells before these become CD34- at the 
level of pre-B-II large cells. Experiments with sorted blasts according to CD19 
expression were performed in order to establish whether or not there is a difference in 
engraftment capability between very early and all later stages of B-cell development. 
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Initially, cell sorts were carried out on bm material that had been passaged through a 
mouse once before. The original patient ALL sample A67 (BCR/ABL1 positive) was 
intrafemorally transplanted with 1 x 106 unsorted cells onto each of 4 mice (M5-M8, 
experiment KR2). All 4 mice reconstituted the patient ALL and the pattern of human CD 
surface antigen expression was analysed by flow cytometry in cells from bone marrow 
punctures and the final bone marrow harvest. In all 4 mice the engrafted leukaemia 
closely resembled the original patient leukaemia immunophenotype. Terminal 
engraftment levels of human cells between 14.8% and 75.8% were determined by the 
dot plot based gating algorithm described in section 3.4.5.  
The bone marrow of two mice (M5 and M7) from the primary transplantation was 
purified into CD34+CD19low and CD34+CD19high subfractions with the BD FACS 
Vantage SE cell sorter. The sort of bm from mouse M5 resulted in a sorting purity of 
97.6% for the CD34+CD19low subfraction and 99.9% for the CD34+CD19high subfraction 
and of each 3 NSG mice were if transplanted with 4.0 x 103 cells/mouse and 2.0 x 104 
cells/mouse respectively (experiment 5). Two of the 3 mice transplanted with 
CD34+CD19low cells showed bm engraftment of human cells at the time point of the first 
bone marrow puncture 8 weeks after transplantation. Engraftment levels determined by 
flow cytometry were 2.7% (M20) and 5.2% (M22). Analysis of bmp2 11 weeks after 
transplantation failed for technical reasons but the third mouse M21 showed human 
blasts (2.3%) in peripheral mouse blood two days later. All 3 mice transplanted with 
CD34+CD19high were engrafted at the time of bmp1 with human chimerisms of 2.3% 
(M23), 0.13% (M24) and 17.9% (M25). Transplanted mice survived between 11and 21 
weeks and final engraftment levels determined from bm harvests (or a bmp in case a 
mouse died without a terminal bm harvest) ranged between 0.13% and 34.9%. Both 
transplanted cell populations reconstituted in the mice with an immunophenotype 
distribution pattern of cells that resembled that of the original patient sample A67. Flow 
Chapter 4  4.4 Results 
167 
 
cytometry analysis, depicted as contour dot plots of human cells in bm of engrafted mice 
is illustrated in Figure 19. 
 
 
Figure 19: CD34
+
CD19
low
 and CD34
+
CD19
high
 sorted blast populations engraft in NSG mice and 
reconstitute the original ALL immunophenotype (patient A67). Mouse M5 was transplanted with 
unsorted diagnostic bm from patient A67 and engrafted in bm to 41% human chimerism. Harvested 
bm was sorted into CD34
+
CD19
low
 and CD34
+
CD19
high
 subfractions and retransplanted into new NSG 
hosts. The mice were monitored for human ALL engraftment using bmps and, unless a mouse died 
unexpectedly, a terminal bm harvest was carried out once mice became ill. The contour dot plot for 
mouse M5 shows the immunophenotype for CD19 and CD34 expression and the sorting gates. In the 
left row of contour dot plots, engraftment in M20 to M22 transplanted with CD34
+
CD19
low
 cells is 
depicted and in the right row, engraftment of M23 to M25 transplanted with CD34
+
CD19
high
 cells. 
Engraftment levels of the harvested bm or last bmps performed are inserted in the plots. Both 
transplanted subpopulations reconstitute human cells in NSG mice with an immunophenotype 
resembling the original transplanted sample. 
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Purities of the sort on mouse M7 were 96.9% for CD34+CD19low cells and 99.5% for 
CD34+CD19high cells. Of both populations 2.0 x 103 cells were transplanted for each 
mouse (KR4). Two of 4 mice transplanted with CD34+CD19low cells showed 
engraftment in aspirates of bmp1 performed 10 weeks after transplantation with 4.0% 
(M15) and 8.9% (M16) human chimerism. M13 had 0.1% engraftment in peripheral 
mouse blood 12 weeks after transplantation and in bmp3, 16 weeks post transplantation, 
36.9% bm engraftment was determined for this mouse and a first positive engraftment of 
0.1% for mouse M14. Of the 3 mice that received CD34+CD19high ALL cells, all were 
engrafted at 10 weeks post transplantation with 0.06% (M17), 37.8% (M18) and 2.6% 
(M19) in bm collected from bmp1. Mice from this experiment died or were killed 
between 13 and 23 weeks after transplantation. Engraftment levels ranged between 2.6% 
and 52.1%. Both transplanted cell populations again reconstituted the 
immunophenotypic pattern established for the diagnostic patient sample. 
In a third experiment setup it was investigated if the results gained from CD19 sorts 
performed on human cells that had already grown in mouse bm could be shown to be the 
same in the original diagnostic patient material. Bm of the Philadelphia chromosome 
positive sample WB51 was directly sorted and 3.1 x 104 CD34+CD19high cells were 
transplanted into each of 4 mice and 4.0 x 103 CD34+CD19low cells into each of 2 mice 
(KR18). In the first bmp 7 weeks after transplantation, all 6 mice showed engraftment of 
human cells with levels of 2.2% (M74), 14% (M75), 1.3% (M76) and 7.4% (77) for 
mice transplanted with CD34+CD19high cells and 0.04% (M78) and 0.05% (M79) for 
mice transplanted with CD34+CD19low cells. All mice of this experiment survived 
between 15 and 20 weeks post transplantation until the terminal bm harvest was 
performed showing high engraftment levels for all mice ranging from 58.6% to 81.9%. 
Similar to the initial experiments on secondary material from patient A67, original 
primary patient material WB51 engrafted both the CD34+CD19high and CD34+CD19low 
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subpopulation with an immunophenotype reconstituted in bm of mice resembling that of 
the presenting patient bm. 
In summary, altogether 19 NSG mice were transplanted in 3 different experiments. All 
mice engrafted the leukaemia to the original patient immunophenotype. The experiment 
with primary cells of patient WB51 (KR18) reproduced the findings of experiments KR4 
and KR5 performed with secondary blasts from patient leukaemia A67. The setup and 
results of these xenotransplantations are illustrated in Table 6. 
 
 
Table 6: A list summarising xenotransplant experiments with ALL blasts sorted according to 
CD19 surface antigen expression.  
 
4.4.1.2 CD19+CD20low and CD19+CD20high ALL cells reconstitute the ALL 
The surface marker CD20 is highly expressed only on cells already progressed to the 
pre-B-II small cell stage in B-lineage development (see section 1.3.3.1 and Figure 3). 
Purification of CD20 high expressing cells therefore separates cells of an advanced 
maturity from all other preceding developmental stages. Several previous publications 
suggested that only cells up to a certain maturity level are able to repopulate mice and 
that this essential stem cell characteristic is lost by immunophenotypically more mature 
precursor cells. Of the CD surface antigens used for cell sorting in this project, CD20high 
cell populations resemble the most mature stage of normal B-cell development. 
Exp. 
No.
Patient / 
Leukemia
Injected Cell 
No.
Injected Cells No. transplanted No. engrafted
2.0 x 103 CD19high 3 3
2.0 x 103 CD19low 4 4
2.0 x 104 CD19high 3 3
4.0 x 103 CD19low 3 3
3.12 x 104 CD19high 4 4
4.0 x 103 CD19low 2 2
Sum 19 19
KR4 A67 sec
KR5 A67 sec
KR18 WB51 prim
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Therefore, CD20high expressing cells would be the most likely cells to have lost the 
ability to repopulate NSG mice. In order to investigate whether or not that is the case, 
several ALL samples, sorted into CD19+CD20low and CD19+CD20high subpopulations 
were if transplanted into mice by intrafemoral injection.  
ALL sample A67 was the first to be used for these experiments (KR11). Mouse M6 was 
initially transplanted with 3.0 x 105 unsorted cells of the original diagnostic ALL sample 
A67 and engrafted to a final level of 15% human chimerism. Harvested human bm cells 
from this mouse were sorted according to CD19 and CD20 surface marker expression 
and both the CD19+CD20low (83.9% purity) and CD19+CD20high (99.9% purity) 
subpopulations were transplanted into 3 NSG mice each with 2.0 x 104 cells per mouse. 
Due to technical reasons the first bmp failed and could not be analysed for engraftment. 
However, analysis of peripheral mouse blood, carried out two days after the first bmp at 
9 weeks after transplantation, showed human circulating ALL blasts in all 6 mice. 
Mouse M44 died unexpectedly after bmp3 but the 5 other mice were killed 14 to 16 
weeks after initiation of the experiment when they appeared to become ill from the 
developing ALL. Terminal bm engraftment levels were between 15% and 72% and did 
not differ between the subfractions of different maturity with high engraftment levels 
determined for both groups. Furthermore, the original immunophenotype of the ALL 
was closely recapitulated in all transplanted mice. Engraftment of bm in mice from this 
experiment is illustrated in Figure 20.  
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Figure 20: CD19
+
CD20
low
 and CD19
+
CD20
high
 sorted blast populations engraft in NSG mice and 
reconstitute the original ALL immunophenotype (patient A67). Mouse M6 was transplanted with 
unsorted diagnostic bm from patient A67. Final bm analysis showed 15% human chimerism. Purified 
bm subfractions with CD19
+
CD20
low
 and CD19
+
CD20
high
 immunophenotypes were transplanted into 
NSG mice and human ALL engraftment was analysed. The contour dot plot for mouse M6 in the 
centre shows CD19 and CD20 expression profiles of its bm cells and the sorting gates. On the left 
side bm analyses of bmp3 for M44 and of terminal bm harvests for M45 and M46 show engraftment 
of CD19
+
CD20
low
 blasts. On the right side, terminal bm harvests of mice M41 to M43, transplanted 
with CD19
+
CD20
high
 cells are depicted. Human chimerisms of the harvested bm or last bmp 
performed are inserted in the plots. Both transplanted subpopulations reconstitute human cells in NSG 
mice with an immunophenotype resembling the original transplanted sample. 
 
Following these initial findings, further samples that had been passaged through mice 
once were transplanted and the question was addressed as to whether cells that have not 
been passaged through mice would also engraft both sorted subfractions of 
CD19+CD20low and CD19+CD20high cells and reconstitute the immunophenotypic pattern 
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of the original ALL. Additionally, the same assay was performed on ALL samples that 
had already been passaged through mice over two generations.  
Altogether, 6 original diagnostic patient samples were sorted according to CD20 
expression (MS45, WB51, HV101, 737c, M120 and 758b) with purities for the 
CD19+CD20low subfractions between 92% and 100% and for the CD19+CD20high 
subfractions between 99% and 100%. For sample MS45 both fractions were transplanted 
into 4 mice each with 3.0 x 103 cells per mouse (KR38). Over the observation time of 34 
weeks none of the 8 mice transplanted engrafted human cells. For all other 5 samples 
human engraftment could be detected. Sample WB51 (KR17) engrafted both the less 
and more mature subfraction to high levels between 60% and 86%. One mouse 
transplanted with CD19+CD20high cells was not engrafted at bmp1 and died shortly after 
due unrelated reasons. Sample HV101 (KR31) as well engrafted both subfractions in all 
but one mouse. CD19+CD20high cells engrafted from 26% to 78% and CD19+CD20low 
cells from 26% to 74%. One mouse injected with CD19+CD20high cells died after bmp5 
at which it was positive outside limits (pol, see section 3.4.6). Diagnostic bm from 
patient 737c (KR42) engrafted all mice transplanted with either the CD19+CD20high or 
CD19+CD20low subfraction. Engraftment levels in the last bone marrow punctures before 
unexpected death or final bm analyses were between 2.4% and 74%. Samples M120 
(KR48) and 758b (KR51) both failed to engraft CD19+CD20high expressing cells. For 
M120 the CD19+CD20low subfraction engrafted 3 of 4 mice transplanted, albeit with 
relatively low levels, between 4.4% and 29%. However, CD19+CD20low cells 
transplanted from ALL sample 758b, resulted in high human chimerism between 29% 
and 88% in 4 out of 4 mice.  
In addition to the first experiment described in this subchapter, another 6 secondary 
samples from 4 different ALLs (A67, WB51, 2510 and 737c) were sorted and 
CD19+CD20high and CD19+CD20low cells transplanted with cell numbers of 1,000 cells 
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or higher per mouse. The second A67 sample that had been passaged through a mouse 
once engrafted all 3 mice of each purified subfraction to levels between 24% and 75% in 
bm harvests and 19% in bmp2 of one mouse transplanted with CD19+CD20high cells 
before early death (KR12). Three separate CD20 sorts were carried out on secondary 
samples from patient WB51. In the first of these experiments (KR26) all transplanted 
mice survived for a terminal bm harvest and engraftment analysis. Final engraftment 
levels were comparable between the both groups transplanted with CD19+CD20high and 
CD19+CD20low cells and ranged between 31% and 81%. Experiment KR27 as well 
successfully propagated the ALL in all 6 mice transplanted with the two differentially 
mature cell populations. Engraftment levels determined in bmps or final bm harvests 
were between 2.3% and 77%. The third secondary transplant experiment (KR34) on 
WB51 with cells sorted in regards to CD20 expression led to engraftment of 4 of 4 mice 
transplanted with CD19+CD20high cells and 3 of 4 mice transplanted with CD19+CD20low 
cells at the time of the first bmp. Only 3 mice survived for a terminal bm harvest with 
engraftment levels between 38% and 62%. The mouse that was not engrafted at bmp1 
died shortly after and could not be assessed again. One secondary 2510 sample was 
included in the CD20 sorts and both subpopulations, the CD19+CD20high and the 
CD19+CD20low, were leading to overt ALL in mice. Analysis of harvested bm resulted 
in human chimerisms between 21% and 69%. While all 4 mice transplanted with 
CD19+CD20low cells engrafted, 2 of 4 transplanted with CD19+CD20high cells did not. 
737c was the last secondary sorting experiment on CD20 (KR55). From this sample, all 
mice engrafted the CD19+CD20high subfraction and 2 of 4 mice engrafted the 
CD19+CD20low subfraction. From all mice, bm could be harvested and analysed for 
human chimerism which ranged from 25% to 67% in the engrafted cases.  
Furthermore, CD20 sorts were performed on two tertiary A67 samples with more than 
1.0 x 103 cells of each subfraction transplanted per mouse. In experiment KR28 all 4 
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mice transplanted with CD19+CD20high cells engrafted to 15% to 68% human chimerism 
in terminal bm harvests and all 4 mice transplanted with CD19+CD20low cells to 36% to 
58%. All harvests were performed between 14 and 17 weeks post transplant. 
Additionally one tertiary sample from patient WB51 was sorted and CD19+CD20high and 
CD19+CD20low subfractions transplanted with only 500 cells into 3 mice each (KR45). 
All 6 mice engrafted but engraftment levels were very low in mice transplanted with 
CD19+CD20high cells (0.08% to 1.0%) and high in mice transplanted with 
CD19+CD20low cells (36% to 77%). In this transplantation experiment, observation 
period was relatively long and mice survived between 24 and 49 weeks. 
In summary, altogether 118 NSG mice were transplanted in 16 different experiments. 90 
mice engrafted the leukaemia and the immunophenotype, as determined by flow 
cytometry, always closely resembled that of the original patient ALL, indicating that 
results were highly reproducible. The setup and results of these xenotransplantations 
with primary, secondary and tertiary leukaemic blasts sorted according to CD20 surface 
marker expression are summarised in Table 7. 
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Table 7: A list summarising xenotransplant experiments with ALL blasts sorted according to 
CD20 surface antigen expression. 
 
 
Exp. 
No.
Patient / 
Leukemia
Injected Cell 
No.
Injected Cells No. transplanted No. engrafted
CD20high 2.0 x 104 3 3
CD20low 2.0 x 104 3 3
CD20high 9.0 x 103 3 3
CD20low 9.0 x 103 3 3
CD20high 1.08 x 104 3 2
CD20low 6.24 x 104 3 3
CD20high 3.06 x 103 4 4
CD20low 3.06 x 103 4 4
CD20high 2.0 x 103 3 3
CD20low 2.0 x 103 3 3
CD20high 1.35 x 103 4 4
CD20low 1.35 x 103 4 4
CD20high 2.4 x 103 4 3*
CD20low 2.4 x 103 4 4
CD20high 3.0 x 103 4 3
CD20low 3.0 x 103 4 4
CD20high 3.0 x 103 4 2
CD20low 3.0 x 103 4 4
CD20high 1.2 x 103 4 4
CD20low 1.2 x 103 4 3
CD20high 3.0 x 103 4 0
CD20low 3.0 x 103 4 0
CD20high 1.5 x 103 4 4
CD20low 1.5 x 103 4 4
CD20high 5.0 x 102 3 3
CD20low 5.0 x 102 3 3
CD20high 3.0 x 103 4 0
CD20low 3.0 x 103 4 3
CD20high 1.5 x 103 4 0
CD20low 1.5 x 103 4 4
CD20high 1.0 x 103 4 4
CD20low 1.0 x 103 4 2
Sum 118 90
KR55 737c sec
KR45 WB51 tert
KR48 M120 prim
KR51 758b prim
KR34 WB51 sec
KR38 MS45 prim
KR42 737c prim
KR29 A67 tert
KR31 HV101 prim
KR33 2510 sec
KR26 WB51 sec
KR27 WB51 sec
KR28 A67 tert
KR11 A67 sec
A67 secKR12
KR17 WB51 prim
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4.4.1.3 CD19+CD10low and CD19+CD10high ALL cells reconstitute the ALL 
CD10 is the surface marker that, with the exception of infant MLL-rearranged cases, is 
commonly expressed on ALL blasts and therefore was named common ALL antigen 
(CALLA). During B cell development it is first expressed at the pre-B-I cell level just 
before CD19 is up-regulated (see section 1.3.3.1 and Figure 3) and stays positive 
through all B precursor stages. In normal B lymphopoiesis, proliferative activity is 
decreasing with higher levels of CD10 expression. Thus ALL samples were as well 
sorted into CD19+CD10low and CD19+CD10high expressing blast populations in order to 
investigate whether or not there was a difference in leukaemia reconstituting potential.  
The first CD19+CD10low (purity of 98.5%) and CD19+CD10high (purity of 96.7%) 
subfractions were transplanted from a secondary sample harvested of mouse M1, which 
originally was injected with 1.0 x 106 unsorted cells from diagnostic material of patient 
8849. After 11 weeks the first bmp was performed and all 3 mice transplanted with 3.0 x 
104 CD19+CD10high cells showed engraftment (M53 1.9%, M54 0.05% and M55 1.1%) 
while no cells of human origin could be detected in the 3 mice transplanted with 3.0 x 
104 CD19+CD10low cells. Terminal engraftment levels between 26 and 50 weeks post 
transplantation were 55.5% for M53, 42.4% for M54 and 4.1% for M55 but 
CD19+CD10low transplanted mice stayed negative for human chimerism until terminal 
bm analysis between 48 and 50 weeks post transplantation. The results of this 
experiment indicated an engraftment deficit for ALL cells with the immunophenotype 
CD19+CD10low, suggesting a hierarchy in the ALL tumour population. However, this 
hierarchy would not mirror a physiological haematopoietic hierarchy, where 
immunophenotypically more mature cells rather than less mature cells have limited or 
no clonogenic potential. Further transplantation experiments were performed to confirm 
or contradict this unusual finding. First of all, another sort was performed on the same 
secondary material. Four mice each were transplanted with CD19+CD10low and 
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CD19+CD10high cells. One mouse of each group showed little engraftment in cells from 
bmp2 19 weeks after transplantation and in final bm harvests, 2 mice of the group 
transplanted with CD19+CD10low cells (M84 41.5% and M85 0.01%) but still only one 
mouse of the group transplanted with CD19+CD10high cells (M80 0.56%) was engrafted. 
Results from this experiment implied that the CD19+CD10low subfraction did not exhibit 
a repopulation deficit. The contradictory results in experiments performed on the same 
secondary ALL sample prompted CD10 sorts on more secondary and also primary 
patient samples. Another 3 secondary ALLs (WB51, 2510 and 737c) and 7 primary 
ALLs (MS45, L831, L784, HV101, 737c, M120 and 758b) were transplanted with cell 
numbers of 1,000 of more injected per mouse. Secondary human cells of WB51, 
harvested with bm from M64 were sorted into the same subfractions and transplanted 
into 4 mice each (KR21). Three of 4 mice transplanted with CD19+CD10high cells and all 
4 mice transplanted with CD19+CD10low cells exhibited engraftment in mouse bm from 
bmp1 10 weeks after start of the experiment and all 8 mice finally reconstituted the ALL 
with terminal engraftment levels ranging from 18% to 61% for the CD19+CD10high and 
from 27% to 67% for the CD19+CD10low transplanted mice respectively. The flow 
cytometry contour dot plot analysis for this experiment is illustrated in Figure 21. 
Chapter 4  4.4 Results 
178 
 
 
Figure 21: CD19
+
CD10
low
 and CD19
+
CD10
high
 sorted blast populations engraft in NSG mice and 
reconstitute the original ALL immunophenotype (patient WB51). Mouse M64 was transplanted 
with unsorted diagnostic bm from patient WB51. Final bm analysis showed 59% human chimerism. 
Purified bm subfractions with CD19
+
CD10
low
 and CD19
+
CD10
high
 immunophenotypes were 
transplanted into NSG mice and human ALL engraftment was analysed. The contour dot plot for 
mouse M64 in the centre shows CD19 and CD10 expression profiles of its bm cells and the sorting 
gates. On the left side bm analyses of terminal bm harvests for M100 to M103 show engraftment of 
CD19
+
CD10
low
 blasts. On the right side, terminal bm harvests of mice M96 and M97 and bmp2 of 
M98 and M99, transplanted with CD19
+
CD10
high
 cells are depicted. Human chimerisms of the 
harvested bm or last bmp performed are inserted in the plots. Both transplanted subpopulations 
reconstitute human cells in NSG mice with an immunophenotype resembling the original transplanted 
sample. 
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Both subfractions of sorted secondary cells also successfully engrafted from ALL 2510 
and 737c. Sample 2510 (KR24) repopulated two of 4 mice of each transplanted 
subpopulation with final human chimerism of 0.01% and 50% achieved by the 
CD19+CD10high population and 0.14% and 1.2% by the CD19+CD10low population. ALL 
737c again led to ALL in all 8 transplanted mice. Mouse bm harboured human cell 
proportions ranging from 55% to 82% (mice transplanted with CD19+CD10high cells) 
and 18% to 73% (mice transplanted with CD19+CD10low cells). Of the transplanted 
primary samples ALL MS45 and L831 never led to any engraftment during an 
observation period of up to 37 weeks. Successful engraftment of both subpopulations, 
however, was demonstrated for the first transplanted primary patient sample L784 
(KR22). One of the 4 mice of the group transplanted with the immunophenotypically 
less mature CD19+CD10low subpopulation died before the first bm analysis presumably 
for non ALL related reasons but all remaining 7 mice of both populations were engrafted 
at bmp1 (15 weeks post transplant) already. At the end of the experiment mice 
transplanted with the more mature CD19+CD10high population were bm engrafted 
between 20% and 55% and mice transplanted with CD19+CD10low cells between 35% 
and 68%. Two samples, 737c (KR43) and M120 (KR47), only repopulated mice with 
human ALL when transplanted with CD19+CD10high populations. Each sample was 
transplanted in groups of 4 for the CD19+CD10high and the CD19+CD10low 
subpopulations respectively. For 737c 3 of 4 mice engrafted the leukaemia to levels 
between 7% and 42% and for M120 two mice engrafted with 9% and 16%. ALL HV101 
engrafted one of 4 mice transplanted with CD19+CD10low cells to a low final human 
chimerism of 0.02% and two of 4 mice transplanted with CD19+CD10low cells to 0.04% 
and 60%. The last experiment with a primary CD10 sort was performed with sample 
758b (KR50). Of this sample all 4 mice transplanted with the CD19+CD10low cell 
fraction reconstituted human ALL cells in mouse bm to human chimerisms between 
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21% and 70% and two of 4 mice transplanted with CD19+CD10high cells engrafted 
human cells in mouse bm with percentages of 0.25% and 1.0%.  
The different primary and secondary transplant experiments show that both the 
immunophenotypically less mature CD19+CD10low and the more mature CD19+CD10high 
subpopulations are able to reconstitute human ALL cells in the mouse bm 
xenoenvironment. Between the ALL samples, this ability varied, but taken together, the 
stem cell characteristic of tumour repopulation ability was not restricted to one 
population only. Furthermore, both sorted subpopulations reconstituted the ALL to its 
original immunophenotype, as illustrated for the secondary sample WB51 in Figure 21. 
In summary, altogether 78 NSG mice were transplanted in 10 different experiments of 
which 44 NSG mice engrafted the leukaemia with an immunophenotype mirroring the 
immunophenotype of the original patient sample. The results of the individual 
experiments were therefore highly reproducible. The xenotransplantations with primary 
and secondary human ALL cells sorted according to CD10 expression are illustrated in 
Table 8. 
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Table 8: A list summarising xenotransplant experiments with ALL blasts sorted according to 
CD10 surface antigen expression. 
 
4.4.1.4 CD19+CD34low and CD19+CD34high ALL cells reconstitute the ALL 
The surface marker CD34 commonly is used as an established haematopoietic stem cell 
marker. It is expressed on normal haematopoietic stem cells and on progenitor cells that 
are capable of long-term reconstitution of the haematopoietic system and is down-
regulated on cells that lack this ability. In the B lineage, CD34 expression is lost during 
the transition of pre-B-I cells to pre-B-II large cells. In the case of a hierarchical 
organisation among ALL blast populations, a discrepant ability to reconstitute the 
malignancy in mice would be likely to be present between subfractions that did or did 
not express CD34. In order to test this hypothesis, 2 primary patient samples (4540a and 
Exp. 
No.
Patient / 
Leukemia
Injected Cell 
No.
Injected Cells No. transplanted No. engrafted
CD10high 3.0 x 104 3 3
CD10low 3.0 x 104 3 0
CD10high 1.44 x 104 4 1
CD10low 2.19 x 104 4 2
CD10high 1.24 x 104 4 4
CD10low 1.35 x 104 4 4
CD10high 2.61 x 104 4 4
CD10low 6.3 x 103 4 3*
CD10high 4.5 x 103 4 2
CD10low 6.9 x 103 4 2
CD10high 3.0 x 103 4 2
CD10low 3.0 x 103 4 1
CD10high 1.5 x 103 4 3
CD10low 1.5 x 103 4 0
CD10high 2.0 x 103 4 2
CD10low 2.0 x 103 4 0
CD10high 1.5 x 103 4 2
CD10low 1.5 x 103 4 4
CD10high 1.0 x 103 4 4
CD10low 1.0 x 103 4 4
Sum 78 44
KR47 M120 prm
KR50 758b prim
KR56 737c sec
KR30 HV101 prim
KR43 737c prim
KR22 L784 prim
KR24 2510 sec
KR13 8849 sec
KR19 8849 sec
KR21 WB51 sec
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L784), one secondary sample (737c) and one tertiary sample (WB51) were sorted into 
CD19+CD34high and CD19+CD34low subfractions and transplanted into NSG mice.  
In order to primarily address the question of general ability to engraft the leukaemia, 
only mice transplanted with 1,000 or more CD19+CD34high or CD19+CD34low cells were 
evaluated. The first ALL to be transplanted was a tertiary WB51 sample. Bone marrow 
from mouse M272 was sorted into CD19+CD34high (population purity of 97.9%) and 
CD19+CD34low (population purity of 97.8%) subpopulations and these were injected into 
4 mice each with 1,000 cells per animal. Of the group transplanted with the 
CD19+CD34high cell fraction one died before the first bmp but the remaining 3 as well as 
all 4 mice of the group transplanted with CD19+CD34low cells showed positive 
engraftment of human cells only 9 weeks after initiation of the experiment. Maximum 
human chimerism at the time of the last available bmp or in terminal bm harvests 16 to 
22 weeks post transplantation ranged from 41% to 71% in the group transplanted with 
CD19+CD34high cells and from 24% to 58% in the group transplanted with 
CD19+CD34low cells. The contour dot plots in Figure 22 illustrate the engraftment of bm 
in mice from this experiment. 
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Figure 22: CD19
+
CD34
low
 and CD19
+
CD34
high
 sorted blast populations engraft the ALL in NSG 
mice (patient WB51). Mouse M272 was transplanted with unsorted secondary bm from patient 
WB51. Final bm analysis showed 66% human chimerism. Purified bm subfractions of this mouse 
with CD19
+
CD34
low
 and CD19
+
CD34
high
 immunophenotypes were transplanted into new NSG mice 
and human ALL engraftment was analysed. The contour dot plot for mouse M272 in the centre shows 
CD19 and CD34 expression profiles of its bm cells and the sorting gates. On the left side bm analyses 
of terminal harvests for M553 to M556 show engraftment of CD19
+
CD34
low
 blasts. On the right side, 
terminal bm harvests of mice M549 and M551 and bmp3 of mouse M552, transplanted with 
CD19
+
CD34
high
 cells are depicted. Human chimerisms of the harvested bm or last bmp performed are 
inserted in the plots. Both transplanted subpopulations reconstitute human cells in NSG mice. The 
immunophenotype resembles the original transplanted sample when CD19
+
CD34
low
 blasts were 
transplanted but only a uniform CD19
+
CD34
high
 blast population is reconstituted from the transplanted 
CD19
+
CD34
high
 subfraction. 
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The finding that both the immunophenotypically less mature CD19+CD34high as well as 
the more mature CD19+CD34low cells are able to repopulate NSG mice was confirmed in 
a sorting experiment with secondary 737c ALL cells. The opposing populations were 
transplanted in groups of 4 mice each and all mice engrafted the leukaemia. The less 
mature population reconstituted human cells to levels between 6% and 94% and the 
more mature population to levels between 13% and 78% in last bone marrow punctures 
or bm harvests.  
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Figure 23: CD19
+
CD34
low
 and CD19
+
CD34
high
 sorted blast populations engraft in NSG mice and 
reconstitute the original ALL immunophenotype (patient 737c). Mouse M327 was transplanted 
with unsorted diagnostic bm from patient 737c. Final bm analysis showed 68% human chimerism. 
Purified bm subfractions of this mouse with CD19
+
CD34
low
 and CD19
+
CD34
high
 immunophenotypes 
were transplanted into new NSG mice and human ALL engraftment was analysed. The contour dot 
plot for mouse M327 in the centre shows CD19 and CD34 expression profiles of its bm cells and the 
sorting gates. On the left side bm analyses of bmp3 for M583 and of terminal bm harvests for M582, 
M584 and M585 show engraftment of CD19
+
CD34
low
 blasts. On the right side, bm analyses of bmp2 
for M579 and bmp4 for M581 and of terminal bm harvests for M578 and M580 show engraftment of 
mice transplanted with CD19
+
CD34
high
 cells. Human chimerisms of the harvested bm or last bmp 
performed are inserted in the plots. Both transplanted subpopulations reconstitute human cells in NSG 
mice with an immunophenotype resembling the original transplanted sample. 
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To provide further proof that these results were not due to prior passage of cells through 
one or two generations of mice, primary diagnostic patient samples were as well sorted 
and transplanted. CD19+CD34high and CD19+CD34low blast fractions of patient 4540a 
were transplanted with 1,000 cells per mouse into 5 mice each. Two mice of the group 
transplanted with CD19+CD34high cells engrafted to levels of 1% (bmp1) and 44% (bm 
harvest) and one mouse of the group transplanted with CD19+CD34low cells to 59% (bm 
harvest). The second primary sample L784 was transplanted with 10,000 cells per mouse 
of each subfraction in groups of 4 mice. All 4 mice that received CD19+CD34high cells 
engrafted human cells with fractions in the bm from bmps or bm harvests of 17% to 
73%. Two of the 4 mice that received CD19+CD34low cells engrafted to human cell 
levels of 41% and 58% respectively.  
All 4 experiments, two primary, one secondary and one tertiary, showed that, unlike in 
normal haematopoiesis, both CD34 positive and negative cells can reconstitute the ALL 
in the murine xenotransplant model. 21 of the 34 transplanted mice engrafted the 
leukaemia. Of note, both sorted cell populations from the samples 737c, 4540a and L784 
reconstituted the original immunophenotype of the patient leukaemia. However, patient 
sample WB51 exhibited a different immunophenotypic engraftment pattern. While mice 
transplanted with CD19+CD34low cells generated human blast subfractions with 
CD19+CD34low as well as CD19+CD34high immunophenotypes, mice transplanted with 
CD19+CD34high did reconstitute the ALL with only CD19+CD34high expressing cells. 
Table 9 summarises the experiments performed on human ALL blasts sorted according 
to CD34 surface marker expression. 
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Table 9: A list summarising xenotransplant experiments with ALL blasts sorted according to 
CD34 surface antigen expression. 
 
4.4.2 Self-renewal capability across ALL blasts of different immunophenotypic 
maturity 
In addition to the capability to generate the heterogeneous lineages of cells within a 
malignancy, cancer stem cells must be endowed with the ability to self-renew. Long 
term self-renewal of candidate leukaemic stem cells was assessed by transplanting sorted 
populations of the ALL over several generations of NSG mice. Human ALL cells 
engrafted in mouse bm after transplantation of diagnostic patient material was sorted 
into populations of different immunophenotypic maturity and re-transplanted into a 
secondary generation of mice. In case of positive engraftment of these animals, bm from 
mice that became ill from overt leukaemia was harvested again and a third generation of 
mice was transplanted after cells had been sorted once more. In the subchapters of 4.4.1, 
it was demonstrated that all leukaemic subpopulations sorted according to the B lineage 
development surface markers CD10, CD19 and CD20 or the stem cell marker of normal 
haematopoiesis CD34 carried the potential to re-constitute the ALL in mice in primary, 
secondary and tertiary generations of mice.  
Exp. 
No.
Patient / 
Leukemia
Injected Cell 
No.
Injected Cells No. transplanted No. engrafted
CD34high 1.0 x 103 4 3*
CD34low 1.0 x 103 4 4
CD34high 1.0 x 103 4 4
CD34low 1.0 x 103 4 4
CD34high 1.0 x 103 5 2
CD34low 1.0 x 103 5 1
CD34high 1.0 x 104 4 4
CD34low 1.0 x 104 4 2
Sum 34 21
L784 primKR62
KR59 WB51 tert
KR60 737c sec
KR61 4540a prim
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Self-renewal ability within normal haematopoiesis is progressively lost with later stages 
of the developmental hierarchy. If ALL was organised in a hierarchy, the stem cell 
characteristic of self-renewal would have to be confined to subpopulations of ALL cells 
and lost in others that had progressed in the hierarchy already. The surface marker CD20 
is only expressed to a high degree at the level of immature B cells, the latest stage of B 
precursor cells. If the inability to self-renew would be an attribute found in 
subpopulations of ALL cells it would be expected in the one mirroring the 
immunophenotype of immature B cells. In order to investigate whether CD20high 
expressing lymphatic cells as well as their less mature CD20low expressing counterparts 
have the ability of long term self-renewal, serial transplantations were performed. 
Human ALL cells from mouse M6 that initially was transplanted with unsorted cells of 
patient A67 (experiment KR2) were sorted according to their CD20 expression. All 3 
mice transplanted with CD19+CD20low as well as all 3 mice transplanted with 
CD19+CD20high cells engrafted the leukaemia and reconstituted the original ALL 
immunophenotype pattern in experiment KR11 as already described in subchapter 
4.4.1.2 and Figure 20. From this sorting experiment, secondary bm of one mouse (M43) 
with overt leukaemia reconstituted from the CD19+CD20high subpopulation and bm of 
another mouse (M45) also presenting with leukaemia but reconstituted from the 
CD19+CD20low population was again sorted into more immature CD19+CD20low and 
more mature CD19+CD20high candidate stem cell populations and re-transplanted into a 
third generation of mice (experiments KR28 and KR29). ALL blasts of both sorted 
populations were again able to reconstitute the full ALL with generation of 
subpopulations containing less and more mature CD19+CD20low and CD19+CD20high 
cells. These sorting experiments over 3 generations of mice are demonstrated in Figure 
24.  
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Figure 24: Self-renewal capability of immunophenotypically less mature CD19
+
CD20
low
 and 
more mature CD19
+
CD20
high
 cells (patient A67). ALL sample A67 was transplanted over 3 
generations of mice. Candidate ALL stem cells with an immunophenotype resembling immature B 
cells (CD19
+
CD20
high
) or earlier B precursor stages (CD19
+
CD20
low
) both reconstitute the leukaemia 
in NSG mice to the original immunophenotype. Leukaemias engrafted from either subfraction can 
again be sorted into CD19
+
CD20
low
 and CD19
+
CD20
high
 blast subpopulations and once more 
successfully engraft new animals. This demonstrates extended self-renewal capability inherent in 
CD19
+
CD20
low
 as well as CD19
+
CD20
high
 ALL blast populations. 
 
Sample WB51 was primarily sorted into CD19+CD20low and CD19+CD20high cell 
fractions and both reconstituted the ALL to the original immunophenotype (experiment 
KR17). In one secondary experiment (KR27) the leukaemia reconstituted in mouse bm 
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(M68) transplanted with the more mature CD19+CD20high cells was sorted again 
regarding CD20 expression and both subfractions were transplanted into 3 new mice 
each. In this second generation of mice all engrafted the leukaemia and reconstituted the 
full immunophenotypic pattern of the patient ALL. Accordingly, another secondary 
experiment (KR34) used bm from mouse M73 which itself was transplanted with less 
mature primary CD19+CD20low cells for sorting into CD19+CD20low or CD19+CD20high 
subfractions. Following transplantation of 4 mice for each subfraction resulted in 
engraftment of all but one mouse transplanted with CD19+CD20low cells. Finally, a third 
generation of mice was transplanted with CD19+CD20low or CD19+CD20high subfractions 
sorted from bm of mouse M152, itself engrafted from CD19+CD20high purified cells. In 
this experiment (KR45) two of 3 mice from each group injected with either 
CD19+CD20low or CD19+CD20high human subpopulations again reconstituted human 
ALL cells of the diverse original immunophenotypes.  
Bone marrow from mouse M68 (sample WB51), primarily transplanted with 
CD19+CD20high cells, additionally was used for another secondary transplantation 
experiment and following this for a tertiary xenotransplantation. In experiment KR39 
unsorted bm cells harvested from mouse M68 were used and resulted in reconstitution of 
the original patient ALL in 4 of 4 mice transplanted with 1.0 x 103 cells. Harvested bm 
from this secondary transplantation (M272) was then sorted into CD19+CD34low and 
CD19+CD34high subpopulations and re-transplanted with 1.0 x 103 cells per mouse in 
groups of 4. One mouse of the group transplanted with CD19+CD34high purified cells 
could not be analysed for human engraftment due to unexpected early death but all other 
7 mice engrafted the ALL. 
The serial transplantation experiments over 3 mouse generations with cells of sample 
A67 and WB51 sorted into subfractions of divergent immunophenotypic maturity 
(CD19+CD20low or CD19+CD20high expression profile) conclusively demonstrated, that 
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the defining characteristic of cancer stem cells, extended ability to self-renew, is not 
limited to earlier developmental stages but can be demonstrated equally in advanced 
stages of the B lineage.  
 
4.4.3 Frequency of leukaemic stem cells in ALL 
In several previous studies, prevalence of ALL cancer stem cells was determined to be 
restricted to rare and immunophenotypically immature blast populations. Furthermore, 
of these already rare cells within the bulk leukaemia a still relatively high number had to 
be transplanted in xenotransplant mouse models to result in positive engraftment. Later 
studies and the work presented in this thesis led to controversial results by showing that 
blasts resembling more advanced stages of B cell development, up to the level of 
immature B cells, were also able to transfer the leukaemia onto mice. If LICs are not 
restricted to rare subpopulations but also can be found in cell populations that form the 
bulk tumour mass, it is self evident that the frequency of cells with stem cell activity 
must be higher than previously thought. Therefore, the frequency of LICs in ALL was 
assessed by transplanting unsorted as well as sorted blast populations in limiting dilution 
experiments down to only 10 cells per mouse.  
 
4.4.3.1 Frequency of leukaemic stem cells in unsorted ALL cells 
First, the frequency of LICs in unsorted bulk ALL cell populations was assessed. The 
detection of stem cell activity within blast populations of different maturity according to 
the immunophenotype described in 4.4.1 and 4.4.2 suggested a higher stem cell 
frequency in unsorted ALL blasts than determined previously. In order to investigate 
whether or not that was the case, primary diagnostic patient material as well as 
secondary and tertiary samples were used for unsorted limiting dilution experiments.  
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Altogether 9 different primary samples (L876 (KR53), 737c (KR44), L858 (KR35), 
M120 (KR46), 758b (KR49), 2003 (KR57), 4917 (KR58), HV101 (KR32) and A67 
(KR52)) were intrafemorally injected into NSG mice in cell numbers of 1.0 x 103, 1.0 x 
102 and 1.0 x 101 cells per mouse. In 4 cases (737c, M120, 758b and A67) one group of 
mice additionally was transplanted with 1.0 x 104 cells per mouse. All mice transplanted 
with 1.0 x 104 cells and available for at least one bm analysis showed engraftment of the 
ALL. When 1.0 x 103 unsorted blasts were transplanted into mice, the 9 primary patient 
samples resulted in engraftment of all (737c, L876) or a fraction of transplanted mice 
(L858, M120, 758b, 2003 and 4917). For samples 758b, 2003 and 4917 transplantation 
of 1.0 x 103 cells additionally was the limiting cell dose for leukaemia reconstitution. 
Mice transplanted with 100 or 10 cells without exception failed to show human 
chimerism in any bm analysis. Patient sample HV101 was injected with 5.0 x 102 
instead of 1.0 x 103 unsorted cells per mouse as the maximum dose only and this 
resulted in engraftment of two out of 4 transplanted mice. In this experiment 1.0 x 102 (4 
mice) or 1.0 x 101 (4 mice) injected cells also failed to engraft any of the NSG mice, 
therefore establishing 5.0 x 102 as the limiting cell dose. For the primary samples 737c, 
L876, L858, M120 and A67 engraftment of mice was achieved with 1.0 x 102 
transplanted cells. However, for all of these samples this was also the limiting cell dose 
as no mouse transplanted with 1.0 x 101 cells only showed engraftment. Engraftment 
rates with the limiting cell dose varied between samples. While 737c and A67 each 
engrafted all 5 transplanted mice, L876 engrafted 4 out of 5, L858 two out of 5 and 
M120 one out of 5 transplanted mice. The calculated LIC frequencies for the primary 
samples determined to be between one in approximately 40 to one in 3 x 103. 
Two patient samples (WB51 (KR39 and KR40) and HV101 (KR54)) were transplanted 
unsorted in limiting dilution after one passage through mice. For sample WB51 two 
separate limiting dilution experiments were performed. The first (KR39) used unsorted 
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bm cells from M68, a mouse that initially was transplanted with CD19+CD20high sorted 
primary cells and terminally engrafted to 86% human chimerism. From this limiting 
dilution all 4 mice transplanted with 1.0 x 103 cells and all 5 mice transplanted with 1.0 
x 102 cells successfully reconstituted the human ALL. Of the 5 mice injected with 1.0 x 
101 one died before a first bm analysis was performed but of the remaining 4 mice two 
still successfully engrafted. In the bm of one of the mice that was counted as not 
engrafted (M281), a cluster of cells was detected in the terminal bm flow cytometry 
analysis that resembled cells of human origin. However, the acquired cell number was 
too low for this sample to be counted as successfully engrafted (positive outside limits, 
see section 3.4.6). The second limiting dilution on secondary cells from WB51 (KR40) 
used unsorted cells from M65, a mouse initially transplanted with unsorted primary cells 
and a terminal engraftment level of 81%. Of the 3 mice transplanted with 1.0 x 103 cells 
one died before the first bmp but both remaining mice engrafted. 5 mice were 
transplanted with 1.0 x 102 cells and in this group all animals reconstituted the ALL. 
Another 5 mice were transplanted with 1.0 x 101 cells. One mouse of that group could 
also not be analysed for bm engraftment due to early death but 3 of the 4 remaining mice 
engrafted human cells. HV101 was the other sample used to transplant unsorted 
secondary cells in limiting dilution. Cells for this experiment came from harvested bm of 
mouse M187 which itself was transplanted with purified CD19+CD20low expressing cells 
and exhibited human chimerism of 74% at terminal analysis. Four mice were 
transplanted with 1.0 x 103 unsorted cells and 5 mice each with 1.0 x 102 and 1.0 x 101 
cells respectively. All but one mouse of the group transplanted with 1.0 x 101 cells only 
repopulated the NSG mice with human ALL cells. Again, the one not engrafted mouse 
(M468) did show signs of engraftment but failed to match the criteria to be counted as 
positively engrafted. Unlike in the experiment performed with diagnostic patient 
material (KR32), 1.0 x 102 as well as 1.0 x 101 unsorted cells were capable of 
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transferring the leukaemia onto mice. However, the experiments are difficult to compare 
as the primary patient sample was transplanted with 5.0 x 102 unsorted cells per mouse 
as the maximum cell dose and not 1.0 x 103. Contour dot plots for the secondary 
unsorted limiting dilution experiment on sample HV101 are depicted in Figure 25. 
 
 
Figure 25: Secondary unsorted limiting dilution experiment on sample HV101. Mouse M187 was 
initially transplanted with CD19
+
CD20
low
 cells of diagnostic patient sample HV101. Unsorted bone 
marrow from this mouse subsequently was transplanted on secondary mice in limiting dilutions of 1.0 
x 10
3
, 1.0 x 10
2
 and 1.0 x 10
1
 cells per mouse. All mice transplanted with 1.0 x 10
3
 and 1.0 x 10
2
 cells 
reconstituted the original patient ALL. Of the 5 mice transplanted with 1.0 x 10
1
 cells per mouse one 
failed to engraft. Bone marrow of the other 4 mice exhibited an immunophenotypic expression pattern 
comparable to that of bm from mice transplanted with higher cell numbers and the original patient 
material. 
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The only tertiary limiting dilution experiment with unsorted cells was performed with 
sample A67 (KR41, bm of mouse M130, terminal engraftment of 73%). Before being 
used for limiting dilution, the sample was transplanted over two generations of mice, 
both times without prior sorting. The 3 mice transplanted with 1.0 x 103 and all 5 mice 
transplanted with 1.0 x 102 unsorted cells reconstituted the ALL in mice and 1.0 x 101 
cells were sufficient to initiate the leukaemia in 3 out of 5 transplanted mice. As in 
primary and secondary limiting dilution assays, less than 1.0 x 101 cells were not 
transplanted. While the limiting cell number in the experiment (KR52) with the primary 
patient sample A67 was determined to be 1.0 x 102 cells, the tertiary A67 sample was 
capable to transfer the ALL on mice when only 1.0 x 101 cells were transplanted. 
Table 10 summarises all limiting dilution experiments carried out with unsorted blast 
populations and provides calculated LIC frequencies. 
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Patient 
ID 
Risk group Transplant 
Transplanted 
blast population 
Number of cells transplanted 
 
(number of mice engrafted/number 
of mice transplanted) 
LIC 
frequency 
(ELDA) 
1000 100 10 
737c 
High risk 
(BCR/ABL1 like) 
Primary Unsorted 4/4 5/5 0/5 42.2 
L876 High risk t(4;11) Primary Unsorted 4/4 4/5 0/5 77.5 
L858 
High risk (MRD 
high) 
Primary Unsorted 4/5 2/5 0/5 463 
M120 High risk t(9;22) Primary Unsorted 1/4 1/5 0/5 1880 
758b 
High risk 
(BCR/ABL1 like) 
Primary Unsorted 2/3 0/5 0/5 1203 
2003 High risk t(9;22) Primary Unsorted 1/3 0/4 0/5 2922 
4917 Standard risk Primary Unsorted 1/3 0/4 0/5 2922 
WB51 High risk t(9;22) Secondary Unsorted 6/6# 10/10# 5/8# 10.69 
HV101 High risk t(9;22) 
Primary Unsorted 2/4* 0/4 0/4 949 
Secondary Unsorted 4/4 5/5 4/5 6.73 
A67 High risk t(9;22) 
Primary Unsorted 4/4 5/5 0/5 42.2 
Tertiary Unsorted 3/3 5/5 3/5 11.40 
Table 10: A list of all primary, secondary and tertiary ALL samples transplanted in unsorted 
limiting dilution experiments. While the limiting cell dose for primary patient material was 1.0 x 10
2
 
or 1.0 x 10
3
 cells, the two secondary and the tertiary limiting dilution engrafted mice even when only 
1.0 x 10
1
 cells were transplanted orthotopically. The frequencies of ALL LICs in unsorted blast 
populations were calculated using the ELDA programme.
  
*
 mice were transplanted with 5.0 x 10
2
 cells per mouse. 
#
 combined engraftment numbers of two 
separate experiments. 
 
Unsorted limiting dilution experiments were as well performed on sample MS45. As for 
the experiments with sorted cell populations, mice transplanted from this diagnostic 
patient sample never showed any signs of engraftment during the observation period of 
36 weeks. 
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4.4.3.2 Frequency of leukaemic stem cells in CD19+CD20low and CD19+CD20high 
ALL subpopulations 
The xenotransplantation experiments performed with ALL blasts highly purified 
according to their CD20 surface antigen expression level described in subchapter 4.4.1.2 
showed that both the immunophenotypically less mature CD19+CD20low as well as the 
more mature CD19+CD20high cell population in principle were able to reconstitute the 
original leukaemia in NSG mice. Additionally, limiting dilution assays with unsorted 
ALL cells demonstrated that between 1 x 103 and 1 x 101 cells only can be sufficient to 
transfer the ALL onto mice. The earlier CD20 sorting experiments were transplanted 
with cell numbers between 3.06 x 103 and 6.24 x 104 cells per mouse and therefore all in 
cell doses higher than the limiting cell dose for engraftment of unsorted ALL blast 
populations. In order to investigate the limiting cell doses for engraftment of 
CD19+CD20low and the CD19+CD20high cell fractions respectively and to determine 
whether or not ALL stem cells are present at the same frequency in the less and more 
mature populations, limiting dilution experiments were performed transplanting purified 
CD19+CD20low and the CD19+CD20high cells. 
The first limiting dilution on CD20 sorted cells used a secondary WB51 sample 
(experiment KR27). Mouse M68 initially was transplanted with CD19+CD20high 
diagnostic patient cells and engrafted in bm to 86% as determined by flow cytometry 
analysis. Recovered bone marrow of this mouse was purified into CD19+CD20low and 
CD19+CD20high expressing blast populations and subsequently these were transplanted 
each in cell numbers of 2.0 x 103, 5.0 x 102 and 1.0 x 102 into groups of 3 mice. 10 
weeks after the start of the experiment, mice transplanted with doses of 2.0 x 103 showed 
engraftment in all 3 mice transplanted with CD19+CD20low cells (mean engraftment 
12.3%) and also in all 3 mice transplanted with CD19+CD20high cells (mean engraftment 
15.9%). All mice transplanted with 5.0 x 102 sorted cells also engrafted with mean 
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engraftment levels of 8.9% for mice transplanted with the CD19+CD20low and of 28.0% 
for mice transplanted with the CD19+CD20high subpopulation. Two of the 3 mice 
transplanted with 1.0 x 102 CD19+CD20low cells engrafted to bm levels of 0.04% and 
3.0% but only two mice transplanted with 1.0 x 102 CD19+CD20high cells were alive at 
the time point of the first bmp at which none of them showed human chimerism. 
However, both mice showed engraftment of 0.04% and 0.3% respectively at bmp2, 15 
weeks after transplantation and the third mouse of the group transplanted with 1.0 x 102 
CD19+CD20low cells was first positive for human cells at a level of 0.2% after 21 weeks 
at bmp3. From the group transplanted with 2.0 x 103 CD19+CD20high cells a terminal bm 
harvest could be carried out only on one mouse (M143). Flow cytometry on bm revealed 
a human chimerism of 76.5%. Mice 144 and M145 of the same group were found dead 
in the weeks after bmp1 and bmp2 respectively when bm engraftment levels were still 
low. Of the group transplanted with 2.0 x 103 CD19+CD20low cells mice M140 and 
M141 were harvested after 15 and 19 weeks post bone marrow transplantation with bm 
engraftment levels of 18.0% and 28.5% respectively. Mouse M142 died after bmp2 had 
revealed 3.9% human cells. However, all mice transplanted with 5 x 102 cells of either 
group survived until they became ill from overt leukaemia. Experiments with mice 
transplanted with CD19+CD20low cells were terminated after 18 weeks (M150) and 20 
weeks (M149 and M151) and terminal bm engraftment levels were determined to be 
78.4%, 82.1% and 79.5% respectively with a mean engraftment of 80.0%. The group of 
mice transplanted with CD19+CD20high cells was harvested slightly earlier after 18 
weeks (M146 and M148) and 20 weeks (M147) with lower engraftment levels of 67.7%, 
31.6% and 66.6% respectively and a mean engraftment of 55.3%. Two mice each from 
the groups that received 1.0 x 102 cells only could be analysed regarding terminal 
engraftment of human cells. M152 and 154, transplanted with the more mature blast 
population, were harvested after 31 and 25 weeks with engraftment levels of 46.7% and 
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39.4% and mice M156 and M157, transplanted with more immature blasts, engrafted to 
42.9% and 70.7% after 19 and 33 weeks respectively. One mouse of each group died 
relatively early in the course of the experiment. M155 of the CD19+CD20low injected 
group died unexpectedly after only 0.22% human ALL cells were detected in bmp2 after 
15 weeks and M153, injected with CD19+CD20high cells, was found dead 6 weeks after 
transplantation. Reliable post mortem analysis of the bm was not possible due to 
extensive cell decay but flow cytometry analysis of a single cell suspension of the spleen 
revealed a small cluster of events of likely human origin. However, the previously set 
thresholds were not met and the mouse could not be counted as positively engrafted. Dot 
plots of all mice transplanted in this first limiting dilution experiment with cells sorted 
according to CD20 expression level are illustrated in Figure 26. 
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Figure 26: Limiting dilution experiment on secondary sorted CD19
+
CD20
low
 and CD19
+
CD20
high
 
cells of sample WB51. Mouse M68 was initially transplanted with CD19
+
CD20
high
 purified cells of 
diagnostic patient bm sample WB51. Recovered bm of this mouse sorted into CD19
+
CD20
low
 and 
CD19
+
CD20
high
 subfractions subsequently was transplanted on secondary mice in limiting dilutions of 
2.0 x 10
3
, 5.0 x 10
2
 and 1.0 x 10
2
 cells per mouse. All mice transplanted with 2.0 x 10
3
 and 5.0 x 10
2
 
cells reconstituted the original patient ALL. Of the 3 mice transplanted each with 1.0 x 10
2
 
CD19
+
CD20
low
 cells all engrafted the ALL. One mouse transplanted with 1.0 x 10
2
 CD19
+
CD20
high
 
cells died early in the course of the experiment before possible engraftment, while the two other mice 
of that group did show engraftment. Bone marrow of all engrafted mice exhibited an 
immunophenotypic expression pattern comparable to that of the sorted bm from mouse M68 and the 
original patient material. 
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Another two leukaemias (2510 and 737c) were transplanted in sorted secondary limiting 
dilution experiments, KR33 and KR55 respectively. Mouse M30 was initially 
transplanted with 1.3 x 106 bm cells of diagnostic patient sample 2510 and engrafted to 
56.5% human chimerism in the mouse bm from the terminal harvest (KR7). This bm 
was sorted according to CD20 surface antigen expression and CD19+CD20low and 
CD19+CD20high purified cell fractions were both retransplanted with 3.0 x 103 and 3.0 x 
102 cells in groups of 4 mice each. 3.0 x 103 CD19+CD20low cells reconstituted the ALL 
in all 4 transplanted mice with terminal engraftment levels of 68% (M206), 21% 
(M207), 28% (208), 51% (M209) and a mean engraftment of 42%. Of the group 
transplanted with 3.0 x 102 cells of this population only one successfully engrafted to a 
maximum bm level of 56% human cells in bmp2. Mice that received the CD19+CD20high 
subfraction engrafted two of the 4 mice transplanted with 3.0 x 103 cells to levels of 67% 
(M203) and 47% (M204) and none of the 4 mice transplanted with 3.0 x 102 cells. The 
other leukaemia sample used for a secondary CD20 sort and limiting dilution 
transplantation was 737c. Recovered bm from mouse M315, originally transplanted with 
1.5 x 103 CD19+CD20low purified diagnostic patient cells (KR42) and engrafted to 69% 
human chimerism in the terminal bm analysis was sorted into CD19+CD20low and 
CD19+CD20high subpopulations. Of either fraction 1.0 x 103 and 1.0 x 102 cells were 
injected into 4 secondary mice and 1.0 x 101 cells were injected into 5 secondary mice 
each. Mice transplanted with CD19+CD20low cells engrafted two of the 4 mice that 
received a cell dose of 1.0 x 103 to final engraftment levels of 40% (M475) and 54% 
(M478) all other mice failed to reconstitute the leukaemia. Mice transplanted with 
CD19+CD20high cells reconstituted the ALL in all 4 mice injected with 1.0 x 103 cells to 
final engraftment levels of 25% (M471), 67% (M472), 60% (M473) and 65% (M474) 
with a mean engraftment of 54% and in two of the 4 mice injected with 1.0 x 102 cells to 
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final engraftment levels of 71% (M481) and 64% (M482) while mice injected with 1.0 x 
101 did not result in a measurable chimerism.  
Additionally, tertiary cells of ALL WB51 were transplanted in numbers of 5.0 x 102 and 
1.0 x 101 cells of either CD19+CD20low or CD19+CD20high purified cells into 3 and 4 
mice each respectively (KR45). The preceding primary as well as the secondary mouse 
was transplanted with CD19+CD20high sorted cells and engrafted to 86% (M68, KR17, 
injected with 1.08 x 104 cells) 47% (M152, KR27, injected with 1.0 x 102 cells). The 3 
mice transplanted with 5.0 x 102 CD19+CD20low cells showed terminal engraftment 
levels of 65% (M346), 36% (M347) and 77% (M348) with a mean engraftment of 59% 
and the 3 mice transplanted with 5.0 x 102 CD19+CD20high had engraftment levels of 
1.0% (M343), 0.08% (M344) and 0.3% (bmp3 of M345) with a mean engraftment of 
0.46%. Mice transplanted with 1.0 x 101 cells only of either purified subfraction did not 
reconstitute human cells in the bm. 
Despite some inter-patient variability the secondary and tertiary limiting dilution 
xenotransplantation experiments on ALL blasts sorted according to the expression of the 
surface marker CD20 indicate that leukaemic stem cells are present at the same 
frequency in the less and more mature blast CD19+CD20low and the CD19+CD20high 
populations respectively. This LSC frequency is also comparable to the frequency in 
unsorted blasts. This is summarised in Table 11. 
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Patient 
ID 
Risk group Transplant 
Trans-
planted 
blast 
population 
Number of cells transplanted 
 
(number of mice engrafted/number of mice 
transplanted) 
LIC 
frequency 
(ELDA) 
1000-3000 300-500 100 10 
737c 
High risk 
(BCR/ABL
1 like) 
Secondary 
CD20high 4/4 - 2/4 0/5 165.8 
CD20low 2/4 - 0/4 0/5 1676 
2510 
High risk 
t(9;22) 
Secondary 
CD20high 2/4 0/4  - 4950 
CD20low 4/4 1/4  - 780 
WB51 
High risk 
t(9;22) 
Secondary 
CD20high 3/3 3/3 2/2 - >49.6 
CD20low 3/3 3/3 3/3 - >308 
Tertiary 
CD20high - 3/3 - 0/4 137.5 
CD20low - 3/3 - 0/4 137.5 
Table 11: A list of secondary and tertiary ALL samples transplanted in limiting dilution 
experiments of CD19
+
CD20
low
 and CD19
+
CD20
high
 cells. The limiting cell dose for secondary and 
the tertiary transplant experiments of CD19
+
CD20
low
 and CD19
+
CD20
high
 cells was determined to lie 
between 1.0 and 5.0 x 10
2
 cells. The frequencies of ALL LICs in the sorted blast populations were 
calculated using the ELDA programme. 
 
4.4.3.3 Frequency of leukaemic stem cells in CD19+CD10low and CD19+CD10high 
ALL subpopulations  
The CD10 surface antigen is first expressed on pre-B-I cells in the B lineage and stays 
positive through all further developmental stages including immature B cells (see 
subchapters 1.3.3.1, 1.3.3.2 and Figure 3). Cell characterisation according to CD10 
expression therefore separates the early, less differentiated pro-B cells from all 
following more mature B precursor cells which have a less pronounced proliferative 
potential than their predecessor. Experiments with CD19+CD10low and CD19+CD10high 
purified cell populations transplanted in numbers exceeding 1,000 cells per mouse 
described in subchapter 4.4.1.3 showed that blasts with high expression of CD10 
generally were not inferior in the ability to repopulate NSG mice with the ALL than 
immunophenotypically less mature blasts with no or only low expression of CD10. 
However, in order to compare the stem cell frequencies in subpopulations of 
CD19+CD10low and CD19+CD10high expressing cells with each other as well as with that 
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of unsorted bulk leukaemic populations, a limiting dilution xenotransplantation 
experiment was performed on secondary CD10 sorted cells from sample 737c (KR56). 
CD19+CD10low and CD19+CD10high purified cells of bm recovered from mouse M320, 
initially transplanted with 1.5 x 103 CD19+CD10high cells and engrafted to 42% human 
chimerism in the terminal bm analysis were transplanted into NSG mice with 1.0 x 103 
cells per mouse (n=4), 1.0 x 102 cells (n=4) and 1.0 x 101 cells (n=5). The first bmp 8 
weeks after transplantation identified human ALL cells in two out of 4 mice that 
received 1.0 x 103 CD19+CD10low cells at levels of 0.42% (M502) and 0.09% (M503) 
and in 3 out of 4 mice that received the same number of CD19+CD10high cells at levels of 
4.1% (M497), 16% (M 498) and 0.73% (M500) with a mean engraftment of 6.9%. No 
human cells could be detected in mice transplanted with less cells of either cell fraction 
at the time point of bmp1. However, one mouse transplanted with 1.0 x 102 
CD19+CD10low cells unexpectedly died before the first bm analysis. In the second bmp 7 
weeks later, 3 of the 4 mice transplanted with 1.0 x 103 CD19+CD10low cells and all 4 
mice transplanted with 1.0 x 103 CD19+CD10high cells were engrafted with mean 
engraftment levels of 16% and 70% respectively. Additionally two mice each were 
engrafted of both groups transplanted with 1.0 x 102 cells. Mice that received 
CD19+CD10low cells engrafted to 2.3% (M509) and 0.01% (M512) and mice that 
received CD19+CD10high cells to 0.02% (M506) and 0.13% (M507) human chimerism. 
Another 8 weeks later, the fourth mouse transplanted with 1.0 x 103 CD19+CD10low cells 
also showed human cell engraftment at a level of 0.3% (M504). No further mouse 
transplanted with 1.0 x 102 cells or any of the 10 mice transplanted with 1.0 x 101 cells 
showed human engraftment in the observation period up to 46 weeks. Engraftment 
levels at terminal bm harvest or the last available bmp for mice transplanted with 1.0 x 
103 cells of the CD19+CD10low subfraction were 73% (M501), 18% (M502), 25% 
8M503) and 22% (M504) with a mean engraftment of 35%. Of mice transplanted with 
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1.0 x 103 CD19+CD10high cells engraftment levels were 81% (M497), 80% (M498), 55% 
(M499) and 82% (M500) and the mean engraftment level was 75%. Highest engraftment 
levels for mice transplanted with 1.0 x 102 CD19+CD10low cells were 71% (M509) and 
7.7% (M512) and for mice transplanted with 1.0 x 102 CD19+CD10high cells 62% (M506) 
and 63% (M507) respectively. Both fractions were able to reconstitute the ALL in NSG 
mice when 1.0 x 102 cells only were transplanted but neither cell fraction resulted in 
human chimerism when individual mice received 1.0 x 101 cells. Similar to the findings 
in the limiting dilution experiments with unsorted blasts and ALL blasts sorted with 
respect to expression of CD20, the limiting dilution experiment with secondary cells 
sorted according to CD10 expression does not suggest, that the frequency of LSCs is 
different in the two subfractions. Figure 27 depicts all contour dot plots and Table 12 
summarises the results of the limiting dilution experiment on CD10 sorted cells from 
patient 737c. 
 
 
 
Figure 27 (page 206): Limiting dilution experiment on secondary sorted CD19
+
CD10
low
 and 
CD19
+
CD10
high
 cells of sample 737c. Mouse M320 was initially transplanted with CD19
+
CD10
high
 
purified cells of diagnostic patient bm sample 737c. Recovered bm of this mouse sorted into 
CD19
+
CD10
low
 and CD19
+
CD10
high
 subfractions subsequently was transplanted on secondary mice in 
limiting dilutions of 1.0 x 10
3
, 1.0 x 10
2
 and 1.0 x 10
1
 cells per mouse. All mice transplanted with 1.0 
x 10
3
 cells of either subfraction reconstituted the original patient ALL. In the groups transplanted with 
1.0 x 10
2
 cells per mouse 2 of 4 mice each engrafted the ALL. None of the mice that received only 1.0 
x 10
1
 cells of CD19
+
CD10
low
 or CD19
+
CD10
high
 sorted cells did show any engraftment. Bone marrow 
of the engrafted mice exhibited an immunophenotypic expression pattern comparable to that of the 
sorted bm from mouse M320 and the original patient material. 
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Patient 
ID 
Risk group Transplant 
Transplanted 
blast population 
Number of cells transplanted 
 
(number of mice engrafted/number 
of mice transplanted) 
LIC 
frequency 
(ELDA) 
1000 100 10 
737c 
High risk 
(BCR/ABL1 
like) 
Secondary 
CD10high 4/4 2/4 0/5 165.8 
CD10low 4/4 2/3 0/5 118.1 
Table 12: A table summarising the results of the secondary limiting dilution experiment of 
CD19
+
CD10
low
 and CD19
+
CD10
high
 cells on ALL sample 737c. The limiting cell dose for this 
secondary transplant experiment of CD19
+
CD20
low
 and CD19
+
CD20
high
 cells was determined to be 
1.0 x 10
2
 cells for both subpopulations. The frequencies of ALL LICs in the sorted blast populations 
were calculated using the ELDA programme. 
 
4.4.3.4 Frequency of leukaemic stem cells in CD19+CD34low and CD19+CD34high 
ALL subpopulations 
In normal bm CD34 expressing cells represent only a minor fraction of all 
haematopoietic cells but these cells constitute the apex of the haematopoietic hierarchy, 
endowed with extensive proliferative and self-renewal capacity which consecutively is 
lost on down-regulation of this surface marker. In the B lineage of lymphoid 
development, CD34 is present on the cell surface of pro-B cells and pre-B I cells but lost 
on the transition to pre-B II large cells as described in section 1.3.3.1 and Figure 3. It 
also has been shown that CD34+ cell subfractions in AML are highly enriched in stem 
cells and some studies claim the same for ALL. Transplanting 1.0 x 103 or more 
CD19+CD34high or CD19+CD34low purified ALL blasts led to engraftment in NSG mice 
after orthotopic injection as described in subchapter 4.4.1.4 above but this allows for no 
conclusion regarding the frequency of stem cells within the different cell fractions. In 
order to determine whether or not in ALL LICs are enriched in CD34 expressing cell 
fractions, CD19+CD34high and CD19+CD34low sorted blast populations were transplanted 
in limiting dilutions. 
Chapter 4  4.4 Results 
208 
 
The first limiting dilution experiment with CD34 sorted cells was performed on a 
tertiary WB51 bm sample recovered from mouse M272. This mouse had a final human 
bm chimerism of 66% after it was transplanted with 1.0 x 103 unsorted cells of mouse 
M68 which itself was injected with 1.08 x 104 CD19+CD20high cells in a primary sorting 
experiment and engrafted to a bm level of 86%. CD19+CD34high or CD19+CD34low 
purified cell populations were transplanted into groups of NSG mice with 1.0 x 103 
(n=4), 1.0 x 102 (n=5) and 1.0 x 101 (n=5) cells respectively. One mouse of the group 
transplanted with 1.0 x 103 CD19+CD34high cells was lost for analysis due to early death 
before bmp1 at 9 weeks after the start of the experiment but the remaining 3 were 
already engrafted to levels of 11% (M549), 1.2% (M550) and 31% (M552) with a mean 
engraftment of 43%. All 4 mice transplanted with 1.0 x 103 CD19+CD34low cells were as 
well engrafted to 4.8% (M553), 4.7% (M554), 0.3% (M555) and 0.5% (M556) with a 
mean engraftment of 2.6%. Low bm engraftment was also found in both groups 
transplanted with 1.0 x 102 cells. Mice M557 and M558 from the CD19+CD34high 
transplanted group reconstituted 0.16% and 0.04% human cells in mouse bm and mice 
M562, M564 and M566 from the CD19+CD34low transplanted group 0.67%, 0.1% and 
0.08% (mean engraftment 0.28%) respectively. Mice receiving 1.0 x 101 sorted cells 
only led to low level engraftment at bmp1 in the group transplanted with CD19+CD34high 
but not with CD19+CD34low cells. Mouse M568 showed 0.4% human cells in flow 
cytometry and M569 0.13%. At the time of bmp2, 3 weeks later, bm of all 3 mice 
(M559, M560 and M561) transplanted with 1.0 x 102 CD19+CD34high cells that were not 
engrafted at bmp1 contained human cells while no further mouse transplanted with 1.0 x 
102 CD19+CD34low cells was engrafted. In the groups transplanted with 1.0 x 101 cells 
two more mice (M567 and M570) reconstituted human blasts from CD19+CD34high cells 
and a first mouse (M573) also from CD19+CD34low cells. Another 6 weeks later (bmp3), 
one additional mouse (M565) engrafted in the group transplanted with 1.0 x 102 
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CD19+CD34low cells and one each (M572 and M574) transplanted with 1.0 x 101 
CD19+CD34high and CD19+CD34low cells respectively. After 23 weeks (bmp4) the last 
mouse (M563) that received 1.0 x 102 CD19+CD34low cells was engrafted and one more 
(M575) that received 1.0 x 101 CD19+CD34low cells. In the final bmp, 32 weeks post 
transplantation, engraftment was detected in a fourth mouse (M576) transplanted with 
1.0 x 101. Mean engraftment levels calculated from terminal bm harvests or a bmp in 
case bm from a harvest was not available, were 54% and 45% for groups transplanted 
with 1.0 x 103, 58% and 56% for groups transplanted with 1.0 x 102 and 53% each for 
groups transplanted with 1.0 x 101 CD19+CD34high or CD19+CD34low purified cell 
populations respectively. In this tertiary limiting dilution experiment, the limiting cell 
dose that was able to reconstitute the human ALL in mice was 1.0 x 101 cells for both 
sorted subfractions. Despite both the CD19+CD34high and CD19+CD34low cell 
populations being able to transfer the leukaemia onto NSG mice, there was a difference 
in the pattern of immunophenotypic reconstitution. While CD19+CD34low purified ALL 
cells led to an engrafted ALL immunophenotype resembling that of the sorted and 
transplanted sample and the original patient ALL with blasts of low and high CD34 
expression, CD19+CD34high purified cells did not generate CD34 low expressing cells in 
the bm of engrafted mice but only reconstituted the immunophenotype of the injected 
cells. This is illustrated in Figure 28 by contour dot plots of all mice from this 
experiment.  
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Figure 28 (page 211): Limiting dilution experiment on tertiary sorted CD19
+
CD34
low
 and 
CD19
+
CD34
high
 cells of sample WB51. Mouse M272 was initially transplanted with unsorted 
secondary cells of sample WB51. Recovered bm of this mouse sorted into CD19
+
CD34
low
 and 
CD19
+
CD34
high
 subfractions subsequently was transplanted on tertiary mice in limiting dilutions of 
1.0 x 10
3
, 1.0 x 10
2
 and 1.0 x 10
1
 cells per mouse. One mouse (M550) transplanted with 1.0 x 10
3 
CD19
+
CD34
high
 cells died before first bm analysis but all other mice transplanted with 1.0 x 10
3
 or 1.0 
x 10
2
 cells of the opposing subfractions reconstituted the original patient ALL. Transplantation of 
only 1.0 x 10
1
 cells per mouse resulted in engraftment of 4 out of 5 mice in the group injected with 
CD19
+
CD34
low
 cells and 5 out of 6 mice injected with CD19
+
CD34
high
 cells. The bm of mice 
transplanted with CD19
+
CD34
low
 sorted cells reconstituted an immunophenotypic expression pattern 
comparable to that of the sorted bm from mouse M272 and the original patient material. Of note, all 
mice transplanted with CD19
+
CD34
high
 sorted cells only reconstituted an ALL with the transplanted 
immunophenotype but did not reconstitute a CD19
+
CD34
low
 blast population. 
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Another CD34 sorted limiting dilution experiment was carried out with secondary cells 
of sample 737c. Mouse M327 was originally transplanted with 1.0 x 104 unsorted patient 
ALL bm cells and reconstituted the leukaemia to 68% in mouse bm. The bm was sorted 
into CD19+CD34high and CD19+CD34low subfractions and both were transplanted into 
mice in numbers of 1.0 x 103 (n=4), 1.0 x 102 (n=5) and 1.0 x 101 (n=5) cells per mouse. 
All 4 mice transplanted with 1.0 x 103 CD19+CD34high cells engrafted the ALL to levels 
of 11% (M578), 76% (M579), 94% (M580) and 6% (M581) with a mean engraftment of 
47% and the same number of CD19+CD34low cells was sufficient to engraft all 4 
transplanted mice to levels of 78% (M582), 13% (M583), 74% (M584) and 61% (M585) 
with a mean engraftment of 57%. In the groups transplanted with 1.0 x 102 cells per 
mouse, one reconstituted the ALL from CD19+CD34high purified cells with a human 
chimerism of 75% (M586) and two mice from CD19+CD34low cells with 82% (M593) 
and 77% (M594). For both subfractions 1.0 x 101 cells only were again the limiting cell 
dose to transfer the leukaemia into NSG mice. 3 of the 5 mice that received 
CD19+CD34high blasts engrafted to 40% (M596), 84% (M597) and 75% (M599) (mean 
engraftment 66%) and one of the 5 mice that received CD19+CD34low blasts engrafted to 
42% (M601). In this experiment, both subfractions were able to reconstitute the 
leukaemia to the original immunophenotype of the sorted sample and the patient ALL 
material independent of the cell number transplanted. Additionally it was determined if 
the sorted subfractions preferentially would first reconstitute one immunophenotype, 
their own or probably the immunophenotypically less mature regardless of the 
transplanted population, and consecutively generate the opponent one or if the full ALL 
immunophenotypic pattern would be re-established from early engraftment on. 
Therefore, contour dot plots of mouse bm at the time point of first flow cytometric signs 
of engraftment were analysed. The immunophenotype expression pattern of these 
contour dot plots already resembled the one finally gained for bm at the time of terminal 
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analysis when mostly overt ALL was present. Contour dot plots for first and terminal 
engraftment in mouse bm are depicted in Figure 29 and Figure 30. 
 
 
 
 
 
Figure 29 (page 214): Limiting dilution experiment on secondary sorted CD19
+
CD34
low
 and 
CD19
+
CD34
high
 cells of sample 737c, early engraftment. Mouse M327 was initially transplanted 
with unsorted primary cells of sample 737c. Recovered bm of this mouse sorted into CD19
+
CD34
low
 
and CD19
+
CD34
high
 subfractions subsequently was transplanted on secondary mice in limiting 
dilutions of 1.0 x 10
3
, 1.0 x 10
2
 and 1.0 x 10
1
 cells per mouse. All mice transplanted with 1.0 x 10
3
 
cells of one of the two subfractions reconstituted the original patient ALL. Transplantation of 1.0 x 
10
2
 cells resulted in engraftment of 2 out of 5 mice in the group injected with CD19
+
CD34
low
 cells 
and 1 out of 5 mice injected with CD19
+
CD34
high
 cells whereas transplantation of 1.0 x 10
1
 cells 
resulted in engraftment of 1 out of 5 and 3 out of 5 mice respectively. Already in bmps with the first 
detectable engraftment in the mouse xenoenvironment both the D19
+
CD34
low
 and CD19
+
CD34
high
 
immunophenotype is reconstituted irrespective of the transplanted subfraction. Furthermore, the bm 
of all mice reconstituted an immunophenotypic expression pattern comparable to that of the sorted bm 
from mouse M327 and the original patient material. 
 
 
Figure 30 (page 215): Limiting dilution experiment on secondary sorted CD19
+
CD34
low
 and 
CD19
+
CD34
high
 cells of sample 737c, final engraftment. Dot plots of the final engraftment levels of 
mice of the same experiment as in Figure 27 are depicted. Compared to the earliest recorded 
engraftment, the immunophenotypic expression pattern of bm blasts from mice transplanted with the 
CD19
+
CD34
low
 or the CD19
+
CD34
high
 subfraction does not alter significantly in highly engrafted 
mice. This holds true irrespective of the cell number transplanted per mouse. 
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In order to exclude that engraftment of the subpopulation of CD19+CD34high cells more 
closely resembling normal HSCs but also the subpopulation with the more mature 
progenitor immunophenotype CD19+CD34low was not an artefact caused by prior 
passage through one or two generations of mice, two primary CD34 sorts on samples 
4540a and L784 were transplanted in limiting dilutions. CD19+CD34high and 
CD19+CD34low purified blasts of sample 4540a were injected into the femora of 4 mice 
each with 1.0 x 103 cells per mouse and of 5 mice each with 1.0 x 102 or 1.0 x 101 cells 
per mouse. Two mice that received 1.0 x 103 CD19+CD34high sorted cells engrafted to 
1.1% (M606, died after bmp1) and 44% (M609) and one mouse (M611) that received 
1.0 x 103 CD19+CD34low sorted cells engrafted to 59%. In the groups transplanted with 
1.0 x 102 cells, 3 mice injected with the CD19+CD34high subpopulation reconstituted 
human blasts to 9% (M616), 22% (M617) and 45% (M620) and the mean engraftment 
was 25%. Flow cytometry on all other mice did not detect human cells. In this 
experiment the limiting cell dose for engraftment of CD19+CD34high expressing cells 
was 1.0 x 102 and for CD19+CD34low expressing cells 1.0 x 103 per mouse. However, 
both subfractions were able to repopulate mice with an immunophenotypic expression 
pattern mirroring the diagnostic ALL sample. Cells sorted according to CD34 marker 
expression from diagnostic bm of L784 (Figure 31) were transplanted in numbers of 1.0 
x 104 (n=4), 1.0 x 103 (n=4), 1.0 x 102 (n=5) and 1.0 x 101 (CD19+CD34high n=5 and 
CD19+CD34low n=6) cells per mouse. All 4 mice transplanted with 1.0 x 104 
CD19+CD34high cells engrafted human cells (M636 17%, M637 32%, M638 19% and 
M639 73%; mean engraftment 35%) as did 2 of the 4 mice transplanted with .0 x 104 
CD19+CD34low cells (M642 58% and M643 41%. 3 of 4 mice each engrafted human 
cells when transplanted with 1.0 x 103 CD19+CD34high or CD19+CD34low cells to 48% 
(M644), 3% (M645) and 21% (M647) (mean engraftment 24%) and 14% (M648), 0.2% 
(M649, died after bmp2) and 63% (M651) (mean engraftment 26%) respectively. From 
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the groups that received 1.0 x 102 sorted cells, one injected with the CD19+CD34low 
subfraction engrafted to a terminal bm level of 52% human ALL cells (M657). Neither 
subfraction reconstituted the leukaemia when 1.0 x 101 CD34 sorted cells were 
transplanted only. Therefore the limiting cell dose for the CD19+CD34high cell 
population was 1.0 x 103 and for the CD19+CD34low cell population 1.0 x 102 cells per 
mouse. Engrafted mice again presented with the complete original patient ALL 
immunophenotype. 
Similar to the limiting dilution experiments on blasts sorted according to CD20 
expression and again with some inter-patient variability the 4 limiting dilution 
experiments on primary, seconday and tertiary CD19+CD34high and CD19+CD34low 
sorted ALL blasts from 4 different patient samples demonstrate, that leukaemic cells 
resembling less mature developmental stages of physiologic B-cell development do not 
harbour a higher frequency of LSCs than presumably more mature blasts. 
 
 
 
 
Figure 31 (page 218): Limiting dilution experiment on primary sorted CD19
+
CD34
low
 and 
CD19
+
CD34
high
 cells of sample L784. Diagnostic patient bm was sorted into CD19
+
CD34
low
 and 
CD19
+
CD34
high
 subfractions and subsequently transplanted on primary mice in limiting dilutions of 
1.0 x 10
3
, 1.0 x 10
2
 and 1.0 x 10
1
 cells per mouse. Of mice transplanted with 1.0 x 10
3 
CD19
+
CD34
low
 
cells 2 out of 4 and of mice transplanted with CD19
+
CD34
high
 cells 4 out of 4 engrafted respectively. 
Mice transplanted with 1.0 x 10
2
 cells of the same subfractions engrafted each 3 out of 4 mice. 5 mice 
each were injected with only 1.0 x 10
1
 cells per mouse and all but one transplanted with cells from the 
CD19
+
CD34
low
 subfraction did not show any human engraftment. The bm of all engrafted mice 
irrespective of the transplanted cell subfraction reconstituted an immunophenotypic expression pattern 
comparable to that of the sorted bm from sample L784. 
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Table 13 summarises limiting dilution experiments carried out with CD34 sorted cells of 
all primary, secondary and tertiary ALL samples. 
 
Patient 
ID 
Risk group Transplant 
Transplanted 
blast population 
Number of cells transplanted 
 
(number of mice engrafted/number 
of mice transplanted) 
LIC 
frequency 
1000 100 10 
L784 Standard risk Primary 
CD34high 3/4 0/5 0/5 1:929 
CD34low 3/4 1/5 0/6 1:662 
4540a 
High risk 
t(9;22) 
Primary 
CD34high 2/5 3/5 0/4 1:839 
CD34low 1/5 0/5 0/5 1:5034 
737c 
High risk 
(BCR/ABL1 
like) 
Secondary 
CD34high 4/4 1/5 3/5 1:120 
CD34low 4/4 2/5 1/5 1:143.7 
WB51 High risk t(9;22) Tertiary 
CD34high 3/3 5/5 5/6 1:6.10 
CD34low 4/4 5/5 4/5 1:6.73 
Table 13: A table of primary, secondary and tertiary ALL samples transplanted in limiting 
dilution experiments of CD19
+
CD34
low
 and CD19
+
CD34
high
 purified cells. The limiting dilution 
dose of 1.0 x 10
1
 CD19
+
CD34
low
 as well as CD19
+
CD34
high
 cells was sufficient to transfer the ALL in 
secondary and the tertiary transplant experiments onto NSG mice. In the primary transplantation 
experiment on sample L784, 1.0 x 10
2
 cells were able to reconstitute the leukaemia from 
CD19
+
CD34
low
 cells and 1.0 x 10
3
 cells from CD19
+
CD34
high
 cells. For primary sample 4540a it was 
the other way round. The frequencies of ALL LICs in the sorted blast populations were calculated 
using the ELDA programme. 
 
4.4.4 ALL immunophenotypic reconstitution patterns originating from diverse 
transplanted subpopulations 
During the hierarchically organised haematopoietic development from early stem cells 
through progenitor cells of the diverse lineages to the mature effector cells, cells acquire 
or lose surface epitopes and exhibit a specific surface marker expression pattern that 
correlates to their maturation stage. This process is not reversible and daughter cells will 
not re-acquire an immunophenotype less mature than that of their predecessor. The 
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occurrence of CD surface markers in physiological B-lineage development is described 
in section 1.3.3.1 and depicted in Figure 3. However, cancer stem cells, in addition to the 
capability to self-renew are required to fulfil a second defining characteristic; the ability 
to differentiate into all diverse cell phenotypes found within a tumour. In the subchapters 
above it has been shown that all subfractions of cells sorted according to the expression 
of CD19, CD10, CD20 and CD34 were able to transfer the ALL onto NSG mice when 
transplanted orthotopically into the hosts’ femora. Generally, the transplanted 
immunophenotypic subpopulations also led to the generation of human cells of the not 
transplanted immunophenotype in the mouse xenoenvironment when dot plots were 
compared. Immunophenotypically less mature cell populations therefore were able to 
reconstitute immunophenotypically more mature cell populations but in contrast to the 
haematopoietic system more mature ALL subfractions were also able to reconstitute less 
mature ALL subpopulations. The only exception was the tertiary limiting dilution 
experiment on CD34 sorted cells from sample WB51 (KR59) where CD19+CD34high 
purified cells failed to reconstitute an immunophenotypically less mature population of 
CD19+CD34low cells in mouse bm.  
Portraying flow cytometry data of surface marker expression in histograms visualises the 
distribution of cells with low and high expression of the respective CD antigen. In order 
to compare the distribution of cells in the bm of mice transplanted with different sorted 
subpopulations with each other and with the parent sample, histograms were created for 
each individual bm sample and then overlaid. Expression of CD19 showed the smallest 
variation within leukaemic samples and was generally high. When cells with the lowest 
and highest expression of CD19 were purified and transplanted, the CD19 expression 
patterns of engrafted mice were similar to each other and to the sample that was sorted 
into these two subfractions (M5, A67, experiment KR5). CD10 expression varied from 
very low to very high among cells of patient WB51. This variation was fully 
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reconstituted in the bm of mice transplanted with CD19+CD10low and CD19+CD10high 
cells purified from bm of mouse M64 (KR21). However, the mean expression level of 
CD10 was lower in bm of the transplanted mouse generation and mice transplanted with 
the CD19+CD10low subfraction generally had a little lower level of CD10 expression 
than the mice transplanted with CD19+CD10high cells. When bm of mouse M6 (A67) was 
sorted into CD19+CD20low and CD19+CD20high cell populations and transplanted into 
NSG mice (KR11), the CD20 expression pattern of all engrafted mice was nearly 
identical but the mean expression level was little lower than in the parent sample. The 
surface marker CD34 had a different expression pattern. The primary patient sample 
L784 contained two major populations of blasts, one with high expression and another 
with low expression of CD34. Both populations were able to reconstitute the opposing 
population in transplanted mice with variable contribution of the two populations to the 
bulk leukaemia (KR62). This was also the case for the CD34 sort on secondary cells 
(M327) from 737c (KR60). Both the CD19+CD34high and CD19+CD34low subfraction, 
reconstituted itself as well as the contrasting subfraction in transplanted mice and the 
two populations were also variable in size. An exception to this was the CD34 sort on 
sample WB51 (KR59). Bone marrow of mouse M272 had a small population of 
CD19+CD34low and a large population of CD19+CD34high expressing cells. When this 
sample was sorted according to CD34 expression levels, the CD19+CD34low subfraction 
reconstituted cells with low and high CD34 expression with the number of 
CD19+CD34low cells exceeding the number of CD19+CD34high reconstituted cells. The 
purified CD19+CD34high subfraction, however, failed to reconstitute a population of 
CD19+CD34low cells and only replicated itself in engrafted mice. Histogram overlays of 
the CD19, CD10, CD20 and CD34 sorts are depicted in Figure 32. 
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Figure 32: Histogram overlays of the sorted ALL sample and engrafted bm from mice 
transplanted with the low or high expressing fraction of the specific surface antigen. a) CD19, 
CD10 and CD20 show a Gaussian distribution of surface antigen expression. The smallest variation is 
present in CD19 expression and is reconstituted in the transplanted mouse generation by 
CD34
+
CD19
low
 and CD34
+
CD19
high
 cell populations. CD10 expression presents a wide variation. This 
is fully reconstituted in bm of transplanted mice by both sorted fractions, CD19
+
CD10
low
 and 
CD19
+
CD10
high
, however, there is a little shift of mean CD10 expression towards the transplanted 
immunophenotype. The CD20 expression spectrum is also re-established in transplanted mice with a 
little lower mean expression compared to the parent sample similar for mice transplanted with 
CD19
+
CD20
low
 or CD19
+
CD20
high
 subfractions. b) The CD34 antigen divides the bulk ALL into one 
population with lower and one with higher CD34 expression. Both populations are generally 
reconstituted in mice by CD19
+
CD34
low
 or CD19
+
CD34
high
 purified fractions with variable size (left 
and middle image). The single exception was a tertiary sort of WB51 from which the CD19
+
CD20
high
 
subfraction only reconstituted daughter cells of the same immunophenotype. 
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4.4.5 Engraftment kinetics of cell populations of diverse immunophenotypes 
In the subchapters above it could be shown that blasts of different maturity according to 
the surface marker expression of CD10, CD19, CD20 and CD34 were able to engraft the 
leukaemia and reconstitute the complete immunophenotypic expression profile of the 
original ALL. Furthermore, it could be demonstrated that diverse sorted blast 
subfractions harboured self-renewal capability and that the stem cell frequencies within 
the different transplanted immunophenotypes did not vary considerably. Despite being 
similar in regards of these decisive stem cell characteristics, it still could be possible that 
the blast immunophenotype affects the engraftment kinetics of leukaemic blasts. In order 
to address this question the human xenograft chimerism caused by CD10, CD19, CD20 
and CD34 sorted blasts over time was determined by flow cytometric analysis of 
sequential bmps. For sufficient numbers of mice at each time point, engrafted mice 
transplanted with comparable numbers of purified human leukaemic blasts were pooled 
for the investigation of engraftment kinetics. When possible, engraftment kinetics were 
determined for mice transplanted with relatively low numbers of sorted cells close to the 
limiting dilution as well as for mice transplanted with higher numbers for each 
subpopulation. 
 
Among all xenotransplantations with CD10 sorted cells only one limiting dilution 
experiment was performed. Secondary CD19+CD10high and CD19+CD10low cells of 
sample 737c were transplanted with 100 cells per mouse into 4 mice each and in both 
groups two mice engrafted the leukaemia (experiment KR56). However, the 
development of the ALL in the transplanted mice followed a similar time pattern in both 
subgroups. More mice were transplanted with cell numbers between 1.0 x 103 and 2.0 x 
103 cells per mouse. Altogether 16 mice engrafted with CD19+CD10high blasts and also 
16 mice engrafted with CD19+CD10low blasts from the primary samples 737c (KR43), 
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M120 (KR47), 758b (KR50) and one secondary sample of 737c (KR56) were pooled 
and mean engraftment was calculated for sequential bmps. Again, detection of first 
engraftment and propagation of the ALL in mice showed a similar time course when 
higher numbers of cells were transplanted. The engraftment kinetics of CD19+CD10high 
and CD19+CD10low blasts are depicted in the graphs of Figure 33. 
 
 
Figure 33: Engraftment kinetics of CD19
+
CD10
high
 and CD19
+
CD10
low
 purified ALL 
subpopulation as assessed by sequential bone marrow punctures. a) Only one experiment was 
performed with 100 CD10 sorted cells transplanted per mouse on sample 737c (KR56). Two mice 
each engrafted from injected CD19
+
CD10
high
 or CD19
+
CD10
low
 blast subfractions. b) Engrafted mice 
transplanted with 1.0 x 10
3
 to 2.0 x 10
3
 cells per mouse from the limiting dilution experiments on 
samples 737c (KR43 and KR56), M120 (KR47) and 758b (KR50) were pooled (16 mice in the 
CD19
+
CD10
high
 as well as in the CD19
+
CD10
low
 group) in order to increase the number of mice in 
each transplanted subgroup. CD19
+
CD10
high
 as well as CD19
+
CD10
low
 purified cells need a similar 
period of time to initiate first detectable human engraftment in NSG mice and for major propagation 
of the ALL. Error bars represent the standard error of the mean (SEM). 
 
Patient samples sorted according to the surface marker expression of CD19 were not 
transplanted in limiting dilution assays. Therefore engrafted mice from all 
transplantations injected with between 2.0 x 103 and 3.0 x 104 cells from the primary 
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sample WB51 (KR18) and the secondary experiments on A67 (KR4 and KR5) were 
analysed together. Altogether 10 mice that received the CD34+CD19high subfraction and 
9 mice that received the CD34+CD19low subfraction could be used for the calculations. 
There is no clear difference in the engraftment kinetics of mice transplanted with either 
of the sorted blast subpopulations. This is illustrated in Figure 34. 
 
 
Figure 34: Engraftment kinetics of CD34
+
CD19
high
 and CD34
+
CD19
low
 purified ALL 
subpopulation as assessed by sequential bone marrow punctures. No limiting dilution 
experiments were performed on CD19 sorted cells with cell numbers of less than 2.0 x 10
3
 
transplanted per mouse. Engrafted mice from the experiments on samples A67 (KR4 and KR5) and 
WB51 (KR18) transplanted with 2.0 x 10
3
 to 3.0 x 10
4
 cells per mouse were pooled (10 mice for the 
CD34
+
CD19
high
 and 9 mice for the CD34
+
CD19
low
 subfraction) in order to increase the number of 
mice in each transplanted subgroup. CD34
+
CD19
high
 and CD34
+
CD19
low
 purified cells need a similar 
period of time to initiate detectable leukaemic growth and to propagate the human ALL in NSG mice. 
Error bars represent the standard error of the mean (SEM). 
 
CD20 was the surface marker that was used for sorting in many experiments as it 
separates leukaemic blasts that resemble lymphoid precursor stages experiments were 
performed to determine whether or not the nearly mature blast populations would need a 
longer time period for reconstituting the leukaemia in mice than their less mature 
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counterparts and if there was a difference in these engraftment kinetics when lower or 
higher numbers of cells were transplanted. In limiting dilution experiments, 10 mice 
each engrafted when transplanted with 1.0 x 102 to 5.0 x 102 CD19+CD20high and 
CD19+CD20low cells respectively. These were mice transplanted from secondary 
experiments on WB51 (KR27), 2510 (KR33) and 737c (KR55) and a tertiary experiment 
on WB51 (KR45). Considerably more mice were transplanted and engrafted with cell 
numbers ranging from 1.0 x 103 to 3.0 x 103 sorted cells. Thirty-one of the engrafted 
mice received CD19+CD20high sorted cells and 39 engrafted mice received 
CD19+CD20low cells. These mice were pooled from primary experiments on samples 
HV101 (KR31), 737c (KR42), M120 (KR48) and 758b (KR51), secondary experiments 
on WB51 (KR26, KR27 and KR34), 2510 (KR33) and 737c (KR55) and tertiary 
experiments on A67 (KR28 and KR29). There is no clear difference in engraftment 
kinetics of mice transplanted with lower or higher numbers of cells of the 
CD19+CD20high or the CD19+CD20low immunophenotype. This is visualised in Figure 
35. 
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Figure 35: Engraftment kinetics of CD19
+
CD20
high
 and CD19
+
CD20
low
 purified ALL 
subpopulation as assessed by sequential bone marrow punctures. a) Engrafted mice transplanted 
with only 1.0 to 5.0 x 10
2
 cells per mouse from the limiting dilution experiments on samples WB51 
(KR27 and KR45), 2510 (KR33) and 737c (KR55) were pooled (10 mice each for the CD19
+
CD20
high
 
as well as for the CD19
+
CD20
low
 subfraction) in order to increase the number of mice in each 
transplanted subgroup. b) Engrafted mice transplanted with 1.0 to 3.0 x 10
3
 cells per mouse from the 
limiting dilution experiments on samples WB51 (KR26, KR27 and KR34), A67 (KR28 and KR29), 
HV101 (KR31), 2510 (KR33), 737c (KR42 and KR55), M120 (KR48) and 758b (KR51) were pooled 
(31 mice for the CD19
+
CD20
high
 and 39 for the CD19
+
CD20
low
 subfraction) in order to increase the 
number of mice in each transplanted subgroup. Regardless of the cell number transplanted per mouse 
CD19
+
CD20
high
 as well as CD19
+
CD20
low
 purified cells need a similar mean period of time to initiate 
first detectable human engraftment in NSG mice and for major propagation of the ALL. Error bars 
represent the standard error of the mean (SEM). 
 
The surface marker CD34 is an established stem cell marker of the haematopoietic 
system. However, the work described in this thesis did not confirm that it can be used as 
a stem cell marker in ALL. Still, it could be possible that proliferation activity and 
therefore engraftment kinetics between CD34 high and CD34 low expressing blast 
populations would be different. This question was addressed by comparing the progress 
of engraftment of CD19+CD34high and CD19+CD34low purified cell fractions over time 
transplanted in smaller and larger cell numbers. When only 1.0 x 102 cells were 
transplanted per mouse from the primary patient samples 4540a (KR61) and L784 
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(KR62), the secondary sample 737c (KR60) or the tertiary sample WB51 (KR59), 
altogether 9 mice engrafted when injected with CD19+CD34high and 8 mice when 
injected with CD19+CD34low expressing lymphoblasts. The time needed for first 
detectable engraftment as well as for major expansion of the leukaemia in the 
xenotransplant environment was comparable. The same held true when 1.0 x 103 sorted 
cells per mouse were transplanted from the same samples. In these experiments 11 mice 
reconstituted the ALL from the CD19+CD34high and 12 mice from the CD19+CD34low 
subfraction respectively. The mean engraftment levels of these mice over time are 
depicted in the graphs of Figure 36. 
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Figure 36: Engraftment kinetics of CD19
+
CD34
high
 and CD19
+
CD34
low
 purified ALL 
subpopulation as assessed by sequential bone marrow punctures. a) Engrafted mice transplanted 
with only 1.0 x 10
2
 cells per mouse from the limiting dilution experiments on samples WB51 (KR59), 
737c (KR60), 4540a (KR61) and L784 (KR62) were pooled (9 mice for the CD19
+
CD34
high
 and 8 
mice for the CD19
+
CD34
low
 subfraction) in order to increase the number of mice in each transplanted 
subgroup. b) Engrafted mice transplanted with 1.0 x 10
3
 cells per mouse from the same experiments 
were as well pooled (11 mice for the CD19
+
CD34
high
 and 12 mice for the CD19
+
CD34
low
 subfraction) 
in order to increase the number of mice in each transplanted subgroup. Regardless of the cell number 
transplanted per mouse CD19
+
CD34
high
 as well as CD19
+
CD34
low
 purified cells need a similar mean 
period of time to initiate first detectable human engraftment in NSG mice and for major propagation 
of the ALL. Error bars represent the standard error of the mean (SEM). 
 
Despite some variability, taken together the data provide convincing evidence that all 
sorted subpopulations engrafted with similar kinetics. In summary, there was no 
enrichment for stem cell activity in any of the populations tested, demonstrating the 
absence of a stem cell hierarchy in ALL.  
  
0
20
40
60
80
100
0 5 10 15 20 25 30 35
e
n
g
ra
ft
m
e
n
t 
[%
]
t [wks]
100 cells/mouse
0
20
40
60
0 5 10 15 20 25
e
n
g
ra
ft
m
e
n
t 
[%
]
t [wks]
1,000 cells/mouse
0
20
40
60
0 5 10 15 20 25
e
n
g
ra
ft
m
e
n
t 
[%
]
t [wks]
1,000 cells/mouse
CD34 high CD34 low
t [wks] t [wks]
100 cells/mouse 1,000 cells/mouse
en
g
ra
ft
m
en
t
[%
]
en
g
ra
ft
m
en
t
[%
]
a) b)
Chapter 4  4.5 Discussion 
230 
 
4.5 Discussion 
Work described in this chapter aimed to identify and characterise leukaemic stem cells 
in ALL. It could be demonstrated that sorted blast populations of diverse maturity 
according to the immunophenotype have the ability to reconstitute the leukaemia in the 
murine xenotransplantation assay and that this potential is not restricted to immature 
blast populations as suggested in several publications. The re-established leukaemias 
closely mirrored the immunophenotypic expression pattern of the transplanted sample 
and the original patient sample respectively, regardless of the sorted subfraction 
transplanted. Furthermore, evidence was provided that the frequency of LICs in the bulk 
leukaemia, as well as in subfractions purified according to the immunophenotype, is 
much higher than previously thought, with only 1.0 x 103 down to 1.0 x 101 cells being 
sufficient to transfer the ALL onto NSG mice. 
 
The ability of blast subpopulations that resemble distinct maturation stages of 
physiologic haematopoietic development to reconstitute the ALL in the xenogenic 
mouse environment was determined for 15 different ALL samples. ALL bone marrow 
cells were sorted according to their expression of the surface antigens CD19, CD10, 
CD20 and CD34. Using these markers it is possible to purify cell populations of distinct 
stages within the B cell lineage. In B cell development populations with a high 
expression of CD20 represent immature B cells, the most mature stage of B precursor 
cells. The first stages in the B lineage, pro-B cells and pre-B-I cells, are characterised by 
expression of CD34 with pro-B cells additionally lacking CD10 and CD19 on the cell 
surface. All sorted subpopulations without exception, from immunophenotypically early 
CD34+ blasts to the most mature CD20high expressing stages, successfully transferred the 
leukaemia onto NSG mice, therefore demonstrating leukaemia initiation ability. 
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Furthermore, the engrafted leukaemias generally reconstituted the full 
immunophenotype pattern of the parent sample. This constitutes one defining 
characteristic of cancer stem cells ie the capability to give rise to all heterogeneous cell 
populations that comprise the original tumour. When more immature blast populations 
of the immunophenotypes CD34+CD19low, CD19+CD10low, CD19+CD20low or 
CD19+CD34high were injected into mice, they reconstituted themselves as well as the 
more mature CD34+CD19high, CD19+CD10high, CD19+CD20high or CD19+CD34low 
subpopulations. This is in line with normal haematopoietic development. Less mature 
cell populations reproduce cells of identical maturity but also differentiate into 
downstream developmental stages. In normal haematopoiesis this process is not 
reversible and more mature haematopoietic cells do not dedifferentiate to generate less 
mature cell clones. However, work presented in this thesis proved a different behaviour 
for B precursor ALL cells. Transplantation of more mature CD34+CD19high, 
CD19+CD10high, CD19+CD20high or CD19+CD34low subpopulations in addition to 
reconstituting cells of an identical immunophenotype also generated less mature 
CD34+CD19low, CD19+CD10low, CD19+CD20low and CD19+CD34high cells,  thereby 
reconstituting the whole original ALL immunophenotype.  
Several scenarios could lead to these observations. One is that the more mature cells are 
able to dedifferentiate to the less mature developmental stage. After this process they 
proliferate to reproduce a cell clone of identical less mature cells but partly also 
differentiate again to give rise to more mature progeny. Another possibility would be 
that immunophenotypically more mature cells directly produce less mature cells 
following cell division. The parent cell itself then would not have to dedifferentiate in 
order to produce more immature progeny. Furthermore, it also could be possible that 
surface marker expression on ALL blasts, unlike in haematopoiesis or AML, does not 
relate to the maturational stage but that expression of all investigated antigens, CD19, 
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CD10, CD20 and CD34, is random and can be up or down regulated on individual cells. 
However, unpublished work from our group (manuscript submitted) does not support 
this alternative. Still, the observation that in the earliest detectable bm engraftments 
generally the final immunophenotype is already established, even when only less than 
0.1% of mouse bm cells are of human origin, favours the two latter possibilities. 
However, it can not be excluded that a dedifferentiation takes place at a time point, when 
the ALL is not detectable using flow cytometry. 
It was clearly demonstrated that all subfractions sorted according to the expression of the 
CD surface antigens 19, 10, 20 and 34 from several ALL samples could re-establish the 
complete original immunophenotype in transplanted mice but there was one individual 
exception. CD19+CD34high cells from the tertiary CD34 sort on ALL WB51 did 
successfully engraft NSG mice but only reconstituted their own immunophenotype 
while CD19+CD34low cells reconstituted the full original variety of CD34 surface marker 
expression. This was somehow surprising and it is difficult to find an explanation for 
this phenomenon. CD34 expressing cells are more immature in their surface marker 
expression profile than cells that do not express CD34. Therefore, in this case, the more 
mature subpopulation was able to dedifferentiate and reconstitute the more immature 
subpopulation while less mature cells failed to differentiate to reconstitute more mature 
cells. However, this observation potentially indicates that rather mature blast 
subfractions do not need to dedifferentiate in order to proliferate and are by themselves 
able to reconstitute the ALL albeit of reduced immunophenotypic variety. 
The other hallmark of CSCs, self-renewal, was also investigated. In serial 
transplantation experiments up to 3 generations of mice were transplanted with ALL 
subpopulations of different maturity and reconstituted the malignancy. Of note, even 
when the most mature cell population according to surface marker profile 
(CD19+CD20high) was purified from diagnostic patient bm, it was able to maintain the 
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disease in three mouse generations over a cumulative period of up to 78 weeks. 
However, the tertiary CD20 sort of WB51 resulted in generally low engraftment levels 
in transplanted mice. This CD20 sort was performed on bm from a mouse initially 
transplanted with CD19+CD20high patient cells, an immunophenotypically more mature 
cell fraction that arguably could have less self-renewal activity than more immature cell 
populations. However, when tertiary cells of the same leukaemia were sorted into 
CD19+CD34high and CD19+CD34low subpopulations transplanted mice engrafted to high 
levels. This tertiary CD34 sort was performed on material that as well initially was 
transplanted with CD19+CD20high cells and then was used for an unsorted limiting 
dilution experiment in a second generation of mice. High engraftment levels were 
achieved in this tertiary limiting dilution experiment, indicating, that CD19+CD20high 
cells do not lose self-renewal capacity when serially transplanted over more than two 
generations of mice. Another reason for the low engraftment level of mice from the 
tertiary experiment with CD20 sorted cells could be that they were all injected with low 
numbers of 5.0 x 102 cells only and were harvested as they were approaching the end of 
their physiological life span. It can not be excluded that these mice eventually would 
have engrafted to high levels.  
Furthermore, engraftment kinetics of opposing subpopulations sorted according to the 
surface marker expression of CD10, CD20 and CD34 were compared and found to be 
similar even at lower transplanted cell numbers. This suggests that LIC frequency is not 
different between sorted subfractions of more immature and more mature 
immunophenotypes but that stemness is evenly distributed across all maturational stages. 
It also suggests that the biological behaviour of assumed stem cells within these 
subpopulations resembles each other in respect to stem cell quiescence and proliferative 
activity. 
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Stem cells in haematopoiesis or AML constitute a rare subset. Several studies on ALL 
indicated that the situation is similar for ALL stem cells. However, demonstrating 
leukaemia reconstitution potential in all investigated subpopulations of different 
maturity according to CD surface antigen expression suggested that LICs might be more 
abundant than proposed by studies that detected LICs only in rare and immature blast 
populations. This created the desire to scrutinize the overall LIC frequency in ALL in 
the orthotopic NSG mouse model. Therefore, unsorted limiting dilution experiments 
were performed on several samples with transplanted cell doses down to 1.0 x 101 cells 
per mouse. The determined LIC frequencies revealed inter-patient variability but for all 
samples 1.0 x 103 cells were sufficient to initiate ALL at least in some transplanted mice. 
In the experiments with primary patient material, several samples were additionally able 
to cause leukaemia in mice from only 1.0 x 102 injected cells but this was the limiting 
cell dose. When secondary or tertiary blasts were transplanted, 1.0 x 101 cells were 
sufficient to transfer the ALL onto the majority of mice. The general tendency that 
higher transplanted cell numbers led to earlier detectable engraftment of human cells and 
earlier onset of overt leukaemia supports the assumption that indeed more than one stem 
cell was present among these higher numbers of injected cells. Otherwise mice 
transplanted with a lower number of cells and successful engraftment would have been 
expected to reconstitute the leukaemia in the same time manner.  
Using the orthotopic NSG mouse model may be one reason to explain why LIC 
frequencies across several ALL samples were found to be higher than those determined 
in other studies that applied the iv transplantation technique on less 
immunocompromised mice. Additionally, the high sensitivity and specificity of the 
developed gating strategy in detecting human cells in the mouse xenoenvironment may 
also have contributed to the difference of LIC frequencies in this work compared to that 
of other groups.  
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The reproducibly found high LIC content in various unsorted ALL samples raised 
important questions. The earlier experiments with sorted subpopulations usually were 
performed by transplanting relatively high cell doses in the range of 1.4 x 103 and 6.2 x 
104 per mouse, cell doses that were higher than the limiting cell numbers required for 
engraftment of unsorted blasts. Taking this into account, although being present in 
subpopulations of dissimilar maturity, the frequency of LICs in these specific 
subpopulations could be significantly different. Therefore, one question was to 
determine whether or not LIC frequencies were comparable between unsorted bulk 
leukaemia cells and sorted cell fractions with a differentially mature surface marker 
profile. The other question arose from the accuracy of cell sorting and its potential 
influence on experiment outcome. Despite high sorting purities, usually in excess of 
95%, contamination of more mature blast subfractions with a substantial number of less 
mature cells and vice versa could not be completely ruled out. This created the 
possibility that human ALL engraftment of mice was not initiated by the presumed 
sorted subfraction but indeed originated from the few cells of the contaminating 
opposing immunophenotype. In order to address these issues, sorted cell subpopulations 
according to the CD surface antigens 10, 20 and 34 were transplanted in limiting 
dilutions as well. As already seen for limiting dilution experiments on unsorted cells, 
there also was inter-patient variability in LIC frequencies in sorted populations and 
secondary or tertiary transplanted cells generally were able to transfer the leukaemia 
onto mice with lower numbers of injected cells as primary patient samples. However, all 
sorted subpopulations were able to engraft the leukaemia at least in some mice when 1.0 
x 102 cells only were transplanted. For CD20 and CD34 sorts, there were examples 
where 10 times more cells were needed to engraft the immunophenotypically more 
mature cell population than the more immature population but equally, for both sorts, 
other samples needed 10 times more cells to engraft the more immature population than 
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the more mature one. A possible explanation for this lies in the small group size of 4 to 5 
mice transplanted with each subfraction of which only 1 to 3 engrafted. Higher numbers 
of mice injected with the different subpopulations would probably have resulted in 
engraftment of both subpopulations in some of the transplanted mice. Taken together, 
the limiting dilution experiments on sorted ALL blast subfractions strongly suggest that 
LIC frequency is evenly distributed across an extended spectrum of 
immunophenotypical maturation stages. Additionally, the finding that as few as 1.0 x 
101 or 1.0 x 102 cells proved to be sufficient to engraft the ALL from purified blast 
populations, regardless of the immunophenotypic maturity level, made it unlikely that 
engraftment originated from contaminating cells of the complementary 
immunophenotype.  
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4.6 Conclusion 
Work presented in this chapter indicates that acute lymphoblastic leukaemia can be 
reconstituted to the complete original immunophenotype and maintained over extended 
periods of time from blast subpopulations of different maturity according to surface 
marker expression profile. Leukaemia initiating cells additionally were frequent in the 
sorted subpopulations with 1.0 x 101 to 1.0 x 102 cells being sufficient to reconstitute the 
leukaemia from secondary or tertiary material and 1.0 x 102 to 1.0 x 103 sorted cells 
being sufficient to reconstitute the leukaemia from primary patient samples. These 
findings strongly argue against a hierarchical organisation being applicable for ALL like 
for normal haematopoiesis or AML and suggest that leukaemic stem cells in ALL best 
fit the stochastic stem cell model.  
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Chapter 5: General Discussion 
5.1 Summary and Discussion 
Improving treatment outcome for patients with different malignancies remains a huge 
challenge in cancer medicine and greatly depends on revealing and understanding the 
biology of a specific cancer in depth. Since the hazard to the organism from cancer 
largely derives from its uncontrolled growth, it is essential to find out which cells within 
the tumour drive unrestrained proliferation, what proportion of the tumour do they 
constitute for and what distinguishes them from other cells in the tumour without this 
capability. Dependent on the answers to these questions two main models are generally 
applied in cancer biology, the stochastic model, in which every cell within the cancer 
potentially is able to maintain the complete tumour and the hierarchical model, in which 
only a rare subset of cells is responsible for sustaining the tumour and gives rise to 
progeny that itself loses this ability but still has limited proliferative potential. These 
tumour maintaining cells are the cancer stem cells that by definition are able to self-
renew and to differentiate into the diverse lineages that make up the complete 
malignancy.  
Leukaemias are commonly believed to mirror the classical hierarchical organisation well 
established for physiological haematopoiesis and therefore the hierarchical cancer stem 
cell model is favoured for haematologic malignancies. However, due to conflicting 
results, there is a continuing debate about the frequency and identity of stem cells in 
acute lymphoblastic leukaemia which divides opinions in regard to which model has to 
be applied.  
The work presented in this thesis had the main aim to determine whether or not stem 
cells in B precursor ALL are rare and restricted to an immunophenotype that resembles 
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early stages in physiologic B cell development or if they are more abundant and not 
restricted to immunophenotypically defined immature blast subfractions. Identification 
of stem cells is highly dependent on the ability of the applied model to serve as a host 
and to provide as similar as possible support for candidate cancer stem cells as the 
genuine organism. Therefore, a prerequisite was to chose and establish a robust 
xenotransplantation model in order to provide the most ideal conditions for the 
engraftment of leukaemic stem cells. Additionally, it was necessary to reliably detect 
engrafted cells in the murine xenoenvironment with a high sensitivity as well as 
specificity.  
The generally accepted gold standard to address the stem cell characteristics of self-
renewal and differentiation in cell populations of human origin is the orthotopic 
xenotransplantation assay (Clevers, 2011; Nolta and Jordan, 2005). However, the 
technical aspects of the applied transplantation procedure as well as the read out of 
results and even more importantly the characteristics of the transplanted mouse strain 
have an essential impact on experiment outcome. The orthotopic intra-bone marrow LIC 
injection model was selected for this project as it was shown to have a profoundly higher 
sensitivity in detecting normal haematopoietic stem cells in the murine model than the 
traditionally applied intravenous transplantation procedure (Kushida et al., 2001; 
Mazurier et al., 2003; McDermott et al., 2010; Wang et al., 2003; Yahata et al., 2003). 
The NSG mouse strain was regarded as the most suitable host for human ALL blasts. In 
addition to the most profound immunodeficiency in comparison to other mouse strains 
NSG mice harbour the advantage of a relatively long lifespan as they are less prone to 
develop lymphomas (Shultz et al., 2005). This was of particular importance for 
experiments with very low numbers of cells transplanted and consequently longer times 
needed for engraftment. The different available mouse strains and the advantages of the 
orthotopic intrafemoral transplantation approach for a project on LICs were introduced 
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and discussed in more detail in chapter 3. Flow cytometry was used for detection of 
human cells in the murine xenoenvironment. As antibodies to human surface CD 
antigens of interest showed some unspecific binding to cells of murine origin, antibodies 
directed against the white and red cell lineage of mouse cells were used in order to 
differentiate between human and mouse cells with more accuracy. With the developed 
and consequently improved gating algorithm it finally was possible to reliably detect one 
cell of human origin in 1.0 x 104 mouse bm cells. An even higher sensitivity probably 
only would have been possible by using RQ-PCR based methods as used for MRD 
monitoring in the clinical setting, however, this was not regarded as being necessary as it 
would have been questionable to count a human chimerism of less than one in 1.0 x 104 
bone marrow cells as engraftment of human ALL. Furthermore, in addition to higher 
costs this method is much more time consuming and results would not be available the 
same day but rather be delayed for a couple of days. On the other hand a timely 
recognition of high bm engraftment was desirable and necessary in order to harvest the 
respective mouse and not lose it due to death from overt leukaemia. Another point is that 
with MRD monitoring alone it would not have been possible to draw a conclusion about 
the specific immunophenotype of the respective reconstituted ALL. In contrary a 
molecular analysis of bm engraftment, the flow cytometry based method satisfyingly 
combined a sufficient sensitivity with the opportunity to determine the reconstituted 
leukaemic immunophenotype in one step.  
ALL is a malignancy that arises within the haematopoietic system and like the formation 
of blood cells it develops within the bm. Therefore, in order to detect engraftment at the 
earliest possible time point and lowest levels, cells from mouse bone marrow punctures 
were scrutinised rather than peripheral blood where blast numbers can be still low or 
undetectable even when blasts already represent a high percentage of cells within the 
bm. Analysing mouse bm samples reliably led to the detection of human ALL cells, 
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however, in the course of an experiment, sometimes engraftment levels in a later bmp 
were found to be lower than those determined in an earlier bmp. Several explanations 
can be given for this observation. The distribution of ALL blasts in the bone cavity can 
be heterogeneous with remaining islands of mouse blood formation. Depending on the 
part of bm aspirated in the bmp, the percentage of human cells can vary. Aspiration of 
bm also requires the application of a considerable negative pressure in the syringe and it 
is impossible to exactly control the amount of bm taken from the punctured bone. 
Removal of large parts of ALL blasts may well lead to a lower number of blasts found in 
the following bmp and while the leukaemia has spread through the organism already and 
repopulated further bones or other organs blast content in the initially transplanted and 
punctured bone cavity has potentially been artificially decreased by the previous bmp. 
Additionally, a bmp causes a trauma to the bone and its cavity. Posttraumatic bleeding 
with a resulting haematoma can consecutively lead to fibrosis of the bone and indeed, at 
the time of bm harvest, sometimes nearly completely solidified bones were observed. 
Attempts to aspirate cells from bones with only a small remaining bm cavity will lead to 
aspiration of larger amounts of contaminating mouse blood cells resulting in 
determination of lower human chimerisms. In future experiments, the influence of bmps 
on human blast engraftment levels potentially can be avoided by non-invasive blast 
detection methods like bioluminescence of lentivirally transduced blast populations, a 
technique which also holds a great promise in elucidating exact modalities of systemic 
involvement in ALL. However, ideally these methods would detect every single ALL 
blast anywhere in the mouse body but it is questionable if it is ever possible to achieve 
such a high sensitivity. Furthermore, an influence of the processes involved in lentiviral 
transduction as well as the inserted lentivirus itself on the engraftment capability of the 
leukaemia can not ultimately be ruled out. Nevertheless, systemic spread in mice closely 
mirroring ALL disease manifestation in humans could already be proved with the 
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applied NSG mouse model. In post mortem analyses a regular involvement of the spleen 
was detected and also infiltration of the liver or the kidneys was demonstrated in this 
study. Additionally, brains of a fraction of mice were collected and blast infiltration was 
demonstrated by another laboratory (work performed by Dr. Christina Halsay, Glasgow; 
unpublished data). These findings indicate that NSG mouse xenotransplantation 
experiments are an excellent model for ALL. 
The data presented in this thesis provide good evidence that a variety of blast 
populations that resemble different stages of B cell development according to CD 
surface marker expression harbour leukaemic stem cells. Furthermore, it was shown that 
LIC frequencies and engraftment kinetics between subpopulations of different maturity 
were comparable. These findings strongly suggest that ALL is not organised in a 
hierarchy but follows the stochastic stem cell model.  
In contrast to the insights presented here, other studies published before and during the 
work for this thesis found much lower frequencies of LICs in ALL that additionally are 
restricted to rather immature B cell precursor stages and therefore proposed the 
hierarchical stem cell model for ALL. However, as already pointed out, the mouse 
model used in these studies has a substantial impact on the outcome; therefore, 
conclusions drawn in the published studies have to be interpreted cautiously in the 
context of the individually applied xenotransplantation model and therefore will be 
discussed in more detail.  
Cobaleda and colleagues took a very similar approach for ALL samples that had been 
successful in identifying AML stem cells. In initial limiting dilution transplantation 
experiments of unsorted MNC they found a LIC frequency of between 0.2 and 41 in one 
million ALL cells. This suggested that the SL-IC was a rare entity within the bulk 
tumour population. To identify the SL-IC they sorted leukaemic samples into 
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CD34+CD38- and CD34+CD38+ fractions and achieved engraftment in mice only from 
the less mature CD34+CD38- fraction regardless of the immunophenotypic composition 
of the bulk leukaemia. This finding was identical to the situation already established for 
normal and AML stem cells. On blasts from engrafted mice they additionally found the 
B-cell lineage marker CD19, indicating that the transplanted cells were able to 
differentiate into the B-precursor lineage but no myeloid differentiation could be 
observed in methylcellulose assays. Cells with the CD34+CD38- immunophenotype were 
also reconstituted in the murine environment over serial transplantations proving self-
renewal capacity of this subfraction. However, all samples were transplanted into 
irradiated NOD/SCID mice which are now known to have considerably more residual 
immunity than the NSG mice used for this thesis. In addition, the route of 
transplantation was by intravenous injection, a technique recognised to be inferior to 
orthotopic transplantation regarding engraftment success. Finally, the transplanted 
material consisted of samples only from Ph+ ALL patients making it difficult to draw 
general conclusions for ALL (Cobaleda et al., 2000). The limitations of the 
transplantation model used might not only explain the inferior engraftment success of 
this study in comparison to the orthotopic NSG mouse model but also the results of 
another project that subsequently extended the search for LSC to standard risk ALL. The 
patient cohort of this study consisted of 16 ALLs of the pre-B and c-ALL subtypes. 
Most were of the standard risk group having no apparently abnormal cytogenetic 
constitution, being hyperdiploid or containing the ETV6/RUNX1 translocation. Only 
one sample was from a relapsed, and therefore high risk, ALL. In initial transplantation 
experiments with again intravenous injection of unsorted samples into irradiated 
NOD/SCID mice 14 out of the 16 ALL successfully engrafted. A minimum of 5 x 105 
cells were injected but most samples only engrafted when one million or more cells were 
transplanted. They then purified patient samples into immunophenotypic subgroups 
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according to their expression of the stem cell marker CD34 and the B-lineage markers 
CD10 and CD19 and repeated the transplantation experiments. Engraftment was 
exclusively found in mice injected with the CD34+CD10- and CD34+CD19- subfractions. 
No other population containing CD34-, CD34+CD10+ or CD34+CD19+ blasts was able to 
transfer the leukaemia onto mice, even when more than 10 times more cells were 
injected. For the engrafted subpopulations, self-renewal capability of SL-ICs was 
demonstrated in serial transplantations. The authors concluded that, comparable to the 
Ph+ ALL, SL-IC in standard risk ALL are restricted to an immature cell fraction that 
have not yet undergone lineage restriction and that a hierarchical organisation exists in 
ALL progenitor cells (Cox et al., 2004).  
Taken together, these two studies suggested that the target cells for leukaemic 
transformation were immature, not lineage restricted, HSC and that ALL was 
hierarchically organised, regardless of prognostic factors. In line with these findings, 
Cox et al published another study in 2009. For purifying candidate stem cell populations 
in childhood ALL this time they used the CD133 mAb in combination with either CD19 
or CD38 mAbs. From 10 ALL samples of different prognostic subgroups only the 
CD133+CD19- and the CD133+CD38- subfractions reconstituted the original leukaemia 
in irradiated NOD/SCID mice after intravenous injection. From this study they derived 
confirmation of their previous finding that ALL SL-IC exclusively are part of 
uncommitted early stem cell compartment and do resemble HSC (Cox et al., 2009). 
However, this study as well was performed with NOD/SCID mice and intravenous 
transplantation at the time when NSG mice were already available and evidence for 
superiority of orthotopic intrafemoral or intratibial injection was published.  
Despite using the same model with irradiated NOD/SCID mice and intravenous cell 
transplantation another group did not confirm the finding of only non-lineage restricted 
blast populations being able to transfer the ALL onto host mice. Castor et al detected a 
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blast population that had aberrant CD34+CD38-CD19+ expression, an immunophenotype 
that is not part of normal haematopoiesis but with expression of CD19 surface antigen 
nevertheless was B-lineage restricted already. This CD34+CD38-CD19+ subfraction was 
able to reconstitute and serially transfer the ALL of ETV6/RUNX1 and p190 
BCR/ABL1 positive samples. Of note, both translocations were not detected in the 
CD34+CD38-CD19- immature cell populations of the diagnostic patient samples. In 
contrast, in ALL with the p210 BCR/ABL1 fusion the CD34+CD38-CD19- compartment 
and even myeloid cell lineages were involved but again LIC activity was only found in 
CD34+CD38-CD19+ purified blasts. In conclusion, LSC in all investigated types of ALL 
were only part of the lymphoid committed precursor cell compartment (Castor et al., 
2005). However, CD19 still is expressed early in B cell development and more mature 
blast populations with expression of CD20 were not investigated. The study also did not 
address the question of LIC frequency and even with the challenging data provided it 
still could not be concluded that ALL was not organised in a hierarchy.  
In support of the findings of Castor et al, Hong et al demonstrated tumour propagating 
abilities in B-lineage restricted lymphocytic blasts as well. They purified the same 
abnormal CD34+CD38low/-CD19+ cells from ETV6/RUNX1 positive c-ALLs. From four 
patient samples this population engrafted and reproduced itself in primary and secondary 
generations of NOD/SCID mice after intravenous transplantation, providing evidence 
for self-renewal (Hong et al., 2008). Again, more mature blast populations or LIC 
frequency were not addressed.  
More studies continued to provide support for the hypothesis that ALL blast populations 
with an already committed B-precursor immunophenotype have leukaemia propagating 
abilities. Kong et al intravenously injected purified populations, not only of the aberrant 
CD34+CD38-CD19+ but also of the CD34+CD38+CD19+ immunophenotype which 
resembles a physiological B-cell precursor, into NOD/SCID/IL2rγnull (NSG) mice. 
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Remarkably, using the more immunocompromised mouse strain, now both subfractions 
were able to transfer the patient ALL onto the mice with a typical ALL dissemination 
pattern and to show self-renewal by serial transplantation. The samples used were from 
higher risk paediatric patients, one defined by a high presenting blast count and two by 
the presence of the MLL-rearrangement. However, again in contrast to the studies 
performed earlier, only normal haematopoietic engraftment was achieved from the 
immature CD34+CD38+CD19+CD10- compartment (Kong et al., 2008). The decisive 
contribution of this work regarding the dispute over the differentiation level of LIC in 
ALL is that it not only determined LIC in the abnormal CD34+CD38-CD19+ population 
but also in the CD34+CD38+CD19+ fraction, that truly resembles a committed stage in 
the physiological lymphoid hierarchy. Additionally, supporting the hypothesis that 
immonophenotypically B-lineage committed blasts harbour LICs, le Viseur et al 
published the observation that not only CD34+CD19- and CD34+CD19+ but interestingly 
also developmentally further progressed CD34-CD19+ and CD19+CD20low/- or 
CD19+CD20+ blasts serially reconstituted the patient leukaemia. This study used mice 
and transplantation techniques most favourable of xenoengraftment known to date. In 
contrast to earlier studies, additionally candidate LSC populations were orthotopically 
injected into the bone marrow of the mice femora. The hosts consisted of NOD/SCID 
mice in which residual natural killer cells (NK-cells) were additionally depleted by anti-
CD122 treatment for the majority of experiments or NSG mice that naturally lack any 
NK-cells. However, only cell numbers of 2.0 x 103 per mouse or higher were sufficient 
for engraftment of NOD/SCID mice and limiting cell doses in NSG mice, used for few 
experiments only, were not determined (le Viseur et al., 2008).  
Another recent study did not address the question of the immunophenotypic identity of a 
potential ALL stem cell but aimed to establish the frequency of LIC within the unsorted 
bulk ALL population. The high frequency that was found in their intravenous NSG 
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mouse transplantation model, with 1 to 100 blasts being sufficient to transfer the 
leukaemia, provided additional support that LIC could not be restricted to the very small 
compartment of immature blast immunophenotypes (Morisot et al., 2010).  
The comparison of these studies confirms the superiority of the orthotopic NSG mouse 
model to the intravenous NOD/SCID mouse model as already established for normal 
haematopoiesis in that it was capable to engraft immunophenotypically more mature 
blast populations and detected a higher frequency of LICs. In line with that, the limiting 
dilution experiments on intrafemorally transplanted NSG mice in this thesis demonstrate 
a much higher frequency of LSC´s in unsorted and sorted populations of ALL than the 
studies performed on NOD/SCID mice. Furthermore, purified blast populations more 
mature in the surface marker expression profile as well were able to engraft the 
leukaemia to the full original immunophenotype. Reconstitution of the 
immunophenotype of the original leukaemia sample was demonstrated before in the 
intravenous NOD/SCID xenotransplant model with the engrafted immature cell fraction 
giving rise to normally lineage restricted and more mature immunophenotypes 
(Cobaleda et al., 2000; Cox et al., 2009; Cox et al., 2004). However, the presented work 
additionally demonstrated that more mature blast populations are able to reconstitute the 
full immunophenotype of the original ALL sample. This suggests that ALL blasts do not 
follow regulations of normal haematopoiesis where development usually is 
unidirectional- probably with the exception of CD34 expression which interestingly has 
been found to be reversible on human bone marrow cells capable of long-term 
multilineage engraftment (Zanjani et al., 2003).  
In addition to the applied xenotransplantation model, another contributing factor for not 
seeing engraftment from some sorted subpopulations or lower transplanted cell numbers 
in the above mentioned studies could lie in the observation time of the transplanted 
mice. This varied considerably between groups and sometimes was less than 10 weeks 
Chapter 5  5.1 Summary and Discussion 
249 
 
and therefore probably not long enough to allow for engraftment of all investigated 
subpopulations. However, this is not too likely to be the case as engraftment kinetics of 
differentially mature blast subpopulations in this study were comparable when ALL 
samples were sorted according to CD10, CD20 or CD34 expression.  
A very important reason why in some studies immunophenotypically more mature ALL 
subpopulations did not engraft in intravenously injected NOD/SCID mice was 
recognized more recently. Identifying normal or malignant populations of cells with 
stem cell characteristics in general involves purification of subfractions according to 
their expression of surface marker antigens. Subfractions of cells can either be flow 
sorted by labelling different CD surface antigens with mAbs conjugated to 
distinguishable fluorescent dyes or separated with the help of columns and magnetic 
beads bound to specific mAbs. Until recently the impact of cell labelling with mAbs 
gained little attention within the research community and they were generally considered 
to be neutral in regards to the outcome of the experiment. Work by Dominique Bonnet´s 
group recently investigated the possibility of antibody mediated clearance of 
transplanted cells by residual immunity of different mouse strains. They found that 
especially certain antibodies directed against CD38 had profound inhibitory effects on 
engraftment of normal haematopoietic as well as AML cells. This inhibitory effect was 
mediated by the Fc receptor of the mAb and could be reduced by additional 
immunosuppression with unspecific IVIG or specific anti-CD122 antibodies. The 
inhibitory effect was also reduced by orthotopic injection of cells into the bone marrow, 
avoiding clearance of iv injected cells by residual peripheral immune cells. Furthermore, 
antibody mediated clearance was less pronounced in more immunodeficient mouse 
strains (NSG and NOD/SCID-β2m-/- mice) as compared to NOD/SCID mice with higher 
residual innate immunity due to production of NK cells (Taussig et al., 2008). CD38 
expression has been an important surface marker in discriminating stem cells in the 
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haematopoietic system and in leukaemias from cells that presumably lacked stem cell 
defining properties. The above described studies that used CD38 in their sorting 
strategies have to be seen in this context. Clearance of candidate stem cells that are 
labelled with anti-CD38 mAbs can explain why earlier studies failed to engraft a 
CD34+CD38+ subfraction of blasts but it can not explain, why the subset of cells 
negative for the CD34 surface marker expression, in contrast to the CD34 positive 
subset, did not engraft in an identical experimental setup when the leukaemia was only 
purified according to CD34 expression. Additionally, the influence of antibodies bound 
to surface antigens on stem cell readout can not explain the higher frequency of LICs in 
unsorted blast populations found in this work compared to frequencies published from 
other laboratories. A likely explanation for both observations again would be the higher 
degree of immune suppression in the NSG mice as opposed to the NOD/SCID mice in 
combination with the injection mode. 
The work from this PhD project demonstrated that a wide variety of subpopulations 
within the ALL purified according to the immunophenotype is able to reconstitute the 
leukaemia in mice therefore demonstrating stem cell characteristics. In other 
experiments it was proved that only very low numbers of blasts were necessary for 
engraftment of mice and consequently it could be argued that engraftment of presumably 
more mature subfractions of blasts was indeed initiated by small numbers of 
contaminating less mature ALL cells. In limiting dilution experiments on sorted 
subpopulations this was found to be unlikely. Engraftment of all paired subfractions 
sorted according to expression of CD10, CD20 or CD34 was initiated by comparable 
and very low cell numbers down to between 1.0 x 102 and 1.0 x 101 cells per mouse 
where contaminating cells become negligible. Furthermore, engraftment kinetics were 
similar, which would be very unlikely in the case that engraftment from one population 
originated only from a very small number of contaminating cells. Still, it can not be 
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completely ruled out that engraftment kinetics or determined LIC frequencies in sorted 
subpopulations were influenced by the bound sorting antibodies as described for the 
CD38 surface antigen. However, the argument of contribution to or exclusive origin of 
engraftment from contaminating cells of the opposing immunophenotype is additionally 
weakened by the tertiary CD34 sorting experiment (KR59) in which the transplanted 
CD19+CD34high cells only gave rise to a population of the identical immunophenotype, 
not merely in mice transplanted with just 1.0 x 101 cells but also when transplanted with 
1.0 x 103 cells. Any contaminating CD19+CD34low LIC would have led to the 
reconstitution of the whole original immunophenotype as seen in mice transplanted with 
the CD19+CD34low subfraction. Nevertheless, contamination can not be ruled out 
definitely for every single experiment that was performed for this thesis. Finding a 
solution for this problem is difficult with the currently available cell sorting options. A 
second round of cell sorting would probably increase purities further but as well have a 
negative impact on the viability of blasts which in reverse would then influence the 
likelihood of engraftment. The ideal solution in the xenotransplantation setting would be 
to orthotopically transplant single cells of a highly purified and viable ALL blast 
population. However, this is technically very difficult to achieve and it is most likely 
that the number of mice needed would yet increase again. Nevertheless, unlike earlier 
less immunocompromised mice, the NSG mouse model already seems to be sensitive 
enough to be permissive for single cell engraftment at least for ALL blasts (Morisot et 
al., 2010). 
In the presented study, much higher LIC frequencies for unsorted and sorted ALL 
subpopulations than previously reported were determined in an improved 
xenotransplantation model but it is very likely that these frequencies are still an 
underestimation and do not match reality. The defining properties of self-renewal and 
differentiation capability of normal and cancer stem cells can currently only be assayed 
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in the potentially hostile animal xenotransplantation models. Only candidate cells that 
can adapt and engraft in the animal host do also have the chance to prove self-renewal 
and to spawn the more differentiated progeny cells that comprise the tumour, the two 
hallmarks of CSCs. This is the problem with probably the highest impact on all stem cell 
research; the xenotransplant setting. Many mechanical steps are involved from the 
preparation of purified candidate populations to the process of transplantation, when the 
transplanted cells finally come across a significantly different microenvironment. Both 
soluble factors and factors bound to membranes in the microenvironment play an 
important and critical role in tumour growth as does accessibility to blood circulation, 
the availability and composition of growth factors and the extracellular matrix provided 
by the host (Gupta et al., 2009; Hanahan and Weinberg, 2011). All this is likely to have 
a significant impact on the seeding efficiency of human malignant cells in the murine 
xenoenvironment and one major step to improve this xenotransplantation mouse model 
could be to further humanise the NSG mouse strain probably most importantly in respect 
to the bone marrow niche with its nurturing cells and growth factors. Still, the possibility 
that candidate human CSCs populate the murine xenotransplant model but would not 
reconstitute a tumour in the appropriate human environment seems unlikely but can not 
definitely be ruled out. However, the contribution of different cells with stem cell 
character within a cancer to the re-established tumour in the mouse could well be 
different than would be the case in humans.  
However, the extent of residual immune function in mice certainly plays a crucial role 
for the sensitivity of the xenotransplant assay. NOD/SCID mice have been used in many 
studies and led to invaluable progress in the field of stem cell research, however, with 
increasing immune suppression of more recently developed mouse strains like the NSG 
mice, normal haematopoietic stem cells and CSCs could be identified in subpopulations 
that evaded detection previously. Another caveat of the xenotransplantation models is 
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that it is possible that only dominant subclones read out thereby imitating a hierarchical 
organisation (Adams and Strasser, 2008; Shackleton et al., 2009). However, the 
xenotransplantation model as developed and used in the work for this thesis with the use 
of severely immunocompromised NSG mice, highly FACS purified candidate cancer 
stem cells and the orthotopic injection method as well as the analytical techniques and 
strategies applied can be used not only for malignant diseases arising from the bone 
marrow. The same model most likely can be applied to most or all other cancer entities, 
including solid tumours or even non-malignant diseases in order to help elucidating the 
origin, progression or physiology. 
To circumvent inter-species barriers syngenic animal transplant models have been 
established. The second major advantage of this approach is that the necessity of 
immune suppression can be avoided. Applying this strategy on Myc-induced T-cell ALL 
in clonal zebrafish, a frequency of self-renewing cells of up to 16% was found in the 
bulk T-cell ALL mass by transplant experiments (Smith et al., 2010). Similar 
experiments were performed with syngenic mice. In an elegant study, re-transplanting of 
pre-B/B lymphoma cells from Eµ-myc transgenic mice into non-irradiated 
histocompatible sibling mice resulted in the development of disseminated lymphoma in 
just over one month even when only 10 cells were transplanted (Kelly et al., 2007). High 
frequencies of LSCs (approximately one in 3 to 4 cells) have also been found for 
MLL/AF9 induced AML in a syngenic mouse model and in contrast to the human 
mouse xenotransplant findings, the large majority was found in already myeloid lineage 
restricted cell fractions and not only in the very small stem and progenitor cell 
populations (Somervaille and Cleary, 2006). Opposed to that xenotransplantation assays 
have determined the leukaemia initiating cell in human AML as being much less 
abundant with approximately 1 in 106 blasts (Hope et al., 2004). Taking into account that 
there will be biological differences between murine and human AML this still points out 
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that the sensitivity for AML LIC detection decreases hugely in an interspecies setting 
and most likely that also holds true for ALL. 
Analysis of the results of xenotransplant assays also needs to consider the limitations 
and caveats of the transplantation technique. Not every cell that potentially has HSC or 
CSC characteristics will find its way into the appropriate niche following transplantation 
and the efficiency of engraftment is influenced by the transplantation procedure. Two 
different groups demonstrated that after injection into the tail vein of NOD/SCID mice 
only around 5% of human progenitor cells from bm, umbilical cord blood (UCB) and 
peripheral blood stem cells (PBSC) home to the bone marrow within 24 hours. The 
majority of cells are most likely to be sequestered in organs with dense capillary 
networks such as the lungs and the liver (Cashman and Eaves, 2000; van Hennik et al., 
1999). This low seeding efficiency of human cells in the murine xenoenvironment 
automatically must lead to a significant underestimation of stem cell frequencies. In 
order to improve seeding efficiencies, orthotopic transplant models that place human 
cells into the closest possible proximity to their niche have been developed and shown to 
be very efficient. However, even when cells are transplanted intrafemorally, they are, 
not directly delivered into the niche. Drilling a hole into the bone sets a trauma with 
consecutive bleeding and it is very likely that some of the delivered cells will be caught 
in a resulting blood clot or be carried away by continuing bleeding. This will lead to a 
reduced seeding efficiency and subsequently to an experiment bias with underestimation 
of LIC frequency. 
On the other hand, it has been shown for AML and ALL samples that the detected SL-IC 
frequency, as determined by limiting dilution experiments in the xenotransplantation 
model, raises after a first passage through the mouse by a factor of approximately 10 
(Cobaleda et al., 2000; Lapidot et al., 1994). This observation forms the basis of 
criticism to assays where first unsorted ALL samples were transplanted into mice and 
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recovered bm of engrafted mice was used for secondary transplantation experiments 
with sorted cell subfractions. It has been suspected that this results in a preselection of 
blasts with the ability to repopulate primary mice (Cox et al., 2009). This argument has 
to be looked at in more detail and used with caution. It may well be possible that 
primary diagnostic patient blasts are heterogeneous in the ability to engraft the 
xenoenvironment of mice and this may explain the disparity of numbers of cells 
necessary for mouse engraftment in primary and secondary or tertiary experiments. 
However, unsorted primary patient cells reconstituted the full immunophenotype of the 
original ALL and thereafter blast populations of different maturity according to the 
immunophenotype were sorted, transplanted and successfully reconstituted the ALL in 
secondary mice. A preselection of cells can not explain why the whole variety of 
differentially mature cells was able to transfer the leukaemia. It can only question the 
frequency of stem cells within the populations. Additionally, cells will go through a 
process of adaption during growth in mice but adaption is a universal response in 
biology to changed environments and conditions. These are certainly present in a 
xenotransplant murine model and some transplanted cells may settle in locations with 
more favourable conditions for adaption in the new environment than others which then 
fail to read out as LICs. Additionally, strong support that the engrafted ALL in mice 
largely resembles the original patient leukaemia and that it is not an in vivo cell line that 
is created upon first transplantation into mice was provided by the studies of Anderson 
et al and Notta et al. They proved that not only one but different subclones of the patient 
leukaemia are reconstituted in the recipient mice (Anderson et al., 2011; Notta et al., 
2011). However, there are other reasons that can explain the differences found for stem 
cell frequencies between primary and secondary samples at least to some degree. The 
viability and fitness to engraft of transplanted cells may well be considerably different as 
well. Patient samples are often collected in a diagnostic bmp in one hospital and then 
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sent to the study centre, ideally over night. However, transport still takes a considerable 
amount of time and samples are exposed to varying temperatures and mechanic forces 
before they are frozen down. Samples are then again often shipped to research centres on 
dry ice before being transplanted. After thawing cells may still appear to be alive 
according to Trypan blue exclusion but it is known that blasts usually are not able to 
survive outside the body for extended periods of time or to maintain their proliferation 
ability. Secondary or tertiary bm samples on the other hand are collected and frozen 
down with minimal delay or even re-transplanted immediately. As this involves less 
people than the multiple steps in which diagnostic patient material is dealt with, these 
processes are self evidently also more standardised. In fact, stem cell frequencies in 
leukaemias of mouse origin have been found to be considerably higher in primary but 
syngenic mouse models. One reason for that in addition to the advantages of a syngenic 
mouse model could also be that the mouse with the original leukaemia and the recipient 
of transplanted material were dealt with in the same lab by the same people and that 
harvested material could be re-transplanted without delay.  
 
Applying the orthotopic xenotransplantation model with NSG mice a LIC frequency for 
several ALL samples somewhere between one in 1.0 x 103 and less than one in 1.0 x 101 
could be demonstrated. Despite this high proportion of LICs in the leukaemic population 
and the still likely underestimation of LIC frequency even in the most advanced 
xenotransplant setting, it could potentially be possible that a hierarchical organisation 
existed if only unsorted bulk ALL populations were considered. However, convincingly 
demonstrating comparable LIC frequencies in defined subpopulations that by surface 
antigen expression resemble different stages of physiological B cell development 
strongly suggests that the hierarchical stem cell model can not be applied to ALL. 
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Otherwise, like in AML, LICs should at least be found more frequently if not 
exclusively within immunophenotypically less mature blast subpopulations.  
 
The proposition that ALL, unlike AML or normal myeloid haematopoietic development, 
follows the stochastic stem cell model potentially can be explained by normal lymphatic 
cell development. Despite a tight regulation, B and T cells do not lose the ability of 
clonal expansion during their progress through different maturation stages and this 
characteristic probably is maintained in malignancies of the lymphoid lineage. 
Interestingly, the insights gained from this study on ALL have been suggested for 
normal lymphoid development already many years ago by one of the pioneers of stem 
cell biology. At the meeting of the American Society of Hematology (ASH) in 1982, 
McCulloch stated in the Henry Stratton Lecture that “a minimum conclusion to be 
reached from a comparison of myelopoiesis and lymphopoiesis is that a firm linkage 
between differentiation and loss of proliferative capacity is not a general characteristic 
of hemopoiesis. The implication is that separate genetic mechanisms may exist for the 
regulation of the two processes” (McCulloch, 1983). The assumption is that in contrast 
to the hierarchically organised myeloid lineage, the ability of clonal expansion is 
maintained at all maturational levels of lymphoid precursor cells.  
The findings described in this PhD thesis potentially have important implications for 
ALL therapy. It is generally accepted that relapse arises from cancer stem cells that 
survive the standard cytotoxic chemo- and radiotherapy. There is also hope that if it was 
possible to directly and effectively target these cancer stem cells with more specific 
treatment patient outcome would improve significantly. It is also generally 
acknowledged that cancers are heterogeneous regarding the composition of cells. 
However, if stem cell properties can be found across all or most cells comprising the 
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malignancy as shown here for ALL, theoretically all of these cancer cells could be 
potential survivors of therapy and eventually would be able to initiate relapse. This gives 
a new aspect that needs to be considered for the design of future studies on ALL. As it is 
already possible to achieve remission in most cases of ALL, it is self evident that current 
treatment regimens successfully eradicate most cells that have stem cell properties. 
Again, the remaining question is which are the cells that eventually give rise to relapse 
and what characterizes them? Is it a certain and defined subset of the cells that have been 
found to be tumour propagating cells or is it a stochastic survival of any random 
phenotype? Furthermore, is there a difference in early and late relapse? Some answers to 
these questions could be given by determining the cycling characteristic of different 
subpopulations which is believed to have a significant impact on the success of 
treatment that is mainly based on antiproliferative drugs. This has been done in in vitro 
experiments performed by Hirt and colleagues. They investigated proliferation kinetics 
in different immunophenotypic subgroups of paediatric ALLs and demonstrated varying 
proportions of blasts in S-phase by assessing bromodeoxyuridine labelling indices. They 
found that the main CD19+ subfraction of blasts was much faster cycling compared to 
the very small populations of CD19-CD10- and CD19-CD34- leukaemic cells which 
remained in a mainly quiescent status (Hirt et al. 2011). These results indicate that 
despite possessing stem cell abilities, leukaemic subpopulations of different 
immunophenotypes are differently amenable for current chemotherapeutic regimens. 
Despite not addressing cycling kinetics directly, the in vivo experiments in this PhD 
project can not confirm the findings of Hirt et al. Engraftment kinetics of rather 
immature and more mature subpopulations sorted according to CD10, CD20 or CD34 
surface marker expression were comparable indicating that average cycling times of 
transplanted cells must be similar. Although the cycling status of cells within one sorted 
subpopulation could still be heterogeneous with parts of cells being quiescent and other 
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parts actively proliferating it then would be likely that the fractions of quiescent and 
cycling cells would be comparable between subpopulations. Therefore, a stochastic 
survival of cells of different immunophenotypically defined maturity is more realistic 
and elucidating the extrinsic factors that have an impact on stem cell protection from 
conventional therapy and their long term survival will be of invaluable importance. On 
the other hand, despite the finding in this work that all sorted blasts of different 
immunophenotypes do reconstitute the ALL with similar kinetics, it could still be 
possible, that some immunophenotypes are more sensitive to chemotherapy than others. 
Still, as all different blast immunophenotypes do reconstitute the complete original 
immunophenotype of the patient leukaemia, the immunophenotypes that are potentially 
easier to eradicate would be immediately reconstituted during recovery phases of 
chemotherapy regimens by the other immunophenotypes that are less responsive to the 
applied chemotherapy. If that would be the case, one approach could be to force the 
leukaemic blasts with yet unknown strategies to express only the immunophenotype that 
is more amenable to chemotherapy. A following project to this work could aim to assess 
the sensitivity of leukaemias reconstituted from different sorted blast populations to the 
chemotherapeutic drugs commonly used in ALL treatment regimens. Groups of mice 
could be transplanted with different blast immunophenotypes of ALL subtypes. The 
most important drugs used in the treatment of precursor B-ALL, steroids (Prednisone, 
Dexamethasone), Vincristine, L-Asparaginase, Cyclophosphamide, Methotrexate, 
Anthracyclines (Daunorubicine, Doxorubicine), Cytarabine, 6-Mercaptopurine could 
then be applied in adapted doses to the transplanted mice starting at the time of 
transplantation or at the time when the leukaemia is already engrafted and the mouse 
shows the full picture of overt systemic ALL. This would provide data about drugs that 
are more relevant in reducing the tumour burden in initial treatment and drugs that could 
be more efficient in a maintenance therapy that aims at potentially remaining blasts that 
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potentially are the origin of relapse. Furthermore, in a second step, combinations of 
drugs could be used and synergistic effects could be evaluated. The findings of these 
experiments could then potentially have an impact on the adaption of current treatment 
regimens. Application of single drugs or drug combinations is most likely to reduce the 
tumour burden and it can also be expected that transplanted, engrafted and then treated 
mice go into complete morphological or even molecular disease remission. However, 
alike in patients it is not likely that this remission is stable in nature and it must be 
assumed that the leukaemia will eventually relapse unless a treatment regimen with the 
different blocks of remission induction, consolidation and maintenance is applied. This 
provides an interesting model of disease relapse. The relapsed leukaemia then can be 
genetically compared to the initial ALL using expression arrays and conclusions 
regarding the clonal evolution can be drawn. The relatively long life span of the NSG 
mice would probably even allow investigating secondary and tertiary relapses as well. 
Furthermore, it would be interesting to address differences of relapses that araise in the 
bone marrow, the brain and in male mice potentially also in the testes. Examining the 
brains of mice from experiments of this work already could prove leukaemic infiltration 
of the meninges in NSG mice (work performed by Dr. Christina Halsay, Glasgow; 
unpublished data) and this provides an excellent opportunity to investigate the blasts that 
remain in this sanctuary site more closely. 
The work for this thesis included several BCR/ABL1 positive ALL and the clinical 
picture of the ALL reconstituted in NSG mice closely resembles that of the ALL in 
human beings. Again, this makes the NSG xenotransplant model an ideal setting in order 
to investigate the effects of the different tyrosine kinase inhibitors in pre-clinical studies. 
In a first setting, Imatinib, Dasatinib and Nilotinib could be applied to mice transplanted 
with unsorted BCR/ABL1 positive ALL blasts but surely, the effect on different 
subpopulations sorted according to the immunophenotype could be tested as well. 
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Furthermore, chemoresistance is a common problem faced in cancer therapy. The NSG 
model would also allow testing for the development of chemoresistance. In serial 
transplantation experiments it could be established if clones evolve that are resistant to 
the applied tyrosine kinase inhibitors. It then would be of major importance to 
characterise these clones by expression arrays. This could contribute to elucidate the 
mechanisms of clonal evolution in Philadelphia chromosome positive ALL.  
The Philadelphia chromosome is regarded to play a major role in malignant 
transformation. However, secondary events are necessary before unlimited growth of 
ALL blasts is initiated but also, during clonal evolution a leukaemia eventually can 
become independent of this chromosomal translocation (t(9;22)). The NSG mouse 
model could also be used to elucidate the steps that are involved in this process and 
sufficient amounts of material of BCR/ABL1 positive ALL was generated and 
conserved in liquid nitrogen during the work for this thesis. Short hairpin RNA (sh-
RNA) can be efficiently used to silence the expression of the BCR/ABL1 RNA via RNA 
interference leaving the ALL blasts devoid of the BCR/ABL1 protein. Plasmids 
containing a specific sh-RNA directed against BCR/ABL1 transcripts can be delivered 
to Philadelphia chromosome positive ALL blasts by viral vectors and these blasts then 
can be transplanted into mice. Primary patient material but also material that was 
passaged through mice already over one or two generations could be used for these 
experiments. Again it would be interesting to investigate whether or not there are 
differences in engraftment between the primary, secondary or tertiary leukaemia. 
Furthermore, this experimental setup could be used not only on ALL that were serially 
transplanted into mice or that relapsed in mice treated with chemotherapy but probably 
even more interestingly on primary material of patients at the time points of initial 
presentation with the ALL and blasts from relapse after chemotherapy. It is not unlikely 
that blasts of the primary leukaemia biologically behave differently compared to blasts 
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from relapse in the way that they became independent of the BCR/ABL1 fusion protein. 
Similar experiments could as well be performed on leukaemias with the ETV6/RUNX1 
(TEL/AML1) translocation and on leukaemias with MLL rearrangements or other 
translocations. These experiments would aim at engraftment potential of the various 
blast populations but it would be also interesting to investigate how an overt leukaemia 
behaves in the case of withdrawel of BCR/ABL1, ETV6/RUNX1 or MLL rearranged 
fusion proteins. The development of inducible vectors containing sh-RNA directed at the 
individual transcripts would be the solution for these experiments. Transduced ALL 
blasts would be transplanted applying the NSG mouse model and once the leukaemia 
was established in the mouse the sh-RNA would be induced by application of usually 
Doxocycline. The effect on the leukaemia after deprivation of fusion proteins could then 
be assayed again in primary and serially transplaned human ALL samples. 
However, important conclusions regarding effects of the current treatment protocols can 
be drawn from the data of this work. The stochastic distribution and high frequency of 
stem cells in ALL can potentially already explain the necessity for prolonged 
maintenance chemotherapy as all cells need to be reached, especially those in cell cycle 
quiescence or others residing in sanctuary sites like the CNS or the testes. The ability of 
potentially long periods of cycle quiescence, if present, additionally could be a 
difference between lymphatic and myeloid malignancies and lymphoblasts, like the 
potential of clonal expansion, could have taken this over from their normal lymphocyte 
counterparts which apply this ability in the memory B or T cells.  
On the other hand, the proposition that lymphoid clonal expansion is regulated in a 
different way than malignant proliferation of myeloid cells holds attractive prospects for 
the development of more specific and better tolerable therapeutic strategies. Elucidating 
the intracellular pathways that are activated in lymphoid clonal expansion but not 
involved in the self-renewal of adult stem cells opens a new and broad field of research 
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and could potentially lead to the discovery of druggable targets. Previously, it was 
difficult to investigate physiologic or malignant lymphoid development. Unlike with 
myeloid lineages, there were no in vitro assays that enabled growth of lymphoid 
progenitors. The developed NSG xenotransplant mouse assay now provides the most 
ideal means to date to model the involved stages of the lymphoid hierarchy. If it now 
would be possible to elucidate and specifically target the pathways responsible for 
uncontrolled malignant lymphoid proliferation, myeloid development potentially will 
not be affected. This would lead to an invaluable improvement in ALL therapy away 
from more or less uniform and generally cytotoxic chemotherapy towards a specifically 
targeted and ultimately even tailored patient specific treatment regimen. Current 
antiproliferative treatment modalities result in sometimes prolonged phases of 
neutropenia that put patients at high risk for opportunistic infections which potentially 
can be lethal. Concomitant anaemia increases the probability of infections and mucositis 
with loss of integrity of the gut lining, another side effect of unspecific antiproliferative 
agents, provides entry sites for pathogens to the human organism. Avoiding these side 
effects on ALL patients would lower the risks of chemotherapy considerably. 
Additionally, the probability of secondary malignancies caused by the unspecific 
antiproliferative chemotherapy also potentially could be diminished. Knowledge about 
the involved mechanisms of lymphoid clonal expansion would not only provide a 
chance for a great step forward in the treatment of lymphoblastic leukaemias but as well 
could potentially be implemented in treatment strategies for other lymphoid 
malignancies, lymphoproliferative diseases or even autoimmune diseases, especially if it 
would be possible to modulate and not only interrupt the involved pathways.  
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5.2 Overall Conclusions 
Using the most advanced xenotransplantation model the data presented in this PhD 
thesis provide strong indication that leukaemia initiating cells in acute lymphoblastic 
leukaemia are by far more frequent than previously thought and equally present in 
subfractions of diverse maturity according to CD surface antigen expression profile. 
Therefore the long defended assumption that ALL is organised in a hierarchy can not be 
maintained and now clear evidence is given that the stochastic stem cell model has to be 
applied to ALL. 
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APPENDICES 
 
  
 
Appendix 1- Raw Data 
 
Raw data of mouse experiments 
 
The following 22 pages contain a list of all mouse xenotransplant experiments carried 
out as part of this PhD project. For each experiment essential information is provided 
regarding the original patient sample or the engrafted mouse sample used for transplant, 
the sorted immunophenotype and the respective sorting purity as well as the number of 
transplanted cells per mouse. Furthermore, the level of leukaemic engraftment and the 
time after transplantation in weeks for each bone marrow puncture and the final bone 
marrow harvest is provided. Altogether 62 individual experiments with 672 transplanted 
mice are listed. 
Exp. No. experiment number, Wks weeks, BMP bone marrow puncture, * positive 
outside limits, # sample contained a large amount of cell debris, § mouse was found dead 
 
 
  
 
 
Exp. 
No.
Mouse 
ID.
Patient / 
Leukemia
Injected Cells
Injected 
Cell No.
Population 
purity (% )
Wks post 
transplant
BMP1 
Result
Wks post 
transplant
BMP2 
Result
Wks post 
transplant
BMP3 
Result
Wks post 
transplant
BMP4 
Result
Wks post 
transplant
BMP5 
Result
Wks post 
transplant
Final Engraftment
KR1 M1 8849 prim unsorted 1.0 x 106 n/a 8 0.039 10 0.134 13 0.087 16 4.0 21 7.8 25 75.7
M2 8 0 10 0 13 0 16 0 21 0 49 0
M3 8 0 10 0 13 0 16 0 >16
M4 <8
KR2 M5 A67 prim unsorted 3.0 x 105 n/a 9 0.008* 12 1.4 15 5.2 16 4.2 16 40.6
M6 9 0 12 0.057 15 0.041 16 0.32 18 14.8
M7 9 2.1 12 3.7 14 74.8
M8 9 0.51 12 0.064 15 8.6 16 3.2 19 22.5 19 75.8
KR3 M9 HV102 prim unsorted 3.0 x 105 n/a 9 0 12 0 45 0
M10 9 0 12 0 45 0
M11 9 0 12 0 45 0
M12 9 0 >9
KR4 M13 A67 sec CD34+CDC19low 2.0 x 103 96.9% 10 0 13 failed 16 36.9 19 0.466 20 7.0
M14  (of M7) 10 0 13 failed 16 0.11 19 0.174 23 1.9 23 36.9
M15 10 4 13 failed 13 16.8
M16 10 8.9 13 failed 16 13.4 17 0#
M17 CD34+CDC19high 2.0 x 103 99.5% 10 0.059 13 failed 16 1.0 19 3.3 20 46.9
M18 10 37.8 13 failed 16 14.9 19 0.087 19 52.1
M19 10 2.6 13 failed 13 0.68#§
KR5 M20 A67 sec CD34+CDC19low 4.0 x 103 97.6% 8 2.7 11 failed 15 18.0 17 21.4 20 9.8 21 1.2#
M21  (of M5) 8 0 11 failed 15 3.6 17 14.5 20 34.8 20 34.9
M22 8 5.2 11 failed 15 9.6 17 1.1 18 11.5
M23 CD34+CDC19high 2.0 x 104 99.9% 8 2.3 11 failed 15 1.8 >15
M24 8 0.133 11 failed 11 22.6
M25 8 17.9 11 failed >11
KR6 M26 A67 sec unsorted 1.0 x 105 n/a 8 10.5 11 failed 15 1.6 >15
M27  (of M5) 8 14.3 11 failed 11 33.5
M28 8 0 11 failed 15 13.2 >15
KR7 M29 2510 prim unsorted 1.3 x 106 n/a 15 14 21 16.8 25 25.3 25 30.9
M30 15 3.4 21 15.3 25 55.8 25 56.5
M31 15 1.3 21 12.4 25 24.1 25 30.6
KR8 M32 9406 prim unsorted 2.5 x 106 n/a 15 0 21 0 25 0 32 0.0023* 54 0
M33 15 4.6 21 3.7 25 13.2 32 0.057 45 14.5
M34 15 20 21 2.2 25 3.7 26 21.1
  
 
 
Exp. 
No.
Mouse 
ID.
Patient / 
Leukemia
Injected Cells
Injected 
Cell No.
Population 
purity (% )
Wks post 
transplant
BMP1 
Result
Wks post 
transplant
BMP2 
Result
Wks post 
transplant
BMP3 
Result
Wks post 
transplant
BMP4 
Result
Wks post 
transplant
BMP5 
Result
Wks post 
transplant
Final Engraftment
KR9 M35 HS39 prim unsorted 3.0 x 103 n/a 8 0 15 0 21 0 26 0 >26
M36 8 0 15 0 21 0 26 0 31 0
M37 8 0 >8
KR10 M38 HV127 prim unsorted 3.0 x 104 n/a 8 0 15 0 21 0 26 0 49 0
M39 8 0 15 0 21 0 26 0 31 0
M40 4 0
KR11 M41 A67 sec CD19+CD20high 2.0 x 104 83.9% 9 failed 13 4.1 14 46.2
M42  (of M6) 9 failed 13 6.8 14 72.2
M43 9 failed 13 0.071 15 14.9 16 49.6
M44 CD19+CD20low 2.0 x 104 99.9% 9 failed 13 1.9 15 10.0 >13
M45 9 failed 13 2.3 14 62.5
M46 9 failed 13 5.4 15 5.5 15 15.2
KR12 M47 A67 sec CD19+CD20high 9.0 x 103 89.7% 8 24.3 12 50.5 15 7.4 19 61.4
M48  (of M8) 8 1.6 12 18.5 >12
M49 8 21.5 12 9.0 15 22.5 18 69.8
M50 CD19+CD20low 9.0 x 103 99.5% 8 42 12 3.5 15 10.5 19 74.8
M51 8 18.1 12 43.9 18 32.8
M52 8 23.1 12 50.6 18 24.1
KR13 M53 8849 sec CD19+CD10high 3.0 x 104 96.7% 11 1.9 13 1.6 17 0.533 22 1.6 34 0.65 50 55.5
M54  (of M1) 11 0.054 13 0.045 17 1.1 22 0.054 26 42.4
M55 11 1.1 13 0.118 17 1.1 22 1.1 34 0.016*# 36 4.1
M56 CD19+CD10low 3.0 x 104 98.5% 11 0 13 0 17 0 22 0 34 0 48 0
M57 11 0 13 0 17 0 22 0 34 0 50 0.0027*
M58 11 0 13 0 17 0 22 0 34 0 50 0
KR14 M59 unsorted 2.4 x 105 n/a 11 0.079 13 0.17 17 1.4 22 8.4 >22
KR15 M60 A67 sec unsorted 2.0 x 106 n/a 9 3.6 13 7.2 13 20.3
M61  (of M6) 9 16.9 13 33.5 17 4.0 >14
M62 <9
M63 <9
KR16 M64 WB51 prim unsorted 9.8 x 104 n/a 7 11.4 11 58.6
M65 7 19.4 11 8.4 16 80.9
M66 7 43.3 11 12.8 14 51.7
M67 7 27.8 11 7.7 14 55.5
  
 
 
Exp. 
No.
Mouse 
ID.
Patient / 
Leukemia
Injected Cells
Injected 
Cell No.
Population 
purity (% )
Wks post 
transplant
BMP1 
Result
Wks post 
transplant
BMP2 
Result
Wks post 
transplant
BMP3 
Result
Wks post 
transplant
BMP4 
Result
Wks post 
transplant
BMP5 
Result
Wks post 
transplant
Final Engraftment
KR17 M68 WB51 prim CD19+CD20high 1.08 x 104 91.9% 7 1.1 11 7.2 17 12.8 19 86.4
M69 7 0.53 11 33.2 16 77.7
M70 7 0 >7
M71 CD19+CD20low 6.24 x 104 99.9% 7 0.54 11 7.6 15 72.0
M72 7 2.9 11 12.6 15 69.5
M73 7 1.7 11 11.1 15 60.3
KR18 M74 WB51 prim CD34+CDC19high 3.12 x 104 99.3% 7 2.2 11 8.5 16 76.0
M75 7 14 11 14.8 16 76.9
M76 7 1.3 11 11.8 16 45.4 17 71.5
M77 7 7.4 11 1.4 15 58.6
M78 CD34+CDC19low 4.0 x 103 99.0% 7 0.043 11 0.43 16 23.7 20 74.0
M79 7 0.047 11 10.5 16 8.9 19 81.9
KR19 M80 8849 sec CD19+CD10high 1.44 x 104 98.4% 8 0.012* 12 0.013* 19 0.615 23 0.096 41 0.556
M81  (of M1) 8 0 12 0 19 0 23 0 23 0
M82 8 0 12 0 14 0
M83 8 0 12 0 19 0 23 0 26 0
M84 CD19+CD10low 2.19 x 104 99.4% 8 0 12 0.016* 19 0.01 23 0.117 41 41.5
M85 8 0 12 0 19 0 23 0 41 0.012
M86 8 0 12 0 19 0 23 0 41 0
M87 8 0 12 0 19 0 23 0 41 0
KR20 M88 8849 sec CD19+CD10high 1.44 x 104 98.4% 7 0 12 0 22 0
M89  (of M1) 7 0 12 0 >12
M90 7 0 12 0 18 0
M91 7 0 12 0 >12
M92 CD19+CD10low 2.19 x 104 99.4% <7
M93 7 0 12 0 27 0
M94 7 0 12 0 27 0
M95 7 0 12 0 27 0
KR21 M96 WB51 sec CD19+CD10high 1.24 x 104 98.1% 10 0.01* 15 2.4 18 61.1
M97  (of M64) 10 0.388 15 25.3 18 33.4
M98 10 1.8 15 4.3 18 30.9
M99 10 0.2 15 33.9 18 18.1
M100 CD19+CD10low 1.35 x 104 99.4% 10 1.2 14 61.3
M101 10 13.2 15 12.9 18 38.8
M102 10 8.2 15 3.7 21 66.9
M103 10 34.9 15 2.6 15 26.6
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No.
Mouse 
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Leukemia
Injected Cells
Injected 
Cell No.
Population 
purity (% )
Wks post 
transplant
BMP1 
Result
Wks post 
transplant
BMP2 
Result
Wks post 
transplant
BMP3 
Result
Wks post 
transplant
BMP4 
Result
Wks post 
transplant
BMP5 
Result
Wks post 
transplant
Final Engraftment
KR22 M104 L784 prim CD19+CD10high 2.61 x 104 98.3% 15 46.3 20 6.2 29 0.27 39 7.1 41 20.3
M105 15 61.4 20 43.8 29 4.3 36 33.6
M106 15 12.3 20 17.2 29 13.3 33 55.2
M107 14 35.1
M108 CD19+CD10low 6.3 x 103 99.8% 15 0.266 20 22.2 25 35.5
M109 15 15.5 20 3.0 29 16.0 >29
M110 <15
M111 15 36.6 20 17.6 29 46.4 33 67.8
KR23 M112 L831 prim CD19+CD10high 6.0 x 103 98.3% 13 0 18 0 >18
M113 13 0 18 0 36 0
M114 13 0 18 0 >13
M115 13 0 18 0 >13
M116 CD19+CD10low 6.0 x 103 99.9% 13 0 18 0 36 0
M117 13 0 18 0 36 0
M118 13 0 18 0 36 0
M119 13 0 18 0 23 0
KR24 M120 2510 sec CD19+CD10high 4.5 x 103 98.5% 13 0 18 0 21 0 27 0 36 0 46 0
M121  (of M31) 13 0 18 0.082 21 0 27 0 36 0 49 0.013
M122 13 0.017* 18 0.097 21 0.412 27 3.4 36 16.5 39 50.3
M123 13 0 18 0 21 0 27 0 36 0 49 0
M124 CD19+CD10low 6.9 x 103 98.8% 13 0 18 0 21 0 27 0 36 0 49 0
M125 13 0 18 0 21 0 27 0 36 0 49 0
M126 13 0.004* 18 53.6 21 9.2 27 19.7 30 1.2
M127 13 5.1 18 41.1 21 18.9 27 30.4 36 0.066 48 0.142
KR25 M128 A67 sec unsorted 6.0 x 104 n/a 13 1.1 >13
M129  (of M7) 13 74.2 15 #§
M130 13 8.9 15 73.3
M131 13 10.6 15 30.5
KR26 M132 WB51 sec CD19+CD20high 3.06 x 103 93.8% 10 8.2 15 32.5 18 63.8 18 30.6
M133  (of M68) 10 9.4 15 49.9 16 57.4
M134 10 8.1 15 23.6 18 16.9 20 62.8
M135 10 6.4 15 1.5 18 9.4 20 59.4
M136 CD19+CD20low 3.06 x 103 99.8% 10 0.119 15 33.9 18 23.6 21 63.3
M137 10 14.5 15 72.0
M138 10 20.4 15 81.4
M139 10 0.38 15 42.0 18 61.9 21 64.5
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Mouse 
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Leukemia
Injected Cells
Injected 
Cell No.
Population 
purity (% )
Wks post 
transplant
BMP1 
Result
Wks post 
transplant
BMP2 
Result
Wks post 
transplant
BMP3 
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Wks post 
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BMP4 
Result
Wks post 
transplant
BMP5 
Result
Wks post 
transplant
Final Engraftment
KR27 M140 WB51 sec CD19+CD20high 2.0 x 103 94.2% 10 37.1 15 18.0
M141  (of M68) 10 10.4 15 23.4 21 19 28.5
M142 10 0.167 15 3.9 21 >15
M143 CD19+CD20low 2.0 x 103 99.8% 10 32.4 15 76.5
M144 10 2.3 >10
M145 10 2.1 15 3.0 17 #§
M146 CD19+CD20high 5.0 x 102 94.2% 10 18.9 15 37.4 18 67.7
M147 10 33.7 15 39.0 19 66.6
M148 10 31.4 15 20.4 18 31.6
M149 CD19+CD20low 5.0 x 102 99.8% 10 16.5 15 46.4 20 82.1
M150 10 10 15 33.2 18 78.4
M151 10 0.062 15 31.1 20 79.5
M152 CD19+CD20high 1.0 x 102 94.2% 10 0 15 0.039 21 17.8 30 53.7 31 46.7
M153 6 #§
M154 10 0 15 0.3 21 16.8 25 39.4
M155 CD19+CD20low 1.0 x 102 99.8% 10 0.041 15 0.22 >15
M156 10 3 15 47.7 19 42.9
M157 10 0 15 0 21 0.24 30 64.7 33 70.7
KR28 M158 A67 tert CD19+CD20high 1.35 x 103 90.3% 9 0 14 60.8 15 40.0
M159  (of M45) 9 0 14 51.4 16 57.7
M160 9 11 14 20.8 16 68.0
M161 9 11 14 15.4
M162 CD19+CD20low 1.35 x 103 100.0% 9 3 14 44.4 16 47.6
M163 9 4.2 14 4.6 17 58.1
M164 9 40.6 14 29.6 17 36.4
M165 9 14.9 14 4.8 17 54.6
KR29 M166 A67 tert CD19+CD20high 2.4 x 103 92.3% <8
M167  (of M43) 8 0 13 0.048 17 47.3
M168 8 0.188 13 21.1 17 47.6
M169 8 11.1 13 1.5 >13
M170 CD19+CD20low 2.4 x 103 98.5% 8 0.063 18 12.9 22 78.4
M171 8 61 18 16.4 >18
M172 8 47.6 18 13.3 >18
M173 8 0.01* 18 0.13 22 50.0
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KR30 M174 HV101 prim CD19+CD10high 3.0 x 103 100.0% 8 0 14 0 >14
M175 8 0.004* 14 0.012* 20 2.9 27 16.9 34 43.2 42 60.4
M176 8 0 14 0 20 0 27 0.006* 34 0.04 >34
M177 8 0 14 0 20 0 27 0 34 0 46 0
M178 CD19+CD10low 3.0 x 103 100.0% 8 0 14 0 20 0 27 0 34 0 50 0
M179 8 0 14 0 20 0 27 0 30 0.021
M180 8 0 14 0 20 0 27 0 34 0 44 0
M181 8 0 14 0 20 0 27 0 34 0 50 0
KR31 M182 CD19+CD20high 3.0 x 103 99.3% 8 0 14 0 20 0 27 0 34 0.184 50 77.7
M183 8 0 14 0.015 20 4.2 27 25.8 34 42.9 38 64.1
M184 8 0 14 0.015 20 0.0071* 27 14.7 34 26 50
M185 8 0 14 0 20 0 27 0 34 0.0066* >34
M186 CD19+CD20low 3.0 x 103 99.3% 8 0.24 14 27.9 20 30.7 27 54.6 32 66.2
M187 8 0 14 0.026 20 36.2 27 36.4 34 21.8 40 73.6
M188 8 0.0056* 14 0.15 20 7.0 27 12.8 31 65.8
M189 8 0.027 14 5.7 20 33.8 27 15.6 31 25.8
KR32 M190 unsorted 5.0 x 102 n/a 8 0 14 0 20 0.007* >20
M191 8 0 14 0 20 0.155 27 29.2 >27
M192 8 0 14 0 20 0 27 0 34 0 47 0
M193 8 0 14 0 20 0.023 27 8.7 34 48.9 44 57.6
M194 1.0 x 102 8 0 14 0 20 0 27 0 34 0 50 0
M195 8 0 14 0 20 0 27 0 34 0 50 0
M196 8 0 14 0 20 0 27 0 34 0 50 0
M197 8 0 14 0 20 0 27 0 34 0 50 0
M198 1.0 x 101 8 0 >8
M199 8 0 14 0 20 0 27 0 34 0 >34
M200 8 0 14 0 20 0 27 0 34 0 50 0
M201 8 0 14 0 20 0 23 0
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KR33 M202 2510 sec CD19+CD20high 3.0 x 103 94.5% 8 0 12 0 17 0 27 0 >27
M203  (of M30) 8 0.71 12 9.7 17 1.7 27 5.2 30 66.6
M204 8 15.8 12 14.4 17 8.1 25 46.5
M205 8 0 12 0 17 0 27 0 34 0 49 0
M206 CD19+CD20low 3.0 x 103 99.2% 8 28.6 12 12.1 17 4.9 21 68.9
M207 8 9.4 12 52.8 17 d 27 9.4 34 0.43 34 21.4
M208 8 25.5 12 2.2 17 0.71 26 28.0
M209 8 32 12 1.7 17 16.2 26 50.9
M210 CD19+CD20high 3.0 x 102 94.5% 8 0 12 0 17 0 27 0 34 0 49 0
M211 8 0 12 0 17 0 27 0 34 0 >34
M212 8 0 12 0 17 0 27 0 34 0 44 0
M213 8 0 12 0 17 0 27 0 34 0 49 0
M214 CD19+CD20low 3.0 x 102 99.2% 8 0.033 12 55.6 17 31.2 >17
M215 8 0 12 0 17 0 27 0 34 0 45 0
M216 8 0 12 0 17 0 27 0 34 0 44 0
M217 8 0 12 0 17 0 27 0 34 0 45 0
KR34 M218 WB51 sec CD19+CD20high 1.2 x 103 95.0% 11 8.8 >11
M219  (of M73) 11 14.3 14 37.7
M220 11 2.1 16 56.4
M221 11 33.6 >11
M222 CD19+CD20low 1.2 x 103 99.7% 11 2.6 >11
M223 11 34.7 >11
M224 11 3.9 16 61.5
M225 11 0 >11
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KR35 M226 L858 prim unsorted 1.0 x 103 n/a 12 0 17 0 20 0 29 0 36 0 57 0.14
M227 12 0 17 0 20 0.0024* 29 0.048 36 0.305 44 9.5
M228 12 0.004* 17 6.2 20 3.9 29 0.50 36 1.9
M229 12 0 17 0 20 0 29 0 36 0 57 86.7
M230 12 0 17 0 20 0 >20
M231 1.0 x 102 12 0 17 0 20 0 29 0 36 0 38 0
M232 12 0 17 0 20 0 29 0 36 0 57 0.0018*
M233 12 0 17 0 20 0 29 0 36 0 57 57.4
M234 12 0 17 0 20 0 29 0 36 0 57 0.0036*
M235 12 0 17 0 20 0 29 0 36 0 46 17.4
M236 1.0 x 101 12 0 17 0 20 0 29 0 36 0 57 0.0079*
M237 12 0 17 0 20 0 29 0 36 0 57 0.0022*
M238 12 0 17 0 20 0 29 0 36 0 57 0.0023*
M239 12 0 17 0 20 0 29 0 36 0 57 0.0038*
M240 12 0 17 0 20 0 29 0 36 0 57 0.0039*
KR36 M241 MS45 prim unsorted 1.0 x 103 n/a 9 0 17 0 25 0 36 0
M242 9 0 17 0 25 0 36 0
M243 9 0 17 0 25 0 36 0
M244 9 0 17 0 25 0 36 0
M245 1.0 x 102 9 0 17 0 25 0 36 0
M246 9 0 17 0 25 0 36 0
M247 9 0 17 0 25 0 36 0
M248 9 0 17 0 25 0 36 0
M249 9 0 17 0 25 0 36 0
M250 1.0 x 101 9 0 17 0 25 0 36 0
M251 9 0 17 0 25 0 36 0
M252 9 0 17 0 25 0 36 0
M253 9 0 17 0 17 0
M254 9 0 17 25 0 36 0
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KR37 M255 MS45 prim CD19+CD10low 1.2 x 103 90.2% 9 0 17 0 25 0 37 0
M256 9 0 17 0 25 0 37 0
M257 9 0 17 0 25 0 37 0
M258 9 0 17 0 25 0 37 0
M259 CD19+CD10high 1.2 x 103 96.9% 9 0 17 0 25 0 37 0
M260 9 0 17 0 25 0 37 0
M261 9 0 17 0 25 0 37 0
M262 9 0 17 0 25 0 37 0
KR38 M263 CD19+CD20high 3.0 x 103 98.1% 9 0 17 0 25 0 34 0
M264 9 0 17 0 25 0 34 0
M265 9 0 17 0 25 0 34 0
M266 9 0 17 0 25 0 34 0
M267 CD19+CD20low 3.0 x 103 99.8% 9 0 17 0 25 0 34 0
M268 9 0 17 0 25 0 34 0
M269 9 0 17 0 25 0 34 0
M270 9 0 17 0 25 0 34 0
KR39 M271 WB51 sec unsorted 1.0 x 103 n/a 10 2 17 69.7 17 48.5
M272  (of M68) 10 17.8 17 76.9 17 65.5
M273 10 3.2 17 60.5 18 70.3
M274 10 18.7 17 69.7 18 59.0
M275 1.0 x 102 10 2.2 17 32.9 20 72.5
M276 10 0.0026* 17 0 20 0.25
M277 10 1.3 17 12.2 20 54.4
M278 10 0 17 23.2 20 #
M279 10 0 17 0.023 22 4.0 26 36.7 29 74.2
M280 1.0 x 101 <10
M281 10 0 17 0 22 0 26 0 30 0 50 0.0049*
M282 10 0 17 1.2 22 14
M283 10 0 17 0 22 0 26 0 30 0 46 f.d.
M284 10 0.017 17 59.0 21 68.0
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KR40 M285 WB51 sec unsorted 1.0 x 103 n/a <12
M286  (of M65) 12 42.2 12 55.3
M287 12 47.3 14 55.8
M288 1.0 x 102 12 37.1 15 33.1
M289 12 23.1 15 55.3
M290 12 13.4 13 1.3 d
M291 12 1.1 15 35.2
M292 12 5.2 15 57.6
M293 1.0 x 101 <12
M294 12 0 17 0 21 0 25 0 37 61.5 39 76.6
M295 12 0.046 >12
M296 12 8 17 11.7 >17
M297 12 8.1 >12
KR41 M298 A67 tert unsorted 1.0 x 103 n/a 12 39.8 13 68.4
M299  (of M130) 12 50.8 12 33.5
M300 12 23.1 13 36.6
M301 1.0 x 102 12 27.4 15 52.3
M302 12 44.4 15 51.1
M303 12 0.808 >12
M304 12 38.1 15 62.2
M305 12 1.7# 15 52.0
M306 1.0 x 101 12 11.8 >12
M307 12 0.25 17 0.50# 20 68.4
M308 12 0 17 0 21 0.27 25 8.9 28 55.3
M309 12 0 17 0 21 0 25 0 37 0 64 0
M310 12 0 17 0 21 0 25 0 37 0 64 0
KR42 M311 737c prim CD19+CD20high 1.5 x 103 99.0% 12 4 15 44.7 19 70.6
M312 12 17.3 15 38.6 19 73.8
M313 12 2.6 15 2.4 >15
M314 12 16.9 15 58.6 16 56.8
M315 CD19+CD20low 1.5 x 103 98.9% 12 29.7 15 7.0 19 18.6 23 68.9
M316 12 # 15 13.1 >15
M317 12 1.1# 12 24.6
M318 12 23.5 15 20.8 >15
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KR43 M319 737c prim CD19+CD10high 1.5 x 103 97.2% 12 0.112 15 4.8 19 27.4 24 8.3 >24 31.2
M320 12 62.7 12 42.4
M321 12 0.025 15 0 19 0 24 0 29 0.0034*
M322 12 12.4 15 1.3 19 7.3 >19
M323 CD19+CD10low 1.5 x 103 98.7% 12 0 15 0 19 0 24 0 31 0.0042* 44
M324 12 0 15 0 19 0 24 0 31 0 59 0
M325 12 0 15 0 19 0 24 0 31 0 59 0
M326 12 0 15 0 19 0 24 0 31 0 49 0
KR44 M327 unsorted 1.0 x 104 n/a 12 32.6 13 67.5
M328 12 23.4 13 43.6
M329 1.0 x 103 12 12 15 28.8 16 49.2
M330 12 13.1 15 16.0 >15
M331 12 47.1 12 23.4
M332 12 46.8 15 42.0 16 37.5
M333 1.0 x 102 12 0.176 15 3.9 >15
M334 12 3.3 15 55.4 19 4.7
M335 12 0.016* 15 0.208 19 11.9 24 1.7 31 0.323 33 65.1
M336 12 0 15 0 19 0 24 0 31 0 47 0.104#
M337 12 1.3 15 33.4 19 69.5
M338 1.0 x 101 12 0 15 0 19 0 24 0 31 0 63 0
M339 12 0 15 0 19 0 24 0 31 0 >31
M340 12 0 15 0 19 0 24 0 31 0 63 0
M341 12 0 15 0 19 0 24 0 31 0 63 0
M342 12 0 15 0 19 0 24 0 31 0 47 0
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KR45 M343 WB51 tert CD19+CD20high 5.0 x 102 95.6% 9 0 13 0 17 0 24 1.04
M344  (of M152) 9 0 13 0 17 0 29 0 39 0.076
M345 9 0 13 0 17 0.302 29
M346 CD19+CD20low 5.0 x 102 99.8% 9 0 13 0.014* 17 9.9 24 64.8
M347 9 0 13 0.015* 17 0.073 25 36.2
M348 9 0 13 0 17 0.044 29 0.117 41 9.4 46 76.5
M349 CD19+CD20high 1.0 x 101 95.6% 9 0 13 0 17 0 29 0 41 0 56 0
M350 9 0 13 0 17 0 29 0 41 0 43 0
M351 9 0 13 0 14
M352 9 0 13 0 17 0 29 0 41 0 56 0
M353 CD19+CD20low 1.0 x 101 99.8% 9 0 13 0 17 0 29 0 41 0 61 0
M354 9 0 13 0 17 0 29 0 41 0 47 0
M355 9 0 13 0 17 0 29 0 41 0 61 0
M356 9 0 13 0 17 0 29 0 41 0 46 0
KR46 M357 M120 prim unsorted 1.0 x 104 n/a 9 0 15 0.0035* 19 0.154 26 4.9 40 43.1 43 43.6
M358 9 0 15 0.027 19 0.595 26 2.0 40 8.5 43 32.5
M359 9 0 15 0.096 19 0 d 26 8.9 40 18.6 40 33.1
M360 9 0 15 0.071 19 0.242 26 0.30 27
M361 1.0 x 103 9 0 15 0 19 0 26 0 30 0
M362 9 0 15 0 19 0 26 0 40 0 58 0
M363 9 0 15 0 19 0 26 0 40 0 46 0
M364 9 0 15 0 19 0 26 0 40 5 58 29.1
M365 1.0 x 102 9 0 15 0 19 0 26 0 40 0 55
M366 9 0 15 0 19 0 26 0 40 0 56 0
M367 9 0 15 0 19 0 26 0.19 40 2.6 44 0.012*
M368 9 0 15 0 19 0 26 0 40 0 58 0
M369 9 0 15 0 19 0 26 0 40 0 58 0
M370 1.0 x 101 9 0 15 0 19 0 26 0 40 0 >40
M371 9 0 15 0 19 0 26 0 40 0 58 0
M372 9 0 15 0 19 0 26 0 40 0 58 0
M373 9 0 15 0 19 0 26 0 40 0 58 0
M374 9 0 15 0 19 0 26 0 40 0 58 0
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KR47 M375 M120 prim CD19+CD10high 2.0 x 103 99.6% 9 0 15 0 19 0 26 0 40 0 >40
M376 9 0.029 15 10.1 19 5.2 26 22.1 34 15.5
M377 9 0.072 15 0.008* 19 0.01* 26 4.5 40 7.5 58 9.1
M378 9 0 15 0 19 0 26 0 40 0 58 0
M379 CD19+CD10low 2.0 x 103 97.4% 9 0 15 0 19 0 26 0 40 0 >40
M380 9 0 15 0 19 0 26 0 40 0 58 0
M381 9 0 15 0 19 0 26 0 40 0 58 0
M382 9 0 15 0 19 0 26 0 40 0 58 0
KR48 M383 CD19+CD20high 3.0 x 103 96.3% 9 0 15 0 19 0 26 0 40 0 49 0
M384 9 0 15 0 19 0 26 0 39
M385 9 0 15 0 19 0 26 0 40 0 >40
M386 9 0 15 0 19 0 26 0 40 0 58 0
M387 CD19+CD20low 3.0 x 103 98.0% 9 0 15 0 19 0 26 0.039 35 4.4
M388 9 0 15 0 19 0.045 26 28.7 40 7.5 >40
M389 9 0 15 0 19 0 26 0.083 40 10 52 11.1
M390 9 0 15 0 19 0 26 0 40 0 58 0
KR49 M391 758b prim unsorted 1.0 x 104 n/a <9
M392 9 0 13 0 20 7.6 28 50.8
M393 9 0.004 * 13 0 d 20 0.129 34 3.5 42 19.8 48 61.1
M394 9 0 13 0 d 20 0.002* 34 0.009* 42 0.012 48 0.398
M395 1.0 x 103 8 0
M396 9 0 13 0 20 0 34 0 42
M397 9 0.005* 13 0.042 20 4.5 34 68.3 42 37.7 51 64.1
M398 9 0.006* 13 0 20 0.051 34 1.3 42 52.1 51
M399 1.0 x 102 9 0 13 0 20 0 34 0 42 0 51 0
M400 9 0 13 0 20 0 34 0 42 0 51 0
M401 9 0 13 0 20 0 34 0 36
M402 9 0 13 0 20 0 34 0 42 0 50 0
M403 9 0 13 0 20 0 34 0 42 0 50 0
M404 1.0 x 101 9 0 13 0 20 0 34 0 40 0
M405 9 0 13 0 20 0 34 0 42 0 51
M406 9 0 13 0 20 0 34 0 42 0 52 0
M407 9 0 13 0 20 0 34 0 42 0 50
M408 9 0 13 0 20 0 34 0 42 0 52 0
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KR50 M409 758b prim CD19+CD10high 1.5 x 103 99.4% 9 0 13 0.0071* 20 0.0026* 34 0.071 42 0.149 52 1.03
M410 9 0 13 0.011* 20 0.249 >20
M411 9 0 13 0 20 0 34 0 42 0 52 0
M412 9 0 13 0 20 0 34 0 42 0 44
M413 CD19+CD10low 1.5 x 103 100.0% 9 0.087 13 0.056 20 0.073 34 35.6 39 37.7
M414 9 0.46 13 1.3 20 36.7 34 45.5 42 0 48 20.8
M415 9 0 13 0.056 20 3 34 68.3 42
M416 9 0.03 13 0.59 20 54.9 34 0.42 40 69.7
KR51 M417 CD19+CD20high 1.5 x 103 98.4% 9 0 13 0 20 0 34 0 42 0 >42
M418 9 0 13 0 20 0 34 0 42 0 >42
M419 9 0 11
M420 9 0 13 0 20 0 34 0 42 0 >42
M421 CD19+CD20low 1.5 x 103 100.0% 9 0.057 13 0.244 20 3.2 34 87.7 42 0.156 51
M422 9 0.024 13 4.1 20 72.8 34 82.5 42 0.012* 52 84.2
M423 9 0.087 13 0.258 20 7.8 34 86.0 42 0.039 52 64.1
M424 9 0 13 0 20 0 34 0.0073* 42 0.045 52 28.8
KR52 M425 A67 prim unsorted 1.0 x 104 n/a 12 1.4 15 54.3 15 77.9
M426 12 8.2 15 3.0 15 31.1
M427 12 0.26 15 33.5 15 1.8
M428 12 9.4 15 11.0 15 66.1
M429 1.0 x 103 12 5.0 15 16.3 18 74.5
M430 12 36.0 15 55.1 18 66.8
M431 12 2.3 15 0.034# 18 56.0
M432 12 2.2 15 27.2 18 23.6
M433 1.0 x 102 12 0 15 0.013 18 24.5 26 23.8 29 75.5
M434 12 2.7 15 12.0 18 39.1 22 62.7
M435 12 0.068 15 8.7 18 13.9 21 31.7
M436 12 0.18 15 25.3 >15
M437 12 5.2 15 70.4 18 0# 22 73.1
M438 1.0 x 101 12 0 15 0 18 0 26 0 33 0 46 0
M439 12 0 15 0 18 0 19 0
M440 12 0 15 0 18 0 26 0 33 0 46 0
M441 12 0 15 0 18 0 26 0 33 0 46 0
M442 12 0 15 0 18 0 26 0 33 0 46 0
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KR53 M443 L876 prim unsorted 1.0 x 103 n/a 9 0.023 13 0.033 20 0.089 25 0.064
M444 9 0 13 0.133 20 74.4 22 3.4
M445 9 0 13 0.028 20 0.63 27 0 35 0
M446 9 0 13 0.345 20 36.3 27 39 25 26.4
M447 1.0 x 102 9 0 13 0 20 0 27 0 39 31 0
M448 9 0 13 0.008* 20 15.7 27 2.1 31 3.1
M449 9 1.03 13 47.5 19 62.0
M450 9 0.699 13 66.9 20 47.1 27 44.5 32 86.8
M451 9 0.37 13 3.1 20 2.1 27 12.7 32 68
M452 1.0 x 101 9 0 13 0 20 0 27 0 39 0 40 0
M453 9 0 13 0 20 0 27 0 39 0 40 0
M454 9 0 13 0 20 0 27 0 39 0 40 0
M455 9 0 13 0 20 0 27 0 39 0 40 0
M456 9 0 13 0 20 0 27 0 39 0 40 0.014
KR54 M457 HV101 sec unsorted 1.0 x 103 n/a 9 15.2 13 17.3 19 58.7 19 49.1
M458  (of M187) 9 53.1 13 36.1 18 71.7
M459 9 23.1 13 60.3 16 37.2
M460 9 25.8 13 43.1 16 52.9
M461 1.0 x 102 9 0.542 13 35.1 19 30.5 23 57.8
M462 9 0 13 2.9 19 77.5 25 70.0
M463 9 0.85 13 45.7 19 51.2 23 76.0
M464 9 0.197 13 19.7 >13
M465 9 0.017* 13 0.02 18 71.6
M466 1.0 x 101 9 0.003* 13 0 19 0.321 27 28.0 39 29.7 40 25.4
M467 9 0.027 13 8.6 19 23.5 25 51.2
M468 9 0 13 0 19 0 27 0 39 0.013 40 0.0019*
M469 9 0 13 0 19 0 27 0.20 39 8 40 51.5
M470 9 0 13 0.013 19 47.1 27 72.7 28 32.5
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KR55 M471 737c sec CD19+CD20high 1.0 x 103 97.5% 8 0 15 0 23 0.534 30 11.3 36 25
M472  (of M315) 8 0 15 7.3 23 35.5 30 32.8 36 67.2
M473 8 0.01* 15 1.5 23 13.1 30 19.4 36 60.3
M474 8 0 15 8.6 23 73.0 30 49.0 36 64.5
M475 CD19+CD20low 1.0 x 103 98.4% 8 0 15 0.213 23 0.017 30 9.1 36 39.6
M476 8 0 15 0 23 0 30 0 37 0 43 0
M477 8 0 15 0 23 0 30 0 37 0 43 0
M478 8 0 15 1.5 23 22.0 30 0.291 36 53.6
M479 CD19+CD20high 1.0 x 10
2 97.5% 8 0 15 0 23 0 30 0 37 0 45 0
M480 8 0 15 0 23 0 30 0 37 0 39
M481 8 0.206 15 25.2 23 52.9 30 2.9# 33 70.5
M482 8 0 15 0 23 0 30 2.3 36 64.4
M483 CD19+CD20low 1.0 x 10
2 98.4% 8 0 15 0 23 0 30 0 37 0 39 0
M484 8 0 15 0 23 0 >23
M485 8 0 15 0 23 0 30 0 37 0 46 0
M486 8 0 15 0 23 0 29
M487 CD19+CD20high 1.0 x 101 97.5% 8 0 15 0 23 0 30 0 37 0 46 0
M488 8 0 15 0 23 0 30 0 37 0 46 0
M489 8 0 15 0 23 0 30 0 31 0
M490 8 0 15 0 23 0 30 0 37 0 43 0
M491 8 0 15 0 23 0 >23
M492 CD19+CD20low 1.0 x 101 98.4% 8 0 15 0 23 0 30 0 37 0 46 0
M493 8 0 15 0 23 0 30 0 37 0 46 0
M494 8 0 15 0 23 0 30 0 37 0 46 0
M495 8 0 15 0 23 0 29
M496 8 0 15 0 23 0 30 0 37 0 46 0
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KR56 M497 737c sec CD19+CD10high 1.0 x 103 97.3% 8 4.1 15 67.6 18 80.7
M498  (of M320) 8 15.8 15 84.2 21 80.1
M499 8 0 15 54.6 >15
M500 8 0.728 15 73.3 21 81.9
M501 CD19+CD10low 1.0 x 103 99.1% 8 0 15 11 23 79.2 24 73.4
M502 8 0.424 15 5 23 17.8 26
M503 8 0.093 15 31.4 19 24.6
M504 8 0 15 0 23 0.293 27 21.7
M505 CD19+CD10high 1.0 x 10
2 97.3% 8 0 15 0 23 0 30 0 37 0 >37
M506 8 0 15 0.016 23 71.5 30 14.0 36 61.8
M507 8 0 15 0.126 23 62.7 30 2.2 34
M508 8 0 15 0 23 0 30 0 37 0 46 0
M509 CD19+CD10low 1.0 x 10
2 99.1% 8 0 15 2.3 23 70.7 29
M510 8 0 15 0 23 0 30 0 37 0 46 0
M511 4 0
M512 8 0 15 0.011 23 0.042 30 0.779 37 0.695 46 7.7
M513 CD19+CD10high 1.0 x 101 97.3% 8 0 15 0 23 0 30 0 37 0 46 0
M514 8 0 15 0 23 0 30 0 37 0 46 0
M515 8 0 15 0 23 0 30 0 37 0 46 0
M516 8 0 15 0 23 0 30 0 37 0 46 0
M517 8 0 15 0 23 0 30 0 37 0 43 0
M518 CD19+CD10low 1.0 x 101 99.1% 8 0 15 0 23 0 30 0 37 0
M519 8 0 15 0 23 0 30 0 37 0 46 0
M520 8 0 15 0 23 0 30 0 37 0 46 0
M521 8 0 15 0 23 0 30 0 37 0 >37
M522 8 0 15 0 23 0 30 0
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KR57 M523 2003 prim unsorted 1.0 x 103 n/a 3
M524 8 0 14 0 24 0 24 0
M525 8 0 14 0 24 2.7 27 21.0
M526 8 0 14 0 24 0 28 0
M527 1.0 x 10
2 8 0 14 0 33 0 42 0
M528 8 0 14 0 33 0 42 0
M529 8 0 14 0 33 0 42 0
M530 8 0 14 0 33 0 42 0
M531 1.0 x 101 8 0 14 0 33 0 42 0
M532 8 0 14 0 33 0 39 0
M533 8 0 14 0 33 0 42 0
M534 8 0 33 >8
M535 8 0 14 0 33 0 42 0
KR58 M536 4917 prim unsorted 1.0 x 103 n/a 8 0 14 0 24 0 33 0 >33
M537 8 0 14 0 24 0 33 0 36 0
M538 5 0
M539 8 0.0028* 14 0.976 24 4.6 27 20.3
M540 1.0 x 10
2 8 0 14 0 >14
M541 8 0 14 0 33 0 39 0
M542 8 0 14 0 29 0
M543 8 0 14 0 22
M544 1.0 x 101 8 0 14 0 33 0 42 0
M545 8 0 14 0 33 0 39 0
M546 8 0 14 0 33 0 36 0
M547 8 0 14 0 33 0 42 0
M548 8 0 14 0 33 0 42 0
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KR59 M549 WB51 tert CD19+CD34high 1.0 x 103 97.9% 9 11.2 12 59# 16 41.1
M550  (of M272) 2
M551 9 1.2 12 19# 18 67.8 19 71.2
M552 9 30.8 12 49.72# 18 46.1 22
M553 CD19+CD34low 1.0 x 103 97.8% 9 4.8 12 0.175# 18 29.4 22 57.5
M554 9 4.7 12 29.7# 18 0.877# 21 56.9
M555 9 0.262 12 3.4# 18 53 21 23.9
M556 9 0.533 12 0.986# 18 21.7 21 41.1
M557 CD19+CD34high 1.0 x 102 97.9% 9 0.158 12 0.917# 18 57 23 0.049# 30 65.7
M558 9 0.037 12 0.008*# 18 0.108 23 0.013 31 14.8
M559 9 0 12 0.123# 18 36.3 23 67.5 26 64.7
M560 9 0 12 0.011# 18 23.2 23 45.3 27 74.2
M561 9 0 12 0.0189# 18 1 23 0.804 31 68.5
M562 CD19+CD34low 1.0 x 102 97.8% 9 0.673 12 0.498# 18 6.2 23 20.4 26 60.7
M563 9 0 12 0# 18 0 23 0.034 31 45.9
M564 9 0.102 12 1.31# 18 65.2 23 62.7 23 34.4
M565 9 0 12 0# 18 67.7 23 34.6 >23
M566 9 0.076 12 0# 18 62.5 23 28.3 26 73.4
M567 CD19+CD34high 1.0 x 101 97.9% 9 0 12 30.7 18 59 19 65.3
M568 9 0.41 12 0.146 18 0.034# 19 0.474
M569 9 0.127 12 25.7 18 7.9 19 61.4
M570 9 0 12 0.059 18 27.2 23 35.4 28 83.3
M571 9 0 12 0 18 0.0032* 23 0.0086* 28 0.009*
M572 9 0.096* 12 0 18 3.1 22 1.5
M573 CD19+CD34low 1.0 x 101 97.8% 9 0 12 0.04 18 40.5 23 9.1 23
M574 9 0 12 0.014* 18 1.3 23 9 26 53.6
M575        9 0 12 0 18 0 23 0.34 32 26.1 42 59.8
M576 9 0 12 0 18 0 23 0 32 2.3 42 54.8
M577 9 0 12 0 18 0 23 0 32 0 42 0
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KR60 M578 737c sec CD19+CD34high 1.0 x 103 98.5% 9 0.322 12 0.133 17 10.9
M579  (of M327) 9 75.8 12 14.8 15
M580 9 3.5 12 8.4 18 3.7# 19 94.0
M581 9 0 12 0.556 18 5.9 23 2.2 32 25
M582 CD19+CD34low 1.0 x 103 98.8% 9 0.138 12 29.9 18 9 22 77.7
M583 9 0.132 12 6.9 18 13.1 20
M584 9 0 12 0 18 0.4 23 56.4 27 74.4
M585 9 0.538 12 15 18 0.031# 23 9 26 60.8
M586 CD19+CD34high 1.0 x 102 98.5% 9 0 12 0 18 0 23 0.178 32 83.1 42 74.8
M587 9 0 12 0 18 0 23 0 32 0 47 0
M588 9 0 12 0 18 0 23 0 32 0 >32
M589 9 0 12 0 18 0 23 0 32 0 35
M590 9 0 12 0 18 0 23 0 32 0 47 0
M591 CD19+CD34low 1.0 x 102 98.8% 9 0 12 0 18 0 23 0 32 0 47 0
M592 9 0 12 0 18 0 23 0 >23
M593 9 0 12 0 18 9.9 31 81.6
M594 9 0 12 0.456 18 49.9 23 77 >23
M595 9 0 12 0 18 0.0055* 23 0# 31 0.0018*
M596 CD19+CD34high 1.0 x 101 98.5% 9 0.006* 12 0.024 18 13.8 22 40
M597 9 0 12 0.15 18 83.9 >18
M598 9 0 12 0 18 0 23 0# 31 0
M599 9 14 12 54.4 18 74.5 23 62.9 25
M600 9 0 12 0 18 0.013* 23 0# 26 0
M601 CD19+CD34low 1.0 x 101 98.8% 9 0 12 0 18 0.029* 23 1.2 30 42.2
M602 9 0 12 0 18 0 23 0 32 0 47 0
M603 9 0 12 0 18 0 23 0 32 0 40 0
M604 9 0 12 0 18 0 23 0 32 0 39
M605 9 0 12 0 18 0 23 0 32 0 47 0
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KR61 M606 4540a prim CD19+CD34high 1.0 x 10
3 93.8% 8 1.1 8 0
M607 8 0 16 0 22 0 28 0 36 0 0
M608 8 0 16 0 22 0 28 0 36 0 0
M609 8 0 16 0.35 22 30.5 28 39.6 30 43.8
M610 8 0 16 0 22 0 28
M611 CD19+CD34low 1.0 x 10
3 100.0% 8 0.003 * 16 36.9 22 33.8 24 58.9
M612 8 0 16 0 22 0 28 0.005* 36 0 0
M613 8 0 16 0 22 0 28 0 36 0 0
M614 8 0 16 0 22 0 28 0 36 0 0
M615 8 0 16 0 22 0 28 0 36 0 0
M616 CD19+CD34high 1.0 x 102 93.8% 8 0.047 16 0.455 22 13.3 28 58.1 29 8.9
M617 8 0.07 16 0.025 22 10 28 44.2 29 22.2
M618 8 0 16 0 22 0 28 0 36 0 0
M619 8 0 16 0 22 0 23
M620 8 0 16 3.1 22 33.1 27 45.1
M621 CD19+CD34low 1.0 x 102 100.0% 8 0 16 0 22 0 28 0 36 0 0
M622 8 0 16 0 22 0 28 0 36 0 0
M623 8 0 16 0 22 0 28 0 36 0 0
M624 8 0 16 0 16 0
M625 8 0 16 0 13 0
M626 CD19+CD34high 1.0 x 101 93.8% 8 0 16 0 20
M627 8 0 16 0 22 0 28 0 36 0 0
M628 6
M629 8 0 16 0 22 0 28 0 36 0 0
M630 8 0 16 0 22 0 28 0 36 0 0
M631 CD19+CD34low 1.0 x 101 100.0% 8 0 16 0 22 0 28 0 36 0 0
M632 8 0 16 0 22
M633 8 0 16 0 22 0 28 0 36 0 0
M634 8 0 16 0 22 0 28 0 36 0 0
M635 8 0 16 0 22 0 28 0 36 0 0
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KR62 M636 L784 prim CD19+CD34high 1.0 x 10
4 97.7% 9 0.019 13 0.48 19 18.6 25 15 29 17.3
M637 9 0.19 13 40.9 19 0.064# 25 26.1 27 31.9
M638 9 0.005* 13 4.8 19 18.7 25 1.3 0
M639 9 0 13 0.87 19 6.5 25 8.4 29 72.5
M640 CD19+CD34low 1.0 x 10
4 99.6% 9 0 13 0 19 0 25 0 33 0 0
M641 9 0 13 0 19 0 25 0 33 0 0
M642 9 0 13 0 19 2.6 25 31.4 29 58.3
M643 9 0 13 0.16 19 40.6 25 0.21# 33 3.3 36
M644 CD19+CD34high 1.0 x 103 97.7% 9 0 13 0 19 15.5 25 0 d 33 1.4 36 47.8
M645 9 0 13 0.0069* 19 13.5 25 9.3 33 35.7 36 2.7
M646 9 0 13 0 19 0 25 0 33 0.007* 0
M647 9 0.005* 13 0.048 19 52.3 25 0.023# 27 20.5
M648 CD19+CD34low 1.0 x 103 99.6% 9 0.014 13 4.1 19 3.9 25 8.3 33 13.8 36 13.7
M649 9 0.0024* 13 0.22 13
M650 9 0 13 0 19 0 25 0 33 0 0
M651 9 0.019 13 13.2 19 55.6 25 0# 27 63.3
M652 CD19+CD34high 1.0 x 102 97.7% 9 0 13 0 >13
M653 9 0 13 0 19 0 25 0 33 0 0
M654 9 0 13 0 19 0 25 0 29 0
M655 9 0 13 0 19 0 25 0 33 0 0
M656 9 0 13 0 19 0 25 0 33 0 0
M657 CD19+CD34low 1.0 x 102 99.6% 9 0 13 0.0046* 19 1.2 25 63.2 26 52.3
M658 9 0 13 0 19 0 25 0.003* 33 0 0
M659 9 0 13 0 19 0 25 0 33 0 0
M660 9 0 13 0 19 0 25 0 33 0 0
M661 9 0 13 0 19 0 25 0 33 0 0
M662 CD19+CD34high 1.0 x 101 97.7% 9 0 13 0 19 0 25 0 33 0 0
M663 9 0 13 0 19 0 25 0 33 0
M664 9 0 13 0 19 0 25 0 33 0 0
M665 9 0 13 0 19 25 14
M666 9 0 13 0 19 0 25 0 33 0 0
M667 CD19+CD34low 1.0 x 101 99.6% 9 0 13 0 19 0 25 0 33 0 43
M668 9 0 13 0 19 0 25 0 33 0 0
M669 9 0 13 0 19 0 25 0 33 0 0
M670 9 0 13 0 19 0 25 0 33 0 0
M671 9 0 13 0 19 0 25 0 33 0 0
M672 9 0 13 0 19 0 25 0 33 0 0
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In Childhood ALL, Both Blasts With a CD20-/low and a CD20high 
Immunophenotype Have the Ability to Transfer the Leukemia onto Immune-
deficient NOD/scid y-/- Mice  
Kerrie Wilson, Klaus Rehe, Simon Bomken, Julie Irving and Josef Vormoor 
There is an ongoing controversy as to whether cancer is always maintained by a rare 
population of highly specialized cancer stem cells or whether cancer-propagating cells 
may be more abundant in some cancer types. We have previously shown that in a 
heterogeneous group of childhood ALL different blast populations, regardless of their 
expression of the progenitor/stem cell marker CD34 or the lymphoid differentiation 
antigen CD19, contain leukemia-initiating activity (Cancer Cell 2008, 14(1), 47-58). By 
profiling B cell transcription factor expression, these different populations appeared to 
mirror stages of normal B cell development. Here we extend our experiments to another 
lymphoid differentiation marker, CD20, to provide further evidence that ALL blasts at 
different stages of maturation possess the ability to re-initiate the leukaemia.  
Unsorted bone marrow cells from 3 different ALL patients (L754, L736 and A67) were 
transplanted into 12 primary mice. Bone marrow was harvested from leukemic mice and 
flow sorted candidate populations (CD19+CD20-/low and CD19+CD20high) were re-
transplanted into 52 secondary and 8 tertiary mice. As expected from our previous 
experiments both CD19+CD20-/low and CD19+CD20high cells were able to re-
establish the disease in unconditioned NOD/scid y-/- mice (see table). Leukemic 
engraftment ranged from 0.5 to 73% as determined by flow cytometry on bone marrow 
  
 
aspirates. Both populations re-established the complete phenotype of the original 
leukemia including CD20-/low and CD20high blasts. These results were confirmed by 
directly sorting primary ALL blasts from pt. #L754 without prior passage in the mice. 
Cell purity after flow sorting was high (81-99%) and low numbers of cells engrafted 
(5000 for both CD19+CD20-/low and CD19+CD20high). The three patients reflected 
different ALL subtypes (A67: high risk ALL/t(9;22), L754:high hyperdiploid/MRD high 
risk; and L736 intermediate risk ALL: high WBC/MRD low risk). 
Patient  Transplant Mice Population Cell dose Engrafted 
L736 Secondary 9 CD20high 10.000-100.000 
 
6 
11 CD20-/low 10 
Tertiary 4 CD20high 10.000 4 
4 CD20-/low 1 
L754 Primary 4 CD20high 100.000 2 
4 CD20-/low 3 
Secondary 11 CD20high 5.000-100.000 9 
11 CD20-/low 7 
A67 Secondary 6 CD20high 9.000-20.000 6 
6 CD20-/low 6 
 
In conclusion, these results confirm our previous observation that ALL blasts 
irrespective of the expression of lymphoid differentiation markers are able to engraft 
immune-deficient mice. Therefore, leukemia-propagating cells in childhood ALL may 
be more abundant than previously thought. 
  
 
 
Conclusions
●Sorted fractions with both a more immature (CD19+CD20Low) and a more
mature immunophenotype (CD19+CD20High) engrafted immunodeficient NOG
mice.
●Both populations were able to reconstitute the complete leukemic
immunophenotype.
●These findings are supported by recent evidence demonstrating that both
CD34+CD38-CD19+ and CD34+CD38+CD19+ cells initiate leukemia in
immunodeficient mice (3).
●In conclusion, these results confirm our previous observation that ALL blasts
irrespective of the expression of lymphoid differentiation markers are able to
engraft immunodeficient mice. Therefore, leukemia-propagating cells in
childhood ALL may be more abundant than previously thought.
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Introduction
There is an ongoing controversy as to whether cancer is always maintained by a
rare population of highly specialized cancer stem cells or whether cancer-
propagating cells may be more abundant in some cancer types. In AML evidence
had consistently suggested that only immunophenotypically immature cells
possess SCID-repopulating ability indicative of cancer stem cell ability (1),
however, this may be different for different types of leukemia. We have previously
shown that in a heterogeneous group of childhood ALL different blast populations,
regardless of their expression of the progenitor/stem cell marker CD34 or the
lymphoid differentiation antigen CD19, contain leukemia-initiating activity (2).
Here we extend our experiments to another lymphoid differentiation marker, CD20,
to provide further evidence that ALL blasts at different stages of maturation
possess the ability to re-initiate the leukemia.
Methods
Bone marrow samples from patients with acute lymphoblastic leukemia (n=3) were
transplanted into immunodeficient mice (n=12). All 3 leukemias (2 high risk and 1
standard risk) engrafted in primary animals and bone marrow was harvested and
flow sorted into populations of candidate leukemic stem cells; CD19+CD20Low and
CD19+CD20High which were then serially transplanted into secondary and tertiary
recipient mice (n=62). Bone marrow from 1 patient (L754) was directly flow
sorted into these populations and transplanted into primary recipients (n=8).
Results
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In Childhood ALL, Both Blasts with a CD20Low and a CD20High
Immunophenotype Have the Ability to Transfer the Leukemia Onto 
Immunodeficient NOD Scid γ-/- (NOG) Mice
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Table 1 – Overview of all mice transplanted with
CD19+CD20High and CD19+CD20Low cells
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Figure 1 – The leukemic stem cell potential of candidate
populations is assayed by serial transplantation in
immunodeficient NOG mice
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Figure 4 – Our new ALL
stem cell model.
Our previous gene
expression studies (2)
indicate that the different
leukemic populations
mirror the corresponding
stages of normal B cell
development.
Figure 2 – Both CD19+CD20High and CD19+CD20Low populations transfer the
leukemia. Unsorted cells (A) from patient A67 engrafted primary mice (B/C).
Flow sorted cells from the primary mice were re-transplanted (9x103 cells/mouse)
and the original immunophenotype was recapitulated from both sorted fractions.
D
C
B
A E
Figure 3 – CD19+CD20High and CD19+CD20Low populations
display long-term self-renewal. Cells from patient L736 (A)
engrafted primary mice (B). Subsequent flow sorted material was re-
transplanted and the original immunophenotype was recapitulated
from both sorted fractions in secondary (C and D) and tertiary
recipients (E, F and G).
A
B
C
D
E
F
G
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Disease Propagating Blasts in Standard and High Risk Acute Lymphoblastic 
Leukemia are Frequent and of Diverse Immunophenotype 
Klaus Rehe, Kerrie Wilson, Hesta McNeill, Martin Schrappe, Julie Irving and Josef 
Vormoor 
 
Conflicting results in the field of cancer stem cells have reignited debate regarding the 
frequency and identity of cells with the ability to self-renew and to propagate the 
complete phenotype of the malignancy. Initially it was suggested by different studies 
that cancer stem cells represent only a small minority of the malignant population and 
that the immunophenotypes of these cells resemble a rather immature type in the cell 
hierarchy. More recent data from our own and other groups have challenged these 
findings by demonstrating that cells at different maturity levels within the leukemic 
hierarchy have cancer stem cell abilities and that the frequency of the leukemia 
maintaining cell is higher than previously thought (Cancer Cell 2008, 14(1), p47-58). 
We use an in vivo NOD/scid IL2Rγnull (NSG) mouse intra-femoral transplant model to 
determine the clonogenicity of sorted candidate leukemic stem cell populations, 
characterized by specific immunophenotypes. We selected the surface markers CD10 
and CD20, in order to differentiate between rather immature and more mature cells. 
Furthermore we carried out limiting dilution experiments on sorted (CD20) and unsorted 
leukemic blasts to investigate the frequency of the proposed leukemic stem cells. Flow 
sorted ALL blasts of CD19+CD20low and CD19+CD20high as well as of 
  
 
CD19+CD10low and CD19+CD10high immunophenotype were transplanted into NSG 
mice. Sorts were performed on primary patient material and on leukemic blasts that had 
been harvested following prior passage in mice. Different subtypes of ALL were 
included (high risk: BCR/ABL (t9;22) positive (patients L4967, L4951, L49101, L8849, 
L2510), high hyperdiploid/MRD positive high risk (L754, L835), intermediate risk: high 
WBC/MRD negative (L736, L784), age >10 years (L803)). CD20 sorts were performed 
on primary patient material (L4951, L49101, L754, L835 and L776), on secondary 
samples harvested from engrafted primary mice (L4967, L4951, L2510, L736 and L754) 
and on tertiary samples harvested from engrafted secondary mice (L4967 and L736). In 
total 151 mice were transplanted, with 122 showing engraftment in consecutive bone 
marrow punctures or in bone marrow harvests. CD10 sorts were performed on primary 
patient material (L784 and L49101) and on secondary samples harvested from engrafted 
primary mice (L4951, L8849, L2510 and L803) with 31 out of 52 mice transplanted 
with sorted material showing engraftment as seen with CD20 sorted cells. Blasts of all 
selected immunophenotypes were able to engraft the leukemia in unconditioned NSG 
mice as determined by 5 color flow cytometry. In particular, sorted cells of both 
fractions were able to reconstitute the complete phenotype of the leukemia. Harvested 
cells from engrafted mice could then be re-sorted into high and low antigen expressing 
fractions and successfully re-engrafted on secondary and tertiary mice. Cell purities of 
transplanted cells were usually higher than 90% (range 67-100%). The ability of all 
populations to serially engraft mice demonstrates long-term self-renewal capacity. Two 
additional patients were used in the limiting dilution assays (high WBC/t(4;11) high risk 
(L826); low WBC/MRD negative low risk (L792)) and experiments were performed on 
primary unsorted and secondary sorted material. Cell numbers necessary for ALL 
engraftment differed between individual leukemias but as little as 100 cells proved to be 
  
 
sufficient in one unsorted and in both the CD19+CD20low and CD19+CD20high 
fractions (Table 1). Mice transplanted with 10 cells only are still under observation. 
Patient Transplant Population Cell dose Mice engrafted/ 
transplanted 
L4951 Secondary CD20 high 500 3/3 
CD20 low 3/3 
CD20 high 100 3/3 
CD20 low 3/3 
L2510 Secondary CD20 high 3,000 2/4 
CD20 low 4/4 
CD20 high 300 0/4 
CD20 low 1/4 
L49101 Primary Unsorted 500 3/4 
100 0/4 
L792 Primary Unsorted 1,000 5/5 
100 1/5 
L826 Primary Unsorted 1,000 3/4 
100 0/4 
Table 1 
In conclusion we present strong evidence that leukemia-propagating cells are much more 
prevalent than previously thought and that blasts of diverse immunophenotype are able 
to serially reconstitute the complete leukemia in immune-deficient mice. 
  
 
Conclusions
● Sorted fractions irrespective of the expression of CD10 or CD20 
engraft immunodeficient NSG mice.
● All populations are able to re-establish the complete 
immunophenotype of the original leukemia.
● Both fractions of CD10 or CD20 sorted cells serially engraft in 
primary, secondary and tertiary (CD20 sort) mice.
● Limiting dilution experiments show that 10 – 100 ALL blasts are 
often sufficient to reinitiate the leukemia in a xeno-environment.
● In summary, leukemia-propagating cells in childhood ALL are 
abundant and appear not to be restricted to a specific 
immunophenotype. 
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Introduction
Conflicting results in xenograft transplantation models have reignited the
debate on the existence and nature of leukemic stem cells (LSC) (1). While
some studies suggested that acute lymphoblastic leukemia is maintained by
a rare LSC population, some of these results may have been an artifact of
the xenograft model itself: Bonnet and her group have recently shown that
conventional NOD/scid mice are able to clear human cells coated with an
anti-CD38 antibody (2), falsely suggesting that these CD38+ populations lack
the ability to engraft. Using anti-CD122 pretreated NOD/scid or the novel
NSG mice, we have demonstrated that leukemic blasts at different levels of
maturation have the ability to re-establish the disease in vivo (3),
challenging the stem cell model in ALL. Here, we confirm these results by
showing that leukemic blasts irrespective of the expression of the lymphoid
differentiation markers CD10 and CD20 possess leukemia-initiating potential.
More importantly, leukemia-initiating cells are frequent and 10-100 blasts
are sufficient to re-grow the leukemia, even in a xeno-environment.
Results
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Disease Propagating Blasts in Standard and High Risk Acute Lymphoblastic 
Leukemia are Frequent and of Diverse Immunophenotype
Table 1: Summary of all mice transplanted at limiting dilutions.
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Patient Transplant
Risk 
category
Population Cell dose
Mice 
engrafted/
transplanted
Time to 
engraftment
Status
L792 Primary
Standard 
risk
Unsorted
1,000 5/5 <10 -
100 1/5 <10 alive
10 0/5 - alive
L826 Primary
High risk
t(4;11)
Unsorted
1,000 3/4 <13 - <32 -
100 1/4 <50 -
10 0/4 - -
L737c Primary
High risk
(bcr/abl
like ALL)
Unsorted
1,000 4/4 <12 alive
100 3/5 <12 - alive
10 0/5 - alive
L49101 Primary
High risk
t(9;22)
Unsorted
500 3/4 <20 alive
100 0/4 - alive
10 0/4 - alive
L858 Primary
High risk 
(poor 
responder)
Unsorted
1,000 2/5 <16 - alive
100 0/5 - alive
10 0/5 -
alive
L4951 Secondary
High risk
t(9;22)
Unsorted
1,000 7/7 <10 -
100 10/10 <10 - <20 -
10 7/10 <12 - alive
L754 Secondary
High risk
(HeH)
CD20 high
1,000
4/4 <12 - <21 alive
CD20 low 3/4 <12 alive
CD20 high
100
3/5 <12 - <21 alive
CD20 low 2/4 <21 alive
L4951 Secondary
High risk
t(9;22)
CD20 high
500
3/3 <10 -
CD20 low 3/3 <10 -
CD20 high
100
3/3 <15 -
CD20 low 3/3 <10 - <20 -
L2510 Secondary
High risk
t(9;22)
CD20 high
3,000
2/4 <8 - -
CD20 low 4/4 <8 - -
CD20 high
300
0/4 - alive
CD20 low 1/4 <12 - alive
L4967 Tertiary
High risk
t(9;22)
Unsorted
1,000 3/3 <12 -
100 5/5 <12 -
10 2/5 <12 - alive
Population
Number of mice in total 
(primary/secondary/tertiary)
Cell Number
Engrafted mice in total 
(primary/secondary/tertiary)
CD19+CD10high 26 (8/18/0) 3,000-26,000
17 (65%)
( 6(75%)/11(61%) )
CD19+CD10low 26 (8/18/0) 3,000-22,000
14 (54%)
( (3(38%)/11(61%) )
CD19+CD20high 92 (19/59/14) 100-100,000
72 (78%)
( 11(58%)/47(80%)/14(100%) )
CD19+CD20low 91 (19/58/14) 100-100,000
77 (85%)
( 16(84%)/50(86%)/11(79%) )
Methods
Sorted and unsorted blasts from standard/intermediate (n=5) or high risk
(n=9) acute lymphoblastic leukemias were serially transplanted via
intrafemoral injection in unconditioned NSG mice using our standard protocol
(3). Flow sorting was based on the expression of the B cell precursor surface
antigens CD10 and CD20. Limiting dilution experiments were performed with
10 - 10,000 sorted and unsorted cells.
Results
Table 2: Summary of all mice transplanted with sorted cell populations.
Results
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In childhood acute lymphoblastic leukemia (ALL) conflicting reports regarding 
frequency and identity of the leukemia-propagating cell (LPC) highlight the need for 
further investigations. We aim to address these questions of frequency and clonogenicity 
of sub-populations at different maturational stages, using an in vivo xenograft model.  
ALL’s from different risk groups (according to treatment protocol criteria) were 
included (high risk: BCR/ABL positive (6), BCR/ABL-like (2), high hyperdiploid/MRD 
positive high risk (2), intermediate risk: high WBC/MRD negative (2), age >10 years (1) 
and standard risk (1)). Blasts were transplanted intra-femorally into NOD/scid IL2Rγnull 
mice and engraftment patterns in bone marrow were investigated using 5 color flow 
cytometry. To determine the frequency of LPCs we performed limiting dilution 
experiments (10 to 10,000 cells/mouse) on primary patient material or leukemic cells 
previously passaged through mice once or twice (secondary/tertiary material). To 
investigate the immunophenotypic identity of candidate LPC’s we used sorted blast 
populations of CD19+CD10low, CD19+CD10high, CD19+CD20low and CD19+CD20high 
representing different immunophenotypic maturation stages for serial transplantations.  
  
 
Cell numbers successfully engrafting mice in limiting dilution experiments differed 
between individual leukemias, however, 10 cells only were sufficient for two unsorted 
bcr-abl positive leukemias. 
Primary, secondary and tertiary cells sorted into CD19+CD20low and CD19+CD20high 
populations were serially transplanted into 159 mice in total, of which 125 engrafted. 
CD19+CD10low and CD19+CD10high sorted primary and secondary samples engrafted 34 
out of 60 mice transplanted. Engraftment and reconstitution of the complete ALL 
phenotype was observed in all sorted populations. Successful serial engraftment of these 
diverse populations demonstrated long-term self-renewal capacity.  
In conclusion strong evidence suggested leukemia-propagating cells were much 
more frequent than previously thought and that blasts of diverse maturational stages 
were able to serially reconstitute the complete leukemia in a xenotransplant model. 
  
 
Conclusions
● Sorted fractions irrespective of the expression of CD10, CD20 or 
CD34 engraft immunodeficient NSG mice.
● All populations are able to re-establish the complete 
immunophenotype of the original leukemia.
● Both fractions of CD10 or CD20 sorted cells serially engraft in 
primary, secondary and tertiary (CD20 sort) mice.
● Limiting dilution experiments show that 10 – 100 ALL blasts (sorted 
and unsorted) are often sufficient to reinitiate the leukemia in a 
xeno-environment.
● In summary, leukemia-initiating cells in childhood ALL are abundant 
and appear not to be restricted to a specific immunophenotype. 
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Introduction
In acute lymphoblastic leukemia (ALL) no definitive leukemia-initiating cell
has been identified as conflicting results from xenograft models persist (1).
While the acute myeloid leukemic stem cell phenotypically resembles the
rare normal hematopoietic stem cell, studies demonstrating this is also true
for ALL may be flawed, as it has recently been shown that coating of human
cells with anti-CD38 antibody causes residual immune clearance in some
immunodeficient mice (2). In addition, methodological refinements now can
demonstrate much higher frequencies of stem cells in cancers such as
melanoma (3). Using NK depleted NOD/scid or the severely immuno-
suppressed NSG mice, we previously demonstrated that leukemic blasts at
different levels of maturation have the ability to re-establish the disease in
vivo, already supporting the stochastic model of cancer stem cells (4). Here,
we provide further evidence that stemness is prevalent in leukemic blasts
irrespective of the expression of lymphoid differentiation markers CD10,
CD20 and CD34. More importantly, leukemia-initiating cells are frequent in
these subgroups and 10-100 blasts are sufficient to repopulate the leukemia
in a xeno-environment, suggesting that the real frequency is even higher.
Results
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In  Acute Lymphoblastic Leukemia, stemness is frequent 
and ubiquitous
Table 1: Summary of mice transplanted at limiting dilutions.
Figure 3: : Limiting dilutions experiments with tertiary CD34 sorted
cells from a bcr/abl positive patient (L4951)
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Figure 2Both 
CD19+CD10high and 
CD19+CD10low populations 
engraft NSG mice. 
Figure 1: Both 
CD19+CD20high and 
CD19+CD20low
populations engraft 
NSG mice. 
Population
Number of mice in total 
(primary/secondary/tertiary)
Cell Number
Engrafted mice in total 
(primary/secondary/tertiary)
CD19+CD10high 41 (23/18/0) 3,000-26,000
28 (68%)
( 16(70%)/12(67%) )
CD19+CD10low 40 (22/18/0) 3,000-22,000
21 (53%)
( 10(45%)/11(61%) )
CD19+CD20high 113 (30/58/25) 100-100,000
88 (78%)
( 17(57%)/48(83%)/23(92%) )
CD19+CD20low 112 (30/57/25) 100-100,000
98 (88%)
(26(87%)/51(89%)/21(84%) )
Methods
Sorted and unsorted blasts from standard/intermediate (n=5) or high risk
(n=9) ALL’s were serially transplanted via intrafemoral injection in
unconditioned NSG mice using our standard protocol (3). Flow sorting was
based on the expression of the B cell precursor surface antigens CD10 and
CD20 and the hematopoietic stem cell antigen CD34. Limiting dilution
experiments were performed with 10 - 10,000 sorted and unsorted cells.
Results
Table 2: Summary of all mice transplanted with sorted cell populations.
Results
Patient Risk category Blast origin
Blast 
population
Number of mice engrafted/
Number of mice trasplanted
Status
Calculated 
frequency 
(ELDA)
Number of cells transplanted
3000-1000 500-100 10
L4967 High risk 
t(9;22)
Primary Unsorted 4/4 5/5 0/5 alive 41.7
Tertiary Unsorted 3/3 5/5 3/5 alive 10.9
L792 Standard risk Primary Unsorted 5/5 1/5 0/5 - 304
L870 High risk 
(MRD high)
Primary Unsorted 3/4 2/4 0/5 alive 629
L826 High risk 
t(4;11)
Primary Unsorted 3/4 0/4 0/4 - 888
L829 High risk 
(HeH)
Primary Unsorted 3/5 0/4 0/5 alive 1251
L2510 High risk 
t(9;22)
Secondary CD20high 2/4 0/4 - - 4949
CD20low 4/4 1/4 - - 779
L4951 High risk 
t(9;22)
Secondary Unsorted 6/6 10/10 5/10 - 14.24
Secondary CD20high 3/3 6/6 - - >41.7
CD20low 3/3 6/6 - - >41.7
L49101 High risk 
t(9;22)
Primary Unsorted 3/4 0/4 0/4 - 524
L858 High risk 
(MRD high)
Primary Unsorted 4/5 2/5 0/5 alive 463
L737c High risk 
(bcr/abl like)
Primary Unsorted 4/4 4/5 0/5 alive 77.0
L754 High risk 
(HeH)
Secondary CD20high 4/4 4/4 - - >41.7
CD20low 3/3 3/4 - - 72.1
Tertiary CD20high 6/8 1/8 0/8 alive 740
CD20low 6/7 1/9 0/8 alive 590
L758b High risk 
(bcr/abl like)
Primary Unsorted 2/4 0/5 0/5 alive 1727
L49120 High risk 
t(9;22)
Primary Unsorted 2/4 2/5 0/5 alive 812
R2
R3
L737c primary material
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In acute lymphoblastic leukemia stemness is frequent and ubiquitous  
Klaus Rehe, Kerrie Wilson, Simon Bomken, Hesta McNeill, Martin Stanulla, Monique 
den Boer, Julie Irving, Olaf Heidenreich and Josef Vormoor 
Research on cancer stem cells, cells that self-renew and reconstitute the full phenotype 
of the original malignancy, has yielded controversial results regarding their frequency 
and identity for many cancers. The hierarchical stem cell model has been well 
established in some malignancies such as acute myeloid leukemia and states that only 
rare, immunophenotypically immature blasts harbor stem cell activity, resembling a 
normal physiological hierarchy. The opposing stochastic model proposes that stemness 
in cancer cells is supported by extrinsic stimuli and that a substantial fraction of 
malignant cells have this potential. Continued optimization of in vivo 
xenotransplantation modeling recently caused a paradigm shift for some cancers, for 
example in malignant melanoma where stem cell activity was found in as many as 1 in 4 
cells. For acute lymphoblastic leukemia (ALL) we and others previously challenged the 
hierarchical model by demonstrating that both immature and more mature leukemic 
blasts contain self-renewal properties (Cancer Cell 2008, 14(1), p47-58). In this study 
we address the frequency of leukemic stem cells in the bulk leukemia and also, more 
specifically, in subpopulations of different blast maturity by using unsorted and highly 
purified flow sorted cell fractions. Primary patient material as well as leukemic blasts 
harvested from engrafted mouse bone marrow (secondary and tertiary material) were 
  
 
sorted for their CD10, CD20 or CD34 expression followed by orthotopic intrafemoral 
transplantation into severely immunocompromised NOD/scid IL2Rγnull (NSG) mice. 
Engraftment of transplanted CD19+CD10low and CD19+CD10high, CD19+CD20low 
and CD19+CD20high and CD19+CD34low and CD19+CD34high blast populations was 
monitored by 5 color flow cytometry using material from consecutive bone marrow 
punctures, final bone marrow harvests and/or single cell suspensions from spleens. 
Primary ALL samples from 15 high risk (BCR/ABL positive (n=8), BCR/ABL like ALL 
(n=2), high hyperdiploid/MRD positive (n=2), MRD positive (n=1), MLL/AF4 (n=2)), 3 
intermediate risk (high WBC/MRD negative (n=2), age >10 years (n=1)) and 3 standard 
risk (n=3) patients were included. Cells sorted into CD19+CD10low and 
CD19+CD10high fractions were transplanted from primary patient material (n=4, HR; 
n=1, SR) and from secondary samples (n=4, HR; n=1; IR) with cells from one HR 
patient used at limiting dilutions. As few as 100 sorted cells of either fraction were 
sufficient to repopulate the leukemia. CD19+CD20high and CD19+CD20 low fractions 
from primary (n=7, HR; n=1, IR), secondary (n=5, HR; n=1, IR) and tertiary material 
(n=2, HR; n=1, IR) engrafted NSG mice. Limiting dilutions were performed on 
secondary (n=4, HR) and tertiary material (n=2, HR). Cell numbers required for 
engraftment varied between leukemias with as few as 100 cells being sufficient to cause 
engraftment.  
Limiting dilution experiments using CD19+CD34high and CD19+CD34low fractions 
from secondary (n=1, HR) and tertiary (n=1, HR) material yielded engraftment with as 
few as 10 CD19+CD34high and 100 CD19+CD34low cells. Similarly, unsorted primary 
(n=11, HR; n=2, IR), secondary (n=2, HR) and tertiary material (n=1, HR) required as 
few as 10 cells for leukemic reconstitution. Taken together, both unsorted and sorted 
blasts of all immunophenotypes and transplanted with low numbers were able to 
reconstitute the complete original phenotype of the patient leukemia. All limiting 
  
 
dilutions were transplanted down to 10 cells per mouse and those mice not engrafted yet 
are still under observation. Furthermore, the ability to self-renew was demonstrated by 
serial transplantation. Finally, we compared expression of self-renewal associated genes 
(BMI1, EZH2, HMGA2, MEIS1, TERT) in CD19+CD34low and CD19+CD34high 
fractions of 5 HR and 1 SR samples with that in cord blood. Interestingly, expression of 
these genes was not dependent on the CD34 status of the leukemic cells, whereas 
HMGA2, MEIS1 and TERT were upregulated in CD34+ cord blood cells. In summary 
we provide strong evidence for the stochastic cancer stem cell model in B precursor 
ALL by demonstrating that (i) a broad spectrum of blast immunophenotypes exhibit 
stem cell characteristics and (ii) that this stemness is highly frequent among ALL cells.  
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Engraftment of CD20 Sorted Cells
Region Statistics
File: pres ort.001 Log Data Units: Linear Values
Sample ID: pres ort Patient ID: wb51
Tube: Panel: 
Acquisition Date: 05-Aug-08 Gate: G1
Gated Events: 7641 Total Events: 10000
X Parameter: FL1-H CD20 FITC (Log) Y Parameter: FL2-H CD19 PE (Log)
Region Events % Gated % Total X Mean X Geo Mean Y Mean Y Geo Mean Px,Py
R1 7641 100.00 76.41 44.73 19.85 180.94 104.46 1, 2
R2 1110 14.53 11.10 179.83 154.34 240.03 192.02 3, 4
R3 3431 44.90 34.31 10.28 8.87 174.12 133.79 3, 4
R2R3
R1
L4951 primary material
BCR/ABL pos.
Mouse 71
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9
CD20
Mouse 72
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Engraftment of CD10 Sorted Cells
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Malleability of Leukaemic Blasts
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How frequent is the leukaemic stem cell?
Stem Cell Frequency in Unsorted Blasts 
Patient Blast origin 
Number of mice engrafted/ Number of mice transplanted 
Number of cells transplanted 
1000 100 10 
L4967 Primary 4/4 5/5 0/5 
Tertiary 3/3 5/5 3/5 
L792 Primary 5/5 1/5 0/5 
L870 Primary 3/4 2/4 0/5 
L826 Primary 3/4 0/4 0/4 
L876 Primary 4/4 4/5 0/5
L829 Primary 3/5 0/4 0/5 
L2003 Primary 1/3 0/4 0/4
L4917 Primary 1/3 0/4 0/5
L4951 Secondary 6/6 10/10 5/10 
L49101 Primary 3/4 0/4 0/4 
Secondary 4/4 5/5 4/5 
L858 Primary 4/5 4/5 5/5 *
L737c Primary 4/4 4/5 0/5 
L758b Primary 2/4 0/5 0/5 
L49120 Primary 1/4 2/5 0/5 
How frequent is the leukaemic stem cell 
in defined subpopulations?
  
 
  
 
  
 
  
 
Limiting Dilution of CD20 Sorted Cells
C
D
1
9
CD20
2,000 cells
500 cells
100 cells
L4951
Secondary material
CD20 highCD20 low
R4R5
C
D
3
4
CD19
1,000 cells
100 cells
10 cells
CD34 highCD34 low
Limiting Dilution of CD34 Sorted Cells
L4951
Tertiary material
Stem Cell Frequency in Subpopulations
Patient 
Blast 
origin
Blast 
population 
Number of mice engrafted/ Number 
of mice transplanted 
Number of cells transplanted 
1000 100 10 
L2510 Secondary CD20high 2/4 0/4 -
CD20low 4/4 1/4 -
L4951 Secondary CD20high 3/3 6/6 -
CD20low 3/3 6/6 -
Tertiary
CD34high 3/3 5/5 5/6
CD34low 4/4 4/5 4/5
Tertiary
CD20high - 2/3 0/4
CD20low - 3/3 0/4
L737c Secondary CD10high 4/4 2/4 0/5
CD10low 4/4 2/4 0/5
Secondary CD20high 4/4 1/4 0/5
CD20low 2/4 0/4 0/5
Secondary CD34high 4/4 1/5 4/5
CD34low 4/4 3/5 1/5
L754 Secondary CD20high 4/4 4/4 -
CD20low 3/3 3/4 -
Tertiary CD20high 6/8 1/8 0/8 
CD20low 6/7 1/9 0/8 
Do subpopulations share a common 
self-renewal programme?
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Conclusions
 In acute lymphoblastic leukaemia, stem cells are 
frequent
 The frequency of stem cells is comparable 
between different subpopulations
 Preliminary data suggest a self-renewal 
programme common to leukaemic subpopulations
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